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SUMMARY 
There have been many reported associations between hypertension-related phenotypes 
and DNA markers of candidate genes, but none of them have been consistently 
replicated across diverse populations. Part of the inconsistency may be due to the 
fact 
that most DNA markers studied so far do not have a functional impact on the structure 
or expression of the gene product. Thus, most reported genetic associations have been 
attributed to linkage disequilibrium with putative functional changes elsewhere at the 
genetic locus. One strategy to reduce such confounding in association studies may be 
to select DNA markers that are proven, by various assays, to directly mark a 
functional change in the gene of interest. In this context the GNB3 gene encoding the 
human G protein ß3 subunit located on chromosome 12p13 has been proposed as a 
putative candidate gene for hypertension. The 825T allele was associated with the 
occurrence of a splice variant, which produced a 123-base pair deletion of nucleotides 
498 to 620 of exon 9 resulting in the loss of 41 amino acids and 1 tryptophan-aspartic 
acid WD repeat domain of the Gß3 subunit (Gß3-s). It has been hypothesised that the 
C825T polymorphism of the G protein ß3 subunit (GNB3) which leads to the 
formation of a splice variant may be associated with increased signal transduction, 
and hypertension. 
I have studied the GNB3 gene as a candidate gene for hypertension and left 
ventricular mass in a systematic and comprehensive manner. To be absolutely certain 
about association, the studies should be done in large population samples, 
independently replicated, and the association should be observed in both population 
based and family based studies. In addition it should be demonstrated that the alleles 
affect the gene product and function in a physiological meaningful way. 
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I have carried out association studies in three independent populations -A case- 
control study with well characterised hypertensives and their matched controls; a twin 
study looking at echocardiographic LV mass; and a large family based study 
analysing blood pressure and ECG LV mass. In addition I have also looked at three 
additional candidate genes including ACE, aldosterone synthase and beta-1 
adrenoceptor. Though these studies concluded that there was no association between 
the C825T polymorphism and blood pressure or LV mass, I have demonstrated a 
significant heritability of various electrocardiographic measures of LV mass and an 
interaction between GNB3, ACE and SFl explaining the variability of continuous 
measures of LV mass in this population. 
I studied the functional aspects of the GNB3 polymorphism by measuring platelet 
aggregation in normal human volunteers, using it as a marker of G-protein related 
signal transduction. However, there was no association between epinephrine or 
platelet activating factor induced platelet aggregation and the GNB3 genotype. 
Finally, I peformed molecular studies using cells transfected with ß3 (wild-type) and 
ß3_S (splice-variant) of GNB3 along with a fusion construct of a2AG;, and measuring 
of GTPase activity and calcium signalling. There was no significant difference 
between ß3 or 133_s transfected cells, in terms of epinephrine stimulated GTPase 
activity, onset-delay of calcium release and time-to-peak of calcium signal. However, 
cells expressing ß3_S showed a significantly lower rate of calcium release compared to 
cells expressing ß3. These results indicate that the G protein 133_s subunit has no 
functional difference or possible slightly reduced effect compared to the wild type. 
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Thus I have systematically shown that the GNB3 C825T polymorphism does not play 
a major role in the causation of hypertension using a multi-pronged approach 
fulfilling all the stringent criteria needed to confirm association. I have shown that the 
functional difference between the Gß3-s splice variant and the wild type Gß3 subunit 
is small thus may not have a major effect on phenotype independently. It is well 
known that hypertension and its complications are the consequence of interactions 
between many genetic and environmental factors. In this scenario, effects conferred 
by a single gene variant either must be very strong or found at a very high frequency 
to be statistically detectable, and further studies looking at epistatic interactions with 
this polymorphism would facilitate the genetic dissection of hypertension. I have 
shown a statistical interaction in ECG phenotypes suggesting that the net effect of this 
variation may manifest, only when it's associated afferent or efferent pathways are 
also affected. However these findings need to be further tested in large association 
studies especially with ascertainment for high blood pressure, which can identify 
individuals in the extremes of LV mass distribution and also in population cohorts 
followed up over a longer time frame. 
The approach used in this study offers a paradigm for the study of candidate genes 
and loci identified in population based studies of complex human disease. 
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High Blood Pressure 
LD Linkage Disequilibrium 
LVH Left Ventricular Hypertrophy 
LVM LV Mass 
LVMI LV Mass Index 
MAP Mean Arterial Pressure 
MZ Monozygous twins 
NO Nitric Oxide 
PAF Platelet Activating Factor 
PCR Polymerase Chain Reaction 
PTX Pertussis Toxin 
QTDT Quantitative TDT 
SBP Systolic Blood Pressure 
SF1 Aldosterone Synthase C344T Polymorphism 
SNP Single Nucleotide Polymorphism 
SOLAR Sequential Oligogenic Linkage Analysis Routines 
STDT Sibling Disequilibrium Test 
TDT Transmission Disequilibrium Test 
WHR Waist - Hip Ratio 
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1.1 Hypertension 
Hypertension is one of the most common diseases afflicting humans throughout the 
world. Because of the associated morbidity and mortality and the cost to society, 
hypertension is an important public health challenge. Over the past several decades, 
extensive research, widespread patient education, and a concerted effort on the part of 
health care professionals have led to decreased mortality and morbidity rates from the 
multiple organ damage arising from years of untreated hypertension. 
1.1.1 Historical Perspective 
The first report of direct BP measurement dates back to 1726, when Stephen Hales 
cannulated a horse's crural artery and assessed the height of the blood column before 
and after haemorrhage. He described the importance of blood volume in blood 
pressure regulation. The contribution of peripheral arterioles in maintaining blood 
pressure, described as "tone, " was first described by Lower in 1669 and subsequently 
by Senac in 1783. Claude Bernard, Charles E. Edouard, Charles Brown-Sequard, and 
Augustus Waller observed the role of vasomotor nerves in the regulation of blood 
pressure. William Dayliss advanced this concept in a monograph published in 1923. 
Cannon and Rosenblueth developed the concept of humoral control of blood pressure 
and investigated pharmacologic effects of epinephrine. Three contributors who 
advanced the knowledge of humoral mechanisms of blood pressure control are T. R. 
Elliott, Sir Henry Dale, and Otto Loew. 
The monaural stethoscope appeared in the early nineteenth century, well before Riva- 
Rocci's introduction of the sphygmomanometer cuff in 1896. Firmly shifting 
attention away from assessing the pulse wave, ' Korotkoff reported the auscultatory 
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method of measuring arterial pressure in 1905, permitting measurement of diastolic 
pressure and systolic pressure for the first time. 2 
As early as 1827, Richard Bright observed the changes of hypertension on the 
cardiovascular system in patients with chronic renal disease. By 1852, Johnson had 
described medial hypertrophy of the renal afferent arterioles from high BP, and 
Traube associated left ventricular hypertrophy (LVH) with increased arterial tension 
in 1856. Clinical pathologic studies by Sir William Gull and H. G. Sutton (1872) led 
to further description of the cardiovascular changes of hypertension. Frederick 
Mahomed was one of the first physicians to systematically incorporate blood pressure 
measurement as a part of a clinical evaluation. In 1939, Keith, Wagener, and Barker 
published their landmark study of survival curves for four groups of hypertensive 
patients classified by eye ground patterns. 3 With these and many subsequent 
advances, the medical focus shifted from simple measurement of BP to its clinical 
consequences. 
Early efforts to reduce extreme hypertension by adrenalectomy or sympathectomy 
frequently led to disastrous results leading some authorities to conclude that such 
hypertension was not merely primary but "essential, " because aggressive pressure 
reductions were deleterious. Serious work on experimental hypertension started with 
Goldblatt's description of the renal artery clip model in 1934. Thus began a series of 
discoveries of one intriguing complexity after another: renin, angiotensin, atrial 
natriuretic factor, cation fluxes, endothelial factors, vascular remodelling, central 
monoaminergic, and hypothalamic factors, among others. 
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1.1.2 Definition of Hypertension 
Defining abnormally high blood pressure is extremely difficult and arbitrary. 
Furthermore, the relationship between systemic arterial pressure and morbidity 
appears to be quantitative rather than qualitative. A level for high blood pressure must 
be agreed upon in clinical practice for screening patients with hypertension, for 
instituting diagnostic evaluation and for initiating therapy. Because the risk to an 
individual patient may correlate with the severity of hypertension, a classification 
system is essential for making decisions about aggressiveness of treatment or 
therapeutic interventions. 
The classification of hypertension is based on the average of 2 or more properly 
measured, seated BP readings on each of 2 or more office visits .5 Table 1.1-1 shows 
the classification of hypertension for adults aged 18 years or over, based on 
recommendations of the Seventh Report of the Joint National Committee of 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII) .6 
BP Classification 
Normal 
Systolic BP 
<120 And 
Diastolic BP 
<80 
Prehypertension 120-139 Or 80-89 
Stage 1 hypertension 140-159 Or 90-99 
Stage 2 hypertension >_160 Or >100 
Table 1.1-1 JNC VII Classification of hypertension 
Because of the new data on lifetime risk of hypertension and the impressive increase 
in the risk of cardiovascular complications associated with levels of BP previously 
-23- 
considered to be normal, the JNC VII6 report has introduced a new classification that 
includes the term "prehypertension" for those with BPs ranging from 120 to 139 mm 
Hg systolic and/or 80 to 89 mm Hg diastolic blood pressure (DBP). This new 
designation is intended to identify those individuals in whom early intervention by 
adoption of healthy lifestyles could reduce BP, decrease the rate of progression of BP 
to hypertensive levels with age, or prevent hypertension entirely. 
This classification does not make different treatment recommendations according to 
the presence or absence of risk factors or target organ damage. JNC VII6 suggests that 
all people with hypertension (Stages 1 and 2) be treated. The treatment goal for 
individuals with hypertension and no other compelling conditions is 140/90 mm Hg. 
The goal for individuals with prehypertension and no other risk factors or target 
organ damage compelling indications is to lower BP to normal using the 
recommended lifestyle modifications. 
1.1.3 Epidemiology 
Worldwide, hypertension affects an estimated 690 million persons, primarily adults. 
Estimates of prevalence of hypertension are variable because the number of 
measurements made, the method and the circumstances in which measurements are 
made all vary. Also important here are age, gender, race, and socio-economic status 
of the population studied. National health surveys in various countries have shown a 
high prevalence of poorly controlled hypertension. These studies have reported that 
prevalence of hypertension is 22% in Canada, of which 16% is controlled; 26.3% in 
Egypt, of which 8% is controlled and 13.6% in China, of which 3% is controlled. 
Hypertension is a worldwide epidemic; in many countries 50% of the population 
older than 60 years has hypertension. Overall, approximately 20% of the world's 
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adults are estimated to have hypertension (defined as blood pressure in excess of 
140/90 mm Hg). The prevalence dramatically increases in patients older than 60 
years. 
1.1.3.1 United Kingdom studies 
In a representative population sample of 10359 Scottish men and women aged 40 to 
59 years between 1984 and 1986,1262 (25 %) men and 1061 (20 %) women were 
considered to be hypertensive Hypertension was defined in this study as a blood 
pressure of 160/95mmHg or higher, or receiving antihypertensive drug treatment and 
was based on the average of two measurements at a single screening visit in a 
primary care setting. 7 A more recent survey of 12116 English adults aged 16 years or 
more in 1994 yielded similar results 8 Based on the average of the second and third of 
three readings at a single screening visit in the respondent's home, 19% of men and 
20% of women had a blood pressure of 160/95 mmHg or higher or were receiving 
antihypertensive drug treatment. Both surveys probably overestimate the prevalence 
of hypertension in the United Kingdom because they were based on the average of 
readings at a single screening session. 
1.1.3.2 United States studies 
The age-adjusted prevalence of hypertension varies from 18-32%, according to data 
from the National Health Examination Surveys 1988 to 19919 The proportion of the 
United States population having a systolic blood pressure of 140 mmHg or higher, or 
a diastolic blood pressure of 90 mmHg or higher, was 4% for young adults aged 18 to 
29 years, increasing to 65% for those over 80 years. This was based on the average of 
six measurements at two visits, or currently being treated with an antihypertensive 
drug. In 1999-2000,28.7% of NHANES participants had hypertension, an increase 
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of 3.7% (95% confidence interval, 0-8.3) from 1988-1991.10 Overall, in 1999-2000, 
68.9% were aware of their hypertension, 58.4% were treated, and hypertension was 
controlled in 31.0%. 10 
Recent data from Framingham, United States suggest that the increasing use of 
antihypertensive medication has resulted in a decline in the prevalence of 
hypertension. In an analysis of 10333 subjects aged 45 to 74 years, examined over a 
40-year period from 1950 to 1989, the prevalence of hypertension decreased from 
18.5 to 9.2 per cent for men, and from 28.0 to 7.7 per cent for women. This was using 
definitions of 160 mmHg systolic or 100 mmHg diastolic on or off treatment, and 
based on an average of two separate measurements at each visit. " This is in contrast 
to the NHANES study (1999-2000) which suggests that hypertension prevalence is 
increasing. 10 
1.1.3.3 Age 
A progressive rise in blood pressure with increasing age is observed. The third 
NHANES survey10 reported that the prevalence of hypertension grows significantly 
with increasing age in all sex and race groups. The age-specific prevalence was 3.3% 
in white men (aged 18-29 y); this increased to 13.2% in the group aged 30-39 years; 
22% in the group aged 40-49 years; 37.5% in the group aged 50-59 years; and 51% in 
the group aged 60-74 years. In another study, the incidence of hypertension increased 
approximately 5% for each 10-year interval of age. The prevalence of hypertension 
increases with advancing age to the point where more than half of people aged 60 to 
69 years old and approximately three-fourths of those aged 70 years and older are 
affected 9; 10 The age-related rise in SBP is primarily responsible for an increase in 
both incidence and prevalence of hypertension with increasing age. 12 The systolic 
-26- 
blood pressure rises into the eighth or ninth decade, while the diastolic blood pressure 
remains constant or declines after age 40 years. 13 
1.1.3.4 Sex 
The age-adjusted prevalence of hypertension for men was 34%, 25.4%, and 23.2%, 
and for women was 31.0%, 21.0%, and 21.6% among African Americans, whites, 
and Mexican Americans, respectively. In the NHANES III study, the prevalence of 
hypertension in the age group 18-49 years was 12% for white men compared to 5% 
for white women. However, the age-related blood pressure rise for women exceeds 
that for men, thus by 70 years or older the prevalence of hypertension was reported at 
50% for white men and 55% for white women. 
1.1.3.5 Lifetime Risk of Hypertension 
Whereas the short-term absolute risk for hypertension is effectively conveyed by 
incidence rates, the long-term risk is best summarized by the lifetime risk statistic. 
This is the probability of developing hypertension during the remaining years of life 
(either adjusted or unadjusted for competing causes of death). Framingham Heart 
Study investigators recently reported the lifetime risk of hypertension to be 
approximately 90% for men and women who were nonhypertensive at 55 or 65 years 
old and survived to age 80 to 85.14 Even after adjusting for competing mortality, the 
remaining lifetime risk of hypertension was 86 to 90% in women and 81 to 83% in 
men. The impressive increase of BP to hypertensive levels with age is also illustrated 
by data indicating that the 4-year rate of progression to hypertension is 50% for those 
65 years and older with BP 130-139/85-89 mm Hg and 26% for those with BP 120- 
129/80-84 mm Hg. '5 
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1.1.4 Hypertension and Risk 
Hypertension plays a key role in the worldwide mortality and morbidity from 
cardiovascular diseases, which account for 15 million (30% of total) deaths. 
Hypertension is also the key risk factor in fatal and nonfatal cerebrovascular 
accidents, which amount to 5 million stroke deaths per year. Another 30 million 
people live with disabilities caused by stroke. In fact, the Global Burden of Disease 
Study suggested that in 1990 alone, 2.9 million deaths or 5.8% of total deaths were 
attributable to hypertension. 16 
1.1.4.1 Blood Pressure and Cardiovascular Risk 
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Figure 1.1-1 Coronary heart disease (CHD) and stroke mortality in relation to systolic and 
diastolic blood pressure in the MRFIT study. 
Systolic pressure (upper panel) and diastolic pressure (lower panel) on the X-axis and mortality 
rate on the Y-axis. Adapted from Neaton et al. " 
The relationship between BP and the risk of cardiovascular events is continuous, 
consistent, and independent of other risk factors. The higher the BP, the greater the 
chance is of heart attack, heart failure, stroke, and kidney diseases. The risk of both 
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coronary atherosclerosis and stroke increase exponentially as blood pressure rises 
(Figure 1.1_1). 17 
Data from observational studies involving more than 1 million individuals have 
indicated that death from both ischaemic heart disease and stroke increases 
progressively and linearly from BP levels as low as 115 mm Hg systolic and 
75 mm Hg diastolic. 18 The increased risks are present from 40 to 89 years old. For 
every 20 mm Hg systolic or 10 mm Hg diastolic increase in BP, there is a doubling of 
mortality from both ischaemic heart disease and stroke. 
In addition, longitudinal data obtained from the Framingham Heart Study have 
indicated that BP in the 130-139/85-89 mm Hg range are associated with a more than 
2-fold increase in relative risk from cardiovascular disease (CVD) compared to those 
with BP levels below 120/80 mm Hg. 19 
At any blood pressure, the absolute risk of coronary disease is considerably greater 
than for stroke, although the relative risk for stroke increases more rapidly than 
coronary artery disease. An insight into this finding comes from autopsy studies, 
which show that the carotid and intracerebral vascular beds are relatively protected 
from atherosclerosis as compared to the coronary circulation, particularly at lower 
blood pressures "2021 
Probably the major means whereby hypertension accelerates atherosclerosis is 
through pressure-driven convection of LDL and other atherogenic particles into the 
arterial intima. 22"25 Indeed, without at least high arterial pressures, atherosclerosis 
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does not exist in the vascular tree26 even in patients with homozygous familial 
hypercholesterolemia. 27 Increased turbulence (a rare occurrence in the human 
circulatory system) does not increase atherosclerosis; instead higher shear stress is a 
strong stimulus for the release of nitric oxide, which locally decreases the risk of 
atherosclerosis. Focal areas of low shear stress are at inherently increased risk of 
atherosclerotic disease (such as the coronary arteries where flow stops during each 
systole). 28 
Interestingly, in most studies, stroke risk has been little affected by serum total 
cholesterol, 29; 30 although some recent studies identify clear associated risk. 31 At least 
some association with all standard cardiovascular risk factors should be expected, not 
only because thromboembolic stroke may be caused by carotid tree atherosclerosis, 
but because aortic plaques have been strongly implicated as an embolic source for 
ischaemic stroke. 32-34 
1.1.4.2 Metabolic syndrome and dyslipidaemic hypertension 
The frequent coexistence of abnormal plasma lipids and hypertension was termed 
familial dyslipidaemic hypertension as a descriptive, clinical diagnosis . 
35; 36 Studies in 
twins confirmed a genetic predisposition to the coexistence of both hypertension and 
dyslipidaemia and emphasized the markedly greater risk for CAD when both 
hypertension and dyslipidaemia were present as compared to either separately. 37 
Using data from this study, 46% of CAD risk associated with hypertension can be 
attributed to the frequently accompanying lipid abnormalities. This may help explain 
why blood pressure reduction with antihypertensives alone achieves only about half 
the expected reduction in CAD. 38 Much greater reductions in CAD risk were 
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achieved in a Swedish primary prevention trial when both blood pressure and lipids 
were reduced. 39 
Genetic epidemiology strongly points to an interaction between excess accumulation 
of fat, particularly when centrally distributed, and genetic predisposition that leads to 
the major features of the metabolic syndrome: hypertension, diabetes, and 
dyslipidemia. 35 40-43 Figure 1.1-2 illustrates the relationship between metabolic 
LOW HDL CHOL Non-nwdulation HYPERTENSION 
T Plasma AGT P1 Tissue Ang if t Tubular absorption j LPL activity of sodium and uralt 
Renal 
Ärp 
II t Peripheral 
AGT resistance 
t Cortisol, t androgens production in 
t Renal renin ? 
t HTGL , ^"`~ in women, 1 SHBG adipose t SINS Ac 
vity 1 Plasma 
xf uric acid 
\\\ (t 
LepUn 
t Serum insulin 
Small, 
dense LDL rT Visceral, Other 
t CETP signals Muscle and t Ratio fast- 
Tissue Fat ;`'-º 
twitch fibers 
CETP-mediated t Adipose I Glucosed 
CEfTG transfer pose 
11adrenergic 
insulin- 
; sensitivity 
/ 
+ Insulin receptor 
`\y 
// 
stimulated 
tyrosine kinase activity vasodilation 
(t LDL) 
f Lipolysis 
1 mF j GLUT4 glucose 
: 2;: 
Hepc sis j Insulinsdmuiated glueos 0 
uptake (insulin resistance) 
I LPL activity t Swum Insulin 
HIGH TRIG t PAI-t t Pancreatic _-cell ` 
ýNIDOM 
Llpotoxicity -----ý' apoptosia 
FIGURE 1.1-2 METABOLIC SYNDROME 
syndrome and excess fat accumulation (particularly in visceral and in muscle tissues 
but other tissues as well). Recent advance in adipocyte biology revealed that adipose 
tissue is a secretory organ. Such fat-derived secretory factors are now called 
adipocytokines, conceptually. 44 Adipocytokines known to date include leptin, TNF-a, 
resistin, PAI-I, and adiponectin. Physiological production and secretion of 
adipocytokines maintains metabolic and vascular homeostasis, by acting on the 
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adipocyte itself through auto- and para-crine fashions, and on remote organs through 
blood stream. Dysregulated production of too much or too little adipocytokines, in 
obesity and lipodystrophy can lead to the development of metabolic syndrome, 
including insulin resistant diabetes and vascular disease. Restoring the plasma levels 
of adipocyotkines have been shown to reverse such metabolic syndrome associated 
with obesity and lipodystrophy. Adipocytokines are now becoming a central target to 
tackle the metabolic syndrome. 
1.1.4.3 Chronic Inflammation and Atherosclerosis 
A newly emerging metabolic risk factor is a proinflammatory state. 5 Atherosclerosis 
is classified pathologically as chronic inflammation. In this regard it resembles other 
chronic inflammatory diseases such as those caused by bacteria (e. g. tuberculosis) or 
autoimmune diseases (lupus-erythematosus). The difference is that atherosclerosis is 
located in the inner lining of the artery (intima), its causes are different from other 
causes of inflammation, and it is an indolent process. Chronic inflammation is 
characterized by the presence of inflammatory cells in tissues. The major 
inflammatory cell of atherosclerosis is the macrophage. In addition, the smooth 
muscle cells of the arterial wall can acquire inflammatory properties. One unique 
feature of atherosclerosis is that macrophages and smooth muscle cells acquire large 
amounts of cholesterol, which eventually kills the cells. The causes of chronic 
inflammation in the artery include lipoproteins, products of cigarette smoke, and 
elevated blood glucose. Ultimately, when coronary plaques grow large enough, they 
can rupture to produce heart attack. Plaque rupture appears to occur in areas where 
inflammation is most active. 
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In persons with the metabolic syndrome, chronic inflammation in the arterial wall 
appears to be enhanced. This is reflected in the blood by " inflammatory markers". 
One of these is called C-reactive protein, which is released by the liver in the 
presence of enhanced inflammation. High levels of cytokines, which are proteins that 
activate macrophages, are another indication of enhanced inflammation. Excess 
cytokines, which are commonly associated with the metabolic syndrome, may arise 
from an excess of adipose tissue. All the features of the proinflammatory state have 
not been defined; however, the relationship between inflammatory processes and the 
metabolic syndrome is becoming a topic of intense research. If a proinflammatory 
state is in fact one of the risk factors of the metabolic syndrome, importantly, it could 
contribute to the development of premature coronary heart disease, and perhaps even 
to type 2 diabetes. 
1.1.4.4 Other Risks 
Hypertension is not just a risk factor for atherosclerosis. High blood pressure can 
have direct adverse effects on arteries, arterioles, and the heart, resulting in 
potentially severe consequences beyond the more common manifestations of 
myocardial infarction and atherothrombotic stroke. Even modestly elevated blood 
pressure is a major risk factor for congestive heart failure 46°47 Hypertension is a 
major contributor to left ventricular hypertrophy, a major risk factor for sudden death 
independent of other risk factors 46; 48; 49 Hypertension can lead progressively to 
arterial and arteriolar hypertrophy, arteriosclerosis and arteriolosclerosis, and with 
very high pressures to fibrinoid change and fibrinoid necrosis in arterioles. These 
latter changes can result in lumen compromise of arterioles resulting in lacunar 
stroke, Charcot-Bouchard aneurysms, glomerulosclerosis, nephrosclerosis, and 
ultimately malignant hypertension in the kidney and retinal ischaemia and blindness. 
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The risk of intracerebral haemorrhage is increased 33-fold at stage 3 or higher 
pressures compared to normal blood pressure 5° Untreated, malignant hypertension is 
associated with a 5-year mortality rate of 95% with 65% dying from congestive heart 
failure, 14% from renal failure, 11% from myocardial infarction, and just 5% from 
cerebral hemorrhage. 51 
1.1.4.5 Systolic Blood Pressure 
Impressive evidence has accumulated to warrant greater attention to the importance 
of SBP as a major risk factor for CVD. Changing patterns of BP occur with 
increasing age. The rise in SBP continues throughout life, in contrast to DBP, which 
rises until approximately 50 years old, tends to level off over the next decade, and 
may remain the same or fall later in life. '12 Diastolic hypertension predominates 
before 50 years of age, either alone or in combination with SBP elevation. The 
prevalence of systolic hypertension increases with age, and above the age of 50 years, 
systolic hypertension represents the most common form of hypertension. DBP is a 
more potent cardiovascular risk factor than SBP until age 50; thereafter, SBP is more 
important. 52 Clinical trials have demonstrated that control of isolated systolic 
hypertension reduces total mortality, cardiovascular mortality, stroke events. 53-55 Both 
observational studies and clinical trial data suggest that poor SBP control is largely 
responsible for the unacceptably low rates of overall BP control 56'57 In the 
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT) and Controlled Onset Verapamil Investigation of Cardiovascular End 
Points (CONVINCE) trial, DBP control rates exceeded 90%, but SBP control rates 
were considerably less (60 to 70%). 58-60 Poor SBP control is at least in part related to 
physician attitudes. A survey of primary care physicians indicated that three-fourths 
of them failed to initiate antihypertensive therapy in older individuals with SBP of 
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140 to 159 mm Hg, and most primary care physicians did not pursue control to less 
than 140 mm Hg. 61'62 Most physicians have been taught that the diastolic pressure is 
more important than SBP and thus treat accordingly. Greater emphasis must clearly 
be placed on managing systolic hypertension. Otherwise, as the population becomes 
older, the toll of uncontrolled SBP will cause increased rates of cardiovascular and 
renal diseases. 
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Figure 1.1-3 Factors that determine arterial blood pressure. 
SNS=sympathetic nervous system; PNS=parasympathetic nervous system; Ach=acetylcholine; 
RB('=red blood cells; ADH=antidiuretic hormone; ALDO=aldosterone; -*=stimulatory 
(positive) influence; --* =inhibitory (negative influence); Al=angiotensin I; AI1=angiotensin 11; 
ANY=atrial natriuretic peptide; K=potassium; PGE=prostaglandin E. 63 
1.1.5 The physiology of normal BP control 
The mean arterial BP level is determined by the product of cardiac output (CO) and 
total peripheral resistance (TPR). These two principal determinants are importantly 
influenced by many physiologic factors as demonstrated in Figure 1.1-3. Cardiac 
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output, for example, depends primarily on heart rate and stroke volume. Heart rate is 
governed by beta-1 and cholinergic receptors under the control of sympathetic and 
parasympathetic stimulation, respectively. The stroke volume is determined by the 
ventricular force of contraction (also under autonomic stimulation) and the filling 
pressure which is in turn determined by the intravascular fluid volume status and the 
venous capacitance. Similarly, the systemic vascular resistance is influenced by 
multiple vasoactive mechanisms under the control of local, regional, and systemic 
neural, humoral, and renal factors M'65 Importantly, all of these physiologic 
determinants of flow and resistance are interdependently governed by rapid-, 
intermediate-, and late-acting mechanisms that maintain the arterial BP within the 
normal range despite significant variations in the individual parameters. 63; 66 
Receptors i 
a-1 Vasoconstriction' 
Norepinephrine>dopamine>dobuta Prazosin, 
mine labetalol 
a-2, central effect Vasodilation Clonidine, nore ine hrine 
a-2, peripheral 
effect 
Venoconstriction Clonidine, norepinephrine 
a-1, a-2 
Net vasoconstriction; reflex Ergot, midodrine, 
Phentolamine, 
phenoxybenza decreased cardiac output norepinephrine>epinephrine mine 
ß-1 Increased cardiac output, Epinephrine, norepinephrine, low- Atenolol, li of sis, increased renin dose dopamine, dobutamine$ metroprolol 
ß-2 Vasodilation¢ bronchodilation Albuterol, 
e ine brine»nore ine hrine' 
0-1, ß-2 Net increased cardiac output Epinephrine, isoproterenol 
Propranolol, 
pindolol 
a-1, (3-1 
Vasoconstriction and increased 
cardiac output 
Epinephrine, high-dose dopamine Labetalol 
Parasympathetic Decreased cardiac output, decreased heart rate 
Acetylocholine Atropine 
Selective V1 
receptor 
antagonist (not 
V, Increased peripheral resistance Arginine vasopressin commercially 
available) or 
calcium 
antagonists 
Table 1.1-2 Adrenergic receptors in the modulation of arterial blood pressure 
[a] Predominantly arteriolar. [b] Without chronotropic effects (unlike dopamine and 
isoproterenol). 0 
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The complex systems and mechanisms that constitute the feedback and reflex control 
of BP have been extensively studied and characterized. The clinically most relevant 
ones are depicted in Figure 1.1-4. Rapid responses and reflexes, for example, 
occurring within seconds after an acute rise in BP include the baroreceptor system, 
vagus nerve, and the central vasomotor centre of the brainstem. 63 Thus, the rapid- 
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Figure 1.1-4 Feedback mechanisms in the control of blood pressure. 
A=angiotensinogen; AI=angiotensin I; All=angiotensin II; 02=oxygen; ADH=antidiuretic 
hormone; -=stimulatory (positive) influence; -- *=inhibitory (negative) influence. 
acting reflex and feedback mechanisms in response to acute changes in BP are almost 
entirely mediated by changes in activity of the autonomic nervous system. 67 The 
adrenergic receptors, their associated agonists, and their physiologic actions as well 
as the clinically useful antagonists are shown in Table 1.1-2. 
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Intermediate-acting responses that occur over minutes and hours involve the renin- 
angiotensin-aldosterone system, antidiuretic hormone, and the renal juxtaglomerular 
apparatus (Figure 1.1-5). Both local and circulating renin-angiotensin systems (RAS) 
play important roles in this feedback mechanism. In the systemic RAS, a drop in BP 
stimulates renin release via afferent arteriole baroreceptor mechanism and increased 
activity of the renal sympathetic nerves. A macula densa mechanism of renin release 
also exists 68-70 The available evidence suggests that in the control of renin secretion 
there is significant interaction between the renal sympathetic nerve activity and the 
baroreceptor and macula densa mechanisms. 69 Renin released by these mechanisms 
acts by converting angiotensinogen (synthesized in the liver and also produced 
locally) to angiotensin I. Angiotensin I is in turn converted to angiotensin II by 
angiotensin converting enzyme (ACE) produced in the lungs and locally. ACE is a 
non-specific kininase that degrades vasodilatory kinins. The relevant actions of 
angiotensin II include (1) potent vasoconstriction, (2) stimulation of adrenal release 
of aldosterone which leads to sodium retention and volume expansion, and (3) 
directly increasing proximal sodium chloride absorption. In addition to these 
intermediate-acting responses, the RAS has a role in the long-term regulation of 
blood pressure. 7' 
Antidiuretic hormone (ADH) activity and capillary filtration are two other 
intermediate-acting mechanisms for BP regulation (Figure 1.1-5). In response to an 
acute decrease in BP, ADH secretion is increased principally as a result of a decrease 
in the normal inhibitory tone from the baroreceptors to the hypothalamus. 
Conversely, increases in BP cause increased baroreceptor activity to the 
hypothalamus, resulting in increased inhibition of the activity of hypothalamic ADH- 
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releasing neurons. In the setting of acute, severe hypotension, ADH acts as part of the 
rapid response and serves as a pressor agent. During periods of prolonged decrease in 
BP, however, ADH also becomes a part of the late-acting response in continuing to 
conserve water. 
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Figu re 1.1-5 The re nin-angiotensin system in the control of blood pressure. 
Late-acting mechanisms operate in days to weeks and are very important because of 
their long-term efficiency in BP regulation. 64 Pressure natriuresis and diuresis are the 
key mechanisms. 65'72 Very simply stated, an increase in BP level above the normal set 
point leads directly to an increase in salt and water excretion. In fact, Guyton et al 
stated that none of the mechanisms discussed above can operate effectively to 
regulate BP without the participation of this kidney function, a phenomenon they 
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termed the "overriding dominance of the kidneys" in the long-term regulation of 
arterial pressure. 64 
Taken together, these complex interrelated mechanisms help regulate BP. An 
important feature of normal BP control is that significant flexibility is built into the 
normal level around which BP is regulated. This feature permits significant transient 
increases in BP level through marked variations in CO and TPR in order to meet 
physiologic needs. But importantly, counter-regulatory and compensatory 
mechanisms contained in these feedback loops help to restore BP level to within 
normal limits again after the end of the acute physiologic demands. The crucial 
difference between this normal pattern of BP regulation and chronic primary 
hypertension is an adverse neurohumoral activation, impaired renal handling of 
sodium, and an increased TPR, the characteristic hallmark of primary hypertension 
which helps to maintain hypertension and the progression to target organ damage. 
1.1.5.1 Pathophysiologic states of chronic BP elevation 
The relationships described above suggest that chronic elevations of arterial BP may 
result from combinations of inappropriate levels of cardiac output (CO) and total 
peripheral vascular resistance (TPR). The spectrum of these combinations include (1) 
a high CO and a normal or low TPR, (2) a high TPR and a low or normal CO, and (3) 
a high CO and a high TPR. Conditions of high CO and relatively normal or low TPR 
include early phase diabetes mellitus, dialysis patients, and the so-called 
"hyperdynamic" or "hyperadrenergic" hypertension usually seen in youth. A high 
TPR associated with a relatively normal or low CO is seen in accelerated or 
malignant hypertension and hypertension in the elderly. The best example of a 
balanced increase in both TPR and CO is renovascular hypertension. In all of these 
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cases, what is missing is an appropriate compensatory mechanism that could 
normalize the changes in TPR and/or CO in order to return BP level to the normal 
range. 
1.1.6 Pathogenesis of Hypertension (Figure 1.3-1, page 114) 
The pathogenesis of essential hypertension is multifactorial and highly complex. 
Multiple factors modulate blood pressure including humoral mediators, vascular 
reactivity, circulating blood volume, vascular calibre, blood viscosity, cardiac output, 
blood vessel elasticity, and neural stimulation. A possible pathogenesis of essential 
hypertension has been proposed in which multiple factors may interact to produce 
hypertension, including genetic predisposition, excess dietary salt intake, and 
adrenergic tone. Although genetics appears to contribute to essential hypertension, 
the exact mechanism has not been established. 
Essential hypertension, or hypertension of unknown cause, accounts for more than 
90% of hypertension cases. It tends to cluster in families and represents a collection 
of genetically based diseases or syndromes with several resultant inherited 
biochemical abnormalities. 73 The resulting phenotypes can be modulated by various 
environmental factors, thereby altering the severity and timing of blood pressure 
elevation. 
Many pathophysiologic factors have been implicated in the genesis of essential 
hypertension: 
1. Increased sympathetic nervous system activity, perhaps related to 
heightened exposure or response to psychosocial stress 
2. Overproduction of sodium-retaining hormones and vasoconstrictors 
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3. Long-term high sodium intake 
4. Inadequate dietary intake of potassium and calcium 
5. Increased or inappropriate renin secretion with resultant increased 
production of angiotensin ii and aldosterone 
6. Deficiencies of vasodilators, such as prostacyclin, nitric oxide (no), and 
the natriuretic peptides 
7. Alterations in expression of the kallikrein-kinin system that affect 
vascular tone and renal salt handling 
8. Abnormalities of resistance vessels, including selective lesions in the renal 
microvasculature 
9. Diabetes mellitus 
10. Insulin resistance 
11. Obesity 
12. Increased activity of vascular growth factors 
13. Alterations in adrenergic receptors that influence heart rate, inotropic 
properties of the heart, and vascular tone 
14. Altered cellular ion transport 
The novel concept that structural and functional abnormalities in the vasculature- 
including endothelial dysfunction, increased oxidative stress, vascular remodelling, 
and decreased compliance may predate hypertension and contribute to its 
pathogenesis has gained support in recent years. 
Although several factors clearly contribute to the pathogenesis and maintenance of 
blood pressure elevation, renal mechanisms probably play a primary role, as 
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hypothesized by Guyton65 and reinforced by extensive experimental and clinical data. 
As discussed in this paper, other mechanisms amplify (for example, sympathetic 
nervous system activity and vascular remodelling) or buffer (for example, increased 
natriuretic peptide or kallikrein-kinin expression) the pressor effects of renal salt and 
water retention. These interacting pathways play major roles in both increasing blood 
pressure and mediating related target organ damage. Understanding these complex 
mechanisms has important implications for the targeting of antihypertensive therapy 
to achieve benefits beyond lowering blood pressure. 
1.1.6.1 Role of Genes 
An estimated 30-60% of the variation in BP between individuals is attributed to 
genetic factors, after adjustment for age and sex. Depending on the population 
studied, this estimate may vary from 15-20% to 65-70%. An important genetic 
component is also suggested by the observation that a child with a history of 
hypertension in both parents or who has a sibling with hypertension has a 40-60% 
chance of developing hypertension as an adult, but the risk increases to 80% if the 
sibling is a monozygotic twin. The inheritance patterns in primary hypertension do 
not follow classic Mendelian genetics for a single gene locus. Rather, the genetic 
susceptibility to develop primary hypertension results from the effects of multiple 
genes. In this regard, an increased risk for hypertension has been noted in a wide 
spectrum of genetic polymorphisms of angiotensinogen, the endothelial nitric oxide 
synthase, and the ß-2 adrenoceptor. Others have noted an association with a-adducin 
proteins associated with the actin cytoskeleton and sodium transport. Much attention 
is also focusing on genetically mediated alterations in the regulation or expression of 
renal ion channels and transporters. 73 (Detailed discussion in section 1.3) 
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1.1.6.2 Rote of the environment 
The importance of environmental influences on the blood pressure phenotype has 
been well described. 74-76 The environmental contribution to the variation in BP 
between individuals has been estimated to be at least 20%; however, as pointed out 
by Harrap, 74 environmental effects are most demonstrable between populations rather 
than between individuals because of presumably larger and more numerous 
differences. Key environmental factors include geography; dietary intake of sodium, 
calcium, potassium, and other micro- and macro-nutrients; physical activity; 
psychosocial stress; socio-economic status; alcohol intake; cigarette smoking; and 
other lifestyle choices. Among these factors, dietary intake of sodium and salt have 
been the most studied. Epidemiological and interventional studies have strongly 
linked salt (NaCl) intake with hypertension- for example populations with a high 
sodium content in their diet (>4 g/d), such as observed in northern Japan and the 
Southeastern United States, have a high prevalence of hypertension. Conversely, 
populations consuming a low sodium diet, such as the Alaskan Eskimo or the 
Yanamao Indians from the Amazon, have an almost negligible prevalence of 
hypertension. Similarly, diets low in calcium or potassium have also been associated 
with a higher prevalence of hypertension. 77 Increasing potassium intake has been 
found to lower BP in both experimental and human studies. Obesity is perhaps the 
most salient risk factor for hypertension. The proportion of obese individuals as a 
function of the total population is continuing to grow in all westernised societies. This 
parallels the incidence of hypertension in these societies. 
Certain metabolic features are associated with the development of high BP. In 
addition to an elevated glucose (insulin resistance), an elevated haematocrit is also 
-44- 
associated with the development of hypertension. Several studies have also found an 
elevated serum uric acid to be present in 25% of untreated hypertensive subjects, and 
also to predict the development of hypertension as well. Controversy exists, however, 
whether the uric acid is an independent risk factor, or whether it is simply a marker 
for other conditions associated with hyperuricaemia that may have a role in the 
development of hypertension, such as renal insufficiency, obesity, insulin resistance, 
dyslipidaemia, and alcohol use. 
There are other important demographic factors for the development of hypertension. 
Primary hypertension is uncommon in young adults but increases with age, with 65% 
prevalence in the population at age 65, and 75% at age 75. This age-related increase 
in prevalence of hypertension has been observed in most Western countries but has 
not been uniformly observed in all populations. Second, the prevalence of 
hypertension is greater in men, although the prevalence in women approaches that of 
men in the postmenopausal years. Certain racial/ethnic groups are also at increased 
risk based on environmental influences and gene-environment interactions, 
particularly African-Americans. Obesity, insulin resistance, gout, and sleep apnoea 
are also associated with an increased risk, as are low socio-economic status and 
increased stress at work, elevated heart rate and an increased BP response to 
exercise. 78 
1.1.6.3 Inherited Cardiovascular Risk Factors 
Cardiovascular risk factors, including hypertension, tend to cosegregate more 
commonly than would be expected by chance. Approximately 40% of persons with 
essential hypertension also have hypercholesterolaemia. Genetic studies have 
established a clear association between hypertension and dyslipidemia. 37 
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Hypertension and type-2 diabetes mellitus also tend to coexist. Hypertension is 
approximately twice as common in diabetics as in non-diabetics, and the association 
is even stronger in African Americans and Mexican Americans. 79 The leading cause 
of death in patients with type-2 diabetes is coronary heart disease, and diabetes 
increases the risk for acute myocardial infarction as much as a previous myocardial 
infarction in a nondiabetic person. 80 Since 35% to 75% of the cardiovascular 
complications of diabetes are attributable to hypertension, diabetic patients need 
aggressive antihypertensive treatment, as well as treatment of dyslipidaemia and 
glucose control. 
Hypertension, insulin resistance, dyslipidaemia, and obesity often occur 
concomitantly. Other associated abnormalities include microalbuminuria, high uric 
acid levels, hypercoagulability, and accelerated atherosclerosis. This cosegregation of 
abnormalities, referred to as the insulin-resistance syndrome or the metabolic 
syndrome, increases cardiovascular disease (CVD) risk. 80 
1.1.6.4 Sympathetic Nervous System 
Increased sympathetic nervous system activity increases blood pressure and 
contributes to the development and maintenance of hypertension through stimulation 
of the heart, peripheral vasculature, and kidneys, causing increased cardiac output, 
increased vascular resistance, and fluid retention. 81 In addition, autonomic imbalance 
(increased sympathetic tone accompanied by reduced parasympathetic tone) has been 
associated with many metabolic, haemodynamic, trophic, and rheologic abnormalities 
that result in increased cardiovascular morbidity and mortality. 82 Several population- 
based studies, such as the Coronary Artery Risk Development in Young Adults 
(CARDIA) study, 83 have shown a positive correlation between heart rate and the 
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development of hypertension (elevated diastolic blood pressure). Most current 
evidence in humans suggests that sustained increases in heart rate are due mainly to 
decreased parasympathetic tone, supporting the concept that autonomic imbalance 
contributes to the pathogenesis of hypertension. Furthermore, increased sympathetic 
tone may increase diastolic blood pressure by causing vascular smooth-muscle cell 
proliferation and vascular remodelling as diastolic blood pressure relates more closely 
to vascular resistance than to cardiac function. Consistent with these population- 
based observations, norepinephrine spillover studies, which provide an index of 
norepinephrine release from sympathoeffector nerve terminals, demonstrate that 
sympathetic cardiac stimulation is greater in young hypertensive patients than in 
normotensive controls of similar age, supporting the interpretation that increased 
cardiac sympathetic stimulation may contribute to the development of hypertension. 
The mechanisms of increased sympathetic nervous system activity in hypertension 
are complex and involve alterations in baroreflex and chemoreflex pathways at both 
peripheral and central levels. Arterial baroreceptors are reset to a higher pressure in 
hypertensive patients, which reverts to normal when arterial pressure is normalized gs- 
87 Resuming normal baroreflex function helps maintain reductions in arterial 
pressure, a beneficial regulatory mechanism that may have important clinical 
implications. 88 Furthermore, there is central resetting of the aortic baroreflex in 
hypertensive patients, resulting in suppression of sympathetic inhibition after 
activation of aortic baroreceptor nerves. 9 This baroreflex resetting seems to be 
mediated, at least partly, by a central action of angiotensin 11 . 
90 Angiotensin II also 
amplifies the response to sympathetic stimulation by a peripheral mechanism, that is, 
presynaptic facilitatory modulation of norepinephrine release 91 Additional small- 
-47- 
molecule mediators, which suppress baroreceptor activity and contribute to 
exaggerated sympathetic drive in hypertension include reactive oxygen species and 
endothelin 92`93 Finally, there is evidence of exaggerated chemoreflex function, 
leading to markedly enhanced sympathetic activation in response to stimuli such as 
apnoea and hypoxia 94 A clinical correlate of this phenomenon is the exaggerated 
increase in sympathetic nervous system activity that is sustained in the awake state 
and seems to contribute to hypertension in patients with obstructive sleep apnea. 
95 
Chronic sympathetic stimulation induces vascular remodelling and left ventricular 
hypertrophy, presumably by direct and indirect actions of norepinephrine on its own 
receptors, as well as on release of various trophic factors, including transforming 
growth factor-ß, insulin-like growth factor 1, and fibroblast growth factors. 82 Clinical 
studies have shown positive correlations between circulating norepinephrine levels, 
left ventricular mass, and reduced radial artery compliance (an index of vascular 
hypertrophy). 96'97 Thus, sympathetic mechanisms contribute to the development of 
target organ damage, as well as to the pathogenesis of hypertension. 
Renal sympathetic stimulation is also increased in hypertensive patients compared 
with normotensive controls. Infusion of the a-adrenergic antagonist phentolamine 
into the renal artery increases renal blood flow to a greater extent in hypertensive than 
normotensive patients, consistent with a functional role for increased sympathetic 
tone in controlling renal vascular resistance 98'99 In animal models, direct renal nerve 
stimulation induces renal tubular sodium and water reabsorption and decreases 
urinary sodium and water excretion, resulting in intravascular volume expansion and 
increased blood pressure. 100 Furthermore, direct assessments of renal sympathetic 
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nerve activity have consistently demonstrated increased activation in animal models 
of genetically mediated and experimentally induced hypertension, and renal 
denervation prevents or reverses hypertension in these models, 101 supporting a role 
for increased sympathetic activation of the kidney in the pathogenesis of 
hypertension. 
Of interest, peripheral sympathetic activity is greatly increased in patients with renal 
failure compared with age-matched, healthy normotensive individuals with normal 
renal function. 102 This increase is not seen in patients receiving long-term 
haemodialysis who have undergone bilateral nephrectomy, suggesting that 
sympathetic overactivity in patients with renal failure is caused by a neurogenic 
signal originating in the failing kidneys. 
1.1.6.5 Vascular Remodelling 
Peripheral vascular resistance is characteristically elevated in hypertension because of 
alterations in structure, mechanical properties, and function of small arteries. 
Remodelling of these vessels contributes to high blood pressure and its associated 
target organ damage. 103; 104 Peripheral resistance is determined at the level of the 
precapillary vessels, including the arterioles (arteries containing a single layer of 
smooth-muscle cells) and the small arteries (lumen diameters < 300 µm). The 
elevated resistance in hypertensive patients is related to rarefaction (decrease in 
number of parallel-connected vessels) and narrowing of the lumen of resistance 
vessels. Examination of gluteal skin biopsy specimens obtained from patients with 
untreated essential hypertension has uniformly revealed reduced lumen areas and 
increased media-lumen ratios without an increase in medial area in resistance vessels 
1o5 (inward, eutropic remodelling). 
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Antihypertensive treatment with several classes of agents, including ACE inhibitors, 
angiotensin-receptor blockers (ARBs), and calcium-channel blockers, normalizes 
resistance vessel structure. 106 Of interest, ß-blocker therapy does not reverse 
resistance vessel remodelling even when it effectively lowers blood pressure. 107 To 
what extent resistance vessel structure plays a direct role in setting the blood pressure 
and in the pathogenesis of hypertension is a subject of ongoing study and 
controversy. Furthermore, whether antihypertensive agents that normalize resistance 
vessel structure are more effective in preventing target organ damage and CVD than 
agents that lower blood pressure without affecting vascular remodelling remains to be 
determined. 
1.1.6.6 Renal Microvascular Disease 
The intriguing hypothesis, proposed by Goldblatt, 4 that primary renal microvascular 
disease may be responsible for the development of hypertension has recently been 
revived by Johnson and colleagues108 and tested in various animal models. These 
authors have suggested a unified pathway for the development of hypertension 
whereby the kidney undergoes subclinical injury over time, leading to the 
development of selective afferent arteriolopathy and tubulointerstitial disease. They 
hypothesize that the pathway may be initiated by various factors, such as 
hyperactivity of the sympathetic nervous system109 or increased activity of the renin- 
angiotensin-aldosterone system, 110 and that initiation of the pathway may be 
facilitated by various genetic factors that stimulate sodium reabsorption or limit 
sodium filtration, as well as by primary microvascular or tubulointerstitial renal 
disease. These factors result in renal vasoconstriction, which may lead to renal 
(particularly outer medullary) ischaemia, thus stimulating the influx of leukocytes 
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and local generation of reactive oxygen species. "" 13 Local generation of angiotensin 
II at sites of renal injury has been invoked as a stimulus for structural alterations 
(renal microvascular disease) and haemodynamic effects (increased vascular 
resistance, low ultrafiltration coefficient, and decreased sodium filtration), which lead 
to hypertension! 14; While this pathway ties in many of the established theories of 
the pathogenesis of hypertension, it has not yet been confirmed in human disease. 108 
1.1.6.7 Arterial Stiffness 
Systolic blood pressure and pulse pressure increase with age mainly because of 
reduced elasticity (increased stiffness) of the large conduit arteries. Arteriosclerosis in 
these arteries results from collagen deposition and smooth-muscle cell hypertrophy, 
as well as thinning, fragmenting, and fracture of elastin fibres in the media. 116 In 
addition to these structural abnormalities, endothelial dysfunction, which develops 
over time from both aging and hypertension, contributes functionally to increased 
arterial rigidity in elderly persons with isolated systolic hypertension. 117 Reduced NO 
synthesis or release in this setting, perhaps related to the loss of endothelial function 
and reduction in endothelial NO synthase, contributes to increased wall thickness of 
conduit vessels, such as the common carotid artery. The functional importance of NO 
deficiency in isolated systolic hypertension is supported by the ability of NO donors, 
such as nitrates or derivatives, to increase arterial compliance and distensibility and 
reduce systolic blood pressure without decreasing diastolic blood pressure. Other 
factors that decrease central arterial compliance include oestrogen deficiency, high 
dietary salt intake, tobacco use, elevated homocysteine levels, and diabetes. These 
factors may also damage the endothelium. 
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The distending pressure of conduit vessels is a major determinant of arterial stiffness. 
The 2-phase (elastin and collagen) content of load-bearing elements in the media is 
responsible for the behaviour of these vessels under stress. At low pressures, stress is 
borne almost entirely by the distensible elastin lamellae, while at higher pressures, 
less distensible collagenous fibres are recruited and the vessel appears stiffer. 116 
Conduit vessels are relatively unaffected by neurohumoral vasodilator mechanisms. 
Instead, vasodilation is caused by increased distending pressure and associated with 
increased stiffness. Conversely, conduit vessels do respond to vasoconstrictor stimuli, 
including neurogenic stimulation during simulated diving, electrical nerve 
stimulation, and norepinephrine infusion! 18; 119 
Increased arterial stiffness also contributes to the wide pulse pressure commonly seen 
in elderly hypertensive patients by causing the pulse wave velocity to increase. With 
each ejection of blood from the left ventricle, a pressure (pulse) wave is generated 
that travels from the heart to the periphery at a finite speed that depends on the elastic 
properties of the conduit arteries. The pulse wave is reflected at any point of 
discontinuity in the arterial tree and returns to the aorta and left ventricle. The timing 
of the wave reflection depends on both the elastic properties and the length of the 
conduit arteries. 
In younger persons, pulse wave velocity is sufficiently slow (approximately 5 m/s) so 
that the reflected wave reaches the aortic valve after closure, leading to a higher 
diastolic blood pressure and enhancing coronary perfusion by providing a "boosting" 
effect. In older persons, particularly if they are hypertensive, pulse wave velocity is 
greatly increased (approximately 20 m/s) because of central arterial stiffening. At this 
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speed, the reflective wave reaches the aortic valve before closure, leading to a higher 
systolic blood pressure, pulse pressure, and afterload and a decreased diastolic blood 
pressure, in some cases compromising coronary perfusion pressure. This 
phenomenon explains the increase in systolic blood pressure and pulse pressure and 
decrease in diastolic blood pressure in the elderly population and is exaggerated in 
the presence of antecedent hypertension. The increase in systolic blood pressure 
increases cardiac metabolic requirements and predisposes to left ventricular 
hypertrophy and heart failure. Pulse pressure is closely related to systolic blood 
pressure and is clearly linked to advanced atherosclerotic disease and CVD events, 
such as fatal and nonfatal myocardial infarction and stroke. Pulse pressure is also 
shown to be a better predictor of CVD risk than systolic blood pressure or diastolic 
blood pressure. ' 16 
Most antihypertensive drugs act on peripheral muscular arteries rather than central 
conduit vessels. They reduce pulse pressure through indirect effects on the amplitude 
and timing of reflected pulse waves. Nitroglycerine causes marked reductions in 
wave reflection, central systolic blood pressure, and left ventricular load without 
altering systolic blood pressure or diastolic blood pressure in the periphery. 
Vasodilator drugs that decrease the stiffness of peripheral arteries, including ACE 
inhibitors and calcium-channel blockers, also reduce pulse wave reflection and thus 
augmentation of the central aortic and left ventricular systolic pressure, independent 
of a corresponding reduction in systolic blood pressure in the periphery. 
Antihypertensive drugs from several classes have been shown to reduce systolic 
blood pressure and CVD morbidity and mortality in patients with isolated systolic 
hypertension. ' 20; 121 
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1.1.6.8 Renin-Angiotensin-Aldosterone System 
Angiotensin II increases blood pressure by various mechanisms, including 
constricting resistance vessels, stimulating aldosterone synthesis and release and renal 
tubular sodium reabsorption (directly and indirectly through aldosterone), stimulating 
thirst and release of antidiuretic hormone, and enhancing sympathetic outflow from 
the brain. Of importance, angiotensin II induces cardiac and vascular cell hypertrophy 
and hyperplasia directly by activating the angiotensin II type 1 (AT1) receptor and 
122 indirectly by stimulating release of several growth factors and cytokines. 
Activation of the AT1 receptor stimulates various tyrosine kinases, which in turn 
phosphorylate the tyrosine residues in several proteins, leading to vasoconstriction, 
123 cell growth, and cell proliferation. Activation of the AT2 receptor stimulates a 
phosphatase that inactivates mitogen-activated protein kinase, a key enzyme involved 
in transducing signals from the AT1 receptor. Thus, activation of the AT2 receptor 
opposes the biological effects of AT1 receptor activation, leading to vasodilation, 
growth inhibition, and cell differentiation. 124; 125 The physiologic role of the AT2 
receptor in adult organisms is unclear, but it is thought to function under stress 
conditions (such as vascular injury and ischaemia reperfusion). Local production of 
angiotensin II in various tissues, including the blood vessels, heart, adrenals, and 
brain, is controlled by ACE and other enzymes, including the serine proteinase 
chymase. The activity of local renin-angiotensin systems and alternative pathways of 
angiotensin II formation may make an important contribution to remodelling of 
resistance vessels and the development of target organ damage (including left 
ventricular hypertrophy, congestive heart failure, atherosclerosis, stroke, end-stage 
renal disease, myocardial infarction, and arterial aneurysm) in hypertensive 
persons. 122 
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1.1.6.8.1 Angiotensin II and Oxidative Stress 
Stimulating oxidant production is another mechanism by which angiotensin II 
increases cardiovascular risk. Hypertension associated with long-term infusion of 
angiotensin II is linked to the upregulation of vascular p22phox messenger RNA 
(mRNA), a component of the oxidative enzyme nicotinamide adenine dinucleotide 
phosphate [NAD(P)H] oxidase. 126 The angiotensin II receptor-dependent activation 
of NAD(P)H oxidase is associated with enhanced formation of the oxidant 
superoxide anion (02"). Superoxide readily reacts with NO to form the oxidant 
peroxynitrite (ONOO-). A reduction in NO bioactivity may thus provide another 
mechanism to explain the enhanced vasoconstrictor response to angiotensin II in 
hypertension. 127 The NAD(P)H oxidase may also play an important role in the 
hypertrophic response to angiotensin II since stable transfection of vascular smooth- 
muscle cells with antisense to p22phox inhibits angiotensin II-stimulated protein 
synthesis. 128 Other vasculotoxic responses to angiotensin II that are linked to the 
activation of NAD(P)H oxidase include the oxidation of low-density lipoprotein 
cholesterol and increased mRNA expression for monocyte chemoattractant protein-1 
and vascular cell adhesion molecule-1.129`130 
1.1.6.8.2 Aldosterone 
Aldosterone is synthesized in the zona glomerulosa of the adrenal cortex through the 
actions of four enzymes. Cholesterol desmolase (CYP11A), 21-hydroxylase 
(CYP21), and aldosterone synthase (CYP11B2) are cytochromes 450 (CYP), which 
are membrane-bound haeme-containing enzymes that accept electrons from NADPH 
through accessory proteins and use molecular oxygen to perform hydroxylations or 
other oxidative conversions. The other enzyme, 3-beta-hydroxysteroid 
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dehydrogenase, is a member of the short-chain dehydrogenase family. 13' Aldosterone 
is crucial for sodium conservation in the kidney, salivary glands, sweat glands and 
colon. Aldosterone promotes active sodium transport and excretion of potassium in 
its major target tissues. It exerts its effects via the mineralocorticoid receptor (MR) 
and the resultant activation of specific amiloride-sensitive sodium channels (ENaC) 
and the Na-K ATPase pump. Aldosterone and the MR may be involved in the 
regulation of genes coding for the subunits of the amiloride sensitive sodium channel 
and the Na-K ATPase pump, as well as of other proteins. 132 Aldosterone indeed 
increases the number of active sodium channels and augments the action and number 
of the Na-K ATPase pump units in its target tissues. The heart and blood vessels also 
express high-affinity mineralocorticoid receptors that can bind both 
mineralocorticoids and glucocorticoids and contain the enzyme 11 ß-hydroxysteroid 
dehydrogenase II, which inactivates glucocorticoids. Activation of these 
mineralocorticoid receptors is thought to stimulate intra- and perivascular fibrosis and 
interstitial fibrosis in the heart. The nonselective aldosterone antagonist 
spironolactone and the novel selective aldosterone receptor antagonist eplerenone are 
effective in preventing or reversing vascular and cardiac collagen deposition in 
experimental animals. Spironolactone treatment for patients with heart failure 
reduced circulating levels of procollagen type III N-terminal aminopeptide, indicating 
an antifibrotic effect. Spironolactone and the better-tolerated selective aldosterone 
receptor antagonist eplerenone are being used to treat patients with hypertension, 
heart failure, and acute myocardial infarction complicated by left ventricular 
dysfunction or heart failure because of their unique tissue protective effects. 133; 134 
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Evidence is accumulating that aldosterone excess may be a more common cause of or 
contributing factor to hypertension than previously thought. Hypokalaemia was 
thought to be a prerequisite of primary hyperaldosteronism, but it is now recognized 
that many patients with primary hyperaldosteronism may not manifest low serum 
potassium levels. Determining the ratio of the plasma aldosterone level to the plasma 
renin activity in a subject with untreated hypertension may be a more acceptable 
screening method for distinguishing patients with essential hypertension from those 
with primary aldosteronism. Accordingly, screening hypertensive patients for 
hyperaldosteronism has expanded and a higher prevalence of the disorder has been 
revealed. Prevalence rates between 8% and 32% have been reported on the basis of 
the patient population being screened (higher in referral practices, where the patient 
mix tends to be enriched with refractory hypertension and lower in family practices 
or community databases). 135 
1.1.6.9 Vascular Endothelial Dysfunction 
Nitric oxide (NO) is a potent vasodilator, inhibitor of platelet adhesion and 
aggregation, and suppressor of migration and proliferation of vascular smooth-muscle 
cells. Nitric oxide is released by normal endothelial cells in response to various 
stimuli, including changes in blood pressure, shear stress, and pulsatile stretch, and 
plays an important role in blood pressure regulation, thrombosis, and 
atherosclerosis. 136 The cardiovascular system in healthy persons is exposed to 
continuous NO-dependent vasodilator tone, but NO-related vascular relaxation is 
diminished in hypertensive persons. The observation that in vivo delivery of 
superoxide dismutase (an enzyme that reduces superoxide to hydrogen peroxide) 
reduces blood pressure and restores NO bioactivity provides further evidence that 
oxidant stress contributes to the inactivation of NO and the development of 
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endothelial dysfunction in hypertensive models. 137138 It has been suggested that 
angiotensin II enhances formation of the oxidant superoxide at concentrations that 
affect blood pressure minimally. 126 Increased oxidant stress and endothelial 
dysfunction may thus predispose to hypertension. This concept is subject to debate 
and ongoing investigation. It is clear, however, that antihypertensive drugs that 
interrupt the renin-angiotensin-aldosterone system, including ACE inhibitors, ARBs, 
and mineralocorticoid receptor antagonists, are effective in reversing endothelial 
dysfunction. This action may at least partly account for their cardioprotective effects. 
1.1.6.10 Endothelin 
Endothelin is a potent vasoactive peptide produced by endothelial cells that has both 
vasoconstrictor and vasodilator properties. Circulating endothelin levels are increased 
in some hypertensive patients, particularly African Americans and persons with 
transplant hypertension, endothelial tumours, and vasculitis. 139 Endothelin is secreted 
in an abluminal direction by endothelial cells and acts in a paracrine fashion on 
underlying smooth-muscle cells to cause vasoconstriction and elevate blood pressure 
without necessarily reaching increased levels in the systemic circulation. Endothelin 
receptor antagonists reduce blood pressure and peripheral vascular resistance in both 
normotensive persons and patients with mild to moderate essential hypertension, 140 
supporting the interpretation that endothelin plays a role in the pathogenesis of 
hypertension. Development of this drug class for the indication of systemic 
hypertension has been discontinued because of toxicity (teratogenecity, testicular 
atrophy, and hepatotoxicity). However, endothelin antagonists are indicated for 
treating pulmonary hypertension 141 and may prove to be clinically useful in the 
therapy for other forms of vascular disease. 
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1.1.7 Implications for genetics 
The study of hypertension is complicated by the complexity of compensatory 
mechanisms and the difficulty in determining the initiating cause. For example, 
manoeuvres that initially cause volume overload and hypertension in the dog 
eventually lead, through autoregulation of tissue blood flow, to a state of increased 
peripheral resistance and near normal fluid volume. 65 Indeed, the brilliant work by 
Guyton and co-workers, identifying the kidney as the dominant, long-term regulator 
of blood pressure, 64; 142 illustrates the need for an appreciation of pathophysiology 
when considering genetic factors potentially contributing to hypertension. 
Investigators continue to point out the inadequacies of simplistic Mendelian models 
in statistical genetics as applied to common disease and the need to consider 
pathophysiology, biochemistry, and molecular mechanisms in the effort to understand 
the effects of genetic variants in blood pressure regulation. 143; 144 
Recent identification of the genetic basis of most rare, monogenic forms of 
hypertension and hypotension reiterates the central role of the kidney in long-term 
control of blood pressure. 73 Several interesting, unsuspected new drug targets have 
emerged as a result of these studies. These include the chloride channel in the 
basolateral membrane of epithelial cells of the thick ascending loop of Henle and, 
possibly, more effective drugs to inhibit the epithelial sodium channel (amiloride is of 
limited value because it competes with sodium and is hence of little value when it is 
most needed-during a high salt diet). Importantly, all the monogenic hypertension 
syndromes identified to date are caused by defects resulting in renal salt retention, 
whereas all the low blood pressure syndromes share a common mechanism of excess 
renal sodium loss. The absence of syndromes relating to the many short-term blood 
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pressure control systems (baroreceptors, a- or ß- receptors, etc. ) again emphasizes the 
dominant role of the kidney and its pressure-natriuresis function in long-term blood 
pressure control. 
1.1.8 A unifying pathway for the development of hypertension 
A pathway was recently proposed that combines most of the existing hypotheses into 
one unifying schema. 145 According to this pathway, hypertension is often initiated by 
a hyperactive sympathetic nervous system (SNS), possibly related to familial, 
genetic, or environmental influences. Potential factors could include emotional stress, 
smoking, alcohol, medications, obesity, or baroreceptor dysfunction. Furthermore, 
activation of the RAS, through either elevations in angiotensinogen (from genetic 
polymorphisms or oral contraceptives), or increased renin levels (secondary to 
activation of the renal SNS, renal ischaemia, hypokalaemia, or other mechanisms), 
could lead to elevated levels of angiotensin II which also feed back to further 
stimulate the SNS. 
In the early phase of hypertension, the BP elevations may be intermittent and the 
levels may only be in the high-normal range. Unlike normotensive patients, however, 
the BP variability would likely be greater and with higher and more frequent levels 
above normal. During this phase, sodium excretion by the kidney is relatively normal. 
In spite of the fact that norepinephrine and All have sodium-retaining properties, the 
increases in BP caused by these agents result in a pressure natriuresis and lead to 
sodium loss and a normal or low blood volume state. 
According to the hypothesis, the intermittent activation of the SNS and/or RAS 
eventually result in acquired injury to the kidney with an impairment in its ability to 
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excrete salt. Normally, the kidney responds to elevations in BP by a process of renal 
autoregulation. In this situation, the afferent arteriole and interlobular artery 
vasoconstrict secondary to a myogenic reflex (mediated by calcium channels) and by 
tubuloglomerular (TG) feedback in an attempt to prevent transmission of pressure 
distally to the sensitive structures in the glomerulus and peritubular capillaries. 
Presumably, this autoregulatory response explains why arteriolosclerosis of the 
afferent arteriole is the classic renal biopsy finding in patients with essential 
hypertension. 
Indeed, arteriolosclerosis of the afferent arteriole was interpreted by Goldblatt and 
others as the primary disease of the renal arterioles that caused essential hypertension. 
This observation resulted from the fact that arteriosclerosis of this arteriole is both 
sensitive (observed in >95% of cases) and specific (observed in <30% in other 
organs) for essential hypertension. According to the above hypothesis, however, this 
vasoconstriction could be considered a protective, secondary response. 
Over time, injury to the kidney could occur via one of two mechanisms. The first 
mechanism would be some transmission of pressure into the glomerulus caused by an 
imperfect renal autoregulatory response. Indeed, autoregulation is not immediate, so 
with sudden changes in systemic BP, some pressure is transmitted into the 
glomerulus. Certain regions of the kidney, such as the juxtamedullary region, may 
also have a relative defect in autoregulation. Furthermore, there is evidence for 
reduced renal autoregulation in conditions associated with a reduction in nephron 
number, in obesity, and in African Americans. Micropuncture studies have also 
confirmed that norepinephrine infusion can elevate glomerular and peritubular 
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capillary pressures in the rat. 146 The consequence is that some increase in pressure 
can be transmitted, where it could lead to glomerular damage (sclerosis) and 
tubulointerstitial injury. It is thus of interest that Bohle has described a population of 
hypertensive patients in which the renal biopsy shows a decompensated 
nephrosclerosis with glomerulosclerosis and tubulointerstitial damage. 147 Moreover, 
this pattern is similar to what is observed in hypertensive African Americans, in 
obesity, and with aging (all conditions associated with salt-sensitive hypertension). 
The second mechanism by which injury to the kidney could occur is by ischaemia. As 
the afferent arteriole thickens in response to the acute elevations in BP, the arteriolar 
lumen becomes progressively smaller. Eventually, the pressure within the narrowed 
arteriole cannot support the tension in the afferent arteriole, and the arteriole 
collapses, leading to distal glomerular and peritubular ischaemia. In addition, the 
vasoactive properties of both norepinephrine and All cause prominent 
vasoconstriction of the arterioles and vasa rectae, resulting in a decrease in blood 
flow to the peritubular capillaries. Evidence of tubular ischaemia can be found in the 
majority of biopsies of patients with essential hypertension. 148 
1.1.9 Summary 
The complexity of pathophysiologic mechanisms that lead to blood pressure elevation 
is such that selective, mechanistically based antihypertensive treatment is rarely 
possible in any hypertensive patient. Hypertension is highly prevalent among middle- 
aged and elderly persons in our population, and the success rate in controlling blood 
pressure in these individuals is poor. For example, in the ALLHAT trial, 149 34% of 
participants did not achieve the goal blood pressure of less than 140/90 mm Hg 
despite use of combination therapy, including a ß-blocker. Current treatment 
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guidelines generally recommend a generic approach to treating hypertension, with 
little emphasis on selecting therapy on the basis of the underlying pathophysiology of 
the elevated blood pressure. '50152 With increased recognition of specific causes, it 
may be possible to develop therapies selective for distinct pathophysiologic 
mechanisms with fewer adverse effects, resulting in more effective blood pressure 
reduction. 
Use of powerful new techniques of genetics, genomics, and proteomics, integrated 
with systems physiology and population studies, will make possible more selective 
and effective approaches to treating and even preventing hypertension in the coming 
decades. 
The use of genetic investigations to identify underlying pathophysiological 
mechanisms will now be discussed. 
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1.2 Genetics of complex traits 
The modern era of the study of genetics was initiated 135 years ago when the 
Bohemian monk Gregor Mendel published the results of his breeding experiments on 
the garden pea. In Mendel's time, the abounding theory of heredity postulated a 
blending' of the inherited contributions from the two parents. Mendel's work clearly 
showed that such blending did not occur, and led to his conclusion of particulate 
inheritance (the 'gene) and rules of segregation. The relevance of Mendel's work for 
human traits was first delineated around the turn of the century by Garrod, who 
reasoned that similar types of transmission rules explained the 'inborn errors of 
metabolism' typically caused by enzyme deficiencies. At the same time, however, 
there was another school of thought, primarily emanating from statisticians such as 
Francis Galton and his student, Karl Pearson. They observed family resemblance for a 
variety of traits such as anthropometric features and intellectual achievement but they 
could not discern patterns of inheritance in families that were consistent with 
mendelian laws. Rather, a blending'-type theory seemed more apt, as children's 
phenotypes tended to be, on average, midway between the parents, with some 
variability. The resolution of this dilemma did not appear until 1918, when Ronald 
Fisher published his seminal paper describing 'polygenic' inheritance. Fisher 
reconciled the two conflicting schools by recognizing that the critical difference lay in 
the genetic basis for the variation in the trait being studied. 
For the traits Mendel studied, the observed variation was due to a simple difference at 
a single gene (or locus). On the other hand, for the traits studied by the biometrical 
school, individual differences were not attributable to different alleles at a single 
locus. Rather, many different genes, each with allelic variations, contributed to the 
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total observed variability in a trait, with no particular gene having a singly large 
effect. Thus, an individual phenotype results from the sum total of the effects of all 
the numerous contributing loci. Furthermore, application of the central limit theorem 
implicates a continuous normal distribution in the population for such a trait, similar 
to what is observed. Thus, the lack of mendelian inheritance patterns for numerous 
human traits did not require the deconstruction of Mendel's theory, but rather an 
extension of it to a more complex scenario that related genes to phenotype. It is clear 
that Mendel's success hinged entirely on his selection of single-gene traits, for 
otherwise the simple rules of inheritance would not have revealed themselves. 
1.2.1 The genetic basis of human traits and disease 
In human populations, the most common medical disorders with a genetic component 
are complex traits, which are traits influenced by multiple genetic and environmental 
factors - including hypertension, coronary artery disease, asthma, schizophrenia. This 
complexity contrasts with the inheritance pattern of monogenic disorders, in which 
the presence or absence of disease alleles usually completely predicts the presence or 
absence of disease (although the severity or age of onset may vary). For genetically 
complex diseases, risk alleles are less deterministic and more probabilistic-the 
presence of a high-risk allele may only mildly increase the chance of disease. 
Furthermore, it has been proposed that these weakly penetrant alleles may be present 
at high frequency (>1%) in the population. 153; 154 
Complex traits are often called quantitative traits to distinguish them from traits that 
appear in discrete categories. Typically each of the multiple genes underlying a 
complex trait has the feature that the mean difference in phenotype between 
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alternative genotypes is relatively small in comparison with the total variance in 
phenotype in the population. 
The normal distribution occupies such a prominent place in the study of complex 
traits because of a statistical theorem called the central limit theorem, which states 
that the summation of many random independent quantities conforms to the normal 
distribution. Since complex phenotypes are determined by multiple genetic and 
environmental factors, a normal distribution is to be expected if the factors are 
independent and their effects additive. This is the fundamental precept of biometrical 
genetics. (Chapter 10 -Appendix - Quantitative Genetics) 
The widespread presence of high frequency variants in humans was first shown 
experimentally by Harris among others, 155156 who found that many proteins have 
several common, heritable isoforms, thereby demonstrating that common genetic 
variation could lead to variation in protein structure. The widespread presence of such 
variation suggested that common variants might be biologically important. 
Unfortunately, tests of this hypothesis were limited to proteins for which common 
functional variation could be easily assayed (primarily a few enzymes and 
determinants of blood group antigens). 
The advent of gene cloning and sequencing substantially lowered this technical 
hurdle. It became possible to easily detect DNA variants in a given gene. The first 
genetic variants tested were usually restriction fragment length polymorphisms 
(RFLPs), but with the development of the polymerase chain reaction (PCR) and other 
improvements in technology, microsatellites, variable number tandem repeats 
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(VNTRs), insertion/deletion polymorphisms, and single nucleotide polymorphisms 
(SNPs) could all be analysed. 
By determining the genotype of these variants in individuals with disease and in 
unaffected controls, these polymorphisms could be tested for association with 
susceptibility to a variety of diseases. The usual conclusion of such studies is that the 
polymorphism being tested either affects risk of disease directly or is a marker for 
some nearby genetic variant that affects risk of disease (Section 1.2.2.2 Population 
Association Studies, page 77). 
These association studies were further facilitated by the increasingly rapid discovery 
of common polymorphisms in genes, accomplished by resequencing the same stretch 
of DNA in multiple individuals. One of the goals of the human genome project has 
been to identify large numbers of SNPs; indeed, the number of SNPs in public 
databases is now well over 1,000,000.157 Association studies have already identified 
over 600 potential associations between common genetic variants and susceptibility to 
common disease. 
So far, we still have a view that primarily reflects the Mendelist-biometricist dialogue 
of nearly a century ago. Most human disorders that have been genetically 
characterized are Mendelian, essentially because the extant molecular tools have 
enabled the identification of these genes by positional cloning, a procedure now 
described as 'routine'. By contrast, those disorders or traits for which such approaches 
have failed are depicted as 'polygenic', multifactorial or 'complex'. Often unwilling to 
-67- 
cede to a notion of 'infinite' genetic complexity, geneticists refer to these cases as 
'oligogenic' or'multigenic', implicating a tractable degree of complexity. 
If the genetic variation that contributes to a trait is due to myriad genes, each of 
modest effect, the task of identifying those individual contributors becomes 
monumental. However, gene effects typically come in different sizes, even when there 
are many of them - at least, this has been the lesson from a lengthy history of model 
systems. There are several measures of gene effects used by geneticists. Many human 
traits, especially disease outcomes, show family recurrence patterns that are strongly 
suggestive of interactions between genes or epistasis, implying the existence of 
multiple, interacting loci. (Appendix - Quantitative Genetics) 
1.2.2 Strategies to determine the genetic component of 
disease 
1.2.2.1 Linkage analysis 
The situation of gene discovery in humans changed markedly two decades ago when 
it was recognized that variations in human DNA could be assayed directly and used as 
genetic markers in linkage studies where a relatively small chromosome region 
containing the gene of interest is identified through the analysis of co-segregation of 
genetic markers with disease in families. 158 Before this time, human geneticists 
performing linkage studies to identify the chromosomal location of disease genes 
relied on only a handful of blood group and serum protein markers with few 
successes. The identification of restriction-fragment length polymorphism (RLFP) 
markers158 and subsequently abundant highly polymorphic microsatellite (short 
tandemly repetitive DNA) loci159°16° has led to the mapping of myriad mendelian 
disease loci. Development of more efficient molecular tools, especially high- 
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throughput DNA sequencing, has enabled the identification of disease loci and their 
mutations by a process characterized as positional cloning. Naturally occurring 
mutations are identified on the basis of their chromosomal location by taking 
advantage of the meiotic process of recombination as manifest in families segregating 
for the disease. Markers closest to the disease gene show the strongest correlation 
with disease patterns in families, and typically the tracking of recombination events 
can narrow the region harbouring a disease gene to between 100 and several thousand 
kilobases. 
The remarkable success of positional cloning rests not simply on the advances 
observed in molecular technology. It also reflects the enormous power of linkage 
analysis when applied to mendelian phenotypes - that is, those characterized by a 
(near) one-to-one correspondence between genotypes at a single locus and the 
observed phenotype. In terms of biometrical genetics, these are loci with very high 
displacement (Section 10.1.1 Displacement). The observed phenotype corresponds 
precisely to the underlying genotype with little if any misclassification. The 
robustness of linkage analysis applied to mendelian traits can be seen by its historic 
low false-positive rate161 when the stringent lod-score threshold of 3 suggested by 
Morton162 is used (corresponding to aP value of 10-3 for a sequential test or 10-4 for a 
fixed sample-size test163) 
For common multifactorial disorders, linkage studies are also undertaken, often in 
nuclear families and sometimes with the inclusion of additional close relatives such as 
aunts, uncles or cousins. Such families are relatively easy to collect, and they 
minimise the genetic heterogeneity that might be caused from multiple entries of 
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susceptibility alleles in more extended pedigrees. Conceptually, the simplest situation 
arises when studying pairs of affected siblings. The methodology for analysing 
affected sib-pair data is well established and has been used extensively first starting in 
the 1970s to investigate linkage between autoimmune disease and HLA antigen. 164-166 
1.2.2.1.1 Affected sib pair analysis 
In contrast to traditional lod score analysis, which assumes a genetic model for 
familial resemblance of a trait, the affected sib-pair method is `non-parametric' in that 
no explicit assumptions are made about the mode of inheritance. Rather than assaying 
for recombination events between disease and marker, the tests of linkage are based 
on whether affected sib pairs share more than the expected number of marker alleles 
identical-by-descent (IBD) - two alleles are IBD if they are inherited from the same 
ancestor. The observed IBD distribution is compared to the expectation under 
independent segregation of the marker and trait. For independent segregation, each 
parental allele is transmitted with equal probability, and siblings inherit the same 
marker alleles 50% of the time independent of affection status. When the data consists 
of independent affected sib pairs (i. e. each from a different family) with complete 
information on marker inheritance, the test for linkage can be made by a simple chi 
square test comparing observed and expected IBD. In practice, a wide variety of 
approaches has been proposed for affected sib pair tests of linkage. 167 These utilise 
different methods for taking into account multiple affected siblings within a family, 
incomplete IBD information, different assumptions about the probabilities of IBD 
sharing in the presence of linkage, and different statistics for evaluating linkage. 
Overall one of the best performances for type I and II statistical error is obtained by 
analysing affected sib pair families as if they were segregating for a rare recessive 
disease with complete penetrance, while treating unaffected siblings and parents as 
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having unknown disease phenotype, irrespective of true disease status. In this 
approach, the test statistic is simply the maximum logarithm of odds ratio (lod) score 
(MLS) found by estimating a recombination rate between the marker and the `disease' 
locus (also called a `pseudomarker'). 168 However, here the recombination rate has no 
biological significance; it is simply a parameter that adjusts the IBD probabilities for 
affected siblings. Aside from its robust behaviour, the pseudo-markers approach can 
be implemented easily in many of the existing programs for classical linkage analysis. 
Also for this approach, there is no need to decide about weights for sibships with 
different numbers of affected offspring, as this is accounted for in the linkage 
analysis. 
Whatever method is applied, the evidence for linkage is most often assessed by the 
MLS statistic, which is analogous to a classical lod score in that its value is the loglo 
of the odds in favour of linkage. Traditionally, a MLS of 3.0 (odds of 1000: 1) in 
favour of linkage has been assumed at the threshold for declaring significant linkage 
for monogenetic disorders, in part because this corresponds to a genome-wide 
significance level, taking into account the testing of multiple markers throughout the 
whole genome, of about p=0.05.169 For complex diseases, it has become standard 
practice to designate regions of potential linkages with less stringent criteria of 
significance. The idea is that if one is carrying out a genome-wide search, then it is 
appropriate to use a lower threshold (a MLS of -2.0) to indicate which areas of the 
genome should be investigated more thoroughly by typing more markers in the area 
and/or adding more sib pairs to the original study, or attempting replication in a 
different study. 170 
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A number of practical issues arise when undertaking affected sib-pair analysis. First, 
it is very important to genotype parents or unaffected siblings if possible. If parental 
genotypes are completely or partially absent, marker allele frequencies may have a 
profound effect on the test statistic; for example, as the IBD probability for related 
individuals that share a single rare allele is high, erroneously assuming that all marker 
alleles are equally frequent will generally inflate the test statistic in favour of linkage, 
if one or more of the alleles is more common in the general population. Therefore, 
marker frequencies should be estimated either from the data or from a matched 
control population prior to linkage analysis. A second common issue in applying is 
the verification of putative relationships prior to linkage analysis. In general, any 
undetected nonpaternity or other pedigree errors reduces the power to detect linkage. 
There is a high chance of errors being detected if parents or three or more siblings 
have been genotyped. However, for sib pairs, an erroneous relationship cannot be 
detected with certainty, unless genotypes on parents or other relatives are available, 
and a statistical framework must be applied to the total marker data in order to 
evaluate if the relationship is correct or if the putative siblings are half sibs or 
unrelated. 
It is common practice to apply multilocus and single locus techniques for affected sib 
pair linkage analysis. Multilocus analysis overcomes to some extent lack of complete 
knowledge on IBD when parental genotypes are unknown, or when individual 
markers are not fully informative. Because multilocus methods are sensitive to 
genotype errors, and different methods have varying power to detect linkage, it is 
desirable to apply both single marker locus and multiple marker locus to all data 
sets. 
171-174 
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1.2.2.1.2 Linkage Disequilibrium in Linkage studies 
When marker and disease loci are very close together on a chromosome, genetic 
crossing over will have occurred at such a low rate that the marker will appear to 
cosegregate with the gene regardless of the family studied. This is in contrast to the 
situation of two loci further apart but still linked, in which case repeated crossing over 
will allow all possible combinations of chromosomal haplotypes to appear with 
frequencies as predicted by the Hardy-Weinberg equilibrium. Thus linkage 
disequilibrium can be very useful in defining the ancestral haplotype of a disease gene 
in relation to several marker loci; it can be used for fine-mapping of the disease gene 
even when complete linkage is established in families being studied. 
There are many measures of linkage disequilibrium. The most commonly used is the 
disequilibrium coefficient D. 
D=PI1 -Pigi 
Where P11 is the observed frequency of the 1/1 haplotype, pl is the frequency of the 1 
allele at locus 1 in the general population and ql is the population frequency of the 1 
allele at locus 2. Generally the 1 allele at each locus is defined as the most common of 
the alleles at that locus. Because 1 is assigned as the most common allele, the 
coefficient D ranges from -0.25 to 0.25. Positive values of D indicate that the 
common alleles at each locus segregate together. Negative values indicate that the 
common allele at one locus segregates with the rare allele at the other locus. The rate 
of decay of linkage disequilibrium is dependent on the distance between loci: 
D1= Do(1-9)` 
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Where t is the current generation number, Dt is the current amount of disequilibrium , 
Do is the disequilibrium at generation 0, and 0 is the recombination fraction between 
loci. 
Allelic association due to population admixture, selection or genetic drift between 
unlinked loci will decay fairly rapidly in comparison to linkage disequilibrium 
between tightly linked genetic loci and thus is a short-term phenomenon that will be 
almost impossible to detect in a typical study. However linkage disequilibrium will 
decay rather slowly, dependent primarily on the recombination distance between 
markers and the number of generations that has passed since the initial event. The 
slowness of linkage disequilibrium decay makes this a useful mapping tool. 
The general rule of the thumb is that the stronger the disequilibrium, the closer the 
marker is to the disease locus. This is not always the case however, for several 
reasons. First the frequencies of the marker alleles have an impact on the power to 
detect linkage disequilibrium. Mutation rates at the marker locus also affect 
disequilibrium by increasing the chance that the associated marker allele will change 
and so seem to be representing a different chromosome. 
Population bottlenecks, where the effective population size reduced to a very small 
number for a period of time before the population size increases again, can create or 
reinforce an existing association. This is done by the random loss to the genome pool 
of most chromosomes carrying the susceptibility allele; what remains may only 
existed in only one individual who survived the bottleneck. Chance loss of 
susceptibility-allele-bearing chromosome (random genetic drift) can also generate 
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linkage disequilibrium. Two phenomena that can complicate the analysis of allelic 
association are selection in favour of a particular phenotype and new mutations 
arising in the population. 
1.2.2.1.3 Non-Mendelian Inheritance 
As noted above, linkage analysis and positional cloning have had a remarkable track 
record in leading to the identification of the genes for many mendelian diseases, all 
within the time span of the past two decades. Several of these genes account for an 
uncommon subset of generally more common disorders such as breast cancer (BRCA- 
1 and -2), colon cancer (familial adenomatous polyposis (FAP) and hereditary non- 
polyposis colorectal cancer (HNPCC)), Alzheimer's disease (ß-amyloid precursor 
protein (APP) and presenilin-1 and -2) and diabetes (maturity-onset diabetes of youth 
(MODY)-1, -2 and -3). These successes have generated a strong sense of optimism in 
the genetics community that the same approach holds great promise for identifying 
genes for a range of common, familial disorders, including those without clear 
mendelian inheritance patterns. But so far the promise has largely been unfulfilled, as 
numerous such diseases have proven refractive to positional cloning. 
So far, all genes first identified by linkage analysis and subsequently positionally 
cloned are those with low allele frequency and high displacement (mendelian or near 
mendelian inheritance) i. e. with large effect and strong genotype-phenotype 
correlations. By contrast, no genes with moderate or modest displacement, even for 
rare disorders, have been identified in this way. The literature is now replete with 
linkage screens for an array of 'complex' disorders such as schizophrenia, manic- 
depression, autism, asthma, type 1 and type 2 diabetes, multiple sclerosis and lupus, to 
name but a few. Although many of these studies have reported significant linkage 
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findings, none has led to convincing replication. Typically, independent studies of the 
same disorder identify maximal evidence at different chromosomal locations. In 
effect, linkage analysis, traditionally the most reliable of genetic methods when 
applied to mendelian traits, has proven to be much less reliable a tool for the study of 
non-mendelian diseases, with a disappointingly high false-positive rate. The likely 
explanation is that the biometrical view is closer to reality than the mendelian view 
for most human traits and diseases. 
This does not necessarily mean that no genes underlying non-mendelian traits can be 
located by linkage analysis. There are several examples of common alleles that have 
sufficiently large displacement to have been detected by linkage analysis. One 
example is the role of HLA in type 1 diabetes, where allele sharing by affected sib 
pairs (ASPs) has been estimated at about 73%. 175 A second example is the role of 
apolipoprotein E (ApoE) in late-onset Alzheimer's disease, where the ASP allele 
sharing is estimated at about 60%. Other examples probably exist but have yet to be 
identified, although the number is likely to be few. Increasing sample sizes may 
ultimately improve the odds, but there is clearly a limit. In addition, studying more 
extreme (and less frequent) phenotypes is helpful provided such cases are also 
genetically more extreme. However, gene effects with displacements of less than 1 
standard deviation (s. d. ), which are likely to represent most effects, will rarely be 
identified this way. 
Another question relates to whether larger families with many affected individuals 
would provide better power than smaller families, such as sib pairs. The answer 
depends on the frequency of the susceptibility allele. For high-frequency alleles, 
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selection of dense families is likely to increase parental homozygosity at the 
disease 
locus and reduce linkage evidence. On the other hand, for rare alleles with large 
displacement, dense families are usually optimal, because the probability for such a 
family to be segregating the allele is increased, enhancing the linkage evidence. 
However, if genome screens of extended pedigrees have been conducted without 
success, it is reasonable to conclude that rare genes of large effect are unlikely to exist 
for the trait studied. 
1.2.2.2 Population Association Studies 
An alternative to linkage and allele-sharing methods is association-based analysis. 
Rather than relying on cosegregation of a susceptibility gene and linked markers 
within families, association studies looks for significantly increased or decreased 
frequency of a marker allele with a disease trait and represents deviations from the 
random occurrence of the alleles with respect to disease phenotype. Allelic 
association can be due to either direct influence of a DNA variant on phenotype, or 
from linkage disequilibrium creating combinations of alleles that occur more 
frequently than would be expected under random association. That is, such studies 
seek to detect linkage disequilibrium due to linkage between a marker locus and a 
locus bearing a disease-causing mutation. Until recently, association studies have 
generally been candidate gene studies. This involves the testing of populations or 
groups to determine whether a specific allele occurs more frequently in individuals 
with a disease than in those without a disease. Although these associations must be 
interpreted with caution, they raise the possibility of a cause/effect relationship 
between the associated alleles or closely linked loci and the disease. Association 
studies can play a critical role in the analysis of genetically complex traits, in the 
evaluation candidate gene loci as well as in the fine-mapping of a region once linkage 
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studies have indicated a region of interest in the follow-up analysis. The advent of 
technologies that allow rapid discovery of genetic variants, such as SNPs, has greatly 
expanded the potential for such investigations. Considerable attention has focussed 
recently on the scope and feasibility for both genome-wide association and linkage 
studies using SNPs as a source of markers. 176 
Conceptually, linkage disequilibrium is the same as the standard linkage analysis, 
except that the recombination distances being measured now are very small (generally 
< 1cM), and the recombination events can only be inferred based on the level of 
sharing of the same allele. Although it is easy to find situations in which association 
will have greater power than linkage to detect susceptibility loci (for example, when 
the susceptibility is due to a frequent allelic variant that is assayed directly), in 
practice the relative power depends on assumptions, such as the number of 
susceptibility variants at a locus, the magnitude of their linkage disequilibrium with 
other markers, and the comparative frequencies of the marker and the susceptibility 
variants. Population substructure most often occurs with the recent admixture of 
populations. In the case of population substructure, alleles may show a statistical 
association simply by chance due to differences in allele frequencies in the two 
missing populations. This can occur even when there is no biological association or 
true genetic linkage. It is more realistic to think of linkage and association as 
complementary approaches; indeed, association studies are often attempted as an 
approach to isolate a susceptibility gene in a region that has been identified by 
linkage. 
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Association studies are typically conducted using the candidate gene approach. Given 
the multitude of factors that are involved in the regulation of blood pressure, a 
seemingly unlimited supply of candidate genes for hypertension can be imagined. 
When conducting association studies, one must be careful that the subjects with the 
disease of interest and the control subjects are closely matched with respect to ethnic, 
geographic and social backgrounds. If not, one might observe differences in allele 
frequencies between the two groups that have no causal relationships to the disease 
state. 
1.2.2.2.1 Case-control studies 
The approach often used for such studies is the case-control design, in which a 
difference in allele frequency is sought between affected individuals and unrelated 
unaffected controls. This design does not require the ascertainment of family units 
and hence has appeal due to the relative ease of implementation. 
The control populations should be matched with respect to ethnicity as well as other 
factors such as age. Spurious associations can result because of population 
stratification (the existence of multiple population subtypes in what is assumed to be a 
relatively homogeneous population). Such stratification can represent either recent 
admixture or the incorrect matching of cases and controls. The existence of these 
confounding factors can lead to a significant result even in unlinked loci or 
unassociated loci within stratum. 
From an epidemiological perspective, a major limitation in this approach is the 
potential for confounding (that is, spurious association resulting from correlation with 
the true risk factor) leading to artefactual as opposed to causal associations. In this 
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case, the most likely source of confounding is ethnicity, whereby allele frequencies 
vary by ethnicity and cases and controls are not adequately matched in terms of 
ethnicity. Although most investigators would at least attempt coarse matching by 
major demographic groupings (such as race), substratification within racial groups 
can still lead to bias. This drawback of traditional case-control designs was 
recognized early on by Lionel Penrose, who recommended the use of unaffected sibs 
as controls. This paradigm, originally applied to ABO and duodenal ulcer 17, has seen 
a resurgence in the past few years . 
178-18' The disadvantage of this design is that sib 
controls are over-matched to the index cases, leading to a loss of power compared 
with a well-designed study involving unrelated controls. 179 
This problem can be addressed by using `family based controls' as popularised by the 
transmission disequilibrium test (TDT). 182 
1.2.2.2.2 Family based association study 
Family based studies control for the possibility of genetic differences between the 
case and control populations by comparing the frequencies of alleles transmitted to 
the affected child to the alleles not transmitted. The only samples needed are those 
from the affected individual and his or her two parents (the TDT triad). This approach 
eliminates the concern that population substructure may be the cause of the 
association. These studies include the transmission disequilibrium test (TDT), the 
haplotype relative risk test (HRR) and the affected family based control method 
(AFBAC). The TDT approach tests for linkage in the presence of association. The 
AFBAC method is designed to detect association in the presence of linkage. Both 
AFBAC and TDT have little power unless linkage and association coexist. The 
difference between these two methods is that the TDT can also function as a test of 
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association in the presence of population admixture and can be used as a valid test of 
linkage. 
1.2.2.2.2.1 Transmission Disequilibrium Test (TDT) 
This test is based on the premise that a parent who is heterozygous with one 
associated allele and one non-associated allele at the locus under study will transmit 
the associated allele to the affected offspring more often than expected by chance. The 
TDT in effect uses the nontransmitted allele as controls, which are well matched for 
the ancestry of the parent. Stratification is reduced or eliminated as a single individual 
(the parent) contributes both the control and the disease alleles for this observation. 
Transmission Disequilibrium Test (TDT) 182 tests for evidence of both linkage and 
association (linkage disequilibrium) in triplets of father-mother-affected child - the 
TDT triad. Here linkage disequilibrium is defined as an increase in frequency of a 
particular disease-marker haplotype over that expected based on Hardy-Weinberg 
equilibrium, and it requires both linkage of the disease and marker loci and 
association between one or more alleles at the locus and the disease allele. This 
frequency is compared with the Mendelian expectation of 50: 50 transmission of the 
allele. More specifically strong evidence for linkage is detected by examining only the 
meiosis in heterozygous parents, for which affected offspring exhibited IBD 
significantly greater than the expectation of 0.5 under the absence of linkage. The 
disadvantage of this test is that TDT has no power to detect linkage if association is 
not present. When considering only parent-offspring trios, TDT is similar to 
Haplotype Relative Risk (HRR). However when applied to affected siblings, TDT 
provides a test of linkage, not of association. TDT (like other family-based methods) 
is immune to false-positives from ethnic admixture. 182 
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Disadvantages of the TDT are that it is less efficient than a standard case-control 
study - the primary concerns being power and efficiency. 
183 Family-based samples 
are often difficult to collect and that 50% more genotyping is required than in case- 
control studies to achieve similar power (the exact loss of power depends on the 
underlying genetic model). For instance, when parent-child pairs are used for TDT, 
each informative parent-child pair provides two observed alleles (one transmitted and 
one non-transmitted), while in a case-control study, each fully informative case 
control pair provides four alleles for observation. One strategy to balance the concerns 
of efficiency and potential admixture is to use multiplex sibships and include normal 
sibs within a TDT study. 183 However, this strategy brings the additional concern that 
`normal' sibs may not be through the risk period are subject to censoring. 
1.2.2.2.2.2 Likelihood ratio 
In general, it would be desirable to provide an integrated approach to model free 
analysis that would allow simultaneous evaluation of linkage and association while 
incorporating data from different types of study designs such as affected sib pairs, 
parent-offspring and case-control cohorts. Such an approach involves an extension of 
the pseudomarker linkage test described for the affected sib-pair test. 171-174 The 
linkage component can be evaluated by calculating a lod score for a disease locus 
with two alleles, although the test itself is not model dependent. Association is 
incorporated by allowing for linkage disequilibrium between the marker and the 
alleles (denoted D and d) at the putative disease locus. For a marker locus with n 
alleles, under the hypothesis of association and linkage (H2), the likelihood is 
maximised over the recombination rate, the frequencies of n-1 haplotypes associated 
with D and the frequencies of n-1 haplotypes associated with d (2n-1 parameters). For 
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the hypothesis of linkage without association (HI), the likelihood is maximised over 
the recombination rate and the marker allele frequencies, assuming linkage 
equilibrium with D and d which have fixed allele frequencies (a total of n 
parameters). Finally, under the hypothesis of absence of linkage (Ho), the likelihood is 
maximised over the marker allele frequencies only, with recombination fixed at 0.5 
(n-1 parameters). 
The likelihood ratio statistics to test for linkage and association are -2ln(L1/Lo) and - 
21n(L2ILl) respectively, where Li is the likelihood under the ith hypothesis. The 
significance of these test statistics can be judged by comparison to chi-square 
distributions with n-1 and 1 degrees of freedom respectively. 
1.2.2.2.3 Problems with association studies 
Conventional case-control gene-association studies have a long track record of false- 
positive results. The high false-positive rate has often been attributed to confounding 
ethnic admixture resulting in population stratification, variable linkage disequilibrium 
between the polymorphism being studied and the true causal variant, and population- 
specific gene-gene or gene-environment interactions. 184'185 It is more likely that the 
high false-positive rate may result from a low prior probability that the few gene 
polymorphisms examined are in fact causally related to the disease outcomes studied. 
One possibility for the irreproducibility that characterizes the vast majority of 
association studies is that the original observations represent statistical fluctuations 
(type I error). If this were the case, one would predict that only 5% of subsequent 
studies would also reach statistical significance with P<0.05, and most associations 
would never be observed again. However Hirschborn et al186 found in 166 
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associations at least 97 were observed again, many of them multiple times. Thus in 
the absence of a massive publication bias, statistical fluctuation is unlikely to explain 
all of the initial positive reports. 
Another concern is that association studies may be unable to detect disease genes is 
multiple disease-causing mutations, which arose independently on different haplotype 
backgrounds, are represented in the sample under study. Studying association in 
young genetically isolated populations is a strategy to address this. For such 
populations, linkage disequilibrium is expected to extend over greater distances, and 
there are likely to be fewer distinct disease-causing alleles present, than in older, 
outbred populations. 
1.2.2.2.3.1 Population stratification 
This occurs when the cases and controls are unintentionally drawn from two or more 
ethnic groups or subgroups. If one of these subgroups has higher disease prevalence 
than the others, stratification occurs, because that subgroup will be over represented in 
the cases and underrepresented in the controls. Any polymorphism that genetically 
marks the high-risk subgroup (i. e., is found by chance at a higher frequency in that 
subgroup), therefore, will appear to be associated with and will likely be a false 
positive. Interestingly, the frequencies of several of the alleles vary substantially 
between populations, consistent with the possibility of false associations due to ethnic 
admixture. It should be noted that well-defined subgroups are not necessary to 
observe stratification; stratification can also occur in a single admixed population 
where the individuals have varying degrees of genetic contributions from two or more 
ethnic groups. Even apparently homogeneous, isolated populations (such as Iceland) 
are in theory susceptible to admixture if there have been multiple distinct waves of 
I 
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migration from different source populations (e. g., Celtic and Norse, in the case of 
Iceland). 
A few approaches can be used to avoid this problem. First, one can use family-based 
studies such as the transmission disequilibrium test (TDT). 182 Another possibility is to 
study multiple case-control populations, each from different ethnic groups, and 
require that an association be seen in each population. Another approach is by 
Haplotype Relative Risk (HRR), where a comparison is made between alleles that 
were or were not transmitted to affected offspring from their parents. HRR ensures 
that the control and case population are well-matched. 187 Finally, an approach to 
detect and correct for stratification has been proposed: by typing several dozen 
random markers, one can empirically determine the degree of stratification in a case 
control study. 188-190 If significant stratification is detected, one can use these markers 
to more carefully match cases and controls to remove the effects of stratification. 190 
There is some debate as to whether stratification is a significant problem; some 
authors believe that even minimal ethnic matching of cases and controls is adequate to 
prevent stratification. 183 However, there are as yet no empirical data that address the 
degree of stratification found in a typical association study. 
1.2.2.2.3.2 Linkage disequilibrium 
Failure of replication can also occur if the polymorphism being tested is not itself the 
causal variant but is rather in linkage disequilibrium with the causal variant. Linkage 
disequilibrium, in which nearby variants are correlated with each other more often 
than expected by chance, depends heavily on population history and on the genetic 
make-up of the founders of that population. If all examples of a particular stretch of 
DNA in a population derive from a recent common ancestor, there will have been few 
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opportunities for recombination events to separate variants within that stretch of DNA 
and the variants will often be inherited together throughout the population. If, in a 
different population, the time since a common ancestor is longer, more recombination 
events will have occurred, disrupting linkage disequilibrium in the region. 
Furthermore, the particular arrangement of variants in the founders of a population 
will determine which variants are inherited together. Thus, it is possible that a 
polymorphism will be in linkage disequilibrium with a nearby disease allele in one 
population but not in another, leading to variable results of association studies. For 
example, many of the associations with TNF associations with nearby HLA loci 
(HLA is a region with strong linkage disequilibrium over large distances). 186 To 
explore this possibility, positive associations should be followed up by testing 
adjacent markers (both individually and as multi-marker haplotypes). If linkage 
disequilibrium is present (and particularly if any of the haplotypes or adjacent markers 
show stronger association), the possibility exists that the original marker tested is not 
the causal allele, and further studies of the region are warranted. Although it should be 
possible to exhaustively test modest sized regions of linkage disequilibrium, special 
circumstances (e. g., recently admixed populations) may in theory give rise to 
correlation between markers at much greater distances. 
1.2.2.2.3.3 Gene-gene and gene-environment interactions 
Another potential source of variable findings is gene-gene or gene-environment 
interactions that differ between populations. For example, if the effect of a variant 
were only manifest in populations with a particular genetic or environmental 
background, then association would only be seen in populations or subgroups with the 
appropriate genetic or environmental characteristics. This explanation is commonly 
invoked to explain differing results of association studies but is less frequently 
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supported by direct evidence. A further problem arises when considering gene-gene or 
gene-environment interactions: when combinations of alleles and/or environmental 
factors are studied, P values are rarely corrected for the number of tests reported 
(much less the number of tests actually performed). Such "nominally" significant 
results must be considered to be the product of hypothesis generation rather than 
hypothesis testing and, therefore, require replication. Perhaps the best possible 
method of demonstrating that a gene-environment interaction is likely to be correct 
(and not a statistical fluctuation expected when exploring numerous hypotheses) is to 
divide the study population randomly into two parts and require that any findings be 
observed in both parts of the study. Sample sizes need to be increased slightly to 
maintain power, but the ability to generate and then test hypotheses in the same 
sample would seem to outweigh this consideration. Otherwise, one requires a 
replication population that is exactly matched for environmental and genetic 
background, an extremely unlikely scenario. 186 
1.2.2.2.3.4 Weak genetic effects and lack of power 
Finally, associations can be real but nonetheless not reproducible if the underlying 
genetic effect is weak. If the subsequent studies are small in size, they will be 
underpowered to reliably detect weak effects and, therefore, fail to achieve statistical 
significance. This difficulty is heightened by the "jackpot" effect, in which the first 
group to publish a significant association involving a weak locus is more likely to 
have overestimated than underestimated the true effect of the polymorphism. This 
phenomenon occurs because each study imprecisely estimates the strength of the 
effect (due to sampling variation). Because a weak effect would in most cases not 
provide a statistically significant finding in a typically sized study (a few hundred 
cases and controls), the first published study that does manage to achieve statistical 
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significance is almost certain to have overestimated the true effect of the variant being 
tested. Subsequent studies thus need to include much larger numbers of patients to 
achieve statistical significance. In particular, failure to observe the magnitude of 
effect seen in the first study should not be taken as a repudiation of the association. 
This phenomenon is observed for the association of type 2 diabetes and a Prol2Ala 
polymorphism in the PPARy gene, where an initial study estimated the effect on 
diabetes risk to be threefold, 191 but subsequent studies observed very modest risks that 
usually did not achieve statistical significance. 
192'193 Indeed, all of the previous 
studies, both positive and negative, were consistent with a 1.25-fold effect, and two 
194; i9s 
subsequent large studies confirmed this association. Because many alleles may 
have similarly weak genetic effects, large studies and/or meta-analyses of multiple 
studies will often be required to determine whether genetic associations between 
polymorphisms and disease are significant. 
Lohmueller et al. 196 propose three general recommendations. First, in light of the 
seemingly high proportion of false positive reports in the literature, more stringent 
criteria for interpreting association studies are needed. A single, nominally significant 
association should be viewed as tentative until it has been independently replicated at 
least once and preferably twice. A review of 25 associations 196 suggests that two 
studies with P<0.01 or a single study (other than the first positive) with P<0.001 is 
strongly predictive of future replication. 
Second, large studies should be encouraged, with collaborative efforts probably 
required to achieve the sample size of many thousands of case-control pairs that is 
necessary for definitive studies of common variants with modest genetic effects. Even 
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larger samples will be required to detect gene-gene or gene-environment interactions 
or associations specific to defined subgroups or to correct for testing association to 
multiple phenotypes. To help increase the effective sample size, reports of association 
would ideally include a meta-analysis of all available published data to give a more 
robust estimate of the genetic effect. To facilitate such meta-analyses and minimize 
publication bias, all disease association studies that meet minimal quality standards 
should be published. Such standards could include explicit phenotype definitions, 
complete listing of all phenotypes analysed, precise localization of the 
polymorphism(s), low genotyping error rate, analysis that avoids overlap with 
previous studies and availability of genotype counts for cases and controls (or 
equivalent data for family-based studies). Publication of non-significant results could 
be encouraged using forums such as a common association study database or brief 
reports' and 'negative results' sections of specialty journals, with sufficient credit to 
provide incentives for publication. 
Finally, it seems likely that a fraction (perhaps a quarter) of previously published 
associations represent real associations with common disease. Thus, using large 
samples to test all previously reported associations, perhaps focusing initially on those 
associations that have already been replicated at least once, would probably identify a 
significant number of variants that affect the risk of common disease. 196 
1.2.3 Quantitative traits versus Qualitative traits 
Quantitative traits have several advantages in genetic studies compared to a simple 
classification based on the presence or absence of disease. (Appendix - Quantitative 
Genetics) Many diseases can be defined in terms of an underlying quantitative 
liability scale, such as blood pressure for hypertension. Such traits provide a measure 
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of disease severity, but can also be studied in unaffected family members or in 
individuals with extreme values of the phenotype, but who are not clinically 
diagnosed with the disease. For example, young adults who have extreme blood 
pressure for their age and sex may be useful in linkage analysis even if they may not 
yet have been diagnosed with hypertension. Another advantage is that a specific 
quantitative trait may be influenced by a small number of factors, whereas a disease 
classification often represents a genetically and environmentally more heterogeneous 
phenotype. In these instances, the quantitative variable will be correlated more 
strongly with polymorphisms of an underlying gene, and therefore provide a better 
phenotype both for initial mapping purposes, but also for identifying the causative 
susceptibility variants at a locus. 
A sampling strategy using discordant sib-pairs in the opposite extremes of the 
distribution of a quantitative trait can in theory reduce dramatically the number of 
sibling pairs of families that need to be genotyped in order to obtain significant 
evidence of linkage. 197 Direct linkage analysis of the quantitative variable is an 
alternative to its transformation into a qualitative phenotype. Selection of families in 
which some individuals are towards the extremes of the quantitative distribution is 
still necessary to achieve power. For unselected families, the number of families 
necessary to detect even loci accounting for a high proportion trait variance, say 10- 
20% is several thousand. 198 
Several methods have been developed that involve variance component analysis 
without incorporating a parametric model for the hypothesised major gene. 199; 200 
Essentially these methods involve first obtaining estimates of IBD statistics for 
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relative pairs, and then estimating correlations between relatives that are a function of 
IBD. Although this requires no hypothesis about the number of alleles at the major 
gene locus, the estimates and test statistics are usually obtained under the assumption 
of a multivariate normal distribution of the trait within families. Care is needed as 
multivariate normality can be violated by a number of factors in particular by 
ascertainment on the trait locus. 
A popular model-free framework for sib-pair linkage analysis of quantitative traits is 
based on the Haseman-Elston approach. 201 This consists of regression of the square of 
the trait difference on the IBD at the marker locus for sibling pairs; the slope of the 
regression line is expected to be zero in the absence of linkage, whereas it will be 
negative in the presence of linkage (because siblings are then more similar in 
phenotype when they have inherited the same alleles from their parents. A 
nonparametric approach based on the relationship between IBD and the ranks of sib 
phenotype differences, rather than the squared difference has been described by 
Kruglyak and Lander. 202 
A related area that has stimulated extensive methodological investigations recently is 
linkage disequilibrium mapping with quantitative trait loci. This includes methods 
that examine the direct relationships between haplotypes or genotype combinations 
with phenotypes assuming complete identification of the causative variants, 203 and 
TDT extended to quantitative traits. 204 Techniques are also available that take into 
account simultaneously linkage and partial linkage disequilibrium with 
polymorphisms of a gene in either parametric205 or variance components 
approaches. 206; 2°7 The variance component method of Fulker et al and Abecasis et 
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al 206'07 provides a means of controlling for population stratification that may give 
rise to apparent association independently of linkage. This is done by partitioning the 
mean effect for the test locus into two term - one is a nuisance parameter that absorbs 
the effects of population stratification, while the other depends only on the linkage 
disequilibrium at the test locus. The variance partition includes a component that 
enters into the between-relative covariance as a function of IBD at the test locus; this 
component of variance is nonzero if the linkage disequilibrium between the causative 
gene variants and the markers that have been tested is incomplete. 
1.2.3.1 Association based genome wide studies - use of SNPs 
An alternative to genome wide linkage studies and candidate gene studies is the use of 
genomewide association (linkage disequilibrium) studies. The suggestion of genome- 
wide searches for gene effects using large-scale testing of single nucleotide 
polymorphisms (SNPs), or perhaps more appropriately simple nucleotide 
polymorphisms (which could include short deletions and insertions and 
multinucleotide changes as well as single nucleotide substitutions), has led to 
considerable discussion of the efficiency of different approaches. 
SNPs have several advantageous properties as DNA markers. They are abundant in 
the genome: On average, any two copies of a chromosome are expected to differ in 
approximately one nucleotide position every 1000 bases. SNP markers are biallelic 
with a maximum heterozygosity of 50%; hence it is expected that a genome scanning 
set of SNP markers must be denser to be as informative as the highly polymorphic 
microsatellite marker sets currently in use. Kruglyak performed simulations and 
showed that a map of 700-900 moderately polymorphic biallelic markers is equivalent 
to typical 300-400 microsatellite marker maps. 208 
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The original suggestion of Risch and Merikangas209 was to study coding or promoter 
variants with potential functional significance. Collins et al. 210 subsequently suggested 
that non-coding or evenly spaced SNPs with high density could be used to track 
disease loci through linkage disequilibrium. The number of SNPs required for the 
latter strategy has been the subject of debate, primarily because the extent of linkage 
disequilibrium in the human genome has not been well studied on a large scale. As 
opposed to recombination -a biological phenomenon already measured extensively 
in humans - linkage disequilibrium is a property of populations, and thus depends 
heavily on their demographic and social histories. Population isolates such as Finns, 
Ashkenazi Jews and Mennonites have been shown to demonstrate extensive linkage 
disequilibrium (up to several percent recombination) around rare disease mutations. 
The degree to which the same will be true for higher-frequency variants is uncertain, 
although as a general rule the disequilibrium is likely to decline with increasing allele 
frequency owing to an older coalescence time. 
An additional question is whether SNP markers are sufficiently dense in the genome 
to serve as maps for linkage disequilibrium (LD) and association mapping. Simulation 
studies211 to estimate the extent of LD surrounding common gene variants in the 
general human population on in population isolates have shown that on average, a 
useful level of LD is unlikely to extend beyond an average distance of roughly 3kb in 
the general population. This implies that as many as 500,000 evenly spaced SNPs 
may be required to detect linkage disequilibrium of sufficient magnitude for mapping 
purposes, 211 even in population isolates, whereas others have argued that founder 
populations, especially those that have remained small over an extended time period, 
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such as the Saami of Scandinavia212 or isolated Sardinian populations, 
213 would 
require far fewer SNPs. Although such populations should improve the chances for 
detecting rare disease alleles (say less than 5% in frequency), owing to greater linkage 
disequilibrium per base pair, the same is unlikely to be the case for common alleles 
(greater than 5% in frequency). 214 Furthermore, the power of association tests 
diminishes significantly with decrease in linkage disequilibrium, and as a result of 
discordance between the frequencies of disease and marker alleles. 179'215 Although 
increasing marker density greatly enhances the chance of including a marker in strong 
linkage disequilibrium with the disease allele, the same is not true for similarity of 
allele frequencies because correlations between SNP allele frequencies do not 
increase inversely with distance between SNPs. 216 Another complication is that, in 
contrast to linkage analysis, a negative linkage-disequilibrium result in a particular 
genomic region does not exclude a significant gene effect in that region. It may be 
that the SNPs used there are in modest or no disequilibrium with the disease allele, 
and/or the allele frequencies are divergent. Thus, it seems that in a genome-wide 
random SNP approach, even at high density, many disease-causing genes would be 
missed. 
Several arguments favour using SNPs in coding and promoter regions rather than 
random SNPs. First, it is these variants, a priori, that are most likely to be of 
functional significance and to influence directly the traits under study. In fact, these 
are the variants to which random SNP searches are likely to lead. Second, even if not 
the causative variant in a gene, such SNPs are as likely (or more likely) to be in 
linkage disequilibrium with the causative allele as are randomly placed SNPs. 
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1.2.4 Multiple hypothesis testing 
As the number of SNPs evaluated in association testing increases, a concern arises 
with false positives. This is true for candidate gene studies, but more so for whole 
genome random SNP studies where tens to thousands of SNPs will be evaluated. The 
traditional cut-off for assessing statistical significance (p<0.05) by definition can 
result in 5% false associations occurring simply by chance. The difficulty becomes 
distinguishing the true associations from these false associations. To account for the 
multiple hypothesis testing that occurs when many SNPs are evaluated, a simple 
correction can be applied to the p value called the Bonferroni's inequality. This 
correction uses the formula 
P* =1-(1-P)" 
Where P* is the overall p-value, taking into account the observed p-value, P, and the 
number of hypotheses tested, n. 
The major drawback of this method is that Bonferroni's inequality is a conservative 
correction, especially if some of the hypotheses being tested are not independent. 
When many SNPs in the same gene are evaluated, for example, and are in LD with 
each other, the Bonferroni correction would not be appropriate, resulting in the 
possibility of false negatives or failure to detect a true association. A better approach 
would be to test the true level of significance through simulations. 
Another option would be to not apply a correction at all, but rather, to require any 
association, whether in the context of a single hypothesis or several thousand, to reach 
a genome wide significance, similar to what is done in linkage analysis. Genome-wide 
significance may mean achieving a p-value on the order of 10-7 or 10"8 to account for 
-95- 
100,000 to one million multiple comparisons. Regardless of the correction method 
used, sample sizes will have to be substantially augmented to reach a reasonable level 
of statistical significance. 
1.2.5 Genetic heterogeneity in Mendelian disease 
An important issue in the study of Mendelian disease is the phenomenon of genetic 
heterogeneity, whereby distinct mutations at the same locus (allelic heterogeneity) or 
different loci (non-allelic heterogeneity) can cause the same, indistinguishable 
phenotype. Non-allelic genetic heterogeneity is a form of multi-locus model, wherein 
the predisposing alleles at each locus are typically rare and independently capable of 
producing disease. By contrast, common predisposing alleles often lead to epistasis or 
interaction effects among loci. In linkage analysis, allelic heterogeneity does not 
cause a problem because all families (including those with different mutations) will 
show linkage to the same chromosomal region. In fact, allelic heterogeneity also 
provides the strongest evidence for a causal relationship between a cloned gene and 
disease phenotype. Statistically, it is extraordinarily unlikely to find several different 
mutations at the same locus in unrelated families with the same disease. 
Non-allelic heterogeneity can cause a problem in linkage analysis, depending on its 
extent. In the extreme situation that any single gene accounts for a small proportion of 
segregating families, very large families would be required to obtain robust linkage 
evidence, and positional cloning would still be difficult. But for mendelian disease 
this has rarely, if ever, been the case. More typically, when non-allelic heterogeneity 
exists, it involves only a few distinct loci; this degree of heterogeneity usually is not a 
serious impediment either to linkage analysis or positional cloning, essentially 
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because the relationship between phenotype and genotype within families remains 
strong. 
Another important issue relating to mutational heterogeneity is the population under 
study. For mendelian disease, endogamous population isolates with a limited number 
of founders tend to have less mutational heterogeneity and an increased frequency of 
founder effects, which makes them particularly useful in studies of positional cloning. 
When most affected individuals in a population carry a mutation derived from a single 
ancestor, they effectively create a single large extended pedigree, although most of the 
distant relationships are missing. Historic recombination events around the disease 
mutation can still be inferred, however, by examining the extent of DNA shared on 
present-day disease chromosomes. This approach, referred to as linkage 
disequilibrium analysis, has been highly effective in leading to the cloning of 
numerous disease genes. 
1.2.6 Optimal study designs 
The disappointing results from linkage studies coupled with a biometrical view of the 
world has led to the suggestion of alternative approaches to tackling the genetics of 
non-mendelian diseases, namely reversion to the study of candidate genes on a large 
scale209 or high-density genome scans that are dependent on linkage disequilibrium 210 
The recent resurgence of association studies using candidate genes has led to much 
discussion about design issues. However, first it is useful to show directly the greater 
power of detection of gene effects by direct-association (or linkage-disequilibrium) 
analysis when the involved variant is in hand as opposed to depending on linkage 
analysis without linkage disequilibrium. Comparing ASPs (linkage) with case-control 
pairs (association), 209 showed that for genes with high relative risks (g >_4) and 
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intermediate allele frequencies (p = 0.05-0.50) it is realistic to expect linkage analysis 
to provide statistical evidence for the location of a disease gene. However, for more 
modest relative risks (g: 52), linkage analysis will not provide such evidence except in 
unrealistically large samples. By contrast, case-control association studies, even using 
a stringent significance level (5x10"8), provide adequate power for genes with relative 
risks as low as 1.5 (with p=0.10-0.70). 
The simplest design is the epidemiological case-control study, contrasting allele 
frequencies in cases versus controls. As is true for case-control studies generally, 
confounding is a problem for inferring a causal relationship between a disease and 
measured risk factor. One approach to deal with confounding is the matched case- 
control design, where individual controls are matched to cases on potential 
confounding factors (for example, age and sex) and the matched pairs are then 
examined individually for the risk factor to see if it occurs more frequently in the case 
than in its matched control. If cases and controls are not ethnically comparable, then 
one can use a matched case-control design, where controls are ethnically matched to 
cases. This can in theory be accomplished by focusing on homogenous and randomly 
mating populations, where cases and controls will presumably be ethnically 
comparable. However, such populations may be more of a theoretical ideal than a 
reality, as non-random mating patterns exist in nearly all groups. Nonetheless, 
association studies in Finland are less likely to be subject to confounding problems 
than in heterogeneous North American populations. 
Another solution to this problem involves the use of relatives as controls for cases. 
The first such described design proposed the use of unaffected sibs as controls, 177 and 
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this design has recently seen a resurgence of interest. 178181 Designs involving parents 
as controls have also been proposed. 
187; 217-219 Among these, perhaps the test most 
similar in spirit to the epidemiological matched case-control analysis is the 
transmission disequilibrium test, 218 in which an allele transmitted by a parent to an 
affected child is matched to the other allele not transmitted from the same parent; 
MacNemar's chi-square test of discordance is then applied to the resulting pairs187. 
The two alleles carried by a parent are of necessity ethnically matched, and thus the 
stratification artefact is eliminated. The same applies to sib controls, whose genotypes 
are ethnically matched to the cases. 
But a significant result from a design using parent or sib controls still does not imply a 
causal relationship between the tested allele and the disease outcome, because linkage 
disequilibrium with a linked locus (but not an unlinked locus) will also create a 
positive result. Nevertheless, it does at least indicate a significant gene effect nearby, 
if not the tested allele itself. The main drawback of using parents or sibs as controls is 
either unavailability (for example, with parents for a late-onset disease) and loss of 
power, especially with sibs. 
Whereas the simple case-control design is the mainstay of epidemiology, other 
family-based approaches are available that are more efficient. In particular, sampling 
multiplex families, where more than a single individual is affected, can be 
significantly more efficient than sampling singletons. The increase in efficiency is 
also a function of the disease allele frequency, and is most pronounced for rarer 
alleles. 
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Risch154 calculated the number of families and total individuals required to detect a 
gene effect with g=4.0 (for the homozygote) and g=2.0 (for the heterozygote), 
assuming a significance level a= 5 x10-8 and power (1 - /3)= 80%. He evaluated two 
disease allele frequencies, 5% and 20%, and consider designs including one, two or 
three affected sibs, where the (two) control individuals are either the parents of the 
sibship, unaffected sibs, or unrelated. 
For all designs except sibs, the efficiency is approximately the same when affected 
and control samples are pooled. For sibs, greater efficiency is possible with individual 
genotyping, 220 so those cases (pooled versus not pooled) are evaluated separately. The 
results are provided in Table 1.2-1. Rarer alleles (0.05 versus 0.20) are always more 
difficult to detect, but the number of subjects required can be reduced substantially by 
increasing the number affected in the sibship. Using unaffected sibs as controls leads 
to two to five times the required sample size as using unrelated subjects, depending on 
the number of affected sibs. Using parents leads to a 40-80% increase, again 
depending on number of affected sibs. The main conclusion is that if disease- 
susceptibility alleles are typically low frequency (say S20%), multiplex sibships are 
particularly advantageous; they are also advantageous for more frequent alleles, but 
the relative advantage is less. 179 
An important remaining question is whether to use parents or sibs as controls and 
suffer the loss in power (especially with sibs), or use unrelated controls and risk loss 
of robustness. Population stratification has been invoked numerous times as the cause 
for an observed high false-positive rate in association studies using candidate genes, 
yet it has rarely been demonstrated as the culprit. ' 83 More likely, it is the lack of a 
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stringent significance level used in such studies that is the problem. If one assumes 
the prior probability for any particular gene variant to be associated with a disease 
outcome to be low, most reported significant associations would be false positives. 
Des 
No. 
affected 
sibs 
1 
ign 
Two 
controls 
Unrelated 
No. 
Families 
872 
i 
No. of 
Subjects 
2616 
No. 
Families 
300 
No. of 
Subjects 
900 
1 Parents 1251 3753 417 1251 
1 Sibs NP 1715 6145 604 1812 
1 Sibs P 2032 6096 655 1965 
2 Unrelated 265 1060 102 408 
2 Parents 448 1792 173 692 
2 Sibs NP 642 2568 286 1144 
2 Sibs (P) 992 3968 361 1444 
3 Unrelated 121 605 52 260 
3 Parents 218 1090 101 506 
3 Sibs NP 314 1570 177 885 
3 Sibs (P) 605 3025 258 1290 
Table 1.2-1 Sample sizes for candidate-gene studies for different designs. 
p-allele frequency; NP-Not pooled; P- Pooled. Adapted from 179 
An attractive alternative to using family-based controls is to use random or unlinked 
genetic markers typed in the same cases and controls to determine the extent of 
possible confounding by ethnicity. 221 In fact, the same markers can also be used to 
assess the significance of any putative association, 188 or even used to adjust any 
candidate gene analysis for potential confounding by stratified analysis. Given the 
proposals for large-scale genotyping, it seems most likely that this approach will 
ultimately be most efficient. 
1.2.7 Population variation and replication 
As discussed above, rare variants (<5% frequency) are most likely to be population 
specific. In some cases, they may be recent in origin and hence specific to a single 
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founder population or less recent and generally found in one major ethnic group (for 
example, haemochromatosis mutation C282Y found only in Caucasians 
222). These are 
the variants that are most readily detected by a random SNP linkage-disequilibrium 
approach, but at the same time potentially least replicable by studying distinct 
populations. In this case it would be worthwhile to examine the same gene in other 
populations (or even the same population) for other functional variants that are 
associated with a similar phenotypic endpoint. Discovery of such alleles provides the 
strongest evidence for a causal link between the gene and the trait, as is the case with 
family-specific mutations in mendelian diseases. 
Common alleles (>10% frequency) are more likely to be found globally. If so, a 
causal association between a candidate SNP and trait outcome should be reproducible 
in many ethnically diverse populations. However, whereas pan-ethnic replicability 
provides support for a causal relationship, its absence does not necessarily negate it. It 
is well known that the same mutation can cause a major disease phenotype in one 
strain of mouse but no phenotype in a genetically distinct strain. Thus, background 
factors (genetic and otherwise) differentiating populations can modify the expression 
of a gene and lead to different levels of association. For example, this seems to be the 
case for ApoE and Alzheimer's disease, where the association exists pan-ethnically 
but is strongest in Caucasians and Asians, and weaker in Hispanics and African 
Americans. 223 
Another advantage to having an ethnically diverse sample of individuals/families is 
that patterns of linkage disequilibrium may differ ethnically, helping to resolve causal 
from non-causal relationships. While populations with high linkage disequilibrium 
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may be useful for initial detection of SNP associations, several different SNPs may be 
in strong or complete disequilibrium. Populations with lower levels of disequilibrium 
can help resolve which SNP effect is primary. Generally, Africans appear to have the 
lowest levels of linkage disequilibrium and hence are likely to be most useful for such 
analyses. An example is provided by the association of HLA and narcolepsy. In 
Caucasian and Asian populations, the alleles DR2 and DQ-, 6-0602 are equally 
associated with the disease (and in complete disequilibrium with each other), whereas 
in Africans there is incomplete disequilibrium between them and DQ-ß-0602 shows 
the primary effect. 224 
In the next section, I shall summarise the various studies that have applied the above 
concepts in the study of the genetic determination of hypertension. 
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1.3 Genetic determinants of hypertension 
Like premature CAD, hypertension is a familial disease and this was recognized as 
early as 1923 in Germany. 
225 Evidence for genetic influence on blood pressure comes 
from various sources. It is most likely that there are several causal genes, which 
together contribute to between 30-50% of the variation in blood pressure among 
individuals. Using historical family data from over 94,000 individuals, Hunt et al. 226 
found that the risk of developing hypertension after 1970 in persons under age 50 was 
approximately doubled for each first degree relative that had developed hypertension 
before 1970. 
1.3.1 Heritability of blood pressure 
Adoption, twin and family studies document a significant heritable component to 
blood pressure levels and hypertension . 
227 229 Twin studies document greater 
concordance of blood pressures in monozygotic than dizygotic twins, 230 and 
population studies show greater similarity in blood pressure within families than 
between families. The latter observation is not attributable to only a shared 
environment since adoption studies demonstrate greater concordance of blood 
pressure among biological siblings than adoptive siblings living in the same 
household. 231 
More formal estimates of the heritability of resting systolic and diastolic blood 
pressures based on family studies, are generally in the range of 15% to 35%. In twin 
studies, heritability estimates of blood pressure are -60% for males and -30-40% for 
females. 228; 232-234 Ideally an estimate of heritability based on the association model 
would be approximately the same as that derived by multiplying the sib-sib 
correlation by 2. In previous population studies, sib-sib blood pressure correlations 
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have been in the range of 0.14 to 0.18 229 A heritable component to salt sensitivity of 
blood pressure has been described in blacks 
235 Salt sensitivity is defined as a change 
in blood pressure in response to changes in salt and water homeostasis; found in 73% 
of hypertensive and 36% of normotensive blacks, it is generally considered a hallmark 
of hypertension in blacks. Complex segregation analysis continues to show evidence 
for hypertension-related "major" genes. 36'237 A large proportion of the phenotypic 
variation in blood pressure appears to be inherited as a polygenic trait 
238 
Despite very significant recent progress in genomic and statistical tools, the genetic 
dissection of human essential hypertension still provides a major challenge. Three 
main lines of investigation have been developed so far. These include linkage analysis 
in families segregating for rare mendelian forms of hypertension, candidate gene 
approaches and genome-wide scanning strategies. Of the above approaches, the 
search for single-gene mendelian forms of hypertension has been the most successful. 
Single genes can have major effects on blood pressure, accounting for the rare 
Mendelian forms of high and low blood pressure. 73 Although identifiable single-gene 
mutations account for only a small percentage of hypertension cases, study of these 
rare disorders may elucidate pathophysiologic mechanisms that predispose to more 
common forms of hypertension and may suggest novel therapeutic approaches. 3 
Mutations in 10 genes that cause Mendelian forms of human hypertension and 9 
genes that cause hypotension have been described to date, as reviewed by Lifton and 
colleagues. 73°239 These mutations affect blood pressure by altering renal salt handling, 
reinforcing the hypothesis of Guyton65 that the development of hypertension depends 
on genetically determined renal dysfunction with resultant salt and water retention. 
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Improved techniques of genetic analysis, especially genome-wide linkage analysis, 
have enabled a search for genes that contribute to the development of primary 
hypertension in the population. Application of these techniques has found statistically 
significant linkage of blood pressure to several chromosomal regions, including 
regions linked to familial combined hyperlipidemia 240 243 These findings suggest that 
there are many genetic loci, each with small effects on blood pressure in the general 
population. Overall, however, identifiable single-gene causes of hypertension are 
uncommon, consistent with a multifactorial cause of primary hypertension. 
1.3.2 Heritability of end-organ damage 
In addition to heritability of blood pressure, predisposition to end organ damage 
generally attributable to hypertension may be inherited separately from blood 
pressure. There are "stroke-prone" and "stroke-resistant" spontaneously hypertensive 
rats (SHR). Cross-breeding the two strains demonstrated independent segregation of 
the stroke-prone trait. 37 Based on this work in SHR, which found linkage of the 
stroke trait to an area that included atrial natriuretic peptide, these investigators 
identified a variant in the atrial natriuretic peptide gene associated with a 2-fold 
increased risk of stroke in the large, prospective, Physician's Health Study. 244 There 
are relatively rare Mendelian forms of stroke, both hemorrhagic245 and lacunar 
(cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy or CADASIL)246 that are unrelated to hypertension. CADASIL 
has a prevalence of at least 1 per 100,000 and accounts for about 2% of lacunar 
strokes under age 65.247 Leukoariosis is a diffuse lesion of white matter resulting in 
hyperintensity on MRI scans often seen together with lacunae and thought to be due 
to a form of arteriolosclerosis or "microatheroma. i248 The extent of leukoariosis was 
found to be 71% heritable in World War II veteran twins. 249 
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Family history appears to influence more common types of end-organ damage, even 
after adjustment for blood pressure. Thus, family history of atherothrombotic stroke 
was associated with relative risks of 1.5 to 3 for this most common form of stroke. 
250- 
252 Strong evidence (LOD score 4.40) has been presented for linkage of common 
forms of stroke to chromosome 5q12 in Icelandic families, apparently independent of 
known risk factors. 3 Family history of intracerebral haemorrhage was associated 
with 6-fold increased risk of having an intracerebral haemorrhage independent of 
blood pressure. 254 For subarachnoid haemorrhage, risk was increased 4-fold by a 
definite positive family history. 5 Left ventricular mass256 and other measures of left 
ventricular size and function are heritable. 7 Pulse pressure, a measure of arterial 
stiffness or distensibility, was strongly heritable and related to telomere length (which 
was also highly heritable). 258 Carotid intima-medial thickness (IMT) has been 
reported to be up to 30% to 64% heritable. 259-262 Presence of carotid plaque was 23% 
heritable after correction for hypertension. 263 One candidate gene variant (IL6- 
174G>C CC found in 19% of the population) was associated with much higher 
plasma interleukin (IL)-6 and increased carotid IMT at high alcohol intakes. 264 A 
substantial number of gene variants have been associated with carotid IMT; some 
were also associated with CHD. 265 
1.3.3 Gene-environment interaction 
Complex modelling of blood pressure in families suggests inheritance of a gene or 
genes that lead to a steeper rise in blood pressure with age. 266'26' There are multiple 
examples of rat or mouse strains that develop high blood pressure only when exposed 
to a high salt diet, most notable being the Dahl salt-sensitive rat. Chimpanzees living 
in a natural setting exhibit salt sensitivity in some but not all the individuals. 268 
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In humans, environmental stressors include moderate to high salt intake and lack of 
physical exertion together with an excessively rich diet resulting in a high prevalence 
of overweight. 269-271 In contrast, when salt intake is very low (below 50 mEq/day), 
hypertension is rare 269'2'2 More recent observations document that even with a 
relatively high salt intake, blood pressure remains low and hypertension is rare in a 
rural setting with continued exercise and lean body habitus. 273 Low maternal protein 
intake and genetic susceptibility can lead to reduced nephron number in several 
models274-278 Recent identification of a substantial reduction in the number of 
nephrons in kidneys of relatively young primary hypertensive patients who died from 
accidents provide indirect evidence that such early changes in the structure of kidneys 
that may favour salt retention may be relevant in human primary hypertension. 279 
1.3.4 Genome wide scanning strategy 
Genome-wide linkage studies for complex traits such as essential hypertension are 
problematic and require careful study design. Phenotypic traits for a polygenic disease 
aggregate in families but unlike monogenic diseases, they do not segregate in any 
clear Mendelian fashion. A positive result using a linkage approach that generally 
tests related individuals, by its nature, would implicate a general region of genomic 
DNA containing a large number of genes of which the causative gene for a particular 
disease will still have to be identified. For a complex disorder such as essential 
hypertension, many inherent problems exist using a linkage approach where on 
average both parents and children of the affected individual are not available for the 
study. Therefore the construction of a multi-generational pedigree is difficult and the 
mode of inheritance required for parametric linkage analysis cannot be calculated. 
Consequently a non-parametric approach, such as sibpair analysis, that does not 
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require information on the mode of inheritance or penetrance and has been used in 
many studies. 280'281 Positive sibpair linkage findings for particular loci obtained to 
date using microsatellite markers confirm the feasibility of extending this approach to 
a complete genome scan. 110; 282-285 
As a result of there being multiple contributing genes, each with small to moderate 
effects and environmental factors that have to be taken into account, careful study 
design in a genome-wide analyses is necessary. At least 22 genome-wide scans have 
been reported to identify loci for blood pressure using different methodologies. Some 
used blood pressure as a quantitative phenotype while others used hypertension. Some 
scans utilized families, others affected or dissimilar sibling pairs. The results of these 
scans are reviewed in Table 3. Generating much attention is the use of sib pairs with 
extreme phenotypes, a sampling design recognised as being substantially more 
powerful than a design that uses randomly ascertained sibs. Though the use of 
discordant sibs is a powerful tool, as shown by theoretical work and simulation197; 286- 
290 it is counterbalanced by the large screening effort that is required to identify them. 
Xu et a129' carried out a genome scan in search of genes regulating blood pressure and 
used three sib pair types (discordant, highly concordant and concordant siblings) from 
a Chinese population, to extract maximal information from their genotyping effort. 
No chromosomal region was able to achieve 5% genome-wide significance, though 
analyse on either SBP or DBP revealed several promising regions with maximal lod 
scores greater than 2.291 In a similar study, Kruskhal et al using a design that used 
only discordant sib pairs to localise genes that affect interindividual systolic blood 
pressure, 292 identified several regions on chromosome 2,5,6 and 15 with significant 
linkage and chromosome 9,16,18,20,21 with suggestive linkage to differences in 
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systolic blood pressure levels and to contain genes, the products of which have been 
suggested to regulate blood pressure. 
292 These studies demonstrated how difficult an 
undertaking genome-wide searches for genes influencing complex traits can be. 
Caulfield et a1293 carried out the BRIGHT study which represents the largest 
homogenous Caucasian resource that has been published to date (1599 families, 
comprising 2010 sibling-pairs). They reported a principle locus for hypertension on 
chromosome 6q (LOD score of 3.21) that attained genome-wide significance using a 
locus counting method and three further loci with suggestive evidence of linkage on 
chromosomes 2q, 5q and 9q. 293 In contrast the US National Institute of Health funded 
Family Blood Pressure Program (FBPP)294"297 comprising four multi-centre networks 
(GENOA, GenNet, HyperGEN and SAPPHIRe) which recruited participants with 
different selection criteria from multiple ethnic groups found no chromosomal region 
with genome-wide significant evidence of linkage. The highest LOD score, 2.96 was 
linked to diastolic BP on chromosome 1q in Caucasians using variance components 
analysis. 297 
Though linked loci with at least suggestive LOD scores were seen on every 
chromosome, perhaps most striking is the lack of consistently linked loci. This may 
serve to illustrate the heterogeneity of human hypertension as well as the potential 
shortcomings of attempting to compare studies using different methodologies. The 
difficulty in finding reproducible loci for hypertension has been the subject of a 
number of recent commentaries. 29s'299 Currently, identifying susceptibility genes and 
variants from genome scans remains elusive. (Table 1.3-1) 
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1.3.4.1 Metabolic syndrome and dyslipidaemic hypertension 
Genetic insights regarding dyslipidaemic hypertension are beginning to emerge. A 
locus for blood pressure, fasting insulin, and leptin was found on chromosome 7q. 300 
A locus on chromosome 1g21-q23 (near 170 to 180 cM) has been linked in various 
genome scans to familial combined hyperlipidemia, 
301-303 diabetes, 304 and blood 
pressure 24°'242'292 A similar locus on chromosome 4p may exist. 
305 The Lys198Asn 
variant in the endothelin-1 gene (on 6p24-p23) appears to interact with BMI resulting 
in mildly greater risk for hypertension in 198Asn carriers with higher BMI. 
306-308 The 
460Trp variant of a-adducin also appeared to interact with BMI and triglycerides. 309 
A variant of the SA gene (SAH) was associated with increased BMI, waist/hip ratio, 
triglycerides, and blood pressure. 310 The Trp64Arg variant of the ß3-adrenergic 
receptor (ADRB3) has similarly been associated with multiple features of the 
metabolic syndrome. 311 
1.3.5 Linkage analysis 
Major mutations have been identified with the use of this strategy in the following 
genes: 11 -hydroxylase in glucocorticoid remediable aldosteronism, 
312 the ß and y 
subunits of the epithelial sodium channel in Liddle's syndrome, 313; 314 and the 11ß- 
hydroxysteroid dehydrogenase in the syndrome of apparent mineralocorticoid 
excess 315'316 Two further mendelian forms of hypertension, Gordon's syndrome 
(chromosome 1 and 17)317"319 and hypertension with brachydactyly (chromosome 
12)320 have been mapped to defined chromosomal regions but their respective causal 
genes still await identification. It should be noted that these rare syndromes with 
mendelian inheritance account for a very small fraction of the pathological human 
blood pressure variation. The study of these disorders provide not only novel 
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diagnostic tools and an opportunity for targeted therapeutic intervention, but also 
provide an insight into the pathogenesis of the common forms of hypertension. 
The most popular candidate gene strategy, which investigates the genes within 
physiological pathways known to affect blood pressure variation, is a result of lessons 
learnt while studying these rare syndromes. 
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Disease Mutation Molecular 
Effect on 
Blood 
P 
Duplication of genes Ectopic expression of a 
ressure 
encoding aldosterone protein with aldosterone Glucocorticoid-remediable 
synthase and 113- synthase activity regulated by Increased 
aldosteronism hydroxylase, caused by corticotropin; increased 
an unequal crossover plasma volume 
Aldosterone synthase 
Mutations in the gene Defective aldosterone 
encoding aldosterone synthase activity; decreased Decreased deficiency 
synthase plasma volume 
Mutations in the gene Absence of circulating 
21-Hydroxylase deficiency encoding 21- aldosterone; decreased plasma Decreased 
h drox lase volume 
Mutation in the gene Cortisol-mediated activation 
Apparent mineralocorticoid encoding 110- of the mineralocorticoid Increased 
excess hydroxysteroid receptor; sodium retention; 
deh dro enase plasma volume 
Activation of the 
Mutation in the ligand- mineralocorticoid receptor by 
Hypertension exacerbated by binding domain of the steroids lacking 21-hydroxyl Increased 
pregnancy mineralocorticoid groups (probably due in part 
receptor to the rise in progesterone 
levels during pregnancy) 
Loss-of-function Partial loss of function of the 
Pseudohypoaldosteronism mutations in mineralocorticoid receptor, 
type I (autosomal dominant) mineralocorticoid 
impairing salt reabsorption; Decreased 
improvement with age and a receptor high-salt diet 
Mutations in the ENaC 
Deletion of the C-terminal 
Liddle's syndrome a or y subunit 
domain of ENaC, resulting in Increased 
increased ENaC activity 
Impairment of ENaC 
subunits, which is not 
Loss-of-function ameliorated by activation of Pseudohypoaldosteronism 
mutations in ENaC 
the mineralocorticoid receptor Decreased type I (autosomal recessive) 
subunits 
by aldosterone; no 
improvement with age; 
massive salt supplementation 
required 
Salt wasting from the distal 
Loss-of-function convoluted tubule, leading to 
mutations in the activation of the rennin- 
Gitelman's syndrome sodium-chloride angiotensin system; 
Normal or 
cotransporter of the subsequent activation of the decreased 
distal convoluted mineralocorticoid receptor 
tubule increases ENaC activity, 
preserving salt homeostasis 
Loss-of-function Salt wasting in the thick 
mutations in genes ascending 
loop of Henle leads 
Bartter's syndrome required 
for salt 
to activation of the renin- 
angiotensin system and the 
Normal or 
reabsorption in the 
thick ascending loop of mineralocorticoid receptor, 
decreased 
Henle increased ENaC activity, and 
relative salt homeostasis 
Table 1.3-2 Monogenic Diseases That Elevate or Lower Blood Pressure 
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1.3.6 Monogenic syndromes 
Table 1.3-2 summarises the various monogenic syndromes associated with blood 
pressure variation and the molecular mechanism and chromosomal locus. 
1.3.6.1 Glucocorticoid Remediable Aldosteronism (GRA) 
GRA is an autosomal dominant trait with a clinical phenotype varying from severe 
early onset hypertension to a much milder blood pressure elevation and mild 
hypokalaemia. The sine qua non of patients with GRA is that the secretion of 
11-ß hydroxylace Chimaeric gene Aldosterone synthase 
5' 3' 
5' 
CYP11B1 CYP1IB2 
-344C1'1' 
Iniron 2 
CunVcrsiott 
Figure 1.3-2 Genetic variations in the Aldosterone synthase gene. 
aldosterone is regulated by adrenocorticotropic hormone (ACTH) rather than its usual 
secretagogue angiotensin II. It is characterised by moderate hypersecretion of 
aldosterone, suppressed plasma renin activity and rapid reversal of these 
abnormalities with glucocorticoids. Elevated 18-oxocortisol is the most consistent 
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biochemical marker of the condition. The hypertension is of moderate severity and 
becomes apparent early, with young children having blood pressure greater than the 
95th percentile for the age and becoming frankly hypertensive before the age of 20. 
Associated signs of hypertension are frequent with left ventricular hypertrophy and 
retinopathy. Some affected kindreds have history of early deaths from strokes in 
family members before the age of 40. All patients with GRA have a mutation 
localised to a segement of human chromosome 8, containing aldosterone synthase and 
steroid 11 beta-hydroxylase genes (CYP11B2 and CYP11B1). The high 
homology(93%) and proximity(45 kb apart) of CYP11B1 and CYP11B2 genes makes 
it possible for them to become misaligned during meiosis. When this occurs, crossing 
over between the misaligned genes creates two chromosomes, one of which carries 
one CYP11B gene (deletion) and the other carries three CYP11B genes. The middle 
gene of the latter chromosome is a chimera with the 5' and the 3' ends corresponding 
to CYP11B1 and CYP11B2 respectively (Figure 1.3-2). In all kindreds analysed the 
breakpoints(points of transition between CYP11B1 and CYP11B2) are located 
between intron 2 and exon 4 are not identical and represent independent mutations. 
By virtue of the 5' regulatory element of the 11 beta-hydroxylase gene, aldosterone 
synthase gene expression and enzymatic activity are brought under the control of 
ACTH. This results in ectopic secretion of aldosterone from the adrenal fasciculata 
and leads to increased salt and water reabsorption and rise in blood pressure 312 
Studies on chimeric cDNA expression in cultured cells showed that chimeric enzymes 
with amino termini from CYP11B1 and carboxyl termini from CYP11B2 have 18- 
oxidase activity only if at least the region encoded by exons 5-9 corresponds to 
CYP11B2. If the sequence of exon 5 instead correspond to CYP11B1, the enzyme has 
11 beta-hydroxylase but no 18-oxidase activity '331 and there is no location of 
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crossover that yields an enzyme with intermediate levels of 18-oxidase activity. This 
is entirely consistent with the observation that no breakpoints in GRA alleles occur 
after exon 4. 
Subjects with GRA show a wide range of blood pressure including normotension. 
Studies to date indicate that this is not related to environmental factors like sodium 
intake or differences in steroid levels ruling out allelic variations as the cause of 
variations in clinical severity. 
Many kindreds of GRA are of Anglo-Irish extraction 332 312'333 Subjects with a 
maternal inheritance of GRA have a significantly higher plasma aldosterone and 
blood pressure compared to those with paternal inheritance suggesting gene 
imprinting, but it more likely represents exposure of the foetus to elevated levels of 
maternal aldosterone which exacerbates the condition. 334 Moreover the chromosomes 
carrying the chimeric genes tend to occur in association with specific polymorphism 
of the CYP11B genes. This suggests that one of these polymorphism is or is in 
linkage disequilibrium with a structural polymorphism that predisposes to unequal 
crossing over during meiosis. In approximately 40% of alleles in Caucasians, the 
intron 2 of CYP11B2 has a sequence almost identical to that of CYP11B1. This 
region could promote misalignment of chromosomal segments during meiosis and 
thus increase the risk of unequal crossing over. The chimeric genes causing GRA can 
be readily detected by Southern Blotting or PCR and this gives a test of 100% 
sensitivity and specificity. 335 The polymorphic variants of CYP11B2 are discussed in 
section 1.3.7.5 (page 132). 
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1.3.6.2 Liddle's syndrome 
Liddle syndrome is an autosomal dominant form of hypertension characterised by 
hypokalaemia and suppressed renin and aldosterone levels. The high blood pressure 
responds specifically to amiloride, indicative of an upregulation of the amiloride 
sensitive epithelial sodium channel (ENaC) activity. 
ENaC is composed of three subunits (alpha, beta and gamma), each containing a 
COOH-terminal PY motif (xPPxY). Mutations causing Liddle syndrome alter or 
delete the PY motifs of the beta or gamma ENaC which is a conserved motif essential 
for channel internalisation. Most mutations reported to date result in the elimination 
of the last 45-76 normal amino acids from the C-terminus of the beta or gamma 
subunits which lie adjacent on the short arm of chromosome 16313'314'336 The crucial 
role played by the PY motif in beta ENaC and gamma ENaC has been highlighted by 
the identification of the two missense mutations P616L and Y618H in other Liddle 
syndrome patients. 337; 338 No Liddle syndrome mutations have so far been identified in 
alpha ENaC. 
The increased activity of the ENaC is not explained by alteration of single channel 
conductance but rather by an increased number of channels inserted into the plasma 
membrane. 339 Since tyrosine from the PPPXY plays a crucial role, it has been 
proposed that defective endocytosis would lead to an accumulation of ENaC proteins 
at the apical membrane. The ubiquitin protein ligase Nedd4 binds the PY motif of the 
EnaC and inhibits the channel. It acts as a negative regulator of the wild-type 
epithelial channel but is inactive on the Liddle form of the channel. Association 
between Nedd4 and ENaC might bring the ca-lipid binding and ubiquitin-ligase 
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domains in close proximity to the channel, initiating its removal from the apical 
membrane. Loss of the Nedd4 binding sites in ENaC observed in Liddle syndrome 
might explain the increase in channel number at the surface. 
340; 341 
To test the hypothesis that minor mutations of the gene may be responsible for 
attenuated forms of Liddle syndrome, the last exon of the beta ENaC subunit gene 
was analysed in a series of 525 subjects of Caucasian and Afro-Caribbean origin. 
Seven amino acid changes were detected. These variants were more common in those 
of African origin. Functional testing of these variants in Xenopus oocytes did not 
show any significant functional effects, ruling out a substantial role of the beta ENaC 
gene in essential hypertension 342(Polymorphisms in ENaC - page 138) 
1.3.6.3 Syndrome of apparent mineralocorticoid excess 
AME is an autosomal recessive disorder causing pre- and postnatal growth failure, 
juvenile hypertension, hypokalaemic metabolic alkalosis and hyporeninaemic 
hypoaldosteronism. A low salt diet or blockade of mineralocorticoid receptors with 
spironolactone ameliorates the hypertension, whereas ACTH and hydrocortisone 
exacerbate it. Levels of all known mineralocorticoids are low. Cortisol half-life in 
plasma is increased along with the ratios of cortisol to cortisone and of 5alpha- to 
5beta cortisol metabolites in the serum and urine. An elevated ratio of cortisol to 
cortisone metabolites in the urine (tetrahydrocortisol plus allotetrahydrocortisol to 
tetrahydrocortisone [(THF+aTHF)/THE]) is considered pathognomic for this disorder. 
This suggests that cortisol acts as a stronger mineralocorticoid than is normally the 
case. 
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The defect in AME is a deficiency of 11 beta-hydroxysteroid dehydrogenase type 
2(HSD11B2) enzyme activity. Both aldosterone and cortisol in vitro are potent 
activators of the mineralocorticoid receptor in contrast to the situation in vivo where 
aldosterone is a vastly more potent activator of the renal mineralocorticoid receptor. 
Cells that respond selectively to mineralocorticoids contain the enzyme 11 beta- 
hydroxysteroid dehydrogenase that metabolises cortisol to cortisone, a steroid that is 
incapable of activating the mineralocorticoid receptor. This mechanism protects the 
mineralocorticoid receptor from cortisol, resulting in selective activation by 
aldosterone. The active component of liquorice, glycyrrhetinic acid inhibits 11-beta 
HSD in isolated rat kidney microsomes and the similar abnormalities occurring with 
liquorice intoxication in humans is a reversible pharmacological counterpart to the 
syndrome of apparent mineralocorticoid excess. 343 
There are two distinct isoenzymes of the 11 beta-HSD. The liver or type 1 isozyme 
has a relatively low affinity for steroids and is expressed at high levels in the liver but 
poorly in the kidney and is not defective in AME. The kidney or the type 2 isozyme 
has high steroid affinity and is expressed at high levels in the kidney and placenta. 
Thus far 18 different mutations in the HSD11B2 gene have been published involving 
21 kindreds with AME, resulting in neutralising enzymatic activity. There is 
significant correlation between the degree of enzymatic impairment and biochemical 
severity as measured by ratio of cortisol to cortisone metabolites. 44 
While apparent HSD11B2 deficiency causes hypertension, it is reasonable to 
hypothesise that milder decreases in enzymatic activity might be associated with the 
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common 'essential' hypertension. In rats placental 11-HSD activity is inversely 
correlated with placental weight and directly correlated with term foetal weight. 
Patients with AME are often born with mild to moderate intrauterine growth 
retardation. It is likely that low levels of 11-HSD in the placenta permits excessive 
quantities of maternal glucocorticoids to cross the placenta and inhibit foetal growth. 
In retrospective human population studies, low birth weight and increased placental 
weight are increased risk factors for subsequent development of hypertension. 
Although variations in 11-HSD might in principle be responsible for this correlation, 
studies in humans have not found a relation between 11-HSD activity and birth 
weight aas 
1.3.6.4 Pseudohypoaldosteronism type II (Gordon's Syndrome) 
Pseudohypoaldosteronism type II, also known as familial hyperkalaemia and 
hypertension or Gordon's syndrome, is characterized by hyperkalaemia despite 
normal renal glomerular filtration, hypertension and correction of physiologic 
abnormalities by thiazide diuretics. The blood pressure level is not high , and the 
biological phenotype is rather attenuated, composed of fluctuating hyperkalaemia 
with hyperchloraemic acidosis. The response of hyperakalaemia to dietary salt 
restriction and to mineralocorticoids is heterogeneous, suggesting genetic 
heterogeneity. Analysis of linkage in eight PHAII families showing autosomal 
dominant transmission demonstrates locus heterogeneity of this trait, with a 
multilocus lod score of 8.1 for linkage of PHAII to chromosomes 1g31-q42 and 
17p11-g21.317 318 Disse-Nicodeme et al. 319 analysed a large French pedigree in which 
12 affected members over 3 generations confirmed autosomal dominant inheritance. 
Affected subjects had hypertension together with long-term hyperkalaemia, 
hyperchloraemia, normal plasma creatinine, and low renin levels. Genetic linkage was 
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excluded for the 2 previously mapped pseudohypoaldosteronism type II 
loci, PHA2A 
on 1q and PHA2B on 17p11-q21, as well as for the thiazide-sensitive sodium-chloride 
cotransporter gene 16q. Wilson et a1239 identified two genes causing 
pseudohypoaldosteronism type II after a genomewide screen using 380 microsatellite 
markers showed strong linkage to 12p13. Both encode proteins in the WNK family of 
serine-threonine kinases. Mutations in WNK1 are intronic deletions on chromosome 
12p. Missense mutations in hWNK4, on chromosome 17, also cause 
pseudohypoaldosteronism type II. Immunofluorescence assays have shown that the 
proteins localize to distal nephrons and may serve to increase transcellular chloride 
conductance in the collecting ducts, leading to salt reabsorption, increased 
intravascular volume, and diminished secretion of potassium and hydrogen ions. 
Analysis of 2 obvious candidate genes, SCNN1A and GNB3, located within the 
interval showed no deleterious mutation. This is a form of hypertension which most 
closely mimics essential hypertension and the mild phenotype may leave a large 
proportion of patients with Gordon's syndrome undiagnosed 
1.3.6.5 Autosomal Dominant hypertension with brachydactyly 
A unique Turkish kindred was described in 1973 with autosomal dominantly inherited 
brachydactyly and severe hypertension where the two traits cosegregated completely. 
This syndrome has been mapped to a4 million base pair segment in chromosome 
12p 320; 346 A similar syndrome has been described in a family in Canada and another 
in the US347.348 The importance of this syndrome to primary hypertension is 
speculative. A putative mechanism in these families is the presence of a vascular 
anomaly involving the posterior inferior cerebellar artery at the ventrolateral medulla 
which was present in all 15 affected subjects examined and absent in none of the 11 
non-affected siblings. 349 No detailed neurophysiological studies have been done in 
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subjects with this syndrome and hence one is not sure whether this form of 
hypertension has a neurovascular basis. Though recently a direct causal relationship 
has been shown between raised blood pressure and neurovascular compression of the 
ventrolateral medulla in human beings with surgical decompression resulting in a 
decline in blood pressure. 350 
1.3.7 Candidate genes 
One of the logical and promising strategies is the investigation of candidate genes that 
encode key components of the physiological mechanisms impaired in (or 
characteristic of) hypertensive patients. Thus far, the candidate gene approach has 
provided more examples than the linkage approach of gene variants that appear to 
affect blood pressure. Reasonable candidate genes to consider include genes related to 
physiological systems known to be involved in the control of blood pressure and 
genes known to affect blood pressure in mouse models. Lessons learned from the 
studies of candidate genes351 to date include the 
9 shortcomings that result from limited statistical power of many studies 
" expected variation from one population to another 
0 the need for better phenotyping of study subjects 
" the relatively small effect of the genes studied on population prevalence of 
hypertension 
" the lack of sufficient certainty of consequences of any genes studied thus far to 
make treatment recommendations based on genotype. 
There have been many reported associations between hypertension-related phenotypes 
and DNA markers of candidate genes. However, alleles of very few genes are 
consistently related to intermediate phenotypes across diverse populations. Part of the 
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inconsistency may be due to the fact that most DNA markers studied thus far do not 
have a functional impact on the structure or expression of the gene product. Thus, 
most reported genetic associations have been attributed to linkage disequilibrium with 
putative functional changes elsewhere at the genetic locus. Since this may vary 
between populations, factors such as admixture can result in false conclusions about 
genetic associations. One strategy to reduce such confounding in association studies 
may be to select DNA markers that are proven, by various assays, to directly mark a 
functional change in the gene of interest. Additionally, identifying the genetic 
determinants of an intermediate quantitative trait such as blood pressure, may help to 
identify the genetic determinants of a disease, such as hypertension, which is defined 
by threshold values imposed on the quantitative trait. 
1.3.7.1 Angiotensinogen 
The renin angiotensin system regulates blood pressure and sodium balance. 
Angiotensinogen is a key component of this system. The candidacy of 
angiotensinogen for a role in the genetic basis of hypertension is supported by the 
observation that plasma angiotensinogen levels track with raised blood pressure 
through families. Transgenic mice with overexpression of a rat angiotensinogen gene 
develop hypertension and knockout mice with a disrupted gene and absent 
angiotensinogen production develop low blood pressure. 
The potential role of the AGT gene in human essential hypertension has been tested 
using a highly polymorphic dinucleotide GT repeat displaying 10 alleles and located 
in the 3' region of the angiotensinogen gene. When a total of 379 hypertensive sib- 
pairs were studied for the AGT gene, a 17% excess of allele sharing was found when 
the sib-pairs were stratified according to the severity of hypertension. Significant 
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linkage was found in the male pairs while no excess of shared angiotensinogen alleles 
was observed in female-female comparisons, suggesting the influence of an epistatic 
hormonal phenomenon. From this study, it was estimated that mutations at the AGT 
locus might be a predisposing factor in at least 3-6% of hypertensives younger than 60 
years of age-110 Subsequently a large European study involving 630 sib-pairs found no 
evidence of linkage 
352 353 Also no evidence of linkage was found in sib-pair studies in 
Chinese and Afro-Caribbeans 283,354 Conversely in Mexican-Americans, a marginally 
significant linkage was found in 180 affected individuals belonging to 46 families 
355 
Several missense mutations have been found, mainly located on exon 2 of the AGT 
gene. Most of them were rare and detected in a few hypertensive probands. Two 
polymorphisms T174M and M235T were found to be in complete linkage 
disequilibrium. The M235T polymorphism which showed association with 
hypertension and plasma angiotensinogen was studied in many case-control studies. 
The frequency of the AGT T235 allele varies strongly with ethnic groups, being the 
predominant allele in the African population(0.90-0.95) and more frequent in the 
Asians(O. 75) than in the Caucasians(O. 40). In a meta-analysis of all relevant articles 
published between 1992 and 1996, involving 5493 Caucasian patients, the AGT T235 
allele was significantly associated with hypertension in subjects with a positive family 
history of hypertension and in those with more severe hypertension. 356 A positive 
association of the T235 allele with hypertension was found in the Japanese, and native 
adult Canadians. 357; 358 The T174M polymorphism did not show any linkage with 
hypertension in most case control studies. A metaanalysis of 69 association studies 
with 27,906 subjects concluded that the AGT 235 TT genotype conferred 31% greater 
risk for hypertension (P = 0.001), whereas those with the MT genotype had 11% 
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greater risk (P = 0.03) 
359 The effect was most frequently found in Caucasian 
populations and in males. Subsequent studies have continued to find mixed, but 
generally positive association 360-365 Blood pressure responses to an angiotensin 
converting enzyme inhibitor were greater among those with the 235T allele in one 
study, 366 whereas another group reported negative findings. 367 
A G-A substitution at position 6 upstream of the initial transcription site was found to 
be in linkage disequilibrium with the T235 allele and haplotypes containing both the 
G-6A and M235T polymorphism were associated with hypertension. 368 The -6A 
variant in expression studies, was found to result in an increase in function compared 
to the -6G allele. 
369 In the large Family Blood Pressure Program metaanalysis, AGT - 
6A was associated with the diagnosis of hypertension but not with higher blood 
pressure in the normal range. 370 Consistent with the notion that the -6A (or 235T) 
allele of AGT results in increased tissue expression of angiotensinogen, both 
normotensive homozygous carriers of the 235T AGT variant (most with a positive 
family history of hypertension)37' and hypertensive patients with the -6AA 
genotype372 showed significant blunting of renal vascular response to infused 
angiotensin II. This blunting (less than usual reduction of renal blood flow in response 
to infused angiotensin II on a high salt diet) is presumably the result of higher 
intrarenal angiotensin II production resulting in downregulation of vascular 
angiotensin II receptors. There was also blunting of the normal stimulation of adrenal 
aldosterone production by infused angiotensin II on a low salt diet in hypertensive 
patients with the AGT -6AA genotype. 
372 In one study of normotensive and 
hypertensive persons over age 60, the AGT 235T genotype was associated with a 
lesser diastolic response to changes in salt intake. 373 These results may suggest that 
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the ability of the renin-angiotensin system to respond to marked changes in salt over a 
relatively short time remains intact with the relatively modest effects of the -6A 
variant. Nevertheless, 2 long-term intervention studies including a reduction of salt 
intake374'375 and one study utilizing increased fruit and vegetable intake376 have noted 
greater responses to the intervention in persons with the -6AA genotype. Those with 
the -6GG genotype had the least response, whereas heterozygotes were 
intermediate. 
Other phenotypes besides blood pressure may be affected by AGT genotype. Left 
ventricular mass index was found to be increased in persons with the 235T variant in 
a Chinese study. 77 Persons with LVH who had AGT 174M or 235T alleles responded 
to irbesartan with much greater reductions in LV mass than those with other alleles. 
Response to atenolol was not associated with genotype 378 These results may explain 
lower LV mass in (mostly treated) hypertensives with 235 MT and TT but the reverse 
association in normotensives from the HyperGEN echo study. 379 In a family with a 
known gene causing hypertrophic cardiomyopathy, higher activity variants for several 
genes of the renin-angiotensin system (including AGT 235T) were associated with 
greater LV mass in cardiomyopathy gene carriers. 80 Yet another group reported a 
greater increase in brain infarctions associated with the 235T variant, although no 
association with extracranial, carotid atherosclerosis was found. 381 The AGT 235T 
variant has been associated with more rapid progression of IgA nephropathy. 382; 383 
One group384 reported more rapid progression to end-stage renal disease in diabetics 
with the 235T variant while another did not 385 
1.3.7.2 Renin 
The renin gene was the first to be investigated in rats and humans as a candidate gene 
for hypertension. Early association studies with several restriction fragment length 
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polymorphism provided negative results 
386`387 An affected sib-pair study performed 
in French families using a combination of RFLPs grouped in haplotypes found no 
excess concordance for estimated renin haplotypes in affected hypertensive sibs. 
98 
1.3.7.3 Angiotensin-1 converting enzyme gene 
ACE has a key role in angiotensin II generation and bradykinin degradation, and may 
thus markedly affect vascular wall reactivity and morphology and kidney function. 
The ACE gene lies within the genomic region which is linked with hypertension in 
the SHRSP strain of rat. The human ACE gene has been cloned and localised to 
chromosome 17q23 and a 287bp insertion/deletion(I/D) polymorphism in intron 16 
has been identified for use a genetic marker. The polymorphism of the ACE gene 
strongly modulates plasma ACE level. Therefore any relationship found with the ACE 
gene marker would be readily attributable to the biological phenotype associated with 
the polymorphism. 
Two studies have reported a linkage with the ACE locus with diastolic blood pressure 
or mean blood pressure. In a sample consisting of 3095 participants of the 
Framingham Heart Study, there was an association of the ACE DD genotype with 
increased diastolic blood pressure in men but not in women. 389 In a large population 
based sample of 1488 siblings the ACE locus was found to be linked to diastolic 
blood pressure and mean blood pressure in adolescents, at a mean age of 15 years. 390 
The distribution of the common alleles of the ACE gene was studied in 170 Caucasian 
adults with contrasting genetic predisposition to high blood pressure, defined on the 
basis of personal and parental blood pressures. Young adults with the greatest 
predisposition who had high blood pressure and two parents with high blood pressure 
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did not show any significant difference in the distribution of markers of the ACE 
gene, either as genotype or allele frequencies, when compared with young adults with 
the least predisposition to high blood pressure 391 The DD genotype is also associated 
with a higher risk for cardiovascular disease, particularly acute myocardial infarction, 
left ventricular and carotid wall hypertrophy, restenosis after transluminal coronary 
artery angioplasty and reduction in LV mass index in response to enalapril and not 
associated with stroke. 
392-394 
Multiple variants that are in linkage disequilibrium with the I/D polymorphism have 
been described395 but it is unknown whether any of these are implicated alone or in 
combination in the determination of plasma ACE levels. A combined 
cladistic/measured haplotype analysis of ten polymorphisms spanning 26 kb of the 
ACE gene excluded upstream sequences including the ACE promoter from harboring 
the major ACE-linked variant involved in 36% of total trait variability. 205 
More recently, however, evidence for association of the ACE I/D variant have 
emerged in the context of interaction. Thus, associations of the DD genotype with 
hypertension are reported for men but not women389 and in the context of higher risk 
variants of angiotensinogen, 365; 396; 397 a-adducin, 398; 399 and aldosterone synthase 399 
Other variants of ACE may also affect activity and blood pressure association. 00 
ACE DD genotype was associated with greater left ventricular mass index in 
endurance-trained athletes. 401 
1.3.7.4 Angiotensin type I receptor 
There is little data concerning the biology of AT1R in hypertension, as it is a cellular 
component of the RAS and thus less accessible to quantitative measurement. 
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Though polymorphisms have been found in the coding region and in the 3' 
untranslated region, only one polymorphism 1166C of the A1166C polymorphism 
was more frequent in hypertensives. 
402 No evidence for linkage was found in a sib- 
pair study involving 267 pairs from 138 pedigrees, using a dinucleotide microsatellite 
marker. 403 Either the association found with the A1166C polymorphism is spurious or 
the sib-pair study is not sensitive enough to detect the linkage, due to its lower power 
compared to the association study. Another study performed in Australian subjects 
found a positive association with the A1166C polymorphism, but it was not the case 
in German hypertensives 404; 405 Analysing the A1166C polymorphism jointly with the 
ACE I/D polymorphism, showed that the increased risk of MI associated with the DD 
genotype was restricted to subjects bearing the 1166C allele either in the heterozygous 
or homozygous state 406 In a study of Finnish hypertensive twins, two intragenic 
markers for the type 1 angiotensin II receptor (AT1) showed some evidence for 
linkage in the total sample. A closer examination of this gene locus was carried out 
using subgroups of non-obese sibpairs with early onset of hypertension and uniform 
geographical origin. These stratifications yielded suggestive evidence for linkage of 
hypertension to the genetic area containing the AT1 gene, with a maximal multipoint 
logarithm of the odds (LOD) score of 2.9.07 In the same study, a genetic association 
study carried out in an independent series of 50 hypertensive cases and 122 
normotensive controls showed an increase in the frequency of the A1166-->C allele of 
the AT1 gene in the hypertensive individuals 407 
Since no alteration in the coding region of the gene has been detected in 
hypertensives, the next step would be to look for polymorphisms in the regulatory 
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regions of the gene resulting in modification of receptor number rather than receptor 
affinity. 
1.3.7.5 Aldosterone synthase 
Two polymorphisms of CYP11B2 have been studied extensively in hypertension. One 
is a single-nucleotide polymorphism in the 5' promoter region of the gene at -344C/T 
that alters a putative recognition site for the transcription factor SF1408 The 
CYP 11 B2 
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Figure 1.3-3 Top, Relative orientations of the CYP11B2 (aldosterone synthase) and 
CYP11B1 (11ß-hydroxylase) genes. 
Arrows indicate the direction of transcription, and a scale of 10,000 bases (10 kb) is 
marked. Bottom, Schematic of the CYP11B2 gene showing the locations of polymorphisms 
at the -344 position in the promoter and in the second intron (an intervening region that is 
spliced out of mRNA). Protein-encoding regions in the gene are indicated by boxes. A scale 
of 1000 bases (1 kb) is marked. 
immeoiate dioiogic importance of this is unclear, as recent reports suggest that, 
whereas binding of SF1 is reduced 4-fold by the change from C to T, there is no 
discernible effect on gene transcription studied in vitro systems 409 The second 
involves intron 2 of CYP11B2, which is replaced, in part, by the corresponding intron 
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from CYP11B1. The 2 polymorphisms are in close linkage disequilibrium, so that the 
common haplotypes identified are T conversion (38%); C wild-type (45%), and T 
wild-type (16%). 4'0 The T allele has been associated with increased urinary excretion 
of the aldosterone metabolite tetrahydroaldosterone, 410 higher plasma aldosterone 
levels411 lower aldosterone levels. 412 Some studies have found the T allele and 
Intron 2 conversion to be more frequent in patients with essential hypertension by us 
and several other groups, 410'413 while others have not. More recently, the T allele and 
intron 2 conversion have been shown to associated with hypertensive patients with a 
high aldosterone-renin ratio, and allele frequencies were normal in subjects with a 
normal ratio 414 
Though there is some evidence to link the CYP11B2 locus and hypertension, 
particularly that associated with mineralocorticoid excess, Fisher et al 415 showed that 
the variance in renin status attributable to familial factors was -35% and the 
CYP11B2 SF1 polymorphism was not shown to be a major determinant of this. 
Connell et a1416 suggest that the impairment of ß-hydroxylation associated with the T 
allele leads to a subtle, chronic increase in adrenocorticotrophin drive to the adrenal 
cortex, with eventual development of hyperplasia. This might be responsible for the 
long-term development of a resetting of the aldosterone response to angiotensin II, 
giving rise to the phenotype of hypertension with a raised aldosterone-renin ratio. 
1.3.7.6 Endothelial nitric oxide synthase gene 
Several lines of evidence suggest that blood pressure levels result from an equilibrium 
between a vasoconstrictor tone (mainly renin-angiotensin and endothelin systems), 
and a vasodilator tone, due to nitric oxide, prostacyclin and other less characterised 
factors, such as endothelium derived hyperpolarising factor(EDHF). 
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The Nitric Oxide Synthases are a family of complex enzymes that catalyse the five- 
electron oxidation of L-arginine to form NO and L-citrulline. The endothelial isoform 
of NO synthase (eNOS) represents a major candidate gene since this isoform is 
responsible for the constitutive regeneration of NO from arginine by the endothelial 
cells, which in turn activates guanylate cyclase in the vascular smooth muscle cells. 
The involvement of he eNOS gene was demonstrated by basal blood pressure increase 
in mice homozygous for the knockout of the eNOS gene, as compared to wild-type 
mice. 1 No polymorphisms have been detected in the coding region of the of the 
eNOS gene. Using a highly informative dinucleotide repeat inside intron 13, two sib 
pair studies showed no significant excess of allele sharing in siblings 418; 419 These two 
studies do not support a prominent role of the eNOS gene in essential hypertension. 
There is conflicting evidence for effects of variants of endothelial nitric oxide 
synthase (NOS3) with both positive420 and negative 421_423 association studies. Persons 
with the CC genotype of a -786T>C variant had higher blood pressure and were more 
than twice as likely to be hypertensive. 424 
1.3.7.7 Endothelin system genes 
Endothelins (ETs) are 21-amino-acid peptides produced in many cells and tissues. 
The vascular ET system is represented mainly by ET-1 produced in endothelial cells 
and is cleaved from a larger precursor, 38 amino acids in length, by the endothelin 
converting enzyme (ECE). It binds to the ETA receptor on the vascular smooth muscle 
and provokes vasoconstriction. Studies with endothelin receptor antagonists have 
indicated that endothelin-1 probably has complex opposing vascular effects mediated 
through vascular smooth muscle and endothelial ET(A) and ET(B) receptors. 
Endogenous generation of endothelin-1 appears to contribute to maintenance of basal 
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vascular tone and blood pressure through activation of vascular smooth muscle ET(A) 
receptors. At the same time, endogenous endothelin-1 acts through endothelial ET(B) 
receptors to stimulate formation of nitric oxide tonically and to oppose 
vasoconstriction. 
Polymorphisms of the ET-1 and ET(A) receptor genes have shown non significant or 
marginally significant associations with hypertension. 25 The Lys198Asn variant in 
the endothelin-1 gene (on 6p24-p23) appears to interact with BMI resulting in mildly 
greater risk for hypertension in 198Asn carriers with higher BMI 306-ios It is worth 
noting that the ECE gene is located on chromosome 1p36 on which a locus for 
systolic BP was found by sib-pair analysis with a protein marker namely 6- 
phosphogluconate dehydrogenase 426 
1.3.7.8 Adducin 
Genetic hypertension in the Milan hypertensive (MHS) rats is due to a renal 
abnormality in the ability to excrete salt. This alteration is genetically determined, 
since hypertension can be transplanted with MHS kidney in normotensive Milan 
normotensive (MNS) rats, even when the kidney derives from a young 
prehypertensive animal. Na/H countertransport in the brush-border vesicles, Na-K co- 
transport in the luminal membrane of the thick ascending limb, and the activity and 
mRNA expression of the basolateral Na-K ATPase both in the proximal and 
ascending limb tubules are all increased in MHS as compared with MNS. Since these 
differences in ion transport disappear after removal of cytoskeleton, cross- 
immunization studies set up to detect possible differences between the cytoskeletal 
components of the two strains revealed a difference in a protein subsequently 
identified as adducin. 
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Adducin is an a/ß heterodimeric protein which participates in the assembly of 
spectrin-actin cytoskeleton, modulates the actin polymerisation, binds calmodulin, is 
phosphorylated by PKC and tyrosine kinase and regulates cell signal transduction. 
Point mutations in both the a and ß adducin subunits account for around 50% of the 
difference in blood pressure between MHS and MNS strains. 427 Transfection of 
hypertensive and normotensive a adducin variants in rat kidney cells showed that the 
former increases the surface expression and maximal rate of Na-K pump 428 A direct 
and specific interaction between adducin and Na-K ATPase suggests the possibility of 
such an interaction in intact renal membranes. 29 
There is a close homology (94%) for the alpha adducin gene between rat and man. 
Initial positive association studies in humans430 were followed by significant linkage 
in hypertensive siblings and identification of a Gly460Trp variant (with an allele 
frequency of 0.13-0.16 in controls) associated with hypertension. Subsequent 
association studies have been reminiscent of findings after the discovery of the AGT 
association, with mixed but generally positive findings, especially for Caucasian 
populations. 31-433 Province et al found the association of ADD1 Gly460Trp with 
hypertension, with an approximately 50% to 70% increase in risk in Caucasians 
carrying the 460Trp variant, increasing to an odds ratio of 4.2 in older, heavier 
persons with higher triglycerides; no effects of were seen in African-Americans. 309 
Pathophysiological studies in humans are consistent with a significant increase in salt 
retention associated with the ADD1 460Trp variant. Thus, greater reductions in blood 
pressure in response to a diuretic284 and greater increases in blood pressure after a 
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saline load398 were seen in 460Trp carriers. Carriers also showed lower fractional 
excretion of sodium and a flattened pressure-natriuresis curve. 
434 Finally, 460Trp 
homozygotes more frequently had low-renin hypertension and displayed greater 
fraction sodium reabsorption 435; 436 
Effects of the ADD1 gene on blood pressure appear to interact strongly with other 
genes. The increase in blood pressure after a salt load was much greater in carriers of 
the 460Trp ADD1 variant who also had the ACE DD genotype than in those with the 
ACE II genotype. 98 ACE genotype had no effect (or possibly reverse effect) in those 
homozygous for the more common 460G1y variant. A prospective study suggests a 
similar interaction affecting the risk of incident hypertension. 399 In a well matched 
case-control study, Clark et a1437 found no evidence to suggest an association between 
either the alpha-adducin G460W or the ACE I/D polymorphism and hypertension. 
Furthermore, they found no interaction between alpha-adducin G460W, ACE I/D, and 
aldosterone synthase SF-1 and IC polymorphisms in the hypertensive population. 
Other phenotypes may be affected by ADD1 variants. Presence of ADD1 460Trp was 
associated with an approximate 2.5-fold increased risk of CAD or peripheral artery 
disease in a prospective follow-up of hypertensive patients. The risk was not seen in 
normotensive subjects 438 In a case-control study, diuretic therapy was associated with 
a 50% reduction in MI and stroke in 460Trp carriers; noncarriers had no risk 
reduction associated with diuretic use. 439 Risk of left ventricular hypertrophy was 
increased 15-fold in 460Trp homozygotes aao Interestingly, increased salt intake has 
also been strongly associated with increased cardiovascular morbidity and mortality441 
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and left ventricle mass442 independent of blood pressure. Furthermore, salt-sensitivity 
has also been associated with greater total mortality independent of blood pressure 
443 
1.3.7.9 ENaC 
Variants of the endothelial sodium channel initially were not associated with essential 
hypertension, 351 but more recent studies have found some association444; 
445 or 
linkage 446; 447 Hypertensive black Africans with the Thr594Met variant (found in 
about 5% and associated with hypertension in a previous study) were highly 
responsive to amiloride 
448 Approximately 7% (10 of 139 tested) of hypertension in 
blacks was attributable to the Arg563G1n mutation of endothelial sodium channel in 
one study . 
449 
1.3.7.10 GNB3 
Detailed in Section 1.6.3 GNB3, page 183. 
1.3.7.11 Dopamine Receptor 
An indirect association exists between the renal dopamine system and ion transport. 
The renal dopamine system may be considered apart from the sympathetic nervous 
system in that kidney dopamine is synthesized independently of nerve activity. 
Proximal tubule cells synthesize dopamine from L-DOPA in tubular fluid. Synthesis 
of dopamine is increased by a high-sodium diet and is also strongly influenced by 
delivery rate of L-DOPA in filtered fluid in the proximal tubule. Dopamine, by way of 
the dopamine Dl receptor, downregulates sodium transport by NHE3 in the apical 
membrane through cAMP-mediated effects and also downregulates Na+-K+ ATPase 
through diacylglycerol and PKC-mediated effects 45° The Dl receptor has other 
intracellular effects and there are other dopamine receptors 451 Of particular interest 
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are observations of defective receptor coupling associated with increased D1 receptor 
serine phosphorylation in both spontaneously hypertensive rats and humans with 
essential hypertension. 452 This increased receptor phosphorylation (resulting in 
uncoupling of the D1 receptor from downstream adenylate cyclase activation) was 
later traced to increased activity of G protein-coupled receptor kinase 4 (GRK4y). 453 
In particular, several variants of the y subunit of GRK4 showed increased activity by 
biochemical measures and in transgenic mice. Cursory data in human populations 
suggested increased risk for hypertension associated with several GRK4y variants all 
showing higher than normal activity. 453 Significant interaction between variants of 
GRK4y (termed "FJ" in this study) and variants of the renin-angiotensin system was 
also found397 with reportedly high prediction of hypertension status using 
combinations of genotypes 454 There are reports of variants in the D1 and D2 receptor 
genes being associated with hypertension 455; 456 
1.3.7.12 ß-Adrenergic Receptor 
Genome-wide scans have now reported linkage to one or more sites on virtually every 
chromosome. In one of these scans, investigators noted that the ß2-adrenergic 
receptor was a candidate under one of the peaks (a positional candidate gene 
approach). An Argl6Gly variant was found to be associated with a significant 1.8- 
fold increase risk of hypertension. 57 Confirmatory results for this variant have been 
reported in other populations458; 459 as well as a negative study. 460; 461 Attenuation of 
the vasodilatory response in humans with the Gly16 allele provides biological 
plausibility 462 Evidence for association of hypertension with variants of the ß1a63 and 
03-adrenergic receptors311'4M4has also been published. 
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1.3.7.13 Kallikrein 
Several studies find reduced urinary kallikrein in association with human 
hypertension and multiple studies support a role for kallikrein produced in the 
connecting tubule of the kidney (through local generation of kinin and bradykinin) in 
promoting diuresis and natriuresis in the face of a high salt intake. 465 Nevertheless, 
linkage and association studies of human hypertension have generally been negative 
for tissue kallikrein (KLK1) and other genes of the renal kallikrein system 421; 466 
Furthermore, a recently identified variant causing marked decrease in kallikrein 
activity was not associated with increased blood pressure. 467 Potentially, other factors, 
such as dietary potassium intake, may interact to modify associations with urinary 
kallikrein. 468 Whereas gene delivery of human tissue kallikrein reduced blood 
pressure in spontaneously hypertensive rats, 469 mice made deficient in either the 
bradykinin receptor-2 or tissue kallikrein were not hypertensive. 470 Further work will 
be required to provide further clarification of the role, if any, of the renal kallikrein- 
kinin system in hypertension. 
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1.4 Left Ventricular Mass 
1.4.1 LV Mass and LV Hypertrophy 
LV mass shows a continuous distribution in the general population, 
471 whereas LV 
hypertrophy is an operational category that defines the upper end of LV mass 
distribution. 471; 472 Left ventricular hypertrophy is often assumed to be little more than 
a marker for hypertension. In fact, the relation between diastolic or systolic blood 
pressure and left ventricular mass is not always close 
473; 474 Left ventricular 
hypertrophy is an independent risk factor for myocardial infarction and death in men 
and women with hypertension47l; 
472 and in asymptomatic subjects with normal 
blood 49'475 In hypertensive patients it is a stronger coronary risk factor than casual 
blood pressure readings. The Framingham Heart Study showed an apparently 
continuous relation between LV mass and cardiovascular event rate in the general 
population. 76 However, the important clinical issues regarding the shape of the 
relation between LV mass and cardiovascular risk in essential hypertension and the 
prognostic impact of LV mass values below the commonly agreed-on upper normal 
limits have not been addressed. 
Though left ventricular hypertrophy strongly predicts morbidity and mortality in 
individuals with or without known cardiovascular disease, the factors associated with 
the wide variability of LV mass in the general population remain incompletely 
characterized. A number of constitutional and environmental factors have been 
identified that influence left ventricular size; these include age, sex, body size, blood 
pressure, physical activity, salt intake, alcohol consumption, and the presence of heart 
disease or diabetes. 8; 477-479 Other studies have identified additional haemodynamic 
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associations with LV mass-beyond the well-known association of blood pressure-of 
the level of haemodynamic volume load and myocardial contractile efficiency. 
480-482 
Blood pressure, obesity, and age are important determinants of left ventricular mass48; 
however, they account only for part of the observed variance. Body growth influences 
cardiac development. The close relation between body size and left ventricular (LV) 
mass483 during childhood and adolescence is the hallmark of this influence. However, 
in infancy virtually the entire variability of LV mass is explained by body size, 
whereas with increasing age the ability of body size to precisely predict LV mass 
decreases. In fact, the difference between the value of observed LV mass and that 
predicted from body size increases with increasing age (heteroscedastic distribution of 
residuals). 84 This phenomenon might be explained by the progressive haemodynamic 
load that faces the left ventricle right after birth as the fundamental stimulus for LV 
muscular development. 
Although blood pressure, stroke volume, and decreases in contractile efficiency are 
important determinants of LVH, 485 this complication is not present in all patients with 
essential hypertension and can develop before the establishment of hypertension in 
some individuals. 486 Epidemiological studies have demonstrated that subjects with 
LVH may have near normal blood pressure, 48 indicating that additional factors 
besides blood pressure may be important in the development of hypertrophy. Race is 
known to have a significant effect on left ventricular mass even following correction 
for other associations. 87 Left ventricular mass is higher in black subjects than in their 
white counterparts but it is unclear if this represents a greater cumulative exposure to 
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stimulants of hypertrophy such as hypertension or a familial or genetic pre-disposition 
to the development of hypertrophy. 
Studies in families and twins have shown that left ventricular mass is a familial trait, 
indicating the influence of both genetic and environmental factors 488; 489 Evidence that 
left ventricular mass is a familial trait4ss; 
490-492 suggests the influence of genetic 
factors, while the absence of simple mendelian patterns of inheritance (except in rare 
syndromes493) identifies left ventricular mass as a complex phenotype that is 
influenced by interacting genetic and environmental factors. 
Thus the pathogenic mechanism of LVH may be multifactorial, involving both 
haemodynamic and non-haemodynamic factors, such as the sympathetic nervous 
system and the renin-angiotensin system 494 Recent investigations into the genetic 
determinants of LVH have focussed mainly on the renin-angiotensin-aldosterone 
system, with focus on the I/D polymorphism of the ACE gene, but results have been 
conflicting 495-a98 
1.4.2 Measurement of LV Mass 
Definitions of left ventricular hypertrophy have varied and normotensive control 
subjects may have an incidence from 1.3% to 9.4% according to which one of 13 
criteria is applied. 73 For research purposes it is probably better to treat left ventricular 
mass as a continuous variable without categorising it as either normal or abnormal; in 
clinical use, thresholds for hypertrophy of 134 g/m2 in men and 110 g/m2 in women 
seem reasonable. However, even these may vary with population characteristics such 
as age, race, and physical activity, so that matched contemporaneous control groups 
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should ideally be used. LV mass can be measured by echocardiography, ECG or MRI. 
As the major analysis in this thesis is based on Echo and ECG LV mass, these will be 
detailed more extensively here. 
1.4.3 Echocardiographic LV Mass 
Echocardiographically measured LV mass has been the gold standard until recently, 
now it is replaced by MRI. LV measurements are obtained at end diastole. End- 
diastolic measurement criteria include both the American Society of 
Echocardiography (ASE) and the Penn conventions. The ASE convention uses a 
leading edge measurement with end diastole identified at the beginning of the QRS 
complex of the simultaneously recorded ECG. 499 The Penn convention excludes 
endocardial or epicardial surfaces in the measurement of wall thickness and includes 
endocardial surfaces in the LV dimension measurement 
50° End diastole is defined as 
the peak of the R wave of the QRS complex. 
The LV measurements include interventricular septal thickness at end diastole 
(IVSTd), the posterior wall thickness at end diastole (PWTd), and LV internal 
dimension at end diastole (LVIDd). From the diastolic measurements, LV wall mass 
(LVM) is calculated from the Penn convention, according to the Equation of 
Devereux and Reichek50° by the formula 
LV Mass (gms) = 1.04 x (IVSTd +PWTd +LVIDd )3 - (LVIDd)3.13.6 
LV mass index (LVMI, grams per square meter (g/m 2) is calculated by dividing LV 
mass by body surface area 
BSA (m2)=71.84 x height (cm) x 0.725 x weight (kg) x 0.425. 
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Another index (LVMI, grams per meter (g/m)) can be calculated dividing LV mass by 
height 
The diagnostic criteria for LV hypertrophy using LV mass index (g/m2) were >=134 
g/m2 for men and >=110 g/m2 for women, representing the sex-specific 97th 
percentiles of a previously published reference standard in a normal population, 
501 
both based on Penn convention measurements. LV hypertrophy criteria using LV 
mass index (g/m) were >=143 g/m for men and >=102 g/m for women, based on 
similar reference criteria. 502 
M mode echocardiography tends to overestimate left ventricular mass, and two 
dimensional echocardiographic methods are more accurate, particularly when cavity 
size or myocardial thickness is non-uniform 503 Generalisation to the whole left 
ventricle from M mode dimensions recorded at the base of the heart is inappropriate 
in the presence of established infarction; this diminishes the importance of some 
studies 504 
1.4.4 ECG LV Mass 
1.4.4.1 ECG Voltage Criteria 
Electrocardiographic left ventricular hypertrophy (LVH) has been recognized as a risk 
factor for cardiac events for some time and electrocardiographic left ventricular 
hypertrophy (ECG-LVH) was of nearly paramount importance as the primary 
epidemiological tool and clinical diagnostic method for LVH detection in patients 
with hypertension, acquired and congenital valvular and other cardiac defects. The 
clinical significance of ECG-LVH has diminished with the improvement of 
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echocardiographic imaging technology. The epidemiological significance of 
ECG- 
LVH is primarily in the realm of risk evaluation. 
Most of the seminal data on ECG LV mass comes from the Framingham study, 
505 506 
but the assessment of the actual impact of LVH has been confounded by the use of 
different definitions. The most commonly used electrocardiographic definitions of 
LVH have been the voltage criteria of Sokolow and Lyon, 
507 and that of Casale et 
a1508 There have been many attempts at improving the predictive value of the 
electrocardiogram by relating the 12 lead ECG to echocardiographic estimates of LV 
mass 508 510 Casale and colleagues508 found that augmenting the Cornell criterion 
(RaVL+SV3) with information from the T wave in V1 improved the performance of 
the ECG in estimation of LV mass. Okin510 511 suggested the use of a time-voltage 
criterion for identification of LVH. However, considering sex, age, body surface area, 
the duration of the terminal P in V1, and the S voltage in V1 and V4 explains more of 
the variance than this model, 512 than a linear regression model of Wolf " 
513 and 
significantly more than standard criteria. Okin et al 
514 examined the test accuracy of 
the criteria for LVH in relation to body mass index in 250 patients and confirmed the 
need to consider BMI in LVH estimates. This was reinforced by findings from the 
Framingham study where incorporation of obesity and age into ECG algorithms 
consistently improved their performance in the detection of hypertrophy 515; 516 . The 
landmark Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 
used 2 of these ECG criteria to diagnose LVH and confirm reduction of 
cardiovascular events with regression of LVH 517 The study initially used the product 
of QRS duration and Cornell voltage (RaVL+SV3), with an adjustment of 8 mV for 
females and a partition value of 2440 mV"ms (the Cornell product criterion). 510 518 
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More recently, Rautaharju, using data from the third National Health and Nutrition 
survey, and the Atherosclerosis Research in Communities study demonstrated that 
Sokolow-Lyon voltages decreased and Cornell voltages increased significantly with 
increasing breast tissue 519 However, the overall conclusion was that these effects 
were small, and that when entered into a multivariate equation, chest size was the 
dominant variable. 
Crow et a1520 studied the association between eight ECG criteria and 
echocardiographic LV mass estimates in men and women with mild hypertension. 
Electrocardiograms and echocardiograms were recorded at baseline, 3 months, and 
annually for 4 years. The ECGs were computer processed to define 8 different 
criteria, and the researchers found a poor correlation between ECG and the 
echocardiogram. However, this result may have been confounded by poorly 
reproducible echocardiographic measurements. 
Rautaharju derived the optimal ECG models for predicting LV mass adjusted for body 
size from Cornell voltage (CV). 521522 The equations for white men and women for LV 
mass in grams are given below. 
Men: LVM = 0.026* CV + 1.25 *W+ 34.4 
Women: LVM = 0.020 * CV + 1.12 *W +36.2 
Okin et a! 511 showed that time-voltage-area measurements derived from digital ECGs 
improved the ECG identification of LVH beyond that available from standard QRS 
voltage. They found the sensitivity for identification of LVH using 12 lead voltage 
was 46%, 12 lead voltage-time product 54% and 12 lead voltage area 76%. 
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A summary of various ECG criteria for LV mass is given in Table 1.4-1. 
ECG criteria 
Sokolow-Lyon voltage 
Measurement 
SV, + RV5 or V6 
Cornell Voltage RaVL+SV3 
Sokolow-Lyon voltage-duration product (SV, + RV5 or V6)*QRS duration 
Cornell voltage-duration product (RaVL+SV3) *QRS duration 
12 lead voltage Sum of QRS voltage in all 12 leads 
12 lead voltage -duration product (Sum of QRS voltage in all 12 
leads *QRS duration 
LV mass - Rautaharju Men = 0.026* CV + 1.25 *W+ 
34.4 
Women= 0.020 * CV + 1.12 *W +36.2 
Table 1.4-1 ECG criteria for LV mass 
1.4.4.2 Minnesota Code 
The "Minnesota code" early on became the de facto standard for the measurement of 
ECG abnormalities in epidemiological trials. Computerization has solved many of the 
problems that the Minnesota code was designed to address. 523 The most commonly 
used computer coding system in epidemiological trials has been the NOVACODE 
system. 21 The US pooling project categorized ECG findings into major and minor 
groupings. Because some authors have found this useful in achieving statistical 
significance where the individual ECG abnormalities fail to do so, it has intuitive 
appeal for epidemiology. However, the clinical utility of this simple dichotomization 
is uncertain and, remarkably, the final report of the Pooling Project [Pooling Project 
Research Group, 1978] does not make it clear why these particular abnormalities were 
chosen, or indeed why they opted to categorize at all. Despite this, the categorization 
proved popular and was adopted in numerous trials 524 529 The presence of major 0 
waves on the ECG was an exclusion criterion; thus, studies that used the Pooling 
Project categorization did not consider major Q waves. 
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A critical factor in the adoption of any screening test is the prevalence of a positive 
test in the asymptomatic, apparently healthy population. There were few studies that 
fully presented ECG data on asymptomatic participants 
525; 530-535 In addition, there 
was some variation in the exclusion criteria for cardiac disease (symptoms, etc. 
) in 
those studies that did. However, despite the wide inter-population variation in 
prevalence, and despite some studies finding no intra-population difference 
in 
prevalence of ECG abnormalities between those with a diagnosis of heart disease and 
those without, 526 findings from 18,403 British men in the Whitehall study suggest 
caution in the combination of these two groups for analytical purposes. 
A summary of the Minnesota codes used is given below. 
Major ECG findings 
Minnesota codes 
IV1_2 or V1_2 or VI1_2 or VII1_2 or VIII1_3 
Minor ECG findings 13 or 111.2 or III1_2 or IV3 or V3 or IX1 
Only minor ECG findings Minor ECG changes but no major ECG changes 
Ischaemic ECG findings I3 or IV1_3 or V1_3 or VIII 
ST depression IV1_3 
Abnormal T wave V1_3 
Arrhythmias VIII1-6 or VII-2,4 
Bundle branch blocks VII, -2 4 
Left ventricular hypertrophy IIII and (IV1_3 or V1_3) 
Left axis deviation II1 
Table 1.4-2 Minnesota codes and ECG abnormalities 
1.4.5 Reliability of ECG LV Mass estimates 
Any test considered as a screening test should be considered in terms of its sensitivity, 
specificity and predictive value. If we are to assess the prognostic value of a screening 
ECG, we need to compare the test characteristics to the ultimate endpoint: mortality. 
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In this way, we can gain some idea for the amount of variance we are able to account 
for using the ECG. Only one paper in the literature has previously attempted this 
533 
These calculations are displayed in Table 1.4-3. As is clearly seen, the sensitivity 
estimates of individual ECG abnormalities are very low. We know that attributable 
risk relates to population prevalence and that low prevalence will result in low 
sensitivity, and this seems to be what is happening here. The data is calculated only 
from those studies with stringent exclusion criteria, so we could be certain of 
assessing the true screening qualities of the test. The sensitivity values seem to be 
highest for LVH and this almost certainly relates to the higher prevalence of this 
abnormality and (at least when defined by the Framingham investigators using ST 
depression inclusive criteria) greater risk. 
Study "W 
Sens 
aves 
Spec 
ST Dep 
Sens 
ression 
Spec 
BBB 
Sens Sec 
LVII wi 
Sens 
th strain 
Spec 
Framingham 19 98 18 98 37 94 
British Regional 21 96 5 98 2 99 
Table 1.4-3 Sensitivity and specificity estimates of ECG abnormalities to mortality 
Adapted from Menotti et al 533 
All ECG abnormalities increase with age and that some are more prevalent in men (Q 
waves, RBBB) while others are more prevalent in women (ST depression, LBBB). A 
striking finding is that ST depression inclusive-LVH (that is, LVH with strain) has a 
33% five-year mortality in men and a 21% five-year mortality in women 505 Also, 
unrecognised Q wave infarction is associated with the same risk as symptomatic 
infarction 536 Studies have shown that ST depression is poorly reproducible, more 
prevalent in women yet its prevalence is associated with increasing risk. 537 
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Adapted from Rautharju et al. 538 
Rautaharju et a1538 showed that the sensitivity of ECG-LVH criteria varies from 15% 
to at most 55% at varying levels of specificity and that echo-LVH was relatively close 
to 15% in various gender and racial subgroups. The first conclusion of their study was 
that it is impossible to obtain ECGLVH prevalence 20% or higher as reported in some 
studies unless the specificity of the criteria is below 85%. The second conclusion was 
that it is in fact possible to get estimated LVH prevalence values agreeing within +/ - 
10% with the true LVH prevalence with a variety of combinations of sensitivity and 
specificity when the fraction of true cases in the reported prevalence unacceptably 
low. A seemingly good prevalence estimate may be based on false information! On 
0 
the other hand, estimates with a reasonably high correct fraction, such as at least 50%, 
are in most instances associated with a substantial over- or underestimate of the true 
prevalence. Actual data are summarized in Table 1.4-4 demonstrating that even with 
better criteria such as the Cornell voltage, reported prevalence deviated by more than 
10% of the expected prevalence of 15% in all subgroups by race and gender, and the 
correct fraction in the reported 
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Table 1.4-4 Sensitivity, specificity and correct fraction in the reported prevalence by two sets of 
ECG-LVH criteria with Ec, o-LVH as standard. 
prevalence was only approximately 40% except 66% in black males. It can be 
concluded that the comparison of LVH prevalence data from contrasting populations 
with the present LVH criteria is an exercise in futility. 
1.4.5.1 Reasons for Large Fraction of False Negatives by ECG- 
LVH Criteria 
There is a multitude of reasons for the large fraction of echo-LVH missed by ECG- 
LVH models. One rational explanation attractive to frustrated electrocardiographers is 
that these false positives really represent a true diagnostic finding. 
Pathophysiologically valid and clinically important reasons for false negatives include 
situations where fibrotic tissue adds to the anatomical LVM and diminishes body 
surface potentials. CHD, clinical and subclinical, and LVH commonly coexist. 
Ischaemic injury in CHD and myocardial damage can interfere with normal 
ventricular conduction and diminish body surface potentials. Left ventricular 
remodelling in CHD and MI is different from at least initially more physiological 
adaptation in hypertension. The discrepancy between echo and ECG findings calls for 
an explanation when causative pathological condition can be suspected in a clinical 
situation. There are numerous other explanations, however, to account for the large 
fraction of false negative ECG-LVH findings and suggest that either the " gold 
standard" or our ECG-LVH model or both have serious deficiencies. 
Early repolarisation is benign539; 54° and that the risk of bundle branch block depends 
on the population in which it appears 541542 The prevalence of atrial fibrillation rises 
exponentially with age and is associated with higher risk than any other ECG 
abnormality in this age group 543 Sutherland et al. have confirmed the often-quoted 
observation that T wave inversion and high voltage QRS are more common in Blacks 
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than whites, but in general, do not predict coronary heart disease to the same extent 
529 
Wannamethee et al. have also noted that elevated heart rates, but not ventricular 
premature beats, are independent risk factors specific for sudden cardiac death 
544 
1.4.6 LV Mass and Risk 
In the Framingham study, increased left ventricular mass was associated with an 
adverse outcome including cardiovascular death, all cause mortality, and in men, 
sudden death 49 Early data from the Framingham study showed that patients with ST- 
T repolarisation abnormalities ("strain") on the electrocardiogram had a six-fold 
increase in cardiac deaths over a 20 year follow up period 545 Echocardiography, 
however, is 5-10 times more sensitive than the electrocardiogram and detects left 
ventricular hypertrophy in 25-30% of all hypertensive patients. 473 In such patients, 
myocardial infarction or death occurs at the rate of 4.6 events per 100 patient years, 
three times the risk in patients with hypertension and normal left ventricular mass 471 
Even in asymptomatic subjects with normal blood pressure, increased left ventricular 
mass emerges as a risk factor for coronary disease, cardiac death, and all cause 
mortality. 9 The relative risk of all cause mortality is 1.5 in men and 2.0 in women for 
every 50 g/m increment in left ventricular mass indexed to height. The relative risk of 
sudden death is 1.7 per 50 g/m increment. 
In all these studies multivariate analysis shows that, as a risk factor, left ventricular 
hypertrophy is independent of systolic and diastolic blood pressure, smoking, and 
cholesterol concentrations 49; 471; 472; 475 It is not always independent of age 49; 472 The 
relation between left ventricular mass and established coronary artery disease has also 
been examined in black subjects: left ventricular hypertrophy with normal coronary 
anatomy was associated with a five year mortality of 16.1%, which was similar to the 
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mortality (17.6%) with multivessel disease and normal left ventricular mass. Left 
ventricular hypertrophy was a more important independent predictor of death than 
multivessel disease or impaired left ventricular systolic function. 
504 Other studies have 
shown a similar effect on the risk of death and reinfarction after Q wave 
546 or non-0 
wave infarction 547 
What explains the association between left ventricular hypertrophy and increased 
risk? Although left ventricular mass may correlate poorly with casual systolic blood 
pressure and even less well with diastolic blood pressure, it is better related to 24 
hour548 or 30 year history of blood pressure. 549 Therefore, increased left ventricular 
mass could still be a marker for end organ effects of long-term hypertension. Left 
ventricular hypertrophy, however, is also known to be determined by other factors 
that may possibly increase coronary risk--these include obesity, age, blood viscosity, 
salt intake, and various genetically determined influences. The DD genotype of the 
angiotensin converting enzyme gene is linked with left ventricular hypertrophy but 
not with hypertension and has been shown to carry a higher risk of fatal and non-fatal 
myocardial infarction than the II genotype in some but not all studies . 
550-552 Left 
ventricular hypertrophy may also occasionally develop as a result of established 
coronary disease as repeated ischaemia in dogs can induce left ventricular 
hypertrophy. 553 
Left ventricular mass may itself contribute to coronary risk through increased oxygen 
demand and reduced coronary reserve, impaired endocardial autoregulation, and 
possibly small vessel disease 554 Finally, increased left ventricular mass may result not 
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only from cell hypertrophy but also from increases in collagen, which may provide a 
substrate for malignant arrhythmias and sudden death 
555 
The basic pathophysiological mechanisms underlying the association between LV 
mass and cardiovascular risk remain elusive. LV mass may be considered a time- 
integrated marker of exposure to high BP values and as a sensitive indicator of cardiac 
end-organ damage. It is well established that LV mass (1) increases myocardial 
oxygen consumption while reducing coronary blood flow reserve, (2) is associated 
with an increase in atherosclerotic lesions at cardiac and extracardiac levels, and (3) is 
associated with enhanced arrhythmogenesis. 
1.4.7 Prevalence of ECG Left Ventricular Hypertrophy 
The prevalence of ECG-LVH varies vastly with LVH criteria used, source population, 
gender, race, age and the survey period. Most population studies have used either 
Sokolow-Lyon criteria or Minnesota Code that contains Sokolow-Lyon criteria as a 
subset of code 3.3. LVH prevalence in general high with these criteria but drops to 
quite low levels if combined with repolarisation abnormalities. All studies showed 
increases in prevalence of ECG-LVH with increasing age. The high values seen in the 
young men can be readily explained by physical fitness and muscular hypertrophy 
associated with testosterone. One can hypothesize that with aging men are less 
physically active and have correspondingly lower voltage R waves. Then, with further 
increasing age in both men and women, pathological processes set in, and the size of 
the R wave increases again. It has previously been demonstrated that gender 
differences in body size, obesity, and LVM do not completely account for the gender 
differences in QRS duration and voltage measurements 556 In fact, recent studies in 
both humans and animals have emphasized gender differences in the response to 
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pressure overload. Although degree of hypertrophy seems to be similar, 
557; 558 male 
animals exhibit earlier transition to heart failure, with cavity dilatation, 
loss of 
concentric remodelling and diastolic dysfunction. This falls into line with human echo 
studies that show that for obesity and hypertension, relative increase in left ventricular 
mass is similar559 among men and women, but that overall, other factors including 
risk560 are not 56' 
It is not clear why there are such a wide variety of LVH prevalence estimates from 
electrocardiograms carried out in different populations using the same criteria. For the 
50-59 year old males, the Finnish cohort of the Seven countries study had a mean 
prevalence of LVH (Minnesota Code 3-1) of 19%; the Finnish Social Insurance study 
had a mean prevalence of 27.3% and this relative high prevalence even extended to 
females (mean 13.5%). The figures demonstrate how far these points are outliers. Of 
all the other countries with predominant Caucasian populations, only Copenhagen 
(12%) and the Moscow cohort of the European study (18.7%) came close to these 
estimates. Estimates were also high in the black population, both from the Jamaica 
study (29.9% in the 40 to 49 age group) and 19.8% in Evans County. The wide 
variation is demonstrated by studies such as the Whitehall study which found a 
prevalence of less than 1% in British civil servants aged 50-59, and the age-pooled, 
white male cohort of the Charleston study. These wide variations demand some 
explanation. Many studies were rigorous in their training of coders and use of 
independent assessments. In particular, the Finnish social insurance study used 2 
independent coders, and two or three independent medical readers at the University of 
Minnesota read all ECGs from the Seven Countries participating centres. Some 
important points can be made. Firstly, it seems likely that at least some of the 
differences noted are real. It would not seem unreasonable to conclude on the basis of 
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the above, that black populations and the Finnish population have truly higher mean 
R 
wave amplitude than many others. As discussed above, this may not necessarily 
imply 
a greater prevalence of echocardiographic LVH, although comparison of the relative 
weight and skin fold thickness measurements from the Seven Countries study 
suggests no difference between the Finnish population and the others (Finnish relative 
weight: 92.5%, others: 92%. Finnish skin fold: 15, others: 17.7). However, Finland 
did have the highest rates of hypertension and the CHD death rate was higher than all 
other countries. 
A clearer pattern is the lower prevalence of ECG-LVH when the criterion requires ST 
depression. The Belgian study found the age-pooled prevalence of LVH by this 
definition to be 0.8% male and 0.5% female. The Honolulu Heart program found the 
prevalence of high R wave-LVH to be 5.4% compared to the prevalence of 0.6% 
when both high R waves and ST-T depression is used. Although the Charleston study 
found a low prevalence of ST depression inclusive LVH (0.9%) in their age-pooled, 
male-only sample, they in fact found LVH by high R wave criterion to be only 0.3%. 
This contrasted with the findings in the black population where they found the 
prevalence of LVH by these criteria to be 7.8%. This was mirrored in the high R wave 
criteria of the Evans county study that found the prevalence in blacks to be over 
double that in whites (19.8% compared to 7.4%). 
1.4.8 LVH - Outcomes and Risk Prediction 
Although using echocardiographic LV mass as a gold standard to refine 
electrocardiographic estimates is valid, more important is the prognostic value of 
ECG detected LVH. 
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Most risk evaluation studies have found a significant association between ECG-LVH 
and mortality risk only for those criteria that combine high QRS amplitudes with 
repolarisation abnormalities. As expected, mortality risk is highest in hypertension 
clinic populations selected for intervention trials. An example is the report from the 
Italian PIUMA study, 562 which showed that cardiovascular disease (CVD) mortality 
risk was not significantly increased for the Sokolow-Lyon and Cornell voltage. The 
risk was not significant also for the Framingham criteria that included left ventricular 
strain with high QRS amplitudes. CVD mortality risk was over four -fold for the 
authors' Perugia Score that in essence is a logic combination of three criteria (Cornell 
voltage >2,400 µV in men and >2,000 µV in women or Romhilt-Estes score >5 or 
left ventricular strain). The promising feature of the reported risk for this new 
criterion was that its prevalence in the study population was high, 17.8%, with 
concomitant population attributable risk of 37.0%. A high population attributable risk 
has connotations of etiological implications. Encouraging reports about the feasibility 
to use ECG-LVH in identification of subgroups at increased mortality risk have raised 
hopes that monitoring of the reduction of ECG-LVH may open doors for a convenient 
monitoring of the success of hypertension intervention efforts. An early example 
comes from MRFIT with the observation that there was a significant decrease in the 
Cornell voltage in the special intervention group compared with the usual care group 
of the study. Also regression exceeding the limit of short-range variability of the 
Sokolow-Lyon voltage was actually associated with independent excess CVD 
mortality risk, and there was no evidence for reduced risk by other criteria 
evaluated. 563 
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It is now clear from several trials, meta-analyses, 564 and one meta-analysis review565 
that there is a strong relationship between changes in blood pressure and LVH 
regression. The overall ranking of anti-hypertensives according to Jennings & 
Wong565 was: calcium antagonists, angiotensin converting enzyme inhibitors, 
diuretics, alpha-blockers, beta-blockers, and lifestyle change. Percent reductions in 
left ventricular mass were typically 12% for ACE inhibitors, 11% for calcium channel 
blockers, 5% for beta-blockers, and 8% for diuretics. Evidence of LVH regression 
with anti hypertensive treatment also comes from population data. Mosterd et al. " 
presented data from 10,333 participants who were 45 to 74 years of age at entry. From 
1950 to 1989, the rate of use of antihypertensive medications increased from 2.3% to 
24.6% among men and from 5.7% to 27.7% among women, while the age-adjusted 
prevalence of a systolic blood pressure above 160mmHg or diastolic blood pressure 
above 100mmHg declined from 18.5% to 9.2% among men and from 28.0% to 7.7% 
among women. They report that this decline was accompanied by reductions in the 
prevalence of LVH from 4.5% to 2.5% in men and from 3.6 % to 1.1 % in women. In 
fact, the Framingham investigators removed LVH from the most recent version of 
their prognostic score (previously the most important factor in the score) since its 
prevalence has declined probably due to the improved treatment of HBP 5ý 
Some important data from Framingham has shown that reduction of 
electrocardiographic LVH is associated with a decrease in risk. Levy 567 studied 274 
men (mean age, 60 years) and 250 women (mean age, 64 years) who were free of 
overt cardiovascular disease but manifested ECG evidence of left ventricular 
hypertrophy. Logistic regression analyses of pooled biennial examinations were used 
to determine risk for cardiovascular disease as a function of baseline voltage (sum of 
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R wave in aVL plus S wave in V3) and repolarisation abnormality. Subjects with a 
serial decline in voltage were at lower risk for cardiovascular disease; those with a 
serial rise were at greater risk. An improvement in ST depression was associated with 
a marginally significant reduction in cardiovascular risk in men only. Worsening of 
ST depression was associated with increased risk for cardiovascular disease in both 
sexes. 
While high R wave LVH may simply be a marker of physiological response to 
hypertension, ST depression inclusive-LVH is associated with an up to 15 fold 
increase in the risk of cardiac death, making it a more potent risk factor than any 
other, and suggesting that we take seriously its detection and reversal. Of the cross 
sectional studies which presented data on individuals with no history of 
cardiovascular disease, only the Belgian study provided an estimation of ST 
depression inclusive-LVH prevalence. This study estimated the age-pooled 
prevalence (25yrs-74yrs) at 0.8%. That is, screening asymptomatic individuals might 
pick up the one person with unrecognised ST depression inclusive-LVH out of one 
hundred screened. 
The expectation of reduced risk with reduction of ECG-LVH conflicts with recent 
echocardiographic evidence that has failed to demonstrated improved risk with 
LV mass reduction with ACE-inhibitors, at least in high-risk hypertensive patients 
with diabetes. 568 The concept of attributable risk has to be used with caution, and it is 
unrealistic to assert that ECG-LVH in itself would be a causative factor in mortality. 
It is plausible to speculate, however, that certain repolarisation wave features (not 
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necessarily isolated negative T waves) combined with high QRS amplitudes may 
be a 
marker for a substrate for adverse cardiac events. 
1.4.9 Genetics of LV Mass 
Little is known of the genetics of left ventricular mass outwith the narrow confines of 
a rare group of inherited cardiomyopathies569 although these familial disorders may 
provide insight into potential candidate genes for the study of more common forms of 
hypertrophy. However, before embarking on such investigation it is important to 
determine the extent to which left ventricular mass is heritable in the population under 
investigation. 
Even before the advent of echocardiography investigators used populations of twins 
to assess the degree of heritability of left ventricular mass. Cardiac size on CXR was 
studied by Klisouras in 1971570 who found no significant genetic contribution. In the 
1980s a number of small studies of children and young adults investigated LV mass 
and its response to training 491; 492; 57' The conclusions from these studies were 
contradictory with some suggesting a specific genetic component and others simply a 
familial one. 572 Underpowered and highly selected populations go some way to 
explain these differences. The largest twin study to date was performed on 254 twin 
pairs living in the Commonwealth of Virginia. 88 The mean age of the subjects, who 
were identified from school rosters, was 11.2 years. Verharen concluded that a genetic 
input was an important determinant of left ventricular mass in these children. 
Recent attention has concentrated on investigating specific polymorphisms that may 
be important in the aetiology of left ventricular hypertrophy. These have included 
polymorphisms of the angiotensin converting enzyme, G protein beta-3 subunit, 
aldosterone synthase, and beta-1 adrenoceptor genes (Table 1.4-5). 
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In humans the gene for angiotensin-converting enzyme (ACE) occurs in two allelic 
forms, distinguished by the presence (insertion, I) or absence (deletion, D) of a 287- 
base-pair repetitive DNA domain in intron 16. Homozygosity for the D allele was 
recently reported to be an independent risk factor for electrocardiographically 
defined 
left ventricular hypertrophy 573 In a large cross-sectional sample the DD genotype was 
associated with an overall relative risk of 1.76 that was attributable to a fourfold 
increase in risk in a subsample of 172 normotensive men. Some studies have 
associated the D genotype of the ACE gene to LV hypertrophy, sudden cardiac death, 
myocardial infarction 496; 574 However other studies have found no relationship 
495 
The ACE D/I polymorphism is known to account for about half the variance in ACE 
plasma levels, with higher values occurring in persons with two D alleles. 
75 On the 
basis of a number of experimental and clinical observations, the renin-angiotensin 
system was postulated to be in an activated state in DD homozygotes, leading to 
speculation that this genotype was associated with cardiac hypertrophy. Angiotensin 
peptides exert trophic influences on cardiomyocytes in culture, 576 and the expression 
of genes encoding components of the renin-angiotensin system is up-regulated in 
hypertrophy and remodeling 577; 578 The ability of ACE inhibitors to induce the 
regression of hypertensive left ventricular hypertrophy and prevent ventricular 
remodelling after myocardial infarction provides an intriguing clinical correlate to 
these observations. 
The 825T allele of the G-protein beta3 polymorphism is associated with the 
generation of a novel splice variant, enhanced intracellular signal transduction, and 
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arterial hypertension. 579 A recent study showed the T allele related to impaired LV 
diastolic filling in essential hypertensives. 80 It has also been associated with left 
ventricular hypertrophy in essential hypertensives 581 
A polymorphism in the intracellular cytoplasmic tail near the seventh transmembrane- 
spanning segment of the human betalAR has recently been identified in a cohort of 
normal individuals, with the Arg-389 receptors showing higher basal adenylyl cyclase 
activity and enhanced coupling to Gs. 82 This suggests that this polymorphism may 
play a role in regulating cardiac function and may be a risk factor in heart failure and 
hypertension. 
Aldosterone controls sodium balance and intravascular volume and thus helps 
regulate blood pressure. 132 Therefore, genetic variations in the regulation of 
aldosterone synthesis might influence the structure and function of the left ventricle. 
Aldosterone secretion is regulated primarily by the renin-angiotensin system. In 
response to decreased intravascular volume, renin is secreted by the renal 
juxtaglomerular apparatus and converts angiotensinogen to angiotensin I, which is 
then converted to angiotensin II by ACE. 132 
Aldosterone has been shown to stimulate the growth of cardiac myocytes and 
accumulation of cardiac extracellular matrix. Two polymorphisms of the aldosterone 
synthase gene(Figure 1.3-3) - C344T polymorphism at the SF1 transcription factor 
binding site and a gene conversion in intron2 have been associated with LV mass and 
diastolic function in one study. 98 However a larger study found no relationship 497 
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Table 1.4-5 Summary of genetic association studies of LV mass and function 
Gene Date Rcf Journal Country Ethnic Group Cases Assoc 
ACE 1994 Schunkert573 N Engl J Med Germany Caucasian 290 Yes 
ACE 1994 Iwai583 Circulation Japan Japanese 142 Yes 
ACE 1996 Lindpaintner495 N Eng! J Med USA - 2439 No 
ACE 1997 Montgomery584 Circulation England Caucasian - Yes 
ACE 1997 Beige585 J Hypertens Germany Caucasian 343 No 
ACE 1998 Kauma586 Eur Heart J Finland Caucasian 430 No 
ACE 1999 van Suylen587 Am J Respir Crit Care Med Netherlands Caucasian 87 No 
Angiotensinogen 1997 Ishanov588 Am Heart J Japan Japanese 96 Yes 
Angiotensinogen 1997 Beige585 J Hypertens Germany Caucasian 343 No 
Angiotensinogen 1998 Kauma586 Eur Heart J Finland Caucasian 430 No 
AT1R 1998 Ishanov589 Jpn Heart J Japan Japanese - No 
CYP11B2 1998 Kupari498 Circulation Finland Caucasian 84 Yes 
GNB3 2000 Poch581 Hypertension Spain Caucasian 60 Yes 
GNB3 2001 Zeltner590 Hypertension Germany Caucasian 95 No 
GNB3 2001 Semplicini591 Am J Hypertens Italy Caucasian 207 Yes 
GNB3 2002 Sedlacek 592 Hypertension USA Caucasian 1720 No 
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1.5 G proteins 
C-term -- 
L9 loop `-' 
subunits 
Figure 1.5-1 Structure of G Proteins. 
The (xiiy trimer is shown in its probable orientation relative to a 
G protein-coupled receptor and the cell membrane. (: 1)P is 
cradled between two domains of (: (x 
Heterotrimeric guanine nucleotide-binding proteins (G proteins) are signal 
transducers, attached to the cell surface plasma membrane, that connect receptors to 
effectors and thus to intracellular signalling pathways . 
5"3 Receptors that couple to G 
proteins communicate signals from a large number of hormones, neurotransmitters, 
chemokines, and autocrine and paracrine factors. G proteins play important roles in 
determining the specificity and temporal characteristics of the cellular responses to 
signals. G proteins consist of three subunits, a, ß, and y. When signalling, they 
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7 transmembrane domain region 
function in essence as dimers because the signal is communicated either by the Ga 
subunit or the Gßy complex. In most cases, Gßy subunits cannot be dissociated under 
nondenaturing conditions. Currently there are 20 known Ga, 6 Gß, and 11 Gy 
subunits. 
On the basis of sequence similarity, the Ga subunits have been divided into four 
families (Figure 1.5-2) and this classification has served to define both receptor and 
effector coupling, although there are always exceptions to the rule. The GS and Gq 
families have very well defined effector pathways, the adenylyl cyclase and 
phospholipase C-ß (PLC-ß) pathways, respectively. The G; and G. families are more 
amorphous, and here the signal flows through both the Ga and Gßy complexes. 
Perhaps the best understood of the G; family pathways is the transducin pathway, 
which mediates detection of light in the eye. 
These four broad G protein families transduce signals from a very large number of 
extracellular agents. The agents listed in Figure 1.5-2 constitute a very small subset of 
the extracellular signals that can couple to the various G protein pathways. The 
extracellular signal is routed to specific G proteins through distinct types of receptors. 
For example, epinephrine's signal is transmitted through the ß-adrenergic receptor 
coupled to GS, the a2-adrenergic receptor to G;, and the al-adrenergic receptor to Gq 
and G11. The G proteins, in turn, through signalling pathways described in more detail 
below, regulate important cellular components, such as metabolic enzymes, ion 
channels, and the transcriptional machinery. The resulting alterations in cellular 
behaviour and function are manifested in many critical systemic functions, including 
embryonic development, learning and memory, and homeostasis. This results in the 
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propagation of regulated activities through increasingly complex layers of 
organization to serve as the basis of integration at the systemic level. 
Dopamine Histamine Acetylcholine Somatostatin 
TSH 
ILS Serotonin 
LH 
Angiotensin 
Vasopressin 
Epinephrine LPA 
Glucagon ° Thrombin 
Gs Gi/o Gq/i 1 G12/13 
Ion Motility/ 
Metabolic channels and 
Transcriptional 
contractility 
Secretory 
enzymes transporters machinery machinery machinery 
Glucose Steroid Pacemaker Chemotaxis 
Cardiac Synaptic Pituitary 
metabolism production activity function plasticity function 
Organismal Embryonic Gonadal Learning 
homeostasis development development and memory 
Figure 1.5-2 Regulation of systemic functions by signalling through G protein pathways. 
A schematic representation of how signalling through G protein pathways can regulate systemic 
functions. Many extracellular agents, such as hormones (for example, glucagon, luteinizing hormone, 
and epinephrine), neurotransmitters (acetylcholine, dopamine, and serotonin), chemokines (IL-8), and 
local mediators (LPA), signal to the four main G protein families to regulate such cellular machinery as 
metabolic enzymes, ion channels, and transcriptional regulators. Modulation of the activities of the 
cellular machines in turn gives rise to altered cellular functions, such as changes in glucose metabolism 
in liver and muscle or altered activities of pacemaker cells in the heart. These cellular activities 
contribute to the regulation of large-scale systems such as organismal homeostasis and learning and 
memory. Thus, C protein pathways can propagate regulatory information through layers of increasing 
organizational complexity. At all levels, the examples shown here represent only a sample of 
extracellular agents that couple to the four G proteins, and the functions regulated by these 
pathways. Adapted from594 
G proteins are inactive in the GDP-bound, heterotrimeric state and are activated by 
receptor-catalysed guanine nucleotide exchange resulting in GTP binding to the a 
subunit. GTP binding leads to dissociation of Ga"GTP from Gßy subunits and 
activation of downstream effectors by both Ga"GTP and free Gßy subunits. (Figure 
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1.5-3) G protein deactivation is rate-limiting for turnoff of the cellular response and 
occurs when the Ga subunit hydrolyses GTP to GDP. The recent resolution of crystal 
structures of heterotrimeric G proteins in inactive and active conformations provides a 
structural framework for understanding their role as conformational switches in 
signalling pathways. As more and more novel pathways that use G proteins emerge, 
recognition of the diversity of regulatory mechanisms of G protein signalling is also 
increasing. 
1.5.1 G Protein Structure 
Ga subunits contain two domains, a domain involved in binding and hydrolysing 
GTP (the G domain) that is structurally identical to the superfamily of GTPases 
including small G proteins and elongation factors595 and a unique helical domain that 
buries the GTP in the core of the protein(Figure 1.5-1) 596; 597 The ß subunit of 
heterotrimeric G proteins has a 7-membered ß-propeller structure based on its 7 WD- 
40 repeats 598-60° The y subunit interacts with ß through an N-terminal coiled coil and 
then all along the base of ß, making extensive contacts. G protein activation by 
receptors leads to GTP binding on the Ga subunit. The structural nature of the GTP- 
mediated switch on the Ga subunit is a change in conformation of three flexible 
regions designated Switches I, II, and III to a well ordered, GTP-bound activated 
conformation with lowered affinity for G(3y. 601 This leads to increased affinity of 
Gc GTP for effectors, subunit dissociation, and generation of free Gßy that can 
activate a number of effectors. (Figure 1.5-3) 
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Of the five Gß subunits cloned thus far, Gß1-4 share an 80-90% sequence identity 
and contain -341 amino acids. The heterotrimeric G protein crystal structure reveals 
that Gß subunits contain two distinct structural motifs: the first is an a-helical 
structure comprising the amino terminus, and the second is a seven-bladed propeller 
structure. Each of the seven blades comprises a WD repeat (normally bounded by a 
tryptophan (W) and an aspartate (D) residues) that fold into ß-sheets. 602 Ga subunits 
and several effector proteins share several common interacting regions along the Gß 
propeller structure. 
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1.5.2 Mechanism of Activation of G Proteins by Receptors 
G protein-coupled receptors have a common body plan with seven transmembrane 
helices; the intracellular loops that connect these helices form the G protein-binding 
domain (Figure 1.5-1). 6°3'6°4 Both mutagenesis and biochemical experiments with a 
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variety of G protein-coupled receptors suggest that receptor activation by ligand 
binding causes changes in the relative orientations of transmembrane helices 3 and 6. 
These changes then affect the conformation of G protein-interacting intracellular 
loops of the receptor and thus uncover previously masked G protein-binding sites. 605" 
607 When an activated receptor interacts with a heterotrimeric G protein, it induces 
Upon GDP release and in the absence of GTP a GDP release from the G protein 608 
stable complex between the activated receptor and the heterotrimer is formed. 
The conformation of the GDP-bound heterotrimeric G proteins Gt and G 598'60° shows 
the overall shape of the GDP-bound heterotrimer and the residues on the surface that 
can interact with other proteins and provides the structural context for understanding a 
variety of biochemical and mutagenesis studies of receptor-interacting regions on G 
proteins. The N-terminal region of the a subunit and the C-terminal region of the y 
subunit are both sites of lipid modification. 609 These lipidated regions are relatively 
close together in the heterotrimer, suggesting a site of membrane attachment. There is 
good evidence for receptor contact surfaces on all three subunits. 
On the a subunit, the best characterized receptor contact region is at the C 
terminus. 08°610 The last 7 amino acids of the a subunit are disordered in the 
heterotrimer crystal structures, and analysis of receptor-binding peptides selected from 
a combinatorial peptide library shows that these 7 residues are the most critical. 611 
Studies using chimeric Ga subunits confirm that in fact the last 5 residues contribute 
importantly to specificity of receptor G protein interaction. Elegant mutagenesis 
studies have shown that the C terminus of the third intracellular loop of receptors 
binds to this C-terminal region on Ga subunits. 
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It is clear that the ßy subunits of heterotrimeric G proteins enhance receptor 
interaction with a subunits. 610 Single Ala mutations in residues of the ß subunit that 
contact the a subunit block receptor-mediated GTP/GDP exchange 
595 This suggests 
that the ß subunit must hold the a subunit rigidly in place for GDP release to occur. 
Direct binding interactions between receptor and ßy subunit have been reported. 612-614 
A cross-linking study demonstrated that the C-terminal 60-amino acid region of Gß 
can be cross-linked to an a2-adrenergic receptor peptide corresponding to the 
intracellular third loop of the receptor. 613 In addition, the C-terminal region of the y 
subunit of G proteins has been shown to be involved in receptor coupling and 
specificity . 
612; 614 
1.5.3 Mechanisms of Effector Activation 
1.5.3.1 a Targets 
Upon GTP binding to the a subunit, the a"GTP (a*) and ßy subunits dissociate. 598; 601 
In the GTP-bound, active conformation, a new surface is formed on Gar subunits, 615 
and they interact with effectors with 20-100-fold higher affinity than in their GDP- 
bound state. The various Ga*s interact in a highly specific manner with the well- 
studied, classical effector enzymes through this surface. Ga`, activates (and Ga'; 
inhibits) adenylyl cyclase, Ga*t activates photoreceptor cGMP phosphodiesterase, and 
Ga`q activates phospholipase C-ß. However, this conserved switch surface on Ga 
subunits does not explain the exquisite specificity of G protein a subunit effector 
interaction. A chimeric GadGa; approach identified two other regions that underlie 
the specific interaction of Gaq with phosphodiesterase y 615 Similar regions are 
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involved in effector interaction of Gaq with PLC597'616 and Gocs with adenylyl cyclase 
(AC). 610 
1.5.3.1.1 GS Pathway 
The GS pathway is the original cell signalling pathway to be described, and many key 
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Figure 1.5-4 The canonical Gs signalling pathway. 
This schematic diagram demonstrates how the cAMP pathway connects to multiple cellular 
machines, including ion channels, transcription factors, and metabolic enzymes. AC, adenylyl 
cyclase; PKA, protein kinase A; PDE, phosphodiesterase; L-Ca" channel, L-type Ca 
2+ channel; 
CNGC, cyclic nucleotide-gated channel; PhosK, phosphorylase kinase; GlyPhos, glycogen 
phosphorylase; CREB, cAMP response element-binding protein; EPAC, the cAMP- and AMP- 
regulated exchange factor for Rapl; Rapl, a small GTPase; MAPK, mitogen-activated protein 
kinase; Rafl and B-Raf, MAP kinase kinases; MEK, MAPK/ERK kinase; MEKK, MAPK/ERK 
kinase; GRK, G protein receptor kinase; RGS, regulators of G protein signalling; PAR, ß- 
adrenergic receptor. adapted from594 
concepts, including that of second messengers, 617 protein phosphorylation, 618 and 
signal transducers, 593; 619 have come from the study of this pathway. Most connections 
in this pathway have been established through biochemical experiments (Figure 
1.5-4). 
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1.5.3.1.2 G; Pathway 
This pathway was originally identified by the ability of Ga; to inhibit adenylyl 
cyclase. Many important hormones and neurotransmitters, including epinephrine, 
acetylcholine, dopamine, and serotonin, use the G; and Go pathway to evoke 
physiological responses. Signal flow through this pathway is inhibited by pertussis 
toxin, which adenosine diphosphate (ADP)-ribosylates the G protein a-subunit at its 
COOH-terminal region and thus prevents it from interacting with the receptor. In this 
pathway, both Ga and Gßy subunits can communicate signals. Gßy directly couples to 
at least four effector molecules, and indirectly to the small GTPase Ras, to activate 
MAPKs. The effectors directly regulated by Gßy include PLC-ß, KK channels, 
adenylyl cyclase, and phosphatidylinositol 3-kinase (P13K). Although each of these 
effectors exists as multiple isoforms, only specific isoforms are regulated by Guy. Key 
physiological functions, such as muscarinic cholinergic regulation of pacemaker 
activity in the heart, occur through the coupling of M2-muscarinic receptors to G; to 
release a Gpy subunit that activates K+ channels. Ga, and Gao can regulate signals 
from c-Src to signal transducer and activator of transcription 3 (STAT3) and to the 
Rap pathways, as well as inhibit adenylyl cyclase. The well-studied inhibition of 
adenylyl cyclase may be physiologically relevant, especially in inhibiting the effects 
of cAMP to modulate secretion. However, the physiological consequences of Ga; and 
Ga,, regulation of c-Src-STAT3 and Rap pathways remain to be established. Many 
connections in the Ga; and Ga. pathway have been established by biochemical 
experiments, although the newer pathways have been studied in transfected cells. It is 
currently not known how Ga; or Ga. activates c-Src, but some studies indicate 
possible direct interactions between Ga subunits and tyrosine kinases. 
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1.5.3.1.3 Gq Pathway 
The Gq pathway is the classical pathway that is activated by calcium-mobilizing 
hormones and stimulates PLC-ß to produce the intracellular messengers inositol 
trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers the release of calcium from 
intracellular stores, and DAG recruits protein kinase C (PKC) to the membrane and 
activates it. These connections have been well-established biochemically. In many cell 
types, the release of intracellular calcium activates the store-operated calcium 
channels at the cell surface to allow the inflow of extracellular calcium. Gaq, working 
through PKC and possibly directly, also appears to regulate various isoforms of 
phospholipase D. 62° Gay is reported to activate the transcription factor NF-KB through 
PYK2 621 
1.5.3.1.4 G12 and G13 Pathways 
The Ga12 and Ga13 proteins were discovered through sequence similarity to known 
Ga proteins, and which receptors endogenously couple through Ga12 and Ga13 
pathways is still unclear. Although from sequence similarity it appears that Ga12 and 
Ga13 belong to the same family, they may produce different signalling outputs but 
generate a subset of overlapping effects. 
Ga12 has been reported to directly interact with a GTPase-activating protein for Ras, 
RasGAP, and Bruton's tyrosine kinase (Btk) 622 Ga12 is thought to stimulate 
phospholipase D, c-Src, and PKC by as-yet unidentified mechanisms. The endpoint 
physiological responses of these pathways are not yet fully understood. In many cases 
it appears that different members of the MAPK family, such as extracellular signal- 
regulated kinase 5 (ERK5) or c-Jun NH2-terminal kinase (JNK), are activated. This 
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activation should lead to regulation of gene expression. In fact, Ga12 was identified as 
an oncogene in a functional screening assay623 and hence effects on gene expression 
patterns are to be expected. 
Two receptors that couple to Ga13 in the native setting are the lysophosphatidic acid 
(LPA) receptor and the thromboxane A2 receptor. Ga13 directly interacts with and 
activates a guanine nucleotide exchange factor for the GTPase Rho, p115RhoGEF, 
and thus activates Rho, leading to a variety of effects that include regulation of the 
Na+-H+ exchanger. Through the activation of PYK2, Ga13 may engage the P13K 
pathway to activate the protein kinase Akt and regulate NF-xB 
621 How Ga13 activates 
PYK2 is currently not understood. 
In Ga13, knockout mice, lack of Ga13 led to an impaired angiogenesis of endothelial 
cells and caused inability to develop an organized vascular system. In addition, Ga13 
(-/-) embryonic fibroblasts showed greatly impaired migratory responses to thrombin, 
suggesting that chemotaxis was impaired. Interestingly, although Ga12 shares 67% 
amino acid identity to Ga13, it cannot substitute for Ga13. 
The Gs pathway in Figure 1.5-4 illustrates several general patterns that emerge from 
this complex picture. First, all G proteins engage multiple signalling pathways and 
consequently different cellular machines. This often helps produce effects with 
distinct rates of activation and duration of response. In neurons, cAMP can act 
through PKA to produce short-term effects on channel functions, and through Rap and 
MAPK to regulate gene expression and produce long-term effects through regulation 
of the transcriptional machinery. Second, it appears that all G proteins regulate the 
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activity of GTPases such as Rap and Rho. Third, all G protein pathways either 
stimulate or inhibit one or more of the MAPK signalling pathways. All of these 
interconnections result in a complex and likely robust network in which signals from 
G protein-coupled receptors can be fully integrated with signals from other receptors. 
1.5.4 ßySubunit 
Much of the initial focus after the discovery and purification of heterotrimeric G- 
proteins was directed at the G-protein a subunit because it was a GTPase that acted 
on both adenylate cyclase and cGMP phosphodiesterase. Even after the identification 
of the G-protein a and ßy subunits, their role in signalling was somewhat under 
appreciated. However, two pieces of suggestive evidence hinted at a broader role for 
these subunits: (1) the ß and y subunits seemed heterogeneous in different mammalian 
tissues, and (2) the tightly bound ßy complex was an obligatory requirement for 
receptor activation of aG protein. 24As the structures of the ß and y subunits began to 
be elucidated through molecular-cloning methods, the unexpected finding that a 
complex could regulate the function of a heart K+-ion-conducting channel pointed to a 
major function for these subunits as modulators of effector function. In the decade 
following these initial results, the complex began to be treated as an equal to the a 
subunit and as a separate arm in the G-protein-signalling pathway. 
1.5.4.1 ßy Targets 
Once G(x GTP has dissociated from Guy, free ßy is an activator of a vast array of 
proteins, and the list continues to increase. 02 Significantly, the conformation of free 
Gßy is identical to Gßy in the heterotrimer, 599 suggesting that Ga inhibits Gßy 
interactions with its effectors through the Ga-binding site on G. Evidence for this 
comes from the laboratory of Iyengar and co-workers, 125 who found a peptide from 
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ACII (Adenylyl Cyclase 2) that bound to G(3y and blocked its activation of various 
effectors, suggesting that part of the effector binding site is shared between ACII, G 
protein-activated inward rectifier K+ channel (GIRK), and PLCß. Cross-linking and 
docking experiments localized the binding site to a part of the Ga-binding region. 626 
Besides the Ga-binding region, other regions of Gßy subunits that have been 
implicated in effector interaction include the N-terminal coiled coil627 628 and blades 1 
and 7 of the ß-propeller of Gß 629; 
630 
GIy has well defined effects on some isoforms of the classical second messenger 
enzymes, PLC(32 and -ß363l and AC (Gpy stimulates Goss-activated ACII, -IV, and - 
VII whereas it inhibits ACI 632 It also recruits the ß-adrenergic receptor kinase to the 
membrane where the kinase phosphorylates activated ß-adrenergic receptors. It binds 
to the phosphoprotein phosducin, which is thought to sequester ßy and thereby 
regulate its availability via a cAMP-dependent protein kinase-regulated mechanism. 
Phosducin-like proteins have also been shown to bind to Gß7633 Elucidation of the 
crystal structure of the phosducin-Gßy complex showed that there is a shared surface 
on the top of Gßy for interaction with Ga and phosducin but that a second site of 
interaction occurs between phosducin's C terminus and ß-propeller blades 1 and 7 at 
the side of Gp7.634 Interestingly, the phosphorylation site on phosducin, which 
regulates its affinity with Gfy, is far from the protein-protein interface. 
IKAch is the inwardly rectifying KK channel responsible for slowing heart beat in 
response to the parasympathetic transmitter acetylcholine. It is a homo- or 
heteromultimer of GIRK635 monomers found in the heart and brain. Gßy subunits bind 
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the N- and C-terminal intracellular domains of GIRKs and directly activate them. 635- 
637 The Gßy subunit similarly plays an important modulatory role in certain 
presynaptic Ca 2+ channels '638; 
639 especially a1A, a1B, and to a lesser extent alE but 
not a1C, all), or a1S isoforms. 
640 It has been shown that Gßy inhibits Ca 2+ channel 
current by directly contacting two regions on Ca 2+ channel a1 subunits: the 
intracellular I-II loopM1; 642 and the C terminus. 43°ßa4 
Gßy also directly activates more than one phosphatidylinositol 3-kinase isoform, 645 
and a number of kinases as well, for example, the Rafl protein kinase646 and Bruton 
and Tsk tyrosine kinases. M7 
In yeast, Gßy is the activator of a pheromone-stimulated MAP kinase pathway. It is 
known to bind to the N-terminal region of the scaffold protein Ste5 in yeast . 
648 
Recently, Thorner and co-workers 649 showed that Ste5 contains a homodimerisation 
domain, which is required for ß binding. They demonstrated that Gßy interaction leads 
to oligomerisation of this domain on Ste5. Most interestingly, dimerisation of this 
domain by making a glutathione S-transferase fusion protein of Ste5 leads to GßY- 
independent activation of the MAP kinase cascade. Recently, yeast Gßy was also 
shown to activate Cdc24, the exchange factor for the Rho-type GTPase Cdc42 650 G(3y 
has also been reported to bind to other members of the Rho family of GTPases, Rho 
and Rac, 651 as well as to the small G protein Arf (ADP-ribosylation factor), which is 
involved in coat formation and vesicular trafficking 652 
There are multiple genes for Gß and Gy, and most Gßy pairs can form functional 
Gßys 602 One of the first questions posed was whether different Gßys regulated 
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different effectors. The answer from a large number of biochemical experiments was: 
not much. G(31y1 is better than the others at interacting with rhodopsin and phosducin 
in photoreceptor cells and somewhat worse than all the other Gj3y pairs at interacting 
with other effectors. One series of studies that showed selectivity of Gßy pairs at 
interacting with receptors and effectors was done using antisense oligonucleotides to 
suppress the translation of particular proteins, and these studies showed a very high 
degree of selectivity (see below). Other evidence of specificity, using different 
techniques, is slowly emerging. Gß5, a recently discovered Gß subunit found in the 
central nervous system, 653 differentially couples to two MAP kinase pathways. 654 
Because Ga can inhibit all the actions of Gßy, the Ga-binding residues are candidate 
effector activation determinants. Ford et al. 655 tested this idea by singly mutating the 
15 Gu-binding residues of Gß to alanines, and in all effectors that have been 
examined, some of the mutants no longer activate the effector. In each effector 
interaction, however, different residues clustered on the surface of Gß are critical, 
suggesting a mechanism whereby a unique contact surface of Gß can make specific 
interactions with a number of different effectors. Interestingly, in some cases, 
removing the side chain increases the potency of the mutant Goy to activate an 
effector. 
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1.6 G protein 133 subunit polymorphism (GNB3) 
1.6.1 G protein and hypertension 
Most transmembrane receptors rely on heterotrimeric GTP-binding proteins (G 
proteins) to activate or inhibit intracellular signalling cascades. Specifically, a variety 
of vasoactive or growth-stimulating factors communicate via G proteins in virtually 
all cardiovascular tissues. Despite this pivotal role in the transmembrane signalling 
network, only recently an active participation of G proteins was considered in the 
pathogenesis of hypertension. 
A number of endocrine, paracrine, and autocrine factors interact with receptors on 
vascular smooth muscle cells (and endothelial cells) to functionally regulate vascular 
smooth muscle tone and hence peripheral resistance. From this functional perspective, 
peripheral resistance reflects a net balance between vasoconstrictor and vasodilator 
mechanisms. 
Vasoconstrictors 
Angiotensin II (AT) 
Vasodilators 
Adenosine Ala/A2b 
Endothelin (ETA) Glucagon 
Catecholamine (aAR) Catecholamine AR 
Serotonin (5HT2) Serotonin 5HT1 
Substance P (NK2) Calcitonin Gene-Related Peptide CGRP 
Vasopressin Vi Vasopressin (V2) 
Neuro e tide Y (NPY) Vasoactive Intestinal Peptide (VIP) 
Thromboxane A2 (TXA2) Prostanoids (DP, EP, IP) 
Leukotrienes (LTC4) Dopamine D1/D5 
Histamine H1 Histamine (H2) 
Bradykinin 1B2 
Table 1.6-1 Hormones for G-protein-linked receptors on vascular smooth muscle that modify 
contractile state 
Impairment of endothelial-mediated vasodilatation has been identified in subsets of 
hypertensive subjects, particularly in those mechanisms acting via stimulation of NO 
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synthase and consequent guanylyl cyclase activation. Although these findings 
have 
been consistently confirmed in subsets of patients at greatest risk of atherosclerotic 
complications, findings in essential hypertension has not been universally 
consistent 656-658 
In vascular myocytes, activation of receptors linked to adenylyl cyclase and the 
consequent increase in intracellular camp is an important mechanism mediating 
vasodilatation. A number of G protein-coupled receptors linked to adenylyl cyclase 
activation and vasodilatation are expressed in vascular smooth muscle cells namely ß 
adrenergic receptor, EP2, DP, IP prostaglandin receptors, H2 histamine receptor, V2 
vasopressin receptor. It has been shown that impaired vascular adenylyl cyclase- 
mediated vasodilatation is common both to human and animal models of 
hypertension. In spontaneously hypertensive rats, the reduced relaxation by PAR 
agonists of femoral arteries is due to functional loss of GS protein 
659 Also in the renal 
vasculature of young spontaneously hypertensive rats, vasodilators are ineffective in 
counteracting the vasoconstrictor effect of angiotensin II, and this defect is related to 
reduced coupling of the vasodilator receptors to GS proteins 660 In Milan hypertensive 
strain rats, the amount of Gsa protein is reduced in vascular membranes, 
661 but 
paradoxically in the membranes of vascular smooth muscle cells derived from 
thoracic aortas, there appeared to be increased response to adenylyl cyclase activity 
reflecting increased PAR coupling to GS protein 662 This may reflect a generalised 
defect in vascular G protein-coupled receptor-mediated adenylyl cyclase activation. 
Feldman et a1663 showed that in younger white hypertensive subjects fed a normal 
sodium intake, ß-adrenergic-stimulated adenylyl cyclase activation was impaired in 
lymphocyte membranes. They found that this defect paralleled a reduction in the 
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ability to form the high-affinity ligand binding state of the ß adrenergic receptor, 
suggesting a functional uncoupling from G. Mills et a1664 subsequently noted that 
these defects may be race specific; that is in contrast to the impairment to the 
impairment in ß-adrenergic response in white hypertensive subjects, African 
American subjects demonstrate enhanced ß-adrenergic stimulated adenylyl cyclase 
activity. The defect in receptor-G protein coupling could represent an alteration at the 
level of either the receptor of the G-protein. Initially studies focussed on G protein 
alterations, given the appreciation that altered G protein expression and function were 
apparent in several animal models of hypertension. But subsequent studies found no 
alteration in G protein expression, in spite of decreased GS function. 665 Others have 
looked at GPCR phosphorylation which could affect the efficiency with which G 
protein-coupled receptors interact with the G proteins. 
1.6.2 NaH+ Exchanger 
Genes that encode the components of various transport systems that regulate salt and 
water homeostasis are obvious candidates for influencing blood pressure regulation 
and hypertension. 
The ubiquitously expressed pH-regulating ion transport system, Na+/H+ exchanger 
(NHE), swaps extracellular Na` for intracellular H. Five isoforms have been isolated 
in human tissues. Different investigators have demonstrated enhanced NHE isoform-1 
(NHE-1) activity in several blood cell types of patients with essential hypertension 
compared to normotensive control subjects, 666°" and transgenic mice that 
overexpress a recombinant NHE protein developed salt sensitive hypertension. 8 
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Previous investigations have shown that the enhanced Na+/H+ exchanger activity in 
hypertensive individuals is associated with several phenotypes such as left ventricular 
hypertrophy, 669 insulin resistance, 670 and renal sodium retention. 67 Because the gene 
encoding the ubiquitous Na+/H+ exchanger, NHE1 has been excluded as a candidate 
gene in essential hypertension '671 research has been focussed on the intracellular and 
systemic regulations of NHE1. 
Siffert et a1672 immortalized lymphocytes from hypertensive patients with high Na-H 
exchanger activity and normotensives with low activity. Cells derived from the 
hypertensives showed persistently greater Na-H exchange, cell proliferation, calcium 
transients, and inositol phosphate generation in response to agonists such as PAF and 
somatostatin, all suppressible by pertussis toxin, pointing to aG protein as the source 
of the enhanced response. No differences in receptor or G-protein number were 
identified, but increased binding of GTP to G proteins was observed. The finding that 
immortalized cells of hypertensive subjects displayed enhanced G protein-mediated 
signalling suggested a genetic alteration rather than a blood pressure effect as the 
underlying mechanism. Variations in NHE-1 could not be detected, 673 and 
polymorphisms in the genes that encode the subunits of trimeric G proteins, such as 
Gai2, Ga; 3, Gß1, G032 have been ruled out 674 
1.6.3 GNB3 
The molecular basis for the altered intracellular signal transduction affecting ion 
transport in immortalized cells in vitro was found to be a single base change (C--*T) 
at nucleotide 825 in exon 9 of the GNB3 gene on chromosome 12pl3, which encodes 
the ß3 subunit of the heterotrimeric protein 579 The 825T allele was associated with the 
occurrence of a splice variant, which produced a 123-base pair deletion of nucleotides 
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498 to 620 of exon 9 due to alternative splicing. This resulted in loss of 41 amino 
acids and 1 tryptophan-aspartic acid WD repeat domain of the Gß3 subunit. (Figure 
1.6-1) By means of RT-PCR experiments, expression of this alternatively spliced 
mRNA variant was confirmed in B lymphoblasts, 579 neutrophils, 675 and T 
lymphocytes. 676 
Gß proteins belong to the superfamily of propeller proteins, and all Gß proteins 
identified so far consist of 7 WD repeats that form a regular torus like structure. 602 
(Section 1.5.1 page 168) Gß3 results from alternative splicing of GNB3 and lacks the 
equivalent of 1 entire WD domain. The C825T polymorphism is located >1700 bp 
upstream of the alternative splice site, indicating that the effect of the 825T on the 
splice process is a complex mechanisms. However, such mechanisms have been 
proposed for other genes. 77 While homozygous 825C allele carriers express only the 
wild-type gene product, homo- and heterozygous 825T allele carriers apparently 
express both wild-type Gß3 as well as Gß3_S mRNA. Initially it was unclear how a 
remote polymorphism located in exon 10 could affect splicing of exon 9, leading to 
the generation of G03-s- 78 Additional polymorphisms were detected in the intron 
between exons 9 and 10, in the promoter region, and in the 3'-untranslated region. 
Interestingly, these were found to be in unusually tight linkage disequilibrium 679'680 
Hence, there exist two complex haplotypes associated with the 825T and the 825C 
allele which are expected to have an impact on the structure of the Gß3 pre-mRNA 
and may, therefore, affect splicing. 79 A second aberrant splicing process was also 
identified which affects exon 10 (in which the C825T polymorphism is located) 
giving rise to a splice variant referred to as Gß3-s2 681 By means of RT-PCR this splice 
variant was detected in human heart, T cells, neutrophils, peripheral blood 
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lymphocytes, and bladder carcinoma predominantly in cells and tissues from 825T 
allele carriers. 681 
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Figure 1.6-1 G protein ß3 subunit - Deletion in the splice variant. Adapted from 
Farfel"2 
This splice variant is believed to result in a dominant gain of function . 
678 Increased 
binding of [35S]GTPyS in Sf9 insect cells expressing Gß3.5 suggests that this splice 
variant results in enhanced activation of pertussis toxin sensitive G proteins. 579 
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The C825T polymorphism is a candidate gene for hypertension, because the mutation 
entails stimulation of the ubiquitously expressed Na+/H+ exchanger. At the 
level of the 
kidney, this may increase Na' reabsorption and cause chronic volume expansion 
683 
Prevention of intracellular acidosis may also lead to proliferation of vascular smooth 
muscle cells, vascular remodelling and increased peripheral vascular resistance. 
83 
In the context of cardiovascular function, one might expect that expression of the 
variant allele would enhance effects mediated through G; -dependent pathways that are 
involved in vasoconstriction, such as the a2-adrenoceptor-mediated response. 
Paradoxically, decreased a2-adrenoceptor-mediated response at a cellular level has 
been reported in humans with hypertension. 
84 Furthermore, the relation between the 
cellular and the functional responses is unclear and the relation between alpha2- 
adrenoceptors and the GNB3 splice variant is unknown. Alternatively, increased Gi 
activity might tonically attenuate GS mediated responses. Impairment of beta2- 
adrenergic mediated vasodilatation and other Gs-mediated responses have been 
reported in hypertension. 85 Whether these effects are related to expression of the 
GNB3 825T splice variant is yet to be determined. Thus these mechanisms remain 
plausible but as yet unproven hypotheses linking functional abnormalities in G- 
proteins and hypertension 
1.6.3.1 Hypertension 
There has been variable association between the 825T allele and hypertension both 
positive686-690 and nonsignificant69'-693 studies in Caucasian populations where 825T 
gene frequency is about 25%. Increased risk of hypertension associated with 825T 
was also reported among blacks694 who have a much higher gene frequency 
approaching 80%. A negative study was reported in African Americans. 95 Less 
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association has been reported in Asian populations, which have intermediate gene 
frequencies of about 50%, 696-698 although one Japanese study was weakly positive. 699 
Following the initial study by Siffert579 showing the T allele associated with increased 
odds of being hypertensive (odds ratio 1.44; 95% Cl, 1.09 to 1.88), Schunkert et a1690 
reported a mild association between this polymorphism and diastolic blood pressure 
level, but no association for systolic blood pressure level. They also found an 
association with lower renin levels and higher aldosterone to renin ratio, features 
consistent with low renin hypertension. One reason for this may be that some 
vasoactive factors (norepinephrine via (X2 adrenoceptors, angiotensin II and thrombin) 
are known to transmit some of their effects via pertussis toxin-sensitive G; 
proteins . 
700 70' Thus, these vasoconstrictors, if activated, may cause enhanced vascular 
resistance in individuals carrying the mutated GNB3 gene. Alternatively, the higher 
blood pressure in these individuals may be explained by vascular hypertrophy. In 
particular, growth factors of vascular smooth muscle cells like platelet derived growth 
factor are known to activate G; protein-dependent pathways 674 
Renin synthesis (reflected by total renin or prorenin plus renin levels) and renin 
release are strongly augmented by camp, which is under negative control by G; 
proteins. Thus, enhanced G; protein signalling is likely to suppress plasma renin 
levels. However, this study found no differences with respect to aldosterone levels, 
despite genotype related differences in renin levels and presumably angiotensin II 
levels. One explanation of this can be that some stimulatory factors of aldosterone 
release (e. g. angiotensin II) can act via G; proteins in a stimulatory fashion, enhancing 
phospholipase C activity, cytosolic calcium liberation, and the expression of 
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aldosterone synthase gene. 702 Thus, it may be speculated that in individuals with the 
TT genotype, lower angiotensin II levels can be compensated for by enhanced 
postreceptor signalling, and hence explain the inappropriately high aldosterone levels 
given the suppressed renin levels. This needs to be verified experimentally. Zeltner et 
a159° found in young men with normotension or mild incipient essential hypertension 
(mean age 26 years) that carriers of the 825T allele had faster tubular sodium 
reabsorption that CC homozygotes. This they attributed to increased activity of 
Na+/H+ exchanger. 
Date 
1998 
Ref Journal 
Siffert 579 Nat Genet 
Country 
Germany 
Ethnic Group 
Caucasian 
Cases 
426 
Assoc 
Yes 
1998 Kato697 Hypertension Japan Japanese 718 No 
1998 Hegele703 Hypertension Canada Oji-Cree 447 Yes 
1998 Schunkert69° Hypertension Germany Caucasian 474 Yes 
1998 Benjafield`87 Hypertension Australia Caucasian 110 Yes 
1999 Beige 686 Hypertension Germany Caucasian 479 Yes 
1999 Dong694 Hypertension England Afro-Caribbean 185 Yes 
1999 Brand691 Hypertension France Caucasian 393 No 
1999 Brand691 Hypertension Northern Ireland Caucasian 171 No 
2000 Larson695 Hypertension USA Afro-Caribbean 472 No 
2001 Turner704 Hypertension USA Afro-Caribbean 197 No 
2001 Turner 704 Hypertension USA Caucasian 190 No 
2001 Zeltner59° Hypertension Germany Caucasian 95 No 
Table 1.6-2 GNB3 and hypertension 
Hegele et a1703 also reported an association between the T allele and systolic pressure 
in a sample of Canadian aborigines. The Canadian Oji-Cree are and isolated 
community with a low prevalence of hypertension. This study found in the young and 
normotensive population, a very high prevalence of the 825T allele (0.501 compared 
to 0.25 in a general normotensive German population). They also reported a 
significantly lower systolic blood pressure in subjects homozygous for the 825T 
allele, than in subjects with the other two genotypes, and no significant relationship 
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between a diagnosis of hypertension and the 825T allele. This finding is inconsistent 
with the expectation based on the functional impact of the mutation in vitro and the 
association studies in German subjects. One reason for this disparity can be the Oji- 
Cree population were recruited by community screening and not ascertained on the 
basis of a diagnosis of hypertension and they were younger with the average age 34 
years, which may be too early for the effects of other genetic and/or environmental 
factors to contribute to the development of hypertension. Also, it can be speculated 
that the functional impact of the polymorphism could be different when hypertension 
has become the established phenotype. For example, the tendency of the 825T allele 
to predispose to elevated blood pressure at the cellular level could be adequately 
overcome, or perhaps even overcompensated for, by robust counter regulatory 
mechanisms in the younger subjects. Such possible overcompensation may result in a 
lower mean blood pressure in subjects with the T allele. With the passage of time, it is 
possible that the putative counter regulatory mechanisms may become fatigued or fail. 
Thus, the phenotype associated with the 825T allele in older subjects might be 
hypertension, which could represent the endpoint resulting from failure of counter 
regulatory mechanisms. However, there would be few precedents in human 
pathophysiology for such an explanation. Alternatively, the genomic change at GNB3 
position may not have any functional relevance in the Oji-Cree, but may instead be in 
linkage disequilibrium with another genetic change at this locus, which would be the 
actual molecular basis for the association with variation in systolic blood pressure. 
Despite the high frequency of the T allele in this population, only 28 of the 791 
subjects were prescribed antihypertensive medications. Though the frequency of the T 
allele in those taking antihypertensives was 0.571, compared to a frequency of 0.496 
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in those not on antihypertensives, the small numbers prevented any statistically 
significant association being detected. 
A study of whites with a strong family history of hypertension found an association 
between hypertension status and GNB3 genotype. 87 In this study, 110 white 
Australian hypertensives each of whom were the offspring of two hypertensive 
parents and 189 normotensives whose parents were both normotensive beyond age 50 
years, were genotyped for the C825T polymorphism. The T allele tracked with higher 
pretreatment blood pressure: diastolic=105+/-7,109+/-16, and 128+/-28 mm Hg 
(mean+/-SD) for CC, CT, and TT, respectively (P=0.001 by 1-way ANOVA). Blood 
pressures were higher in female hypertensives with aT allele (P=0.006 for systolic 
and 0.0003 for diastolic by ANOVA) than they were in male hypertensives. 
In African Americans, no association was found between this polymorphism and 
hypertension status, 695 704 while Dong et al found an association of the GNB3 
genotype and hypertension among Afro-Caribbean's in England. Turner et a1704, did 
not find any association between the C825T polymorphism and blood pressure, but 
they found the TT genotype to be a significant predictor of greater declines in systolic 
and diastolic pressure in response to thiazide diuretic therapy. They found in blacks 
and non-Hispanic whites with essential hypertension, that systolic and diastolic blood 
pressures declined 5-6 mmHg more in response to diuretic treatment in TT than CC 
homozygotes with intermediate blood pressure falls in CT heterozygotes. However, 
no association was seen between 825T and blood pressure response to change in salt 
intake in young, normotensive men. 705 In the study by Larson et a1695 angiotensinogen 
A[-6], a-Adducin Gly460Trp and GNB3 polymorphisms were examined for 
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association with hypertension status in a sample of 904 African Americans. Tests of 
simple association and multivariate logistic regression analyses revealed no 
association between hypertension status and any of the studied polymorphisms. The 
frequency of the 825T allele in this sample of African Americans was considerably 
higher (0.75 in normotensives and 0.74 in hypertensives) than that reported in whites, 
or the Canadian Oji-Cree. Turner et a1704 In contrast Dong et a1694 in a study of 428 of 
black African descent from south London, reported a 3-fold higher risk of 
hypertension among the 825T allele both as heterozygotes (odds ratio [OR], 3.43 
[95% Cl, 0.94 to 12.4]) and homozygotes (OR, 3.87 [95% Cl, 1.09 to 13.8]). The 
estimate of effect and the blood pressure values in the groups carrying the T variant 
suggested a dominant model for the T allele. This was confirmed by a significant 
association between the T allele and hypertension (OR, 3.71 [95% Cl, 1.05 to 13.1]), 
even when adjusted for age, sex, and body mass index (OR, 4.14 [95% Cl, 1.11 to 
15.4)). 
Brand et a1691 looking at 564 Caucasians from France and Northern Ireland and Kato 
et a1697 studying 718 Japanese hypertensives found no association between the GNB3 
gene and hypertension. 
1.6.3.2 Obesity 
Siffert et a! 706 reported and association of the C825T allele with obesity in young 
German men and in Chinese and Black South Africans of either sex and suggested 
that hypertension associated with the mutation could be mediated via obesity. Reports 
on the association between measures of obesity and the C825T polymorphism tended 
to be more consistent that those on cardiovascular traits. 06-ios Siffert et al looking at 
197 German hypertensive subjects reported the odds ratio for obesity versus normal 
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weight was 3.9 [95% confidence interval (CI) 1.1-14.3; P=0.03] for TT/CC and 
1.8 
(95% CI 0.7-4.6; P=0.18) for TC/CC. 708 Similarly the 825T homozygous genotype 
has been positively associated with higher body mass index, 
707; 708 body weight, 707 or 
skin fold thickness among the Inuit, 
707 Caucasians, 706 Chinese, 706 or blacks. 706 In a 
study of African immigrants and African-Americans, Poston et a1709 found individuals 
with the CC or CT genotype who were physically active had substantially lower BMIs 
(M+/-SE) (i. e., 25.74+/-2.02) than any of the other groups: sedentary CC + CT 
(30.58+/-1.03), sedentary Ti' (30.65+/-1.00) or active TT (29.43+/-1.65). Primiparous 
homozygous carriers of the 825T allele are at increased risk of obesity and post- 
pregnancy obesity, 710 however the association was limited to sedentary primiparous 
women. Hocher et al7l' found that infants whose mothers carried one or two copies of 
the 825T allele had significantly lower birthweights than did infants whose mothers 
were homozygous for the 825C allele. 
Date 
1999 
I. 
Hegele707 Genome Res Canada Inuit 213 Yes 
1999 Siffert706 J Am Soc Nephrol Germany Caucasian 277 Yes 
1999 Siffert706 J Am Soc Nephrol China Chinese 960 Yes 
1999 Siffert706 J Am Soc Nephrol South Africa Afro-Caribbean 275 Yes 
1999 Siffert708 J Hypertens Germany Caucasian 197 Yes 
2000 Gutersohn710 Lancet Germany Caucasian Yes 
2002 Poston7°9 Eat Weight Disord US Afro-Caribbean Yes 
Table 1.6-3 GNB3 and BMI 
Thus the maternal 825T allele seemingly has a dominant effect on neonatal 
birthweight, but a recessive effect on postpartum maternal weight. Poch E et al. 712 
reported an association between the T allele and insulin sensitivity that was 
independent of BMI while Wascher TC et al. 13 found GNB3 825T allele was 
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associated with reduced insulin sensitivity in men with abdominal fat distribution and 
with more advanced carotid atherosclerosis in middle-aged white men and women. 
Benjafield et al. 714 found theC825T splice variant of GNB3 makes little if any 
contribution to obesity in a cross-sectional case-control study of subjects with morbid 
obesity. 
Taken together all these findings suggest that the 825T allele is a marker of adverse 
metabolic phenotypes. As always in theses types of studies, it is not known whether 
the associations directly reflect a causative mechanism, or whether they represent 
linkage disequilibrium with other mutations in GNB3 or other genes. Siffert et al 
speculate that the 825T allele predisposes to obesity and hypertension via 
hyperinsulinaemia and increased circulating catecholamines. 708; 71° Increased 
signalling by pertussis toxin-sensitive G-proteins has been shown to stimulate 
adipogenesis715 and may be one direct mechanism. Furthermore, increased expression 
of the G2 subunit in murine embryonic stem cells has been shown to promote 
terminal differentiation of adipocytes. 716 Alternatively increased G; activity could 
tonically attenuate GS-mediated lipolysis. This potential mechanism is notable since 
impaired GS function (as occurs in the form of pseudohypoparathyroidism from an 
early truncation mutant of the alpha subunit of GS) is characterised by impaired 
adrenergic-mediated lipolysis and obesity. 717 
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1.6.3.3 Cardiac Phenotypes 
Phenotype Date Ref Journal Countr 
Ethnic Cases Assoc: 
Cardiac function 19991 Jacob? "" J Hypertens Germany Caucasian 34 Yes 
Cardiac function 2001 Zeltner59° Hypertension Germany Caucasian 95 No 
CAD 2000 Naber"$ Hypertension Germany Caucasian 585 Yes 
CAD 2003 Becklion erath719 
Atherosclerosis Germany Caucasian 998 Yes 
LVH 2000 Poch581 Hypertension Spain Caucasian 60 Yes 
LVH 2001 Zeltner59° Hypertension Germany Caucasian 95 No 
LV mass Index 2001 Semplicini591 Am J Hypertens Italy Caucasian 207 Yes 
Stroke Volume 2001 Schafers720 Pharmacogenetics Germany Caucasian Yes 
LV mass and 2002 Sedlacek592 Hypertension Germany Caucasian 2052 No 
function 
Table 1.6-4 GNB3 and cardiac phenotypes 
1.63.3.1 LV mass and function 
Poch et a! 581 reported an association between the GNB3 825T allele and LV 
hypertrophy in 86 patients with essential hypertension and a mean age of 51±1 years. 
2-mode echocardiography in these patients showed left ventricular end-diastolic 
diameter (52.0+/-0.7 versus 48.9+/-0.9 mm, P=0.007), posterior wall thickness 
(11.3+/-0.2 versus 10.6+/-0.2 mm, P=0.042), and left ventricular mass index (152.7+/- 
4.4 versus 135.2+/-6.4 g/m2, P=O. 023) were significantly higher in patients with CT 
and TT genotypes considered together (CT+TT) than in CC patients. The distribution 
of the genotypes was significantly different when comparing patients with LVH: 20 
(0.33) CC and 40 (0.67) CT+TT patients had this complication, and 17 (0.65) CC and 
9 (0.35) CT+TT patients did not (P<0.01). The frequency of the T allele was 
significantly different among patients with (0.40) and without (0.20) LVH (P<0.01). 
A logistic regression analysis showed that the association between the T allele and 
LVH was independent of age, mean blood pressure, body mass index, and alcohol 
consumption. The relative risk of LVH in patients bearing the T allele (CT+TT group) 
compared with CC hypertensive patients was 3.03 (95% Cl 1.14 to 8.05). 
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Jacobi et a1580 in a study of 34 white patients with established mild to moderate 
essential hypertension showed that the GNB3 825T allele was not associated with left 
ventricular mass. However, transmitral flow variables reflecting left ventricular 
diastolic filling were impaired in patients expressing the TCTT genotype (ratio of 
peak late (A) to early (E) velocities: CC versus TC/TT, 0.95 +/- 0.24 versus 1.2 +/- 
0.26, P< 0.02; velocity time integrals A/E: CC versus TC/TT, 0.57 +/- 0.16 versus 
0.76 +/- 0.23, P< 0.01) while all co-variables such as age, body mass index, 
ambulatory blood pressure, heart rate and end-diastolic volume were similar between 
the two groups. This suggested that since alterations in left ventricular filling have 
been identified as an early marker of hypertensive heart disease, the GNB3 C825T 
polymorphism might influence cardiac adaptation to increased afterload. An increased 
heart stroke volume in young, normotensive volunteers was reported. 20 
Zeltner et a159° in a study of 95 white male students with normal or mildly elevated 
blood pressure found no association between the GNB3 825T allele and indices of left 
ventricular mass, left ventricular systolic or diastolic function. 
In a study of 2052 individuals from a large population based sample in Germany, 
Sedlacek K et a1592 showed GNB3 T allele had no strong and clinically relevant effect 
on the variability of LVM. 
It is hypothesised that GNB3 subunit gene polymorphism may constitute a genetic 
basis for the enhanced growth phenomena observed in essential hypertension, such as 
i 
LVH and media hypertrophy of the vessel wall, because it is directly associated with a 
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functional change and may not merely represent a DNA marker. G proteins mediate 
part of the actions of vasoactive hormones, such as angiotensin II and 
norepinephrine. 70° Angiotensin II exerts trophic effects on cardiomyocytes in 
culture, 721 while growth factors, such as platelet-derived growth factor, can act in part 
through pertussis-sensitive G proteins in skin fibroblasts, vascular smooth muscle 
cells, cardiac fibroblasts and may participate in the pathogenesis of LVH 494 
Indeed, LVH is a complex genetic trait, and a single gene variant, albeit functionally 
relevant, may carry a minute contribution to the final phenotype. Therefore, it is 
inherently complicated to demonstrate its influence in even large-scale and well- 
powered association studies. By contrast, smaller studies have been shown to carry a 
risk of an -error. 
722 Thus, a cautious interpretation of such studies may be advisable. 
1.6.3.3.2 Coronary artery disease 
Several reported characteristics of the GNB3 C825T polymorphism make it a 
candidate gene for coronary artery disease. The 825T allele has been shown to be 
associated with hypertension and obesity which are established risk factors for MI. 
The 825T allele carriers display an enhanced activation of neutrophils675 and 
plateletS723 which could play a role in plaque disruption and subsequent MI. The 825T 
allele has also been shown to be predictive of enhanced vasoconstriction and 
myocardial ischaemia after intracoronary a2-adrenoceptor activation. 24 
Naber et a1718 studied 585 patients with angiographically confirmed coronary artery 
disease (270 with and 315 without previous MI). There was no significant association 
between GNB3 genotypes and BMI, hypercholesterolaemia, hypertension, diabetes, 
smoking and previous MI. However the odds ratio for MI associated with the 825T 
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allele though statistically significant was relatively small at 1.5. Assuming that the 
complex polygenic nature of ischaemic heart disease implies that 
interaction of 
various candidate genes substantial to increase the risk of MI, they followed on to test 
for interaction of GNB3 with the ACE gene in this population. The D allele of the 
ACE I/D polymorphism is associated with increased serum ACE concentrations, and 
thus may become pathophysiologically important in individuals whose genetic 
makeup comprises an allelic variant that causes an increased cell responsiveness. In 
this respect the GNB3 825T allele is an attractive candidate to interact with the ACE 
gene. 
OR(TT vs. CC) OR(CT vs. CC) OR(TT/CT vs. CC) 
ACE DD 7.5(1.5-37.3) 2.2(1.1-4.3) 2.4(1.2-4.8) 
=0.006 p=0.03 =0.02 
ACE ID 1.4(0.6-3.4) 2.0(1.2-3.2) 1.9(1.2-3.0) 
>0.05 p=0.005 =0.01 
ACE II 0.5(0.1-1.7) 0.6(0.3-1.1) 0.5(0.3-1.0) 
p>0.05 p>0.05 p>0.05 
Naber et al found a significantly increased OR for MI associated with the 825T allele 
in individuals with the ACE DD genotype. The increased OR associated with the 
825T allele was smaller in individuals with the ACE ID genotype and completely 
disappeared in conjunction with the ACE II genotype. 
Von Beckerath et al. 719 tested whether GNB3 C825T was associated with an increased 
risk of coronary artery disease (CAD) in 998 angiographically examined, consecutive 
patients with CAD and 340 angiographically examined, sex- and age-matched 
controls with no evidence of CAD. The proportion of T allele carriers was 
significantly higher in the group with CAD compared with the control group (55.6 vs. 
48.5; P=0.02). T allele carriage was associated with a 33% increase in the unadjusted 
risk (OR 1.33 [95% confidence interval, 1.04-1.70]) and a 37% increase in the 
adjusted risk (OR from the multivariate model 1.37 [95% CI, 1.06-1.76]) for CAD. 
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Moreover, an increase in T allele carriage was associated with an increase in disease 
severity (P=0.006; test for trend). The strongest association was observed between T 
allele carriage and three-vessel disease (unadjusted OR 1.47 [95% CI, 1.10-1.961). 
This observed interaction might result from synergistic but independent effect of each 
genetic factor. However functional considerations support the hypothesis of a true 
interaction between both alleles. Hormones of the rennin-angiotensin-aldosterone 
system, which is affected by the ACE ID polymorphism, activate G protein-coupled 
receptors, whose signalling properties may be altered in the presence of an 825T allele 
at GNB3. G protein ßy-subunits play a role in modulating agonist-receptor affinity of 
the AT-II receptors, 725 and AT-II in particular increases the expression of pertussis 
toxin-sensitive G proteins, 726 whose signalling properties are in turn enhanced in the 
presence of an 825T allele at GNB3 579 In addition, several pathways downstream of 
the AT-II receptors affect signalling cascades in which G protein ßy-subunits are 
assumed to be involved, for example activation of phospholipase C727 and D, 728, 
regulation of Ca2+ channels, 729 and the transactivation of growth factors. 730 For 
example such an interaction may result in further enhanced platelet aggregation 723; 731 
with an increased susceptibility for acute coronary thrombosis. Unfortunately, little is 
known about the specific contribution of GNB3 and its splice variant to these 
processes. Moreover, besides increased ACE levels, an effect of the ACE D allele on 
AT-II concentration has not yet been proven. Thus, the molecular nature of the 
interaction of the GNB3 825T allele and the ACE D allele remains to be elucidated. 
Also this study was confined only to patients with coronary artery disease, and such a 
selection may cause a specific bias, this need to be replicated in studies that involve 
healthy subjects as well. 
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1.6.4 Haplotypes 
A number of other variants have been identified that are in linkage disequilibrium 
with 825T. 79 Six novel single nucleotide polymorphisms in the GNB3 gene termed 
according to their location as G76A, G1906T, G2906A, A3882C, G5177A, and 
G5249A and a CACA-insertion-deletion polymorphism position 6496 were found. 
Genotyping and association studies resulted in the definition of two major GNB3 
haplotypes, termed 'C-haplotype' (alleles 825C, 3882A, 5249G, 6496CACA-) and T- 
haplotype' (alleles 825T, 3882C, 5249A, 6496CACA+) 679 
A strong association was seen between 825T and the generation, through an alternate 
splice site, of yet another short variant of GNB3 (Gß3-s2), which also showed greater 
signal transduction activity 681 Gß3_. 2 is generated by alternative splicing using non- 
canonical splice sites. Transcripts for Gß3_. 2 are lacking 129 bp of the coding sequence 
of the wild-type Gß3 protein. Thus the predicted structure consists of only six 
propeller blades, which resembles the structure of Gß3-S. Co-immunoprecipitation 
analyses indicated that G(33-s2 dimerises with different Gy subunits, e. g. Gy5, Gys and 
Gy12. In Sf9 insect cells, expression of Gß3-s2 together with Gy12 enhances receptor- 
stimulated activation of Gait. Expression of Gß3_. 2 in mammalian cells activated the 
mitogen-activated protein kinase cascade 681 The precise mechanism explaining the 
strong association of 825T and the shorter variants has not yet been elucidated. The 
fact that only a minority of clones expressed the Gß3-second variant suggests, 
perhaps, that there exists another linked site or sites in the gene that control 
expression. 
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1.6.4.1 Other Associations 
Other associations with the 825T variant include enhanced vasoconstriction in 
response to endothelin-1, norepinephrine, and angiotensin 11,732 but not an a-2 
agonist720 and a substantially increased response to sildenafil. 733 Radial artery 
hypertrophy was 3 times more frequent (P < 0.001) in a healthy population carrying 
the 825T variant, 734 carotid atherosclerosis, 713 and increased risk of stroke. 735 
Despite the epidemiological evidence, the in-vivo function- at either a cellular or 
integrative level- of the GNB3 splice variant remains largely unknown. Thus, to 
determine cause and effect between clinical phenotypes and GNB3 825T, studies are 
still needed of the relation between this allele and intermediate biochemical and 
physiological phenotypes. All association studies, taken together highlight the 
challenges involved when attempts are made to translate genotypic differences into 
mechanisms that underlie complex phenotypes. 
In summary since G protein activation is the key event in intracellular signal 
transduction, it is logical to assume that the C825T polymorphism may have an 
impact on a variety of disease processes, signal transduction in human cells and 
tissues, as well as responses to common drugs. This has been tested in various clinical 
settings, in some studies, the 825T allele was shown to variably increase the risk for 
obesity, 
706; 708; 710 hypertension, 689; 690 coronary heart disease, 718 719 stroke, 
713,735 
and 
depression 736; 737 in the white human population of European descent. By contrast, the 
association of the 825T allele with these disorders in other, non-Caucasian ethnicities 
remains controversial. 695; 697-699; 738 Furthermore, the 825T allele serves as a 
pharmacogenetic marker to predict responses to diuretics, 704 antidepressants, 737 
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sildenafil, 733 clonidine, 739 angiotensin 11,732 endothelin-1,732 and responses to 
vaccination against hepatitis B. 
676 One study showed GNB3 polymorphism was 
associated to response to diuretics. 
704 This has however not been replicated. It is not 
clear if this is a causal association as it is not clear that the polymorphism is 
functional. Finally, the molecular and biochemical mechanisms underlying these 
associations are largely obscure. 
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Chapter 2- OBJECTIVES 
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Despite the initial molecular work by Siffert et al., subsequent genetic association 
studies have not confirmed if the GNB3 polymorphism is indeed a candidate gene for 
hypertension. Many questions remain in relation to the biochemistry associated with 
the truncated G protein ß3 subunit (Gß3_,, ) and its overall relevance to essential 
hypertension and other cardiovascular phenotypes. The work presented in this thesis 
is a detailed study of the C825T G protein ß3 subunit (GNB3) polymorphism in 
human essential hypertension 
The objective is to investigate if the GNB3 polymorphism is indeed functional and if 
so, to determine the biochemical, cellular and clinical phenotype associated with it. 
The plan of the study is to answer the following questions - 
" Is the 825T allele associated with blood pressure phenotypes? 
o Case-Control study - To study the association with hypertension 
o Twin study - To study the association with echocardiographic LV 
Mass 
o Family study - To study the association with blood pressure and ECG 
LV mass 
" Does C825T GNB3 polymorphism increase signalling through GPCRs acting 
via Gj2a ? 
o Platelet aggregation in normal volunteers should show that the 
presence of 825T allele is associated with increased platelet 
aggregability 
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9 Does presence of Gß3_, lead to increased activation of G;,? 
o Use a GPCR-G protein fusion strategy to measure GTPase activity in 
HEK293 membrane preparations following co-expression with either 
Gß3 or Gß3_,, and 75- 
9 Is there any difference in effector activation by the two variants of GNB3 
subunit? 
o Use a GPCR-G protein fusion strategy to measure single cell calcium 
signal in EF88 membrane preparations following co-expression with 
either Gß3 or Gß3_, and ys. 
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Chapter 3- MATERIALS AND METHODS 
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3.1 Genomic DNA Extraction: 
Genomic DNA was isolated by phenol-chloroform extraction of EDTA-blood 
samples. 
740 
3.1.1 Reagents 
10 ml blood collected into EDTA tubes (Vacutainers - Becton Dickinson) 
The following solutions were prepared prior to DNA extraction. 
Erythrocyte lysis mix 
Water -10 L 
Sucrose (0.32 M) - 1090 g 
Tris Base (10 mM) - 12.1 g 
MgC12 (5 mM) - 10 g 
Adjust to pH 7.5 with conc. HC1 
Autoclave at 121°C for 20 minutes 
After cooling to room temperature add Triton X-100 - 1%) 
Nucleic Lysis Mix 
Tris Base (10 mM) - 0.6 g 
NaC1(0.4 mM) - 11.7 g 
EDTA (2 mM) - 0.2 g 
Adjust pH to 8.2 
Autoclave at 121°C for 20 minutes 
10% Sodium Dodecyl Sulphate (Lauryl Sulphate - SDS) 
SDS-100g 
Distilled water - 100 ml 
Proteinase K solution 
Proteinase K- 100 mg 
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10%SDS-1 ml 
Distilled water -9 ml 
Saturated NaCl 
NaCl -175 g 
Distilled water - 500 ml 
Phenol/Chloroform 
Phenol (equilibrated with 0.1M Tris Rathburn) - 500 ml 
Chloroform (equilibrated with 1: 24 iso-amyl alcohol)- 500 ml 
8-hydroxyquinoline -2g 
ß-mercaptoethanol- 200 µl 
3.1.2 Apparatus 
9 0.5 ml Eppendorf tubes (Alpha Labs) 
" Finnpipettes - 1-10 µl; 5050 µl; 50-200 µl; 200-1000 µl; 1-5 ml 
" Universal containers - 30 ml (Sterilin) 
" Falcon tubes -50 ml (Becton Dickinson) 
" 1.5 ml microtubes (Alpha) 
3.1.3 Methods 
DNA is extracted from 10 mis of EDTA blood using the following protocol. 
In a 50 ml Falcon tube 40 ml of the erythrocyte lysis mix is added to 10 mis of whole 
blood from EDTA tube collection. They are mixed by inverting five times and then 
centrifuged at 2800 rpm for ten minutes. The pellet is resuspended in 3 mis of the 
nucleic acid lysis mix. To this 200 µl of 10% SDS and 100 µl Proteinase K solution 
are added and incubate at 37°C for 18 hours. After this 1 ml of saturated NaCl is 
added and the tube shaken vigorously for 15 seconds. 5 mis phenol chloroform 
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solution is then added to the mix in a taking precautions in a fume cupboard. 
This in 
now centrifuged at 2500 rpm for 20 minutes. After centrifugation, the top partitioned 
layer is transferred to a 30 ml Universal container and 2 volumes 99% ethanol added. 
The DNA precipitates and it is spooled out carefully and rehydrated in 400 µl distilled 
water in labelled 1.5 ml microtube. This is left at room temperature for 48 hours and 
then transferred to -70°C freezer. 
3.1.4 DNA Quantification 
DNA was quantified using UV spectrophotometry. Initially DNA purity is determined 
by adding 15 µl of each sample to 735 µl TE, mixing well, and reading the optical 
density at 260 nm and 280 nm (OD260 and OD0). The ratio OD260/ODo should be 
determined in order to assess the purity of the sample. If this ratio is 1.8-2.0, the 
absorption is probably due to nucleic acids. A ratio less than 1.8 indicates that there 
may be proteins and/or other UV absorbers in the sample, in which case the DNA is 
reprecipitated. A ratio higher than 2.0 indicates the samples may be contaminated 
with chloroform or phenol and should be re-precipitated with ethanol. 
After determining purity, the DNA is quantified by measuring OD260 and using the 
following formula. 
DNA concentration (µg/µ1) = OD260 x 50 (dilution factor) x 50/1000 µg/ml 
3.2 Genotyping C825T G-protein ß3 subunit 
polymorphism 
PCR was conducted in a 50 µl volume reaction in a 96 well plate using Perkin-Elmer 
thermal cycler, using the method of Siffert et al 579 
3.2.1 Instrumentation 
Thermal Cycler: Perkin Elmer 
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Electrophoresis 
Bio-Rad PowerPac 300 
Submarine Gel System Bio-Rad Sub-Cell GT 
3.2.2 Reagents 
The following solutions were prepared for the PCR reaction 
Electrophoresis Buffer (EB) 
a) Prepare 5N NaOH - 200 g NaOH in 1L distilled water 
b) In a 10L beaker add 186.12 g EDTA to 1L distilled water 
c) Add 5N NaOH to (b) until the solution clears at pH 7.0 
d) Dissolve 2420 g Tris Base in 5L distilled water and add to (b) 
e) Ass approximately 570 ml glacial acetic acid to (b) until pH 8.0 
f) Make (b) upto 10 L with distilled water 
Agarose: 2.5% GIBCO-BRL agarose 
a) Add 2.5 g GIBCO-BRL agarose to 100 ml electrophoresis buffer in a 
250 ml conical flask 
b) Bring to boil in a microwave oven for 60 seconds 
c) Transfer the flask to fume cupboard and add I µ1 Ethidium Bromide 
(10 mg/ml) 
d) Gently swirl liquid to disperse the ethidium bromide and allow to cool 
for 2 minutes before pouring into gel tray casting assembly 
e) Allow the agarose to gel in fume hood at room temperature then 
transfer to submarine gel tank 
Reaction mixture 
DH2O - 34.8 µL 
Buffer -5 µL -20 mM/L Tris-Hcl (pH 8.4), 50 mMl/L KC1 
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MgC12 -3 µL -1.1 mM/L 
(1: 10) Primers -1 µL X2- 20 pmol each 
(1: 10) DNTPs -1 µL X4 - 200 µM/L each 
Taq Polymerase - 0.2 µL 
Genomic DNA - 100 ng 
3.2.3 PCR components 
Sense primer: 5'-TGACCCACTTGCCACCCGTGC-3' 
Antisense primer: 5'-GCAGCAGCCAGGGCTGGC-3' 
PCR product with the flanking primers: 
TGACCCACT TGCCACCCGT GC cctcagtt cttccccaat ggagaggcca 
tctgcacggg ctcggatgac gcttcctgcc gcttgtttga cctgcgggca gaccaggagc tgatctgctt 
ctcccacgag agcatcatct gcggcatcac gtccgtggcc ttctccctca gtggccgcct actattcgct 
ggctacgacg acttcaactg caatgtctgg gactccatga agtctgagcg tgtgggtaag 
gGCCAGCCCT GGCTGCTGC 
3.2.4 PCR protocol 
The PCR reaction is carried out in 96 well Thermowell Plates (MADGEBIO) in 
Perkin Elmer thermal cycler. Each reaction mix per well is made up with 34.8 µL of 
distilled water, 5 µL of buffer which contains-20 mM/L Tris-Hcl (pH 8.4) and 50 
mMl/L KCI, 20 pmol of each primer made as a 1: 10 dilution solution, 200 µM/L of 
each nucleotide, 0.2 µL of Taq Polymerase and 100 ng of genomic DNA. The stock 
solution is initially made up using strict hygienic standards to avoid any cross 
contamination. The DNA was added last. Once all the wells were loaded, the 96 well 
plate is sealed and transferred to the thermal cycler. The PCR reaction is carried out 
with the initial denaturation phase for 5 minutes at 94°C followed by 35 cycles 
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comprising denaturation at 94°C for 1 min, annealing at 60°C for 45 seconds and 
extension at 72°C for 1 minute followed by a final extension step at 72°C for 7 
minutes. After the PCR reaction is completed, the digestion mix is loaded in another 
96 well plate. The restriction enzyme placed on ice during loading and taken out of 
the freezer for the minimum possible time. The digestion mix consists of the 
restriction enzyme BseDl-0.04 µL (Helena Biosciences), 1.5 µL of Y/TangoBuffer, 
8.46 µL of distilled water and 5µL of the PCR product. The 96 well plate is sealed 
and transferred to the thermal cycler and incubated for 2 hours at 55°C. 
3.2.4.1 Electrophoresis and visualization 
The digested PCR products are electrophoretically resolved on 2.5% agarose and 
visualized under UV illumination after ethidium bromide staining. First 10 µl of PCR 
product is added to 5 µl sucrose dye in a 96 well plate using a8 channel pipette. This 
is loaded into 2.5% agarose gel and run for 1 hour at 100 Volts. 
The electrophoresis bands are read as follows. The non-digested product (TT 
genotype) shown a single band of 268 bp, and complete digestion of the PCR product 
(CC genotype) generates bands of 116 and 152 bp. Heterozygotes (CT genotype) 
display three bands (Figure 3.2-1). 
Figure 3.2-2 and Figure 3.2-3 show the sequencing of the PCR product from two 
different genotypes to verify that the PCR detected the right genetic polymorphism. 
Figure 3.2-2 shows the sequence of the CC genotype PCR product after digestion and 
Figure 3.2-3 the sequence of the CT genotype. At position 140 which corresponds to 
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the location of the GNB3 C825T polymorphism, Figure 3.2-3 shows a dual peak with 
both C and T nucleotides present. 
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3.3 Cell Transformation and Amplification of 
plasmid DNA 
All materials for tissue culture were supplied by Life Technologies Inc. (Paisley, 
Strathclyde, UK). The a2-adrenoreceptor antagonist [3H]RS-79948-197 (90 Ci/mmol) 
was purchased from Amersham International. [g-32P]GTP (30 Ci/mmol) was 
obtained from DuPont/NEN. Cholera toxin and pertussis toxin were purchased from 
Sigma (St. Louis, MO). 
3.3.1 GPCR-G Protein Fusion construct (Porcine a2A 
Adrenoceptor-GaCys 351 -Ile) 
a2A adrenoceptor-Cys35'Giia is a GPCR-G protein fusion construct obtained from Prof 
Milligans laboratory and used to study the functional characteristics of the G protein 
P3 subunit and its splice variant. The Cys35'Ile mutation renders the fusion construct 
pertussis toxin resistant. The construction this fusion protein is described by Wise et 
a1741 and Jackson et al. 742 
3.3.2 Cell Transformation 
The following reagents were made prior to commencing cell transformation. 
L-Broth medium (LB) 
Tryptone - lOg 
Yeast Extract -5g 
NaCl -10 g 
Water - 1000 ml 
Adjust pH to 7.0 
Sterilise in an autoclave 
L- Agar 
Tryptone - lOg 
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Yeast Extract -5g 
NaC1-10 9 
Water - 1000 ml 
Adjust pH to 7.0 
Agar -15 g 
Sterilise in an autoclave 
After cooling add stock ampicillin to a concentration of 20-60 µg/m1 
Ampicillin 
Ampicillin 50 mg/ml in distilled water 
Working concentration - 20-60 µg/m1 
Add stock ampicillin solution to media 1: 1000 dilution 
First an aliquot of competent bacteria (XL1) is thawed on ice, and 50 µl per 
transformation is added to a 10 ml sterile tube. Then add 2 µl of selected plasmid 
DNA (1-5 µl) to the competent bacteria and leave it on ice for 15 minutes. 
Transformation is done by heat shock at 42°C for 90 seconds in a water bath. After 
exactly 90 seconds, the tube with the bacteria is returned to ice for 2 minutes. Then 
450 ti of L-Broth is added to this and shaken at 37°C for 45 minutes. After this 200 
µl of this mix is plated onto ampicillin-agar plate and left inverted at 37°C overnight 
in an incubator. 
The next morning distinct colonies of the transformed bacteria are seen on the agar 
plate. A single distinct colony from the overnight culture plate is added to a 30 ml 
sterile universal tube containing 5 ml of L-broth and 5 µl Ampicillin stock using the 
standard precautions. For control a similar tube is used but without adding the 
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bacterial colony. The tubes are incubated in a shaker at 37°C for 6 hours, and 
afterwards the universal container with bacteria is seen to be cloudy while the control 
container remains clear. 
The entire contents of the universal is added into an autoclaved conical flask 
containing 100 ml of L-broth and 100 µ1 of ampicillin using standard precautions. The 
flasks are incubated at 37°C overnight with constant shaking. 
The next day Maxiprep of the plasmid DNA is carried out using Qiagen Maxi Kit 
using instructions provided by the manufacturer. 
3.3.3 Quantifying plasmid DNA 
The plasmid DNA obtained after maxiprep is diluted to 1: 100 solution. Add 1 ml of 
water to a quartz cuvette as control and add 1 ml of the diluted DNA to another quartz 
cuvette. Auto zero the photometer with the blank sample at 260 nm and using the 
cuvette containing the DNA sample, readings are taken at 260 nm and 280 nm. 
Knowing that 50 µl/ml of DSDNA has an optical density at 260 nm (O. D. 0) of 1, the 
concentration of DNA can be calculated as 
O. D. 260 X 50 = DNA concentration in µg/m1 
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Table 3.3-1 Concentrations of the four plasmid DNA used for subsequent experiments. 
3.4 Transfections and membrane preparation of 
HEK293 and COS-7 cells 
3.4.1 Transfection 
All tissue culture experiments were carried out in the tissue culture laboratory using 
strict tissue culture protocols. HEK293 and COS-7 cells were cotranfected with 
GPCR-G protein fusion protein, Gß3 or G133_, and ys DNA. The cells were maintained 
in Dulbecco's modified Eagle's medium (DMEM) containing 10% (v/v) foetal-calf 
serum, 2 mM L-glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin. Cells 
were seeded in 60-mm culture dishes and grown to 60-80% confluency (18-24 h) 
before transfection with pCDNA3 containing the relevant cDNA species, using 
lipofectamine reagent (Life Technologies Inc. ). 743 Optimem is pre-warmed by placing 
in a 37°C water bath. DNA is prepared by diluting an appropriate volume of each 
DNA to 0.1 µg/µ1. 
The Lipofectamine/Optimem (Lipof/Opt) is prepared for the required number of 
plates as follows 
PCDNA3 240 - - 120 360 
a2AG; 120 120 120 - - 
3 - 120 - 120 - 
3-s - - 120 - - 
5 - 120 120 120 - 
O timem 2040 2040 2040 2040 2040 
Li of/O t 2400 2400 2400 2400 2400 
For each 10 cm3 plate of cells add 9 gg of DNA per plate. Make up the following 
tubes for transfecting 4 plates with each mixture. The Lipofectamine/Optimem 
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mixture is added last and drop wise. These tubes are then 
incubated at room 
temperature for 30 minutes. Following this add 19200 µl of Optimem to each tube. 
For each plate to be transfected, first wash out with 10 ml Optimem, then to each plate 
add 6 ml of the DNA mixture, which equals 9 µg of DNA per plate. Incubate the 
plates at 37°C for 5 hours and then add 10 ml of Dulbecco's modified Eagle's medium 
to each plate and incubate overnight. The next morning, replace the media with 9 mIs 
of fresh Dulbecco's modified Eagle's medium and after 6 hours add Pertussis toxin (25 
ng/ml) to each plate as follows in order to bring about ADP-ribosylation of the 
endogenous G; -family G-proteins, 
744 and thus prevent potential interactions between 
these and the fusion protein. 
For 22 plates 
Dulbecco's modified Eagle's medium - 22 ml 
Pertussis toxin - 27.5µl 
Add 1 ml of the mixture to each plate 
The plates are incubated overnight at 37°C and the cells harvested the next day for 
membrane preparation or used for calcium signalling experiments. 
3.4.2 Membrane preparation 
The cells in each plate are detached mechanically by scraping and suspended in TE 
buffer containing 0.5 ml of 10 mM Tris/HCI, 0.1 mM EDTA, pH 7.5. The cell 
suspensions in media are centrifuged at 4000 rpm for 15 minutes at 4°C and the 
supernatant discarded. The cells are resuspended in Phosphate Buffered Saline (PBS) 
by vortexing. The suspension is then centrifuged at 4000 rpm for 15 minutes at 4°C 
and the supernatant discarded. The pellet is frozen at -80°C. After 2 hours, the cell 
pellets are resuspended in 0.5 ml of 10 mM Tris/HCI, 0.1 mM EDTA, pH 7.5 (TE) 
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and rupture of the cells achieved with 50 strokes of a hand-held Teflon/glass 
homogeniser followed by passage (10 times) through a 25-gauge needle. The cell 
lysates were centrifuged at 1000 g for 10 min at 4°C in a Beckman TJ-6 centrifuge to 
pellet the nuclei and unbroken cells and P2 particulate fractions were then recovered 
by centrifugation of the supernatant at 200000 g(50000 rpm) for 30 minutes at 4°C 
in a Beckman TL 100 bench-top ultracentrifuge using a Beckman TLA 100.2 rotor. 
The membranes are seen as translucent pellets. All the supernatant is removed and the 
pellet is resuspended in 300 µl of TE buffer. This suspension is added to a tube with 
TE buffer made upto 4 mis. This is then aliquoted into eppendorf tubes each 
containing 300 µl and stored at -80°C 
3.4.3 Membrane protein assay 
Protein concentrations are determined with the bicinchoninic acid (BCA) procedure745 
using BSA as standard. The reaction mix is made up with 1 part of Reagent B (4% 
copper sulfate) to 49 parts of Reagent A (sodium carbonate, sodium bicarbonate, BCA 
detection reagent, and sodium tartrate in 0.1N sodium hydroxide). Graded 
concentrations of bovines serum albumin is used for generating the standard protein 
curve. From this the concentration of the protein is estimated. The reaction is done in 
triplicate using differing concentration of the protein (1: 1,1: 2,1: 3 dilutions). The 
reaction is carried out in a 96 well plate with 10 µl of the protein preparation and 200 
µl of reaction mix added to each well. The plate is covered with an adhesive strip and 
incubated at 37°C for 20 minutes. The fluorescence from each well is measured at 492 
nm in a plate reader. An example of the plate set-up and the calculated protein 
concentration is given below. 
The membrane preparations thus obtained are used for subsequent experiments 
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BSA 
1 
0.077 
2 
0.093 
3 
0.104 
4 
0.117 
5 
0.141 
1 
0.153 0.174 0.209 0.199 0.229 0.231 
0.079 0.087 0.099 0.120 0.135 0.153 0.175 0.176 0.192 0.229 0.230 
Membrane 0.180 0.170 0.152 0.132 0.121 
1: 110 Al 0.185 
0.142 0.151 0.119 0.108 
Membrane 0.164 0.144 0.136 0.124 0.105 
1: 2 10 1 0.158 0.133 0.132 0.11 0.1 
Membrane 0.165 0.131 0.143 0.111 0.093 
1: 3 10 1 0.141 0.122 0.122 0.112 0.098 
Final protein concentrations 
HEK - 3.286 µg/µ1 
a2A-G; - 2.351 µg/µ1 
a2A-Giß3y5 - 2.353 µg/µ1 
P375 - 1.586 µg/µ1 
PCDNA3 - 1.051 µg/µ1 
3.5 Expression Levels of a2A adrenoceptor 
This assay is used to determine the levels of expression of a2A adrenoceptor in the 
membrane preparations, assessed using a2-adrenoceptor selective antagonist [3H]RS- 
79948-97. Non-specific binding was determined in the presence of 100 µM idazoxan. 
Radioligand binding assays are performed to determine accurately the expression 
levels of both receptor and G protein, as both signalling molecules are constrained 
within the same polypeptide and are therefore present in 1: 1 molar ratio. 
The membrane preparations were made up into a concentration of 0.1 µg/µL and 0.2 
µg/µL in TE buffer buffer (10 mM Tris/HC1,50 mM sucrose, 20 mM MgC12, pH 7.5) 
so that assays could be done with both 5µg and 10 µg of membrane. 500 µL of 
membrane solution were made up for each concentration. 
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Membrane Membrane TE r ane M TE 
cone 1 1 
! j 
1 
M1- H EK 3.286 1 15.2 484.8 30.4 469.6 
M2 - a2A-G; 2.351 1 21.3 
478.7 42.5 457.5 
M3 - a2AG; 2.353 µg/µ1 21.3 478.7 42.5 457.5 
35 
M4 - 
P3 Y5 1.586 1 31.5 468.5 63.1 436.9 
M5 - 1.051 µg/µ1 47.6 452.4 95.2 404.8 PCDNA3 
RW 1 45 450 
[3H]RS-7 
For each reaction 1.8 nM of [3H]RS-7 is needed. The stock [3H]RS-7 solution is 
diluted such that adding 20 µL of this to the 180 µL of the reaction mixture will result 
in a concentration of 1.8 nM of [3H]RS-7. For example the Kd of [3H]RS-7 is 0.3- 
0.4 nM. The stock [3H]RS-7 solution is 2.41 µM. Thus diluting the stock solution 
133.9X will yield a solution of 18nM. When 20 µL of this is added to 180 µL of the 
reaction mixture, it will yield a final concentration of 1.8nM of [3H]RS-7. For this 
experiment 3.8 mis of l8nM [3H]RS-7 was made using 28.4 µL of the stock solution 
and 3771.6 µL of TEM buffer (75 mM Tris/HC1,5 mM EDTA, 12.5 mM MgC12, pH 
7.4). 
The reaction mixture was set up as follows with the membrane being added last and 
each done in triplicate. 
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Tube 
No. 
1-3 50 L (0) 20 L 
1 1 
130 L 5 
4-6 50 plýO) 20 L 20 L 110 L 5 
7-12 50 Ii IXM 20 L 130 L 5 
13-18 50 ýi IAM2) 20 L 20 L 110 44 5 ýig 
19-24 50 M3 20 L 130 L 5 jig 
25-30 50 M4 20 L 20 L 110 L 5 
31-36 50 0 20 L 130 L 10 
37-42 50 g L(Ml) 20 L 20 L 110 L 10 
43-48 50 M2 20 L 130 L 10 Itg 
49-54 50 M3 20 L 20 L 110 L 10 
55-60 50 t iL(M4) 20 L 130 L 10 lig 
61-66 50 R 20 L 20 L 110 L 5 
Specific 
activity 
184.2 DPM/fmol 
Reaction 
Vol 200 µL 
Standard 30059 30 779.9 0.8159 nM 
30117.2 29869.1 
5 
4 . 30165 .4 
1116.7 
4 30060. 
79.8 
Net. 
Average SE 
average 
Net-SE fmol/mg pmol/mg 
1136.29 19.59 1039.23 23.20 1128.37 1.12 
90.16 97.06 12.44 
1155.88 121.22 
a2AGi 5 1977.58 53.98 1932.07 72.12 1869.18 72.25 2029.51 2.02 
1790.78 67.35 62.88 4.45 
2027.85 67.32 
0315 5 89.99 83.12 0.01 9.22 7.50 10.01 0.01 
83.14 106.36 92.35 7.50 
83.11 80.7 
a2AGi 
03'SYS 5 2159.45 144.14 2188.07 59.94 2032.55 60.49 2206.90 2.20 
2303.21 171.21 155.51 8.10 
2101.55 151.19 
-03'SYS 
5 138.06 134.46 142.70 7.20 19.30 16.93 20.96 0.02 
156.85 93.11 123.40 15.32 
P 133.21 142.63 184.39 101.75 
Table 3.5-1 Calculation of levels of expression of a2A adrenoceptor. Ida - Idazoxan 
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The tubes were incubated in a water bath at 30°C for 30 minutes. After this, the 
membranes were filtered out through Whatman GF/C filters using a Brandel vacuum 
filter with TE buffer. The membranes embedded in filter paper discs were then placed 
in scintillation tubes. One filter paper disc with membrane immersed in 5 mis of 
Scintillin in 66 Scintillation tubes. The tubes were vortexed and allowed to stand 
covered with cap and transferred to a scintillation counter. Radioactivity was 
determined by liquid scintillation counting. Specific binding is the difference between 
total and non-specific binding. The following table shows the calculation involved. 
3.6 High affinity GTPase assays 
These were performed essentially as described by Koski et al. 746 with Vmax estimates 
being obtained following transformation of enzyme velocity vs. substrate (GTP) 
concentration experiments as described. 747 Non-specific GTPase was assessed by 
parallel assays containing 100 µM GTP. 
Determination of high affinity-GTPase activity is achieved by measuring the agonist- 
mediated breakdown of substrate y[32P]-GTP to GDP and [32Pi], which is counted as 
an index of enzymatic activity. Although receptor stimulation of GTPase as a 
measurement of activity of Gsa has been reported, the degree of stimulation is 
modest. On the other hand, robust GTPase activity measurements mediated through 
pertussis toxin-sensitive G proteins are common, a reflection of their cellular 
abundance and higher intrinsic rate of GTP hydrolysis. 
To decrease non-specific hydrolysis of GTP, ATP, creatine phosphate and creatine 
kinase are included in the assay as an ATP regenerating system to prevent the 
nucleoside diphosphokinase-mediated transfer of [32P] to endogenously present ADP, 
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which can in turn be hydrolysed by specific ATPases. In addition App(NH)P (5'- 
adenylimidodiphosphate) is added to inhibit the nucleoside triphosphatases and 
ouabain in included as an inhibitor of Na+/K+ ATPase. Exogenous Mgt+, an important 
cofactor in G protein activation is also added. 
The experiments were carried out in HEK293 cells transfected with a2A Gi along 
with ß3y5 or ß3-sy5 and the high-affinity GTPase activity measured. High affinity 
GTPase activity was also measured over a range of concentrations of GTP in the 
absence and presence of epinephrine. By varying the concentration of the substrate 
(GTP), it is possible to measure Vmax and Km values for the Ga. In all experiments, 
cells were exposed to pertussis toxin for 24 hours to eliminate any potential 
interactions between the receptor element of the fusion protein and endogenously 
expressed Gi family G proteins. 
The membrane preparations were diluted to 0.5µ&L with TE buffer so that addition 
of 20µL of the membrane preparation would give 10µg of membrane protein in the 
reaction mixtures. Thus the membrane preparations were made up as follows 
M1- HEK 3.286 1 33.5 186.5 
M2 - a2A-G; 2.351 1 46.8 173.2 
M3 - a2AG43 5 2.353 1 46.8 173.2 
M4 - 
P375 1.586 1 69.4 150.6 
MS - PCDNA3 1.051 1 105 115 
RW 1 110 110 
[32P]GTP is used as substrate and for each reaction mixture 50,000 counts per minute 
is required. This is calculated as follows 
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[32P]GTP activity(activity) - (activity date-22/07/2000) -2 µCi/µL 
Date of experiment - 26/07/2000 
Day difference -4 days 
t'/i of [32P] -14.3 days 
Daysdifference 
t 
Present activity = 0.5 `Z x Activity 
4 
Present activity = 0.5143 Jx2 
= 1.65 µCi/µL 
To have 50000 counts per minute in each tube and make up a reaction mix for 100 
tubes - 
Total [32P]GTP required = 
100 x 50000 
=3 µL 
XjX106 
The reaction mixture is prepared as follows 
2x10- Ascorbic acid 500 L 
2.5 U/ml Creatine Kinase 200 L 
0.4 M Creatine Phosphate 250 L 
0.04 M ATP pH 250 L 
0.04 M APP 25 L 
0.01 M Ouabain 1000 L 
4M NaCl 250 L 
1M MgC12 50 L 
0.1M DTT 200 L 
0.02M EDTA pH 7.5 50 L 
2M Tris HC1 pH 7.5 200 L 
10 M GTP pH 7.5 50 L 
P GTP 3 L 
Water 1972 L 
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50 µL of the reaction mixture is aliquoted in each well of a 96 well plate as follows 
with the membrane being added to each well last. During the whole procedure, the 
plate is kept on ice. 
Wells 
1-3 
Me 
20 
mb 
L 
rane 
M1 
Epi nephrine 
- 
GTP 
- 
Wat 
30 
er 
L 
Reactio 
50 
n mix 
L 
4-6 20 L M1 - 10 L 10-3 M 20 L 50 L 
7-9 20 L[ Ml] 10 L 10-3 M - 20 L 50 L 
10-12 20 L[ M21 - - 30 L 50 L 
13-15 20 L M2 - 10 L 10-3 M 20 L 50 L 
16-18 20 L M2 10 L 10-3 M - 20 L 50 L 
19-21 20 L M3 - - 30 L 50 L 
22-24 20 L M3 - 10 L 10"3 M 20 L 50 L 
25-27 20 L [M31 10 L 10"3 M - 20 L 50 L 
28-30 20 L M4 - - 30 L 50 L 
31-33 20 L [M41 - 10 L 10"3 M 20 L 50 L 
34-36 20 L M4 10 L 10"3 M - 20 L 50 L 
37-39 20 L M5 - - 30 L 50 L 
40-42 20 L MS - 10 L 10 
3M 20 L 50 L 
43-45 20 L [M51 10 L 10-3 M - 20 L 50 L 
46-48 20 L RW - - 30 L 50 L 
49-51 20 L RW - 10 L 10"3 M 20 L 50 L 
52-54 20 L RW 10 L 10"3 M - 20 L 50 L 
The plate is covered with an adhesive trip and vortexed. This is centrifuged at 4°C to 
sediment the contents to the bottom of each well. The reaction in initiated by 
incubating the plate in a water bath at 37° C for 30 minutes. At the end of 30 minutes, 
the reaction is terminated by removal of the plate to ice and adding 900 µL of 5% w/v 
charcoal slurry into each well. 5% w/v activated charcoal in 20mM phosphoric acid is 
used to separate free [32P] from the unhydrolysed [32P]GTP. The plate is then 
centrifuged at 4000 rpm for 15 minutes at 4°C to pellet out the charcoal and the 
unhydrolysed [32P]GTP. The free [32P] is present in the supernatant. 300 µL of the 
supernatant from each tube is pipetted into a microtube and closed with a stopper. 
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Each tube is placed into a scintillation tube and free [32P] is measured by scintillation 
counting from which the rate of hydrolysis of GTP is calculated. Low affinity 
hydrolysis of [32P]GTP is assessed by incubating parallel tubes in the presence of 100 
µM GTP. The basal and stimulated GTPase activity are calculated as follows. 
Basal hGTP 1000 1 1000 
_ GTPase = CPM x pg _ membrane 
x 30 x Vol 
- 
Scin 
_ 
tube -pmol/mg/min 
pmol 
Stir hGTP 1000 1 1000 
GTPase = CPM " 
pg 
_ 
membrane 
x 30 x Vol 
- 
Scin 
_ 
tube -pmol/mg/min 
pmol 
3.7 Single cell (EF88) calcium signalling 
EF88 is a fibroblast cell line derived from the embryos of mice in which expression of 
the a subunits of both Gq and G11 had been eliminated by targeted gene disruption. 748- 
750 The transfection procedure is similar to that described above in section 3.4(page 
217). In summary, the cells were grown in DMEM supplemented with 10% (v/v) heat- 
inactivated foetal bovine serum and L-glutamine (1 mM) in a 95% air and 5% CO2 
atmosphere at 37 °C. A portion of the cells harvested during trypsinisation was plated 
on to glass coverslips, and after a 24-h growth period they were transfected using 
Lipofectamine (Invitrogen) according to the manufacturers' instructions. After 3h 
cells were washed twice with Opti-MEM I and then cultured in DMEM growth 
medium for a further 24 h, pertussis toxin being added 6 hours into this period as 
described in section 3.4(page 217). A total of 3 µg of pCDNA3 containing the 
relevant cDNA species were used to transfect each coverslip. 
3.7.1 [Ca2+11 Imaging 
Transfected cells were loaded with the Cat+-sensitive dye Fura-2 by incubation (15-20 
min, 37 °C) under reduced light in DMEM growth medium containing the dye's 
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membrane-permeant acetoxymethyl ester form (1.5 µM). Loaded cells were 
illuminated with an ultra high point intensity 75-watt xenon arc lamp (Optosource, 
Cairn Research, Faversham, Kent, UK) and subsequently imaged using a Nikon 
Diaphot inverted microscope equipped with a Nikon 40x oil immersion Fluor 
objective lens (NA = 1.3) and a monochromator (Optoscan, Cairn Research), which 
was used to alternate the excitation wavelength between 340/380 nm and to control 
the excitation band pass (340 nm band pass = 10 nm; 380 nm band pass =8 nm). 
Fura-2 fluorescence emission at 510 nm was monitored using a high resolution 
interline-transfer cooled digital CCD camera (Cool Snap-HQ, Roper 
Scientific/Photometrics, Tucson, AZ) 7S1 MetaFluor imaging software (version 4.6.8, 
Universal Imaging Corp., Downing, PA) was used for control of the monochromator, 
CCD camera, and for processing of the cell image data. Sequential images (2 x2 
binning) were collected every 2 s, exposure to excitation light was 100 ms/image, and 
all experiments were undertaken in the absence of extracellular Ca 2+ in saline solution 
comprising: 130 mM NaCl, 5 mM KC1,1 mM MgC12,20 mM HEPES, 10 mM D- 
glucose, 0.01 mM EGTA, pH adjusted to 7.4 using NaOH. 
3.7.2 [Ca2+J, Image Analysis 
Ratio images were presented in MetaFluor intensity-modulated display mode, 752 
which associates the colour hue with the excitation ratio value and the intensity of 
each hue with the source image brightness. Briefly background subtracted images 
acquired at 340 and 380 nm excitation were first used for calculating the 340/380 nm 
ratio of each pixel. After determination of the upper and lower thresholds, the ratio 
value of each pixel was associated with one of the 24 hues from blue (low [Ca2+]i) to 
red (high [Ca2+]1). Pooled average intensity-modulated display ratio intensity values 
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Figure 3.7-1 Calcium signals in cells transfected with a2AGj, a2AGj (33yS and a2AGj P3-s75 
showing the difference in calcium signal in cells coexpressing the py subunit. The top panel 
shows the transfected EF88 cells after stimulation with epinephrine. The bottom panel show the 
rate of change of Fura-2 fluorescence after stimulation with epinephrine for a single cell selected 
per experiment. 
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Chapter 4- GNB3 AND HYPERTENSION -A Case 
Control Study 
-230- 
4.1 Introduction 
After the initial report by Siffert et al, 579 there have been numerous association studies 
in different populations trying to replicate their results. However the association is not 
clear as summarised in Table 1.6-2. Inconsistency among populations has been noted 
for a number of other proposed candidate genes for hypertension and the reasons for 
varying results in case-control studies are detailed in Section 1.2.2.2 (page 77). It is 
important, therefore, to identify within specific groups the local relevance of 
particular genetic markers. I performed a case-control association study for the GNB3 
locus in a Scottish group where all the participants were recruited at the same institute 
with relatively clear classification criteria. The case-control method is a powerful 
epidemiological method in the study of genetics in complex disease. Cases are 
defined as those affected with a particular disease of interest. The controls are those 
who although are at risk of developing the disease are unaffected with the disease. To 
achieve valid case-control comparison, controls should be selected so that they 
represent the same source population as the cases. The case and control subjects are 
then compared with respect to the proportion having the exposure or characteristic of 
interest. In the candidate gene approach, the frequency of the disease susceptibility 
gene in the cases is compared with the frequency in a group of controls. As with all 
case-control studies, selection of an appropriate control group is important to avoid 
spurious associations that can result from confounding due to recent admixture and 
selection or drift between unlinked loci. 753 
4.2 Recruitment of subjects 
4.2.1 Cases 
Approval for this study was obtained from the appropriate hospital and community 
medicine ethics committees, and all subjects gave informed consent. Caucasian 
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patients with essential hypertension (n=100) were recruited from the Blood Pressure 
Clinic of the Western Infirmary, Glasgow. All were less than 64 years of age. 
Secondary hypertension was excluded by physical examination and biochemical and 
radiological investigations where appropriate. All subjects had a positive family 
history of hypertension; high blood pressure was diagnosed before the age of 60 
years. Subjects with a history of alcohol excess (>21 U per week) and obesity (body 
mass index [BMI) >33 kg/m2) were excluded. Blood pressure was measured in the 
clinic by a trained observer with a mercury sphygmomanometer. The diagnosis of 
hypertension was based on a minimum of 3 blood pressure readings of >160/90 mm 
Hg before initiation of treatment, although most patients were receiving treatment at 
the time of the study. 
4.2.2 Controls 
Control subjects were drawn from the North Glasgow coronary risk survey, which 
had 200 randomly selected members of the North Glasgow population in each 10-year 
age/gender band from 25 to 64 years who were part of the World Health Organization 
Monitoring Trends and Determinants in Cardiovascular Disease (MONICA) project 
and their inclusion in this study was approved by the West ethics committee. They 
were normotensive (<140/90 mm Hg), and none were receiving antihypertensive 
therapy, treatment for heart disease, or hormone replacement therapy. They were 
individually age- and gender-matched with the cases by random selection from all 
control subjects who matched the criteria of the cases. Blood pressure was measured 
on 2 occasions with the Hawksley random-zero sphygmomanometer, with results 
averaged. 
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4.3 Laboratory methods 
The DNA samples from the cases and controls were genotyped for the GNB3 
polymorphism as described in Section 3.2 Genotyping C825T G -protein ß3 subunit 
polymorphism (page 208). 
4.4 Statistical methods 
Comparisons between cases and control subjects of demographic variables and 
genotype frequencies were carried out by paired t test and McNemar's test, 
respectively. Hardy-Weinberg equilibrium was checked by a x2 test with ldegree of 
freedom. Genotype and allele frequencies were compared between groups by a x2 test. 
The details of case-control analysis are summarised in Section 1.2.2.2.1 Case-control 
studies (page 79). 
When there is no association between genotype and disease, the genotype frequencies 
will be similar in cases and controls. Although a general test to detect any difference 
in genotype frequencies can be derived, a trend test that is sensitive to monotonic 
differences may be the most powerful for genotypic data. The Armitage test for trend 
has two advantages over other statistical tests of association. First, the test does not 
require that the genotype frequencies comply with Hardy-Weinberg proportions. 
Sasieni754 demonstrated that statistical tests based on the comparison of allele 
frequencies-rather than genotype frequencies-between unrelated cases and controls 
can have an increased rate of false-positive conclusions when genotype frequencies 
do not fit Hardy-Weinberg proportions. Second, the Armitage test for trend provides a 
flexible analysis method, because different scores can be used to test the dosage of the 
high-risk allele, depending on whether there is prior knowledge of the disease. 
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4.5 Results 
The clinical characteristics of the study group are given in Table 4.5-1. It shows that 
the age and gender matching of the groups was accurate. The patient blood pressures 
were those at the time of the study when many were receiving treatment. Despite this, 
blood pressure in the patient group was significantly higher than in the control group 
(P<0.00005). 
The distributions of genotypes and alleles for the two polymorphisms in the case and 
control populations are shown in Table 4.5-2. The frequencies of the GNB3 C and T 
alleles were 69% and 31% respectively among controls and 75% and 25% 
respectively among cases. It can be seen that the frequencies of the GNB3 T allele 
was not significantly different between the two groups (p=0.404). 
Males ( 
Cases 
n=46) 
Controls 
Females 
Cases 
(n=54) 
Controls 
Age ears 47.8 11.1 47.9(11.1) 49.5(11.3) 49.2(11.1) 
BMI (Kg/m2) 27.8 2.9 
- 
25.8 3.5 28.1 3.7 25.4 3.2 
Systolic (mmHg) 67.8 20.8 167.8(20.8)7 129.2(13.5) 170.4(24.9 120.6(15.4) 
Diastolic (mmHg) 98.4(11.2) 80.5 8.7 101.3(11.8) 74.4 8.3 
Cholesterol mmol/L 6.2(0.4393) 1 5.8(1.1) 6.2 1.1 6.1(1.2 
Table 4.5-1 Demographic Data 
Clinical details of the subjects studies. Study included 100 cases and 100 control subjects. Data 
are mean(SD). 
1 P<0.00005 (paired t test, comparing cases with control subjects). 
Table 4.5-2 - Distributions of Genotypes and Alleles for GNB3 C825T Polymorphisms in Case 
and Control Populations 
Confidence interval is for difference in proportions between cases and control subjects 
discordant for T allele expressed as percentage. 
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The control and the case groups were in Hardy-Weinberg equilibrium for the 
polymorphism (cases, P=0.42; control subjects, P=0.81)(Table 4.5-3). A convenient 
way to view Hardy-Weinberg proportions is the De Finetti diagram. The three sides 
are the relative frequencies of the three genotypes CC, CT and TT (Figure 4.5-1). Any 
point within the triangle can be considered a population. If the triangle is drawn with 
an arbitrarily chosen altitude of 1.0 (since the allele frequencies together will equal 
1.0, or 100% of all alleles), the three perpendiculars drawn from any population give 
the proportions of the three genotypes. Populations in Hardy-Weinberg equilibrium 
trace a parabola extending from base to base of the triangle. In Figure 4.5-1 both the 
cases and controls are shown to be in Hardy Weinberg Equilibrium. 
CC (%) 
Controls 
49 (48.3) 
Cases 
58 (56.2) 
CT (%) 41(42.4) 34 (37.5) 
Ti' (%) 10 (9.30) 8(6.3) 
freq C 0.69 +/-0.03 0.75 +/-0.03 
F 0.033 0.093 
p (Pearson) 0.74 0.35 
p (Exact) 0.81 0.42 
Table 4.5-3 Tests for deviation from Hardy-Weinberg equilibrium among cases and controls 
Table 4.5-4 shows the results of the association test carried out using the Armitage 
test for trend. Whether T or the C allele is taken as the high risk allele, there is no 
significant association noted in the presence of one or more high risk alleles. 
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De Finetti diagram with Hardy-Weinberg parabola 
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Figure 4.5-1 De Finetti diagram showing the controls and cases in Hardy 
Weinberg Equilibrium. 
Tests for association 
Allele freq. Heterozygous Homozygous Allele positivity 
Armitage's 
difference trend test 
Risk allele T 
[C] p [T] [CC] q [CT] [CC+CT] >[TT] [CC]<->[CT+TT] 
common odds 
ratio 
Odds Ratio 0.76 (0.49-1.18) 0.70 (0.39-1.27) 0.68 (0.25-1.85) 0.69 (0.39-1.22) 0.79 (95%C. I. ) 
X2 1.51 1.09 0.59 1.63 1.42 
p 0.22 0.24 0.44 0.20 0.23 
Risk allele C 
[T] p [C] [TT] p [Cl'] [TT+CT]p[CC] [CC+CT]q[TT] common odds 
ratio 
Odds Ratio 
(95%C. I. ) 
1.32 (0.85- 
2.04) 
1.04 (0.37-2.92) 1.48 (0.54-4.04) 1.28 (0.48-3.38) 1.26 
x2 1.51 0.0 1.59 0.24 1.42 
p 0.22 0.95 0.44 0.62 0.23 
Table 4.5-4 Test for association using the Armitage test for trend in case control population 
------------------- ------------------ 
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Ethnic Freq(T) Freq(T) No No 
Group 
Country Phenotype Control 
Reference 
Afro- USA 
Essential 0.75 0.74 432 472 
Larson, N. et 
69s Caribbean Hypertension a1 
Afro- England 
Essential 0.77 0.82 243 185 Dong, et l Caribbean Hypertension . a 
Afro- South Obesity 0.83 0.9 275 
Siffert, W. et 
l 706 Caribbean Africa a . 
Caucasian Germany 
Diastolic Blood 0.33 474 Schunkert, rt, H. 
Pressure et al. 
Caucasian Germany 
Essential 
t i H 
0.28 0.34 1000 479 Beige, J. et 
l bs6 yper ens on a 
Caucasian France 
Essential 0.313 0.353 308 394 E. et Brand69 
Hypertension al. 
Caucasian 
Northern Essential 0.298 0.307 163 171 E. et Brand69 
Ireland Hypertension al. 
Caucasian France 
Essential 0.306 0.33 470 393 E. et Brand69 
Hypertension al. 
Caucasian German y 
Essential 0.25 0.31 427 426 Siffert, W. et 579 Hypertension al. - 
Caucasian Spain LVH 0.2 0.4 26 60 Poch, E E. et 
al. 
Caucasian Germany Obesity 0.29 0.47 277 Siffert, W. et 706 al. 
Caucasian Germany Renal Transplant 0.32 320 Bei ge, J. et ýSs al. 
Chinese China Obesity 0.46 0.58 960 Siffert, W. et 706 al 
Inuit Canada Obesity 0.504 213 Hegele, R. A. 7°' et a1 
Japanese Japan Essential 
H ertension 
0.496 0.492 515 718 
Kato, N. et 
697 l yp a . 
Oji-Cree Canada Systolic Blood 0.501 447 Hegele, R. A. Pressure et al. 
703 
Caucasian Scotland Essential 0.31 0.25 100 100 Hypertension 
Table 4.5-5 Frequencies of T allele in various studies 
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4.6 Discussion 
In the present study, we found no evidence of a significant difference in the frequency 
of the GNB3 C825T polymorphism between our Scottish hypertensive and 
normotensive populations. There was no significant difference between the T allele 
frequency between hypertensives (0.31) and controls (0.25). The odds ratio for 
hypertension in the presence of the T allele (CT+TT versus CC) was 0.69 (95% C. I., 
0.39 - 1.21; p=0.20). Siffert et a1579 demonstrated a significant association of the 825T 
allele with essential hypertension in a study of 426 hypertensive and 427 
normotensive control subjects; the odds ratio for hypertension in the presence of the 
825T allele (CT + TT versus CC) was 1.44 (95% C. I., 1.09 -1.88; p=0.025). The Cl in 
the present study and that of Siffert et a1579 partially overlap. If the results of these two 
studies potentially represent the same value of effect measure, the sample size 
required to confirm the susceptibility in question must be very large. For example, it 
is roughly estimated that >1000 individuals are required in each group of cases and 
controls for detecting an odds ratio -1.2 with 80% power at a 5% type I error 
probability. 756 Thus no conclusive claims can be made from this study as the 
statistical power is insufficient based on this assumption. 
The lack of association in this study does not appear to be due to ethnic variation. The 
numbers in other case control studies looking at hypertension are larger. The allele 
frequencies between cases and controls in this study are comparable with other 
European studies. There has been variable association between the 825T allele and 
hypertension both positive 
686-690 
and nonsignificant691-693 studies in Caucasian 
populations where 825T gene frequency is about 25%. Increased risk of hypertension 
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associated with 825T was also reported among blacks694 who have a much higher 
gene frequency approaching 80%. A negative study was reported in African 
Americans 695 Less association has been reported in Asian populations, which have 
intermediate gene frequencies of about 50%, 696 698 although one Japanese study was 
weakly positive. 699 Although case-control studies can be criticized because of the risk 
of false-positive findings, particularly where populations are not homogeneous, we 
were careful to ensure that the matching of cases and control subjects was exact. 
Furthermore, all subjects were drawn from an ethnically and geographically limited 
catchment area. 
It is also possible that a true mutation as yet unidentified may be in linkage 
disequilibrium with the GNB3 T allele. Use of genetic linkage analysis, haplotype 
analysis or intermediate phenotypes would allow for further investigation of this 
candidate gene in relation to hypertension. 
- 239 - 
Chapter 5- GNB3 AND CARDIAC MASS - Analysis of 
four candidate genes in a twin study 
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5.1 Introduction 
Left ventricular hypertrophy detected on echocardiography is a powerful and 
independent predictor of cardiovascular complications and death in subjects with 
uncomplicated essential hypertension. LV mass shows a continuous distribution in the 
general population, 48 and LV hypertrophy is an operational category that defines the 
upper end of the LV mass distribution 471'472 Further details of ventricular mass and 
risk is detailed in Section 1.4.6 LV Mass and Risk (page 153). Section 1.4.9 Genetics 
of LV Mass (page 161) summarises the studies done to elucidate the genetic factors 
involved in LV hypertrophy. Previous reports have suggested an association between 
left ventricular indices and ACE, GNB3, aldosterone synthase genes '495-498; 
574; 580 As 
shown in Table 1.4-5 most of the candidate genes studied have shown inconsistent 
results. 
In this study I have used the twin model to look at the heritability of LV mass and 
determine if any component of the heritability could be explained by variations of the 
GNB3 gene. In addition I have also studied polymorphisms in the ACE and 
Aldosterone synthase gene, which have previously shown inconsistent associations 
with LV hypertrophy. 
5.1.1 Twin study 
The twin approach relies on the fact that monozygotic (MZ) twins are genetically 
identical whereas dizygotic (DZ) twins share, on average, one-half of their genes. If 
both twins of a pair are affected, they are said to be concordant. By estimating and 
comparing concordance rates between MZ and DZ twins, one can get an idea of the 
role of genetic factors in the aetiology of the disease. If the concordance rate is 100% 
in MZ twins and between 25%-50% in DZ twins, it may be concluded that the disease 
- 241 - 
is strictly genetic and probably due to a single recessive 
(if the concordance rate is 
-25%) or dominant (concordance -50%) gene. 
For a disorder in which genetic factors 
are important in aetiology but not the sole factor, the concordance rate 
in MZ twins 
will still be greater than for DZ twins, and the concordance rate for MZ twins reared 
apart will be about the same as for MZ twins reared together. Low concordance in MZ 
twins or equal concordance between MZ and DZ twins suggests a strong 
environmental influence on the development of disease. Since most disease have 
variability in the age of onset, unless the genes involved tightly control the age of 
onset, twin pairs may become concordant only over time. Thus follow-up of twins is 
important. 
5.2 Objective 
To determine if any of the echocardiographic measurements of left ventricular mass, 
left ventricular systolic and diastolic function have a heritable component in a study 
of 146 twins. 
To determine in any of those parameters showing heritability, if polymorphisms of 
four candidate genes -G protein beta3 subunit, beta-1 adrenoceptor, angiotensin 
converting enzyme and aldosterone synthase play a role. 
5.3 Study design 
5.3.1 Study population 
The population studied were a group of monozygotic and dizygotic twins aged 
between 30 and 85 years of age (146 adult twins - 69 monozygous and 77 dizygous 
pairs). Twins were recruited from the general population via the media. To prevent 
self-selection bias, the purpose of the study was not specified in the advertisement. 
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The West Ethics Review Committee approved the study. Each twin pair attended the 
same study morning and completed a health screening and lifestyle questionnaire. 
5.3.2 Confirmation of zygosity 
Zygosity was determined by validated questionnaire and verified by analysing tandem 
repeat polymorphisms. Four markers were used - AFM238xd10, AFM288vb9, 
AFM273yfl and AFM199zb6 (Centre d'Etudes du Polymorphisme Humain, Paris, 
France). Monozygotic twins were homozygous for each marker where dizygotic pairs 
were heterozygous for at least one marker. The probability of inaccurate assessment 
of zygosity using this technique was less than 10-5 
5.3.3 Genetic analysis 
Genomic DNA was isolated by phenol-chloroform extraction of EDTA-blood 
samples as described in Section 3. lGenomic DNA Extraction: (page 206). The 
subjects were genotyped for the Insertion/Deletion ACE gene, C825T G-protein 03 , 
SF1 binding site , intron 2 gene conversion and G1165C beta-1 adrenoceptor 
polymorphisms by polymerase chain reaction. Genotyping was performed by PCR by 
the method previously described for C825T G-protein beta-3 subunit 
polymorphism, 579 (Section 3.2 page 208) ACE I/D polymorphism757, SF1 RFLP498 
and Beta-i adrenoceptor polymorphism. 582 Dr G Inglis performed the genotyping of 
the ACE and Aldosterone synthase polymorphisms. 
5.3.4 Echocardiography 
The measurement of echocardiographic LV mass is described in section 1.4.3 (page 
144). Standard two-dimensional echocardiography was carried out on all the twin 
subjects by Dr L Swan. Trans-thoracic echocardiography was performed and analysed 
in line with the American Society of Echocardiography guidelines 499 Measurements 
were made over a least 3 cardiac cycles by a single observer blinded to the twins other 
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results and zygosity determination. Left ventricular mass was calculated using the 
Penn convention. 500 With the use of these measurements, left ventricular mass was 
determined by the following equation: 
LV mass (in grams) = 1.04[(LVIDD + VST + PWT)3 - (LVIDD)3] - 13.6 
where LVIDD is end-diastolic left ventricular internal diameter, VST is ventricular 
septal thickness, and PWT is posterior-wall thickness. Left ventricular mass was used 
as an unadjusted variable and was also adjusted for height and body surface area (the 
mass in grams divided by the height in meters). 
Other left ventricular dimensions measured were LV end diastolic and endsystolic 
diameter, posterior wall thickness, interventricular septal thickness and fractional 
shortening. LV diastolic function was determined by deceleration time, peak E, peak 
A and E/A ratio on doppler. 758 
5.3.5 Anthropometry and BP 
Resting blood pressures and anthropometric parameters were measured at baseline. 
Ambulatory blood pressure monitoring was performed in a non-hospital environment 
using a Spacelabs monitor fitted to the non-dominant arm. Tracings were disregarded 
if less than 85% of the readings were unacceptable. 
5.4 Statistical analysis 
Descriptive data for the cohort are quoted as mean values and standard deviations. 
Differences between twin groups were compared using a paired t-test. 
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Twin analysis was performed using the methodology described by Falconer. 759 In this 
method the genetic effect is assessed by differences in within-pair variances between 
monozygotic and dizygotic twins. Intra-class correlation coefficients were calculated 
for the twin pairs using a statistics software programme (MINITAB 11.2). This test 
included a test of homogeneity. Heritability, an estimate of the degree to which a 
variable is genetically determined was calculated for the major phenotypes of left 
ventricular structure. For each variable in the MZ and DZ groups, intraclass 
correlations (r) were then compared between the two groups by Fisher's z test. For the 
variables where r was significantly different in the MZ group than in the DZ group, 
H2 was calculated (H2 = VA + VD, where VA is the additive variance and VD the 
dominance variance) by the method of Haseman and Elston. This was calculated 
using the equation h2 = 2(rMZ-rDZ) where rMZ is the correlation coefficient for the 
monozygotic group and rDZ that of the dizygotic group. Ap value of less than 0.05 
was taken to be statistically significant. For traits with 100% genetic determination, 
the H2 values would be 1. All those parameters showing significant genetic 
determination were tested for within pair difference in MZ, DZ concordant and DZ 
discordant for the four polymorphisms. 
5.5 Results 
5.5.1 Demographic data 
The demographic data are shown in Table 5.5-1. The age range of the twins was 31- 
83 years. The MZ group was slightly older and contained a greater proportion of 
women. There was no significant difference in BMI, systolic and diastolic blood 
pressure between MZ and DZ groups. 
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"Iml 
Zygosity 69(47.3%) 77(52.7%) 
Sex (M: F) 16: 122 47: 107 <0.01 
Age 58.17 ± 0.9 53.47 ± 1.06 <0.01 
Pulse 74.25 ± 0.80 74.20 ± 0.82 0.96 
Weight 62.25 ± 1.4 67.58 ± 1.3 0.22 
Height 161.1 ± 0.66 165.1 ± 0.79 <0.01 
BMI 25.05 ± 0.45 24.54 ± 0.34 0.36 
Systolic BP 132.1 ± 1.4 129.8 ± 1.2 0.20 
Diastolic BP 81.9 ± 0.81 80.6 ± 0.74 0.21 
Table 5.5-1 Demographic data of twin pairs (Mean ± SD) 
MZ - Monozygous twins; DZ- Dizygous twins 
5.5.2 LV mass and function 
Table 5.5-2 and Table 5.5-3 show the indices of LV mass and systolic and diastolic 
function in MZ and DZ twins. There is clearly no significant difference between MZ 
and DZ groups with regard to any of the indices of LV mass and function. 
ýILV 
Mass 176.6 ± 5.83 174.6 ± 4.24 0.78 
LV Mass Index 104.4 ± 3.39 100.6 ± 2.69 0.38 
IVSd 1.08 ± 0.02 1.05 ± 0.02 0.44 
IVSs 1.41 ± 0.02 1.40 ± 0.02 0.85 
LVDd 4.6 ± 0.05 4.75 ± 0.04 0.15 
LVDs 2.9 ± 0.05 2.97 ± 0.04 0.12 
PWd 0.81 ± 0.01 0.81 ± 0.01 0.71 
PWs 1.24 ± 0.02 1.24 ± 0.02 0.90 
IVS/PW 1.35 ± 0.03 1.31 ± 0.02 0.22 
Frac. Shortening 38.55 ± 0.71 137 . 45 ± 0.58 0.23 
Table 5.5-2 LV mass and systolic function in twin pairs (Mean ± SD) 
MZ - Monozygous twins; DZ- Dizygous twins IVSd - Interventricular septal thickness (Diastole), 
IVSs- Interventricular septal thickness (Systole), LVDd - LV end-diastolic diameter, LVDs- LV end- 
systolic diameter, PWd - Posterior wall thickness (Diastole), PWs - Posterior wall thickness (Systole) 
Table 5.5-3 LV Diastolic function in twin pairs (Mean ± SD) 
MZ - Monozygous twins; DZ- Dizygous twins, Decel Time - Mitral Deceleration time, Peak E- Peak 
mitral E velocity, Peak A- Peak mitral A velocity 
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5.5.3 Heritability 
The infra-class correlation coefficients for the monozygotic and dizygotic groups and 
their comparison (z) are displayed in Table 5.5-4 and Table 5.5-5. Left ventricular 
internal dimensions in diastole and left ventricular mass were both under a significant 
degree of genetic determination (heritability estimates of 0.68 and 0.66 respectively). 
Two thirds of the variation in LV mass could be explained by a genetic influence. LV 
mass showed a significant heritability of 0.66 while LV mass indexed to height 
showed a heritability of 0.99. 
Following correction for age, sex, blood pressure and weight (LVMI) there was still a 
strong genetic component to left ventricular mass (heritability estimate of 0.53). 
Although there was a trend towards a genetic contribution to diastolic wall posterior 
wall thickness this did not reach significance. 
There was no evidence of genetic determination for the indices of LV systolic and 
diastolic function namely Fractional shortening, Deceleration time, E/A ratio (Table 
5.5-4 and Table 5.5-5). 
LVMass 46 0.66 0.79 43 0.17 0.17 2.84 0.66 0.002 
LVMI 39 0.58 0.67 37 0.09 0.09 2.46 0.99 0.007 
IVSd 45 0.32 0.32 43 0.11 0.11 0.99 0.31 0.160 
IVSs 45 0.31 0.31 43 0.34 0.36 -0.22 -0.08 0.588 
LVDd 45 0.71 0.88 43 0.36 0.38 2.29 0.68 0.011 
LVDs 44 0.59 0.67 43 0.45 0.48 0.83 0.26 0.202 
PWd 45 0.42 0.44 43 0.09 0.09 1.61 0.65 0.053 
PWs 44 0.46 0.50 43 0.34 0.36 0.62 0.22 0.267 
IVS/PW 45 0.16 0.16 43 0.05 0.05 0.51 0.22 0.305 
FracS 44 0.16 0.16 43 0.27 0.27 -0.50 -0.21 0.693 
Table 5.5-4 LV mass and systolic function - Intraclass correlation coefficient for MZ(r-MZ) and DZ(r-DZ), Z level, broad heritability estimates(H-sq) and p values 
MZ- Monozygous; DZ- Dizygous, r- Intraclass correlation, H2 - Broad sense heritability, IVSd - Interventricular septal thickness (Diastole), IVSs- Interventricular septal thickness (Systole), LVDd - LV end-diastolic diameter, LVDs- LV end-systolic diameter, PWd - Posterior wall thickness (Diastole), PWs - Posterior wall thickness (Systole), FracS- Fractional Shortening 
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5.5.4 Association Study 
As LV mass and LV diastolic diameter showed evidence of genetic determination in 
the twin study. The next step is to determine if variation in any of the four candidate 
genes selected plays a role in the genetic determination. This was tested using two 
approaches. 
Firstly one member of each twin pair was selected. Selecting either twin 1 or twin 2 
did not influence the results. This was a simple association study using one-way 
ANOVA to check for an association between genotype and phenotype. Table 5.5-6 
shows the genotype frequency of the four genes studies - ACE, GNB3, B1AR and 
Aldosterone synthase polymorphism. There is no significant association between any 
polymorphism and LV mass. After correcting for age, sex, blood pressure and weight, 
by regression and testing the residuals also showed no significant association. Figure 
5.5-1 shows LV mass index plotted by genotype for the four genes studies. The results 
show no association. Though there is a trend to lower LVM index with the G allele of 
the B1AR polymorphism, it did not reach statistical significance. 
Secondly the intrapair differences were compared between MZ concordant (MZ) and 
concordant and discordant DZ (DZc and DZd) twins for each of the genes studied 
(ACE, GNB3, B1AR, SF1) separately. Were a second gene locus exerting an effect, 
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Table 5.5-5 LV Diastolic function - Intraclass correlation coefficient for MZ(r-MZ) and DZ(r- 
DZ), Z level, broad heritability estimates(H-sq) and p values 
MZ- Monozygous; DZ- Dizygous, r- Intraclass correlation, If - Broad sense heritability, Decel Time - 
Mitral Deceleration time, Peak E- Peak mitral E velocity, Peak A- Peak mitral A velocity 
the within pair difference of concordant DZ twins would be expected to lie between 
those of MZ and discordant DZ twins. 
No significant within-pair difference is seen between MZ and DZ concordant twins 
for each of the genes studied with respect to LV mass, LVDd and PWd (Table 5.5-7). 
Also no significant within-pair difference is observed between DZ concordant and DZ 
discordant twins for each of these three echocardiographic indices. With respect to the 
B1AR gene, the within-pair difference is small in MZ twins and similarly great in DZ 
concordant and discordant twins, though there is an indication of a trend towards 
greater within-pair difference in DZ discordant twins. 
Genotype frequency 0.18 0.47 0.35 
LV mass 174.9(53.4) 178.1(71.3) 182.2(59.4) 0.92 ACE 
LVDd 4.75(0.45) 4.68(0.59) 4.74(0.57) 0.84 
PWd 0.80(0.13) 0.81(0.14) 0.80(0.13) 0.99 
cc CT TT 
Genotype frequency 0.51 0.41 0.08 
p 
LV mass 174.0(56.8) 180.5(76.1) 191.5(65.9) 0.90 GNB3 LVDd 4.74(0.60) 4.64(0.52) 4.75(0.63) 0.83 
PWd 0.80(0.11) 0.81(0.14) 0.82(0.22) 0.98 
Genotype frequency 0.47 0.49 0.04 
LV mass 184.8(63.3) 171.9(49.1) 146.7(22.5) 0.43 Beta IAR 
LVDd 4.81(0.52) 4.66(0.61) 4.5 0.34 0.49 
PWd 0.82(0.15) 0.79(0.12) 0.77(0.11) 0.84 
Genotype fre uen 
Tr 
0.24 
TC 
0.55 
cc 
0.21 
p 
SF! 
LV mass 162.4(44.5) 187.3(75.0) 178.1(48.0) 0.29 
LVDd 4.64(0.37) 4.78(0.55) 4.60(0.60) 0.33 
PWd 0.75(0.10) 0.82(0.14) 
__0.81(0.13) 
0.12 
Table 5.5-6 LV mass indices in groups with different genotypes. Association study using one 
member from each twin pair. 
ACE - ACE I/D polymorphism, GNB3- GNB3 C825T polymorphism, B1AR - B1AR G1165C 
polymorphism, SF1- CYP11B2 C344T polymorphism, LVDd - LV end-diastolic diameter, PWd - 
Posterior wall thickness (Diastole). Data given as mean (SD). 
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LVMI-GNB3 LVMI-BETA I 
200 200 
100 100 T 
00 
CC CT TT CT-TT CC ßC 00 OC-00 
P value 0.7299 P value 0.0755 
LVMI, ACE LVMI-SF1 
enn 
200 
10D 
0 
D DD D-DD 
P value 10 4796 
100. 
TT TC CC 
P value 0.9180 1 
Figure 5.5-1 LV mass index displayed by genotype. 
Box plots represent means and SD. ACE - ACE I/D polymorphism, GNB3- GNB3 C825T 
polymorphism, B1AR - B1AR G1165C polymorphism, SF1- CYP11B2 C344T 
polymorphism 
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LV 37.9 46.9 40.2 
1) p 
mass (29.4-46.5) (32.3-61.6) 22.3-58.0 
0.24 0.79 
0.34 0.39 0 43 
ACE 
LVDd 0.28-0.41 (0.29-0.50) . (0.25-0.61) 0.42 0.24 
0.12 0.12 0.11 PWd (0.09-0.15) (0.07-0.17) 0.06-0.17 0.96 0.89 
LV 35.8 44.0 41.9 
mass (26.6-44.9) (27.6-60.5) (20.2-63.6) 
0.33 0.52 
0.34 0.39 42 0 
GNB3 
LVDd (0.27-0.43) (0.27-0.52) . (0.23-0.54) 0.51 0.26 
PWd 
0.11 0.12 0.12 0 71 0 72 (0.08-0.14) (0.07-0.17) (0.06-0.18) . . 
LV 37.7 40.2 49.9 
mass (28.4-46.9) (26.5-53.8) (23.3-76.5) 
0.75 0.25 
LVDd 0.33 0.37 0.38 0 50 0 51 B1AR (0.28-0.41) (0.25-0.50) (0.29-0.57) . . 
PWd 0.12 0.11 0.12 0 76 0 83 (0.09-0.15) (0.06-0.15) (0.05-0.19) . . 
LV 37.9 44.0 44.7 
mass (29.3-46.5) 26.0-62.1 (30.2-59.2) 
0.48 0.38 
0.34 0.33 47 0 
SFl LVDd (0.28-0.41) (0.19-0.46) . (0.35-0.59) 0.82 0.15 
PWd 0.12 0.14 0.10 0 51 0 46 (0.090.15) (0.08-0.19) 0.06-0.14 . . 
Table 5.5-7 Within pair differences in MZ twins, DZ twins concordant (DZc) and DZ twins 
discordant (DZd) for genotypes. 
ACE - ACE I/D polymorphism, GNB3- GNB3 C825T polymorphism, B1AR - B1AR G1165C 
polymorphism, SF1- CYP11B2 C344T polymorphism, LVDd - LV end-diastolic diameter, PWd - Posterior wall thickness (Diastole). Data given as mean difference (95% C. I. ). 
5.6 Discussion 
This study confirms a genetic influence over many aspects of left ventricular structure 
persisting into adulthood. Left ventricular mass, uncorrected, demonstrated a 
significant degree of heritability with approximately 70% of LV mass being 
genetically determined. A familial effect and a trend towards a genetic effect are 
noted in the measurements of septal and posterior wall thickness. It is, however, left 
ventricular internal dimensions, rather than wall thickness that were influenced by 
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genetic factors. Mass remained significant even following correction for basic 
anthropometric and blood pressure measurements with approximately half of the 
variation being due to other genetic influences. 
Previous twin studies in children and young adults have given conflicting results 
regarding the heritability of left ventricular structure and function. In the largest twin 
study to date left ventricular mass was under genetic control in a group of 11 year old 
children. However, the degree of genetic influence over a given phenotype varies with 
age and different genes are important at various stages in life. In adult life when many 
of these disease processes are clinically relevant, the effects of genes may be 
diminished or "watered-down" by the cumulative effect of environmental and lifestyle 
factors 760 
Functional assessments of the left ventricle such as fractional shortening and 
fractional thickening did not reveal a significant genetic component, environmental 
factors being more important. Mitral valve E wave forward flow, reflecting the early 
diastolic filling of the left ventricle, did have a degree of heritability a finding 
consistent with previous studies ago The determinants of the E/A ratio in this 
population were age and systolic blood pressure but not LV mass. 
Twin estimates of heritability are often higher than those of sibling and family cohorts 
and indeed the estimates from this study were higher than those obtained from the 
Framingham family study that estimated adjusted LV mass heritability at between 
0.24-0.32.489 In the largest twin echo study in children the estimates of heritability 
varied from between 63-77%. This study reveals that this genetic influence persists 
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into adulthood and identifies LV mass in adults as a target for further genetic study 
and in particular the further study of potential candidate genes. In addition it would 
be of interest, once the data is available, to compare the proportion of genetic control 
over LV mass in this "high risk" West of Scottish population to other adult cohorts 
using a similar twin methodology. 
Though previous reports have suggested an association between left ventricular 
indices and ACE, GNB3, aldosterone synthase genes, 
495-498; 574; 580 in this twin group 
we found no association between any of the echocardiographic parameters of LV 
mass and function and the four candidate genes ACE, GNB3, Betal adrenoceptor and 
Aldosterone synthase. In a twin study, Busjahn et a1574 showed a correlation between 
serum ACE activity and any parameter of cardiac size. They also showed LV 
posterior wall thickness was greater in subjects with DD genotype. However their 
twin analysis showed that posterior wall thickness was not merely a function of the 
ACE genotype but rather a polygenic trait. Additionally, they did not find any 
association between the ACE genotype and septal thickness. Their study is similar to 
this twin study as it involved normotensive twins. In previous studies, the relation 
between GNB3, Aldosterone synthase and LV mass were variable, and this study 
shows no clear association. The single gene effects on LV mass are probably small 
and thus genetic dissection of this trait is difficult. Another disadvantage inherent in 
twin studies is that because they tend to be small studies, any estimates derived from 
them have necessarily large confidence limits or standard errors. 
Poch et a1581 recently provided data from 86 previously untreated hypertensive 
patients, suggesting an association of GNB3 polymorphism with LVH. In particular, 
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carriers of the T allele displayed a 3-fold increased risk of presenting with LVH. By 
contrast, Sedlacek et a1592 evaluated a substantially larger and epidemiologically 
phenotyped population sample and failed to show any association between the GNB3 
T allele and cardiac structure. Though the results of our study is similar to that of 
Sedlacek et al. 592 it must be pointed out that the phenotypes under investigation may 
be different in the 2 studies. In this respect, Poch et a1581 focused their work on 
untreated hypertensive patients. Such selected patients may be more informative to 
detect minor effects of a given candidate gene with respect to LVH compared with the 
normal population sample. However, Sedlacek et a1592 analysed multiple subgroups 
potentially related to the effects of the GNB3 C825T polymorphism, including 
hypertensive subjects without antihypertensive medication and found no differences 
according to the genotype status. Furthermore, other phenotypes related to LVH 
independent of echocardiographic measurements, such as the serum levels of atrial 
and brain natriuretic peptide, did not display an association with the GNB3 
polymorphism. In the present study, normal twins were analysed who were not 
selected for any cardiovascular phenotype and thus similar to the study of Sedlacek et 
al 592 
Another explanation for the differences between the Spanish and the present study 
may be that the clinically based ascertainment strategy in Spain favoured a higher 
prevalence of the T allele. In fact, previous studies documented an association of T 
allele particularly with severe hypertension, including combination antihypertensive 
therapy6s9; 69° and end-organ damage. 687 Thus, a positive association of the GNB3 T 
allele may not reflect only a causative nature of this polymorphism for LVH, but also 
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differences in ascertainment strategies, resulting in differences in underlying 
mechanisms such as more severe hypertension in some selected patient groups. 
Diastolic left ventricle dysfunction is yet another finding related to hypertension and 
LVH. Jacobi et a158° reported in 34 mild to moderate hypertensive patients an 
association of the GNB3 T allele with impaired diastolic filling (CC versus TC/TT) 
and velocity time integral A/E (CC versus TC/TT) and concluded that this 
polymorphism contributes to the development of hypertensive heart disease. In the 
present study, however, 2 parameters of diastolic left ventricle function (E/A and 
Deceleration time) and indices of systolic left ventricle function failed to show any 
association with the T allele status, even in subgroups of untreated hypertensive 
subjects. Sedlacek et a1592 also failed to show any association with the T allele status 
and diastolic left ventricle function (E/A and IVRT) and indices of systolic left 
ventricle function, even in subgroups of untreated hypertensive subjects. 
The most likely explanation of the present negative study is that the GNB3 T allele 
has no strong and clinically relevant effect on the variability of LV mass. Indeed, 
LVH is a complex genetic trait, and a single gene variant, albeit functionally relevant, 
may carry a minute contribution to the final phenotype. Therefore, it is inherently 
complicated to demonstrate its influence in even large-scale and well-powered 
association studies. By contrast, smaller studies have been shown to carry a risk of an 
a-error. 722 Thus, a cautious interpretation of such studies may be advisable. 
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Chapter 6- GNB3 AND BLOOD PRESSURE AND LV 
MASS IN THE RENFREW/PAISLEY POPULATION 
-256- 
6.1 Introduction 
Complex traits are typically divided into two major categories - qualitative or 
dichotomous traits and quantitative or continuous traits. Most association analyses use 
categorical definitions of disease. But a complex trait like blood pressure or LV mass 
is inherently a non-mendelian trait (Section 1.2.2.1.3 Non-Mendelian Inheritance, 
page 75), and thus may provide more effective descriptions of disease. For many of 
these conditions, all or nothing definitions of disease are arbitrary and unsatisfactory. 
In quantitative trait analysis, the strength of the genetic component is measured by the 
heritability (h2) (Heritability is explained in section 10.4 Broad sense heritability, 
page 322 and section 10.5 Artificial selection and narrow-sense heritability). The 
most commonly used method for examining linkage between a quantitative trait and a 
marker locus is the one proposed by Haseman and Elston 201 Details of quantitative 
trait analyses are explained in section 1.2.3 Quantitative traits versus Qualitative 
traits, page 89. As described in Section 1.2.2.2.3 Problems with association studies, 
page 83, part of the drawbacks in association mapping can be overcome by using 
family members in TDTs (Transmission Disequilibrium Tests). An accurate analysis 
should use all the information in a pedigree to construct powerful tests of association 
that are robust in the presence of stratification (Section 1.2.2.2.2 Family based 
association study, page 80). In this study, I study the association of GNB3 
polymorphism to blood pressure and ECG measures of LV mass as quantitative traits, 
in a population of middle-aged siblings, who were not ascertained for any 
cardiovascular risk factor. I shall also look at three other genes namely ACE, Beta-1 
adrenoceptor and aldosterone synthase polymorphism which have been previously 
associated with LV mass, and with the exception of beta t-adrenoceptor with blood 
pressure. 
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6.2 Aims 
To estimate the heritability of blood pressure and LV mass as determined by various 
ECG indices in a large population of siblings. 
To perform candidate gene studies to see if variations of four candidate genes 
(including GNB3) could explain the variance in the population of those phenotypes 
that show significant heritability. 
6.3 Study design 
This study is a family based study of the Renfrew/Paisley offspring population 
recruited between 1993-94. The details of the population are given below. The data 
available included blood pressure, anthropometry, digital ECG and DNA samples. 
The objective of the analysis is to test for association between the four candidate 
genes and its association with blood pressure and ECG indices of LV mass. As they 
comprised only siblings with no parental data, the sibling-TDT test is used in the 
analysis. The population was not selected for any phenotype and hence the analysis is 
conducted using the data as quantitative traits. The West Ethics committees approved 
the study protocol. 
6.4 ECG Indices 
The ECG indices of LV mass studied include the Rautaharju equation which gives the 
LV mass in grams adjusted for weight (Men: LVM = 0.026* CV + 1.25 *W+ 34.4; 
Women: LVM = 0.020 * CV + 1.12 *W +36.2 ). 521°522 Also other indices of LV mass 
studied include the Sokolow-Lyon voltage (SV1+RV5 or RV6), Cornell voltage 
(RaVL+SV3), Cornell product [(RaVL+SV3)*QRS duration], 12 lead voltage, the 
time product of these indices and the voltage time area because as previously 
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described, they have increased sensitivity and specificity for identification of LVH 
507- 
511 A summary of these indices are given in Table 1.4-1. 
6.5 Recruitment of subjects 
6.5.1 Family Ascertainment 
The subjects upon whom this research is based were offspring of 4064 married 
couples who were screened in the Renfrew-Paisley (Midspan) Study in 1972-76.761; 
762 
In 1993-4, attempts were made to trace offspring either through direct contact with 
the original study couple or, where both husband and wife were dead, through 
contacts with informants mentioned on their death certificate. Altogether 4829 
offspring aged 30-59 were identified from 2365 couples with children; 3202 of these 
offspring lived within 45 minutes of Paisley and Renfrew. Of these, 1040 men and 
1298 women from 1477 families completed a questionnaire and examination in 
1996-a response rate of 73%. 
6.5.2 Phenotyping 
Information on subjects' personal and family medical history, socio-demographic 
information, and smoking habits was obtained from detailed self-completed 
questionnaires. Examinations were carried out in clinics staffed by six research nurses 
who rotated between measurement stations. Measurements included: 12 lead ECG; 
blood pressure-recorded using a Dinamapp 8100, three readings were taken from the 
left arm with the subject seated and allowed to rest for five minutes-the mean of the 
last two reading for systolic and diastolic blood pressure was used; non-fasting venous 
blood samples were analysed for total and HDL cholesterol, fibrinogen, white blood 
count and glucose; FEV1 and FVC were measured using a Vitalograph Spirotrac III. 
Standing height and sitting height were measured without shoes in the Frankfort plane 
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to the nearest millimetre using a Holtain stadiometer. Weight was measured to the 
nearest 100 g with Seca digital scales in stockinged feet wearing 
indoor clothes. 
6.6 Genetic analysis 
Genomic DNA was isolated by phenol-chloroform extraction of EDTA-blood 
samples (Section 3.1 page 206). The subjects were genotyped for the 
Insertion/Deletion ACE I/D, C825T G-protein P3, Aldosterone synthase SF1 binding 
site, G1165C beta-1 adrenoceptor polymorphisms by polymerase chain reaction. 
Genotyping was performed by PCR by the method previously described for C825T G- 
protein beta-3 subunit polymorphism, 
579 (Section 3.2, page 208) ACE I/D 
polymorphism757, SFl RFLP498 and Beta-i adrenoceptor polymorphism. 
582 Dr G 
Inglis performed the ACE and Aldosterone synthase polymorphism PCR and Dr T 
Stanton performed the beta-i adrenoceptor PCR. 
6.7 Statistical methods 
The analytic strategies used in this study were designed to consider all the traits as 
continuous variables namely ECG indices, blood pressure and anthropometric 
measurements. This avoids the inherent limitations of choosing arbitrary cut-off 
points for categorisation. Family based studies control for the possibility of genetic 
differences between the case and control populations by comparing the frequencies of 
alleles transmitted to the affected child to the allele not transmitted. The only samples 
necessary are those from the affected individual and his or her two parents - the TDT 
triad (Section 1.2.2.2.2.1 Transmission Disequilibrium Test (TDT), page 81). In cases 
where the parental DNA is unavailable, the traditional TDT approach is impossible. A 
novel approach that circumvents this difficulty is to use unaffected siblings as controls 
rather than relying on parental controls. This sib-TDT (S-TDT) approach compares 
marker allele frequencies in affected and unaffected siblings. The test requires only a 
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simple affected/unaffected sibling pair, although power can be increased if additional 
siblings are available. It provides a test for linkage and association and 
is immune to 
the effects of sampling bias. (Section 1.2.6 Optimal study designs, page 97) 
6.7.1 Heritability 
Heritability quantifies the strength of family resemblance and represents the 
percentage of variance in a trait that is due to all additive familial effects including 
additive genetic effects and those of the familial environment. Estimates of 
heritability for each phenotype was calculated using the variance component method 
implemented in the programme SOLAR. 199 The procedure involved the comparison 
of a sporadic model (assuming no familial resemblance) with a polygenic model 
(including familial correlations) to determine the best fit for the data. 
6.7.2 Association analysis 
A two-stage approach was used in the investigation of association between the 
polymorphisms of the four genes and blood pressure and ECG measures of heart size. 
Firstly, the eldest individual from each family was investigated by a mixed effects 
ANOVA to identify associations between genotype and phenotype. In the mixed 
effects ANOVA, the data was analysed in a general linear model in SPSS, with the 
trait as the dependent variable, genotypes as fixed effect and age, systolic blood 
pressure, weight and height as covariates for the ECG phenotypes, and age, sex BMI 
as covariates for blood pressure. 
In the second stage of the analysis, family based association analysis was carried out 
using the variance components models of association implemented in the QTDT 
program and FBAT programs. 
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6.7.3 QTDT 
QTDT206 allows variance component models to be constructed which include the 
effect of polygenes, shared family environment and any effect of linkage at the locus 
under study. Association can be tested allowing for linkage and background 
polygenes. The effects of genotypes on phenotypic means are partitioned into 
between-family and within-family components, by comparing the association of 
alleles and trait values across siblings from different families to the association of 
alleles and trait values across siblings within the same family. Sibling pairs are by 
definition ethnically and racially homogeneous and any difference in trait scores 
between siblings of different genotypes at a candidate marker, therefore, reflect true 
genetic association. QTDT also allows for the partitioning of any observed association 
into between-family and within-family components, thus providing a check on 
whether the result could have arisen due to unsuspected population stratification 
amongst the families studied. This method is designed for families of any size and 
uses all available genotypic information. 206; 207 
Simple linear models do not provide valid tests of linkage disequilibrium when 
multiple offspring per family are considered. When evaluating if a candidate 
polymorphism is the disease mutation, it is important to evaluate not only the 
evidence for association, but also estimate the significance of individual components 
of variance. QTDT uses variance components to model the phenotypic similarities 
that are common in family data. A typical model for the variances might include 
environmental (e), polygenic (g) and additive (a) components of variance. To evaluate 
the significance of one variance component, two alternative variance models are 
specified. For example, to estimate the heritability of the trait in the sibling data, a 
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model with only an environmental variance is compared with a model with polygenic 
and environmental variances. 
To test for association, a model is defined including not only a linear model for the 
means with the covariates but also a model for the variances. Means and variances are 
fitted by maximum likelihood using a numeric minimiser. The analysis was carried 
out using BMI, age and sex as covariates. 
NULL MODEL 
Means = Mu + Covariate +B 
Variances = Ve + Vg + Va 
FULL MODEL 
Means = Mu + Covariate +B+W 
Variances = Ve + Vg + Va 
This model includes a mean term (mu), a between family component of association 
(B) and, in the full model used under the alternative hypothesis, a within family 
component of association (W). 
Variance components models can be sensitive to the phenotypic distribution, 
especially in small or selected samples. In small samples, in selected samples or when 
the variance model is incomplete, estimates of the variance components may be 
biased. Empirical p-values were calculated using a Monte-Carlo permutation 
framework for the within family component of association. These permutations 
condition on the trait distribution, linkage and familiality, and provide a test for 
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linkage disequilibrium. Another attractive feature of using Monte-Carlo permutation 
to estimate p-values, is that they can provide a global p-value with a built-in 
adjustment for multiple testing. To do this transmission scores for all markers are 
permuted simultaneously and the most significant association observed in each 
replicate is noted. The most significant association in the actual data is then compared 
to this reference distribution. 
6.7.4 FBAT 
FBAT763 provides a2 test statistic that tests the composite null hypothesis of no 
linkage or no disequilibrium without concerns about confounding because of 
admixture. FBAT has the advantage over the conventional transmission 
disequilibrium test (TDT) of being able to use data from all family members, not just 
case-parent trios. 
The FBAT method763 defines a statistical test that reflects association between a 
phenotype (T) and a marker value (X). The tests uses the generic form S= ET"X as a 
test statistic, where summation is over all offspring in all families in the dataset. The 
distribution of S under HO is calculated using the distribution of offspring genotype, 
conditional on the trait T and on the parental genotype, or the sufficient statistics 
when parental genotype is unobserved. The value S- E(S)NVar(S) follows a Normal 
(0,1). As this is in a region of linkage, with several individuals in each family, 
calculating an empirical variance provides a valid test of association. 
6.8 Results 
6.8.1 Clinical characteristics of the subjects 
The Renfrew/Paisley offspring population comprised 2338 individuals from 1477 
families. There were a variable number of offspring from each family. 
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Electrocardiograms were available from 2308 individuals (1035 men and 1273 
women) out of 1466 families. The summary of the eligible families is given in Table 
6.8-1. The average age of the male subjects was 48 years and the female subjects 44 
years. 593 families had more than one sibling. 873 families had only one offspring 
and thus were not included in the sibling based association study. In order not to lose 
this group, the analysis was carried out in two strands. First the eldest member of each 
family was analysed for gene association. This did not include the family data and is 
thus a simple cross-sectional association study. Secondly all the families with more 
than one offspring were underwent the family based association study. 
1 873 873 
2 
7 
424 848 
3 112 336 
4 41 164 
5 12 60 
6 2 12 
7 1 7 
8 1 8 
Total 1466 2308 
Table 6.8-1 - Structure of the 1477 families analysed 
Table 6.8-2 shows the demographics of the population using only the eldest offspring 
so as to include single offspring families into the study. Males had significantly higher 
BMI, body surface area, waist/hip ratio compared to women. The various indices of 
ECG LV mass were also significantly higher in men. There was however no 
significant difference in BP between men and women. 
Table 6.8-2 shows the baseline characteristics and ECG phenotypes of the population. 
All the phenotypes differed significantly by gender. The mean value of ECG LV mass 
was 170 gms for men and 130 gms for women. Table 6.8-3 outlines the proportion of 
variance of the ECG phenotypes that was explained by the covariates in the 
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population that included just the eldest member from each family. The covariates 
retained in the final model were age, systolic blood pressure at recruitment, weight 
and height. The inclusion of BMI, body surface area, diastolic blood pressure, waist- 
hip ratio did not significantly improve the fit of the models. Age, systolic blood 
pressure, weight and height accounted for 5-12% of the variation in different ECG 
phenotypes while Sex, age, systolic blood pressure, weight and height accounted for 
18-28% of the variation (except for ECG LV mass which is a compound phenotype 
that includes weight in its calculation). All the adjusted phenotype values 
(standardized residuals) had an approximately Normal distribution (Kolmogorov- 
Smirnov Z value <1.30, P>0.05 for all the traits). 
N 1035 1273 
Age 44.9(6.3) 45.4(6.0) 0.055 
SBP mmHg 131.1 15.2) 123.5(15.7) <0.001 
DBP mmHg 79.2(10.9) 70.9(10.0) <0.001 
BMI 26.5(4.0) 25.9(5.4) 0.003 
Creatinine 107.1(23.1) 89.7(13.2) <0.001 
Cholesterol 5.4(1.0 5.2(0.9) <0.001 
Diabetes (%) 0.8 2.0 
LVM (Rautaharju) gms 170.1(23.2) 130.2(18.6) <0.001 
Cornell Voltage V 1295.5(528.1) 925.8(428.5) <0.001 
Sokolow Lyon V 2407.8(704.2) 2082.5(579.9) <0.001 
12Lead V 14999.4(2941.2) 12296.1(2495.7) <0.001 
Sokolow Lyon product V. s 229.2(73.7 182.2(55.1) <0.001 
Cornell Voltage product V. s 123.7(53.9) 81.7(41.3) <0.001 
12 Lead product V. s 1431.8(356.6) 1080.2(268.5) <0.001 
Table 6.8-2 - Demographics and ECG phenotypes of the eligible study population. (mean and 
standard deviation) 
Table 6.8-3 - R2 for models predicting adjusted ECG phenotypes (p<0.001 for all models) 
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6.8.2 Heritability 
Phenotype 
BMI 
Heritability 
0.55±0.06* 
Waist/flip ratio 0.39±0.07* 
Systolic BP 0.35±0.07 
Diastolic BP 0.53±0.06* 
LVM (Rautaharju) gms 0.55 ± 0.07* 
Cornell Voltage V 0.32 ± 0.06* 
Sokolow Lyon V 0.32 ± 0.06* 
12Lead V 0.44 ± 0.06* 
Sokolow Lyon product V. s 0.28 ± 0.06* 
Cornell Voltage product V. s 0.28 ± 0.06* 
12 Lead product V. s 0.36 ± 0.07* 
Table 6.8-4 - Heritability estimates (± standard error) for ECG indices of 
LV mass, blood 
pressure, BMI and waist/hip ratio. 
* P<0.00001 for testing sporadic vs polygenic models in SOLAR. 
Heritability was used to summarise the overall extent to which phenotypic variation is 
due to additive genetic effects was calculated using individuals from families with 
more than one offspring. In Table 6.8-4 the heritability estimates are shown from the 
analysis of these phenotypes performed in SOLAR. The heritability estimates for 
systolic blood pressure was 35% and diastolic blood pressure 52%. BMI showed a 
heritability of 55%. The heritability of the electrocardiographic phenotypes that are 
based on the Cornell voltage (RaVL+SV3) were 48-62% for LV mass, 26-38% for 
Cornell Voltage, Sokolow-Lyon voltage and Sokolow-Lyon product had a heritability 
of 22-38%, and the electrocardiographic phenotypes based on 12 lead voltage (12 
Lead Voltage and 12 Lead product) had a heritability of 29-50%. These findings 
provide a strong rationale for genetic studies focused on quantitative assessment of 
electrocardiographic variables related to LV hypertrophy to identify genes that 
contribute to these phenotypes and cardiovascular risk. These estimates of heritability 
for Cornell Voltage is in agreement with previous reports in Caucasian families which 
range from 26-32%, 256'489 but are lower than an estimate of heritability of 65-72% 
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obtained in siblings of African ancestry. {Kotchen, 2000 13847 /id} The ECG criteria 
for LVH that are based on Cornell Voltage was developed using echocardiographic 
validation, 508 522 therefore it is not surprising that the heritability estimate for this 
is 
similar to echocardiographic LV mass. 
256; 489 
For the ECG measures of LV mass, the maximum heritability was shown by LVM- 
Rautaharju equation and 12 lead voltage, so further family based association analysis 
will be done on these indices. 
6.8.3 Association study 
N 654 812 
Age 46.5(5.8) 46.9(5.7) 0.18 
SBP mmHg 132(15.4) 125.1(16.4) <0.001 
DBP mmHg 80.1(10.8) 71.4(10.1) <0.001 
Height 1750.2(63.9) 1611.4(80.4) <0.001 
Weight 81.5(13.4) 67.5(13.1) <0.001 
Cholesterol 5.5(1) 5.2(0.9) <0.001 
LVM (Rautaharju) 170.7(23.2) 130.9(18.8) <0.001 
Cornell Voltage mV 1315.8(534.7) 942.5(443) <0.001 
Sokolow Lyon mV 2387.1(692) 2078.2(597.2) <0.001 
12Lead mV 14941.5(2822.2) 12305.7(2596.1) <0.001 
Sokolow Lyon product mV. s 227(70.7) 182.2(56.7) <0.001 
12 Lead product mV. s 1425.3(341.8) 1083.2(278.6) <0.001 
Cornell Voltage product mV. s 125.6(54.4) 83.4(43.3) <0.001 
Table 6.8-5 - Demographics and ECG phenotypes of the eldest member of each of eligible 
families in the study population. (mean and standard deviation) 
The summary of the demographic and ECG phenotypes of the subset comprising the 
eldest member from each family is shown in Table 6.8-5. None of the four 
polymorphisms showed any association with blood pressure or BMI. The results are 
summarised in Table 6.8-6, which also shows that all four genes are in Hardy- 
Weinberg Equilibrium. In the mixed effects ANOVA model shown in Table 6.8-7, 
B1AR was associated with the variability in the Cornell-Voltage based ECG 
phenotypes. An interaction between GNB3 and SF1 was found to have a significant 
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association with variability in LV mass based on Cornell Voltage, while an 
interaction 
between GNB3, ACE and SF1 was associated the LV mass indices based on 12 lead 
voltage. GNB3 alone did not have any major effect on LV mass or blood pressure. 
The main effect of the association with the B1AR polymorphism persisted after 
Bonferroni correction was applied. 
"I MCC 
CT TT HW` ANOVA 
N 496 481 97 F 
SBP a 127.5(0.8) 127.4(0.8) 126.5(1.6) 23 
0.19 0.82 
DBP a 74.8(0.6) 74.8(0.6) 73.9(1.1) 
0. 
0.33 0.72 
BMI 26.5(0.3) 26.5(0.4) 26.2(0.9) 0.87 0.42 
CC CO GG HW ANOVA 
N 587 415 72 F 
SIIP a 127.2(0.7) 127(0.8) 127.3(1.8) 0.02 0.98 
DBP a 74.9(0.5) 74.3(0.6) 74.4(1.2) 
0.93 
0.46 0.63 
IIMI 25.9(0.3) 26.6(0.4) 26.7(0.9) 0.15 0.86 1 
II ID DD HW` ANOVA 
N 239 501 334 F 
SBP a 127.2(1.1) 126.2(0.9) 128(1) 1.57 0.21 
DBP a 74.7(0.8) 73.6(0.6) 75.3(0.7) 
0.05 
2 98 0.05 
BMI 26.4(0.6) 26.3(0.4) 26.5(0.6) 0.12 0.89 
CC CT TT HW ANOVA 
N 240 528 306 F 
SBP a 126.2(1.1) 128(0.9) 127.2(1.1) 1.17 0.31 
DBP a 74(0.8) 75.2(0.6) 74.2(0.7) 
0.67 
1.55 0.21 
MI B 26.5(0.5) 26(0.4) 26.6(0.6) 0.26 0.77 
Table 6.8-6 - Mixed effects ANOVA of blood pressure and BMI using the eldest member of each 
family, showing the main effects of the four genes. 
a Covariates - age, sex, BMI; 
bCovariates 
- age, sex; `Hardy Weinberg Equilibrium - 
Exact p value; dMixed effects ANOVA performed using blood pressure and BMI as 
continuous variables adjusted for covariates. 
HW - Hardy Weinberg Equilibrium; ACE - ACE I/D polymorphism, GNB3- GNB3 C825T 
polymorphism, B1AR - B1AR G1165C polymorphism, SF! - CYP11B2 C344T polymorphism. 
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F 
Cor nell 
F 
Co 
F 
rnell 12 
F 
Lead 
GNB3 2.87 0.06 2.88 0.06 1.23 0.29 2.84 0.06 0.68 0.51 
B1AR - 4.05 0.02 3.83 0.02 0.27 0.76 3.29 0.04 0.21 0.81 
ACE 0.02 0.98 0.07 0.93 0.77 0.47 0.14 0.87 1.53 0.22 
SF1 0.82 0.44 1.48 0.23 0.02 0.98 1.28 0.28 0.3 0.74 
GNB3 * WAR 1.17 0.32 1.58 0.18 0.61 0.65 1.75 0.14 0.32 0.86 
GNB3 ACE 1.31 0.26 1.32 0.26 0.19 0.94 1.2 0.31 0.65 0.63 
°' GNB3 " SF1 2.72 0.03 2.9 0.02 1.94 0.1 2.92 0.02 3.11 0.01 
B1AR * ACE 1.03 0.39 0.79 0.53 0.32 0.86 0.66 0.62 0.51 0.73 
B1AR * SFi 0.15 0.96 0.22 0.93 0.84 0.5 0.16 0.96 1.74 0.14 
ACE " SFi 1.45 0.21 1.21 0.31 0.29 0.89 0.87 0.48 0.39 0.82 
GNB3 * MAR " 
ACE 1.38 0.2 1.31 0.24 1.49 0.15 1.52 
0.15 1.14 0.33 
GNB3 * WAR 2.18 0.03* 1.29 0.25 0.92 0.49 1.59 0.13 1.46 0.18 
GNB3 * ACE * SF1 1.31 0.23 1.29 0.24 3.11 <0.01 1.29 0.24 2.17 0.03 
B1AR * ACE' SFi 1.3 0.24 0.78 0.62 1.2 0.29 0.62 0.76 1.25 0.26 
V G 
ACE 
BSA R 1.38 0.02* 1.26 0.07 1.22 0.1 1.26 0.07 1.24 0.09 
Table 6.8-7 - Mixed effects ANOVA of the adjusted electrocardiographic phenotypes using the 
eldest member of each family, showing the main effects of the four genes and their interactions. 
ACE - ACE I/D polymorphism, GNB3- GNB3 C825T polymorphism, 
B1AR - B1AR G1165C 
polymorphism, SF1- CYP11B2 C344T polymorphism. 
6.8.4 Family Study 
In the family study, the entire pedigree is analysed for all families with more than one 
offspring. The phenotypes analysed were systolic BP (SBP), diastolic BP (DBP), LV 
Mass by Rautaharju equation, 12 lead voltage (12Lead V). Association was tested in 
QTDT using the orthogonal model and allowing for linkage and background 
polygenes. Empirical p-values were calculated using a Monte-Carlo permutation with 
built-in adjustment for multiple testing. As seen in Table 6.8-8, the strongest 
association was for B1AR gene polymorphism and 12 Lead Voltage. 
Unsuspected population stratification amongst the families studied can lead to 
spurious results. Population stratification was tested by partitioning the observed 
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association into between-family and within-family components using the QTDT 
program. This showed no evidence of population stratification in the study group. 
As there is no stratification except for 12 Lead Voltage and the B1AR polymorphism, 
the next step is to test the total evidence for association (i. e., not a TDT). The results 
are summarised in Table 6.8-9, which shows no association by variance component 
testing for all the polymorphisms and the phenotypes tested. 
PROBANDS 610 64 5 70 3 610 
z z 2 p z 
SBP 1.96 0.16 0.0 1 0.15 0.69 2.01 0.16 
DBP 1.0 0.32 0.45 0.50 0.49 0.48 1.17 0.28 
MAP 0.0 1 0.06 0.81 0.05 0.82 0.01 0.92 
LV mass 1.01 0.3 0.38 0.5 0.06 0.8 0.96 0.3 
12Lead V 0.12 0.7 4.07 0.04 1.18 0.3 0.13 0.7 
Table 6.8-8 - Variance component analysis of association between candidate genes and 
cardiovascular phenotypes in the Renfrew Paisley offspring population. 
ACE - ACE I/D polymorphism, GNB3- GNB3 C825T polymorphism, B1AR - B1AR G1165C 
polymorphism, SF! - CYP11B2 C344T polymorphism. Systolic BP (SBP), diastolic BP (DBP), 
mean arterial pressure (MAP), LV Mass by Rautaharju equation, 12 lead voltage (12Lead_V). 
PROBANDS 1992 2161 2122 1992 
2 p z P z p z p 
SBP 1.13 0.28 0.0 1 0.40 0.53 1.23 0.27 
DBP 1.07 0.30 2.21 0.14 1.04 0.31 1.14 0.29 
LV mass 1.48 0.2 0.02 0.87 0.36 0.6 1.43 0.20 
12Lead V 0.38 0.50 0.61 0.4 0.52 0.45 0.38 0.51 
Table 6.8-9 - Total association in the whole family using age, BMI and sex as covariates. 
ACE - ACE IID polymorphism, GNB3- GNB3 C825T polymorphism, B1AR - B1AR G1165C 
polymorphism, SF1- CYP11B2 C344T polymorphism. Systolic BP (SBP), diastolic BP (DBP), 
mean arterial pressure (MAP), LV Mass by Rautaharju equation, 12 lead voltage (12Lead_V). 
Finally the whole analysis was carried out after excluding all those ECG's which 
showed any abnormality namely ischaemia, conduction defects as defined by their 
Minnesota codes (the Minnesota codes used are shown in Table 1.4-2). Table 6.8-10 
shows the results of the analysis that included tests for Association, Linkage, Linkage 
-271- 
in the presence of association, population stratification, and total association. The 
results are similar with no association detected. 
Linkage Stratific- Total 
Association 
LV MASS 
GNB3 540 0.17 0.70 0 1.00 0 1.00 0.14 0.70 0.03 0.90 
B1AR 579 1.47 0.20 0 1.00 0 1.00 2.17 0.10 0.07 0.80 
ACE 648 1.46 0.20 0 1.00 0 1.00 2.01 0.20 0.02 0.90 
SF! 540 0.18 0.70 0 1.00 0 1.00 0.15 0.70 0.02 0.90 
12L -V 
GNB3 540 0.99 0.30 0.04 0.80 0.18 0.70 0.67 0.40 0.32 0.60 
B1AR 579 3.88 0.05 0.02 0.90 0.04 0.80 3.48 0.06 0.52 0.50 
ACE 648 0.32 0.60 0 1.00 0 1.00 0.06 0.80 0.48 0.50 
SF! 540 1 0.30 0.03 0.90 0.27 0.60 0.68 0.40 0.32 0.60 
Table 6.8-10 Analysis of the ECG indices excluding abnormal ECG's using the Minnesota Code. 
Age, sex and BMI used as covariates. 
ACE - ACE I/D polymorphism, GNB3- GNB3 C825T polymorphism, B1AR - B1AR G1165C 
polymorphism, SF! - CYP11B2 C344T polymorphism. LV Mass by Rautaharju equation, 12 lead 
voltage (12Lead_V). 
6.8.5 Family based Association 
The next analysis was carried out using the same phenotypes but using the FBAT 
program. The results are presented in Table 6.8-11. Similar to the results of the 
variance component analysis, B1AR shows a significant association with respect to 12 
lead voltage measures. The other genes show no association. 
GNB3 
N/ families' 610/244 
BIAR 
645/245 
ACE 
703/283 
SH 
610/244 
Z p z p z p z p 
Systolic BP -0.61 0.54 -1.75 0.079 -1.03 0.30 -0.61 0.54 
Diastolic BP -0.62 0.53 -1.17 0.24 -0.67 0.49 -0.62 0.53 
BMI 0.36 0.72 -1.23 0.22 0.07 0.94 0.36 0.71 
LV mass 1.3 0.19 -0.72 0.47 -0.09 0.93 1.3 0.19 
12Lead V -0.25 0.80 2.07 0.03 1.06 0.28 -0.25 0.80 
Table 6.8-11- FBAT analysis of the Renfrew Paisley Offspring phenotypes and candidate genes. 
a- Number of informative families for the polymorphism 
Systolic BP, Diastolic BP and BMI used as continuous variables adjusted for age and 
sex. LV mass and 12 lead voltage adjusted for age, sex, height and weight. 
ACE - ACE I/D polymorphism, GNB3- GNB3 C825T polymorphism, BIAR - BIAR G1165C polymorphism, SF! - CYP11B2 C344T polymorphism. 
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6.9 Discussion 
This study is a cross-sectional study of an unselected population of siblings from the 
Renfrew/Paisley area of Scotland. Both a simple association study and a sibling-TDT 
analysis including family structure were used to look for an association between 
GNB3 and blood pressure and ECG indices of LV mass. The phenotypes were 
analysed as quantitative traits. Three other genetic polymorphism of ACE, ß1 
adrenergic receptor and aldosterone synthase were also analysed. All these genes have 
been variably associated with blood pressure and LV mass. 
The advantage of this study is that it uses a family based approach to detect 
association with candidate genes. Transmission disequilibrium testing is more 
powerful in assessing genetic linkage and association and is immune to the effects of 
sampling bias, thus avoid the misleading results that occur when the study population 
is not genetically homogeneous. I also used quantitative traits in the analysis, as 
hypertension and LV mass are inherently non-mendelian traits and quantitative traits 
may provide more effective descriptions of these complex phenotypes. 
6.9.1 Blood Pressure 
I found no association between systolic and diastolic blood pressure in the association 
study using the eldest offspring in each family. Analysing separately for males and 
females or together using sex, age and BMI as covariates consistently showed no 
association. I also found no association using a family based analysis. There was no 
evidence of population stratification and the lack of association was evident with 
quantitative transmission disequilibrium test (QTDT) and this was verified by the less 
conservative EV-FBAT. 
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I studied the West of Scotland population known to have a high cardiovascular risk, 
and found no relation between GNB3 polymorphism and blood pressure levels at 
recruitment when the average age of the population was 38-50 years. The association 
studies between GNB3 and hypertension have been inconsistent and are detailed in 
Section 1.6.3.1 page 186. Two longitudinal studies from Europe show contrasting 
results for association between GNB3 polymorphism and risk of hypertension in a 
non-hypertensive population 
693'764 In a population based prospective cohort study 
from Finland of 903 men, aged 42-61 years at baseline and followed up for an 
average time of 4.2 years, Snapir et a1693 found no statistically significant difference 
between the GNB3 genotype groups in respect to baseline and end-of-follow-up risk 
for hypertension or obesity, systolic or diastolic blood pressure, or body mass index. 
Sartori et al7M looked at 461 participants of the Hypertension and Ambulatory 
Recording Venetia Study (HARVEST) study (age, 18 to 45 years) at low 
cardiovascular risk, according to 1999 ISH/WHO criteria. The study end point was 
eligibility for antihypertensive medication, that is, progression to grade II 
hypertension during the first year of observation or office systolic blood pressure 150 
mm Hg and/or office diastolic blood pressure 95 mm Hg in two later consecutive 
visits during follow-up. At baseline, there was no statistically significant difference 
among genotypes with respect to body mass index, blood pressure, and heart rate. 
According to survival analysis, the patients carrying the 825T allele had an increased 
risk of reaching the blood pressure end point (Cl, 1.108 to 1.843; P=0.006). They 
reasoned that in these young hypertensive patients with low cardiovascular risk 
profile, the genetic influences on blood pressure could be more pronounced than in 
obese, older patients with long-lasting hypertension, in whom the effects of 
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environmental factors may prevail. Though at baseline they found no difference in 
genotype frequencies, they suggest 825T allele of GNB3 gene is associated with 
earlier blood pressure increase and a more frequent need of antihypertensive therapy 
during a mean follow-up of 4.7 years. In this study the phenotype studied is slightly 
different in that, I used the age and sex adjusted blood pressure values as a continuous 
variable and performed variance component analysis. While most of the other 
association studies have been case-control studies. One of the drawbacks of variance 
component analysis is that observations on subjects with incomplete data are assumed 
to be missing at random and hence ignorable. In this population for blood pressure 
and BMI, only those who had all the phenotypes recorded were used in the analysis. 
This large study is a negative association study that supports the results of the case 
control study described in Chapter 4 -. 
6.9.2 ECG LV mass 
The primary aim of this study was to identify measures of cardiac hypertrophy 
determined by ECG that are most likely to have a genetic basis and determine if 
variations in the GNB3 genotype had any role in relation to hypertensive LVH as 
previously reported 581 I also looked at other candidate genes implicated in LVH 
namely aldosterone synthase, ACE and betal adrenoceptor. 
The pathogenic mechanism of LVH is multifactorial, involving both haemodynamic 
and non-haemodynamic factors, such as the sympathetic nervous system and the 
renin-angiotensin system. In addition, epidemiological studies have demonstrated that 
subjects with LVH may have near-normal blood pressure, 48 indicating that additional 
factors besides blood pressure may be important in the development of hypertrophy. 
Studies in families and twins have shown that left ventricular mass is a familial trait, 
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indicating the influence of both genetic and environmental factors. Recent 
investigation into the genetic factors for LVH have focused mainly on the renin- 
angiotensin system, with focus on the insertion/deletion polymorphism of the 
angiotensin-converting enzyme gene associated with LVH, 
573 but results have been 
conflicting 495 
This study quantifies the significant heritability of ECG indices of LV mass namely 
LV mass as measured by the Rautaharju equation, Voltage indices namely Sokolow- 
Lyon, Cornell, and 12 lead voltages. I have also analysed voltage time product and 
found them to be significantly heritable. The estimates for heritability for these ECG 
indices were lower than the heritability determined for the twin population (Table 
5.5-4). One reason is that it is known that twin estimates of heritability are often 
higher than those of sibling and family cohorts. It has also been suggested that 
anatomical and ECG indices of LVH may reflect different phenomena, and they have 
been found to have independent effects on morbidity and mortality. 506; 581; 765 The ECG 
voltage provides a complex measure of cardiac hypertrophy derived from the 
magnitude of electrical potential generated by the left ventricle and the electromotive 
forces generated by the heart. In addition to the biological differences between the 
electrical and anatomic phenotypes, the accuracy and reliability with which a 
phenotype can be measured can influence familial correlations and heritability 
estimates. Our heritability estimates are comparable to those reported by Mayosi et al 
who found Sokolow-Lyon voltage, electrocardiographic left ventricular mass, Cornell 
voltage, and Cornell product had heritability estimates of 39-41%, 12-18%, 19-25%, 
and 28-32%, respectively. 766 
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Sedlacek et a1592 evaluated a large and epidemiologically phenotyped population 
sample and failed to show any association between the GNB3 T allele and 
echocardiographic cardiac structure and diastolic function. This study population is 
comparable with the of Sedlacek et a1592 in that the population was not selected for 
any cardiac phenotype, but unlike Sedlacek et a1592 the present study is a family based 
study using ECG indices of LV mass. The results of my study is similar to that of 
Sedlacek et al 592 it must be pointed out that the phenotypes under investigation are 
different, though the ECG indices of LV mass correlate with ECHO LV mass. Poch et 
a1581 focused their work on untreated hypertensive patients and such selected patients 
may be more informative to detect minor effects of a given candidate gene with 
respect to LVH compared with the normal population sample. However, Sedlacek et 
a1592 analysed multiple subgroups potentially related to the effects of the GNB3 
C825T polymorphism, including hypertensive subjects without antihypertensive 
medication and found no differences according to the genotype status. Furthermore, 
other phenotypes related to LVH, independent from echocardiographic measurements 
such as serum levels of atrial and brain natriuretic peptide, did not display an 
association with the GNB3 polymorphism. In the present study, normal siblings, who 
were not selected for any cardiovascular phenotype were analysed and did not show 
any association with the GNB3 polymorphism. 
This study shows an association between B1AR and ECG LV mass in the association 
study, which used only one individual per family. The effect is also seen in the 
variance component based analysis of the entire population and on family based 
association testing. It must be pointed out that the phenotype values were not entirely 
normally distributed when the entire population was considered, though it showed a 
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normal distribution when only one member of each family was included. However 
GNB3 consistently showed a negative single gene association with the ECG 
phenotypes. 
This study also shows a significant statistical interaction between GNB3, ACE and 
SFl polymorphisms. It is well known that complex traits like LV mass are the 
consequence of interactions between many genetic and environmental factors. In this 
scenario, effects conferred by a single gene variant either must be very strong or 
found at a very high frequency to be statistically detectable, even if the sample of the 
association study is large. The candidate genes I have looked at have previously been 
inconsistently associated with LV mass. The statistical interactions we have shown 
may explain some of the previous inconsistent results if they can be replicated in other 
studies. Biologically, it is reasonable to speculate that as G proteins are signal 
transduction molecules through which the actions of the renin-angiotensin-aldosterone 
system and the adrenergic system are mediated, they may exert a major effect only in 
association with variation in these genes. G proteins mediate part of the actions of 
vasoactive hormones, such as angiotensin II and norepinephrine. Angiotensin II exerts 
trophic effects on cardiomyocytes in culture and is known to stimulate growth in other 
cell systems. 721 On the other hand, growth factors, such as platelet-derived growth 
factor, can act in part through pertussis-sensitive G proteins in skin fibroblasts, 
vascular smooth muscle cells, and cardiac fibroblasts and may participate in the 
pathogenesis of LVH 494 G-protein ß3 subunit gene polymorphism may constitute a 
genetic basis for the enhanced growth phenomena observed in essential hypertension, 
such as LVH and media hypertrophy of the vessel wall, if it is directly associated with 
a functional change and does not merely represent a DNA marker. 
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Though the functional effect of the GNB3 splice variant is in dispute, whether its 
function is enhanced as hypothesised by Siffert et a1672 or whether the splice variant 
is associated with loss of function as described by Ruiz-Velasco and Ikeda767, the net 
effect of this variation could be manifest only when its associated afferent or efferent 
pathways are also affected. However these findings need to be further tested in large 
association studies especially with ascertainment for high blood pressure that can 
identify individuals in the extremes of LV mass distribution. In this setting, the 
practicality of measuring electrocardiographic phenotypes are much greater than that 
of measuring echocardiographic left ventricular mass in many thousands of 
individuals. Such ascertainment is also necessary to give power at the stage of 
defining genotype-phenotype association. 169 
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Chapter 7- FUNCTIONAL STUDY OF GNB3 - Platelet 
Aggregation 
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Platelet aggregation plays a central role in the pathogenesis of acute thrombosis 
in 
coronary heart disease. 
768 Endothelial injury, as well as atherosclerotic lesions, 
enhances the adhesion of platelets to the subendothelial matrix through interactions of 
the platelet glycoprotein (GPIb/IX) complex with von Willebrand factor. 
69 
Subsequent platelet activation is triggered by many agonists, most of them, including 
thrombin, ADP, epinephrine, and thromboxane A2, bind to heptahelical receptors 
coupled to heterotrimeric G proteins. 
Some specific endogenous and other environmental factors have been described to 
affect platelet aggregability such as age, 
770 stress, 77 773 hypertension, 774 cigarette 
smoking and alcohol consumption, 
775 but these factors only partially explain the 
interindividual variability in aggregation responses. 
The activation of platelets results in platelet aggregation and release of several 
vasoactive substances such as catecholamines, 5-hydroxytryptamine, thromboxane 
A2, and platelet-derived growth factor. 776 These vasoactive substances in turn can 
promote vasoconstriction, vascular hypertrophy, and atherosclerosis, as well as 
thrombus formation. 776 In essential hypertension, platelets are believed to be 
preactivated or hyperresponsive to vasoactive agents. This hypothesis is supported by 
the evidences demonstrating that platelet release product -thromboglobulin, 
intraplatelet calcium, intracellular pH, density of platelet 2-adrenoceptors, or platelet 
aggregatory responses to vasoactive substances are increased in patients with essential 
hypertension compared with normotensive subjects. 77-783 Especially in essential 
hypertension, platelet might be overactivated by mental stress or exercise because of 
the exaggerated responses of systemic haemodynamics and sympathoadrenal system 
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to 784 The repeated enhancement of platelet activity during daily stress may 
accelerate vascular injury and hypertensive organ damage, thereby exposing 
hypertensive patients to risks of cardiovascular complications. 785°786 Accordingly, it is 
suggested that platelets play an important role in the genesis of cardiovascular 
complications in hypertension. In fact, the recent clinical study, called Hypertension 
Optimal Treatment (HOT) study, has demonstrated that adding 75 mg/day of aspirin 
to antihypertensive treatment reduced major cardiovascular events by 15% and all 
myocardial infarctions by 36% in hypertensive patients. 
787 Similarly, another study 
demonstrated that aspirin had a 44% reduction of myocardial infarction in primary 
prevention. 788 Therefore, it is desirable that antihypertensive agents would have 
favourable effects on platelet function as well as pressure-lowering effect. The effects 
of antihypertensive drug on platelet function have been extensively studied in the 
clinical setting and in in-vitro experiments. Most clinical data suggest that angiotensin 
converting enzyme inhibitors, calcium antagonists, and ß-blocking agents inhibit 
platelet function in essential hypertension. 778; 789; 790 However, the results of the 
previous reports are not consistent in detail regarding antiplatelet effect of these 
drugs, possibly as a result of differences in study design, subjects selected, or 
methodology used. 
7.1 G Protein and Platelet Aggregation 
The physiology of G protein function is described in section 1.5 (page 165). The G 
protein subunits which are activated in human platelets by common agonists have 
been described: vasopressin (VP) induces platelet aggregation via the V1 receptor 
involving the pertussis toxin (PTX)-insensitive Gq. 791 Using a knockout mouse 
model, Offermanns et al. 792 documented that Gq is essential for aggregation in 
response to TXA2, thrombin, and ADP, whereas G12/13 proteins mediate the platelet 
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shape change reaction. 793 Activation of human platelets with thrombin receptor- 
activating peptide (TRAP) results in the activation of Gi, Gq, and G12/G13,794 the 
thromboxane A2 (TXA2) receptor agonist U46619 activates Gq, G12 and G13, but 
not Gi 794'795 Therefore, platelet aggregation induced by thromboxane A2 requires the 
secretion of ADP to inhibit the adenylyl cyclase. 796 Epinephrine-induced platelet 
aggregation is considered to be exclusively mediated by Gi2 after activation of the 
a2A adrenoceptor, 797 whereas ADP mediates platelet activation through two G- 
protein-coupled receptor subtypes Gq and Gi. 798 Signalling via G protein-coupled 
receptors leads to the binding of fibrinogen and von Willebrand factor to the 
glycoprotein (GP) IIb/IIIa receptor of platelets as a final common pathway by a 
process described as inside-out signalling. 799 The following are the agonists and their 
G protein targets which will be studied in this experiment. 
Weak Agonists 
  ADP - Gq, Gi 
  Epinephrine - Gi2 
0 Strong agonists 
  PAF - Gi 
7.2 Hypothesis 
Given the activation of PTX-sensitive G proteins by epinephrine together with the 
observation that the a2A adrenoceptor activates G protein heterotrimers containing 
G03,800 epinephrine-mediated platelet aggregation should be enhanced in GNB3 825T 
allele carriers. In contrast, platelet activation evoked by thrombin, ADP, or U46619, 
TRAP and VP may not be influenced by the allele status at the 825 positions of 
GNB3. 
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7.3 Methods 
7.3.1 Subject recruitment: 
Normal volunteers were recruited by advertisement. Any individual above 18 years of 
age, non-smoker, non-diabetic, non-hypertensive, not on any medications including 
NSAIDs was invited to take part in the study. They were advised to attend the Clinical 
Investigation Research unit at 9AM fasting from midnight. On arrival, they were 
asked to lie on a bed in the research unit and after 5-10 minutes rest, they filled in a 
questionnaire, signed a consent form and their blood pressure and vital signs recorded. 
The research protocol was approved by the West Ethics Committee. 
7.3.2 Collection of Blood: 
Venous blood was collected from the subjects after overnight fast. All subjects 
confirmed on the day of study that they were non-smokers and they were not on any 
medications including aspirin or other over-the-counter medications. Blood was 
drawn from a large vein, usually the antecubital vein without stasis using an 18G 
butterfly needle into a 50m1 plastic syringe. The 50 ml sample of blood for platelet 
aggregation was anticoagulated with 3.15% Sodium Citrate (9: 1 vol/vol), pH 7.4. 
Also blood samples for routine haematology, biochemistry and a sample of blood for 
DNA extraction were obtained. 
7.3.3 Preparation of Platelet-Rich Plasma (PRP) and Platelet- 
Poor Plasma (PPP) 
Platelet-rich plasma was obtained by a 20 minute centrifugation at 100g at room 
temperature. The two-thirds of the supernatant PRP was transferred to a polystyrene 
tube and allowed to sit at room temperature for 20 minutes. Platelet-poor plasma was 
prepared by further centrifugation of the remaining blood specimen at 2000g for 20 
minutes at room temperature. 
- 284 - 
7.3.4 Reagents: 
ADP (Sigma) was prepared as a stock solution of 1000 µM in 1 ml distilled water. 
Platelet activating factor (PAF) (Sigma) was prepared as a solution of 1000 nM in 
0.35% Bovine Serum Albumin (BSA) and 0.15M NaCl. Epinephrine (Sigma) was 
prepared as a stock solution of 100 µM in 1 ml distilled water. All the stock solutions 
were frozen at -20°C. Before the start of the experiments, the aggregating agents were 
made up in the following concentrations for the dose response curves. ADP : 200, 
100,50,25,12.5,6.25,3.125,1.56 µM in distilled water; Epinephrine: 100,50,25, 
12.5,6.25,3.125,1.56 µM in distilled water; PAF: 500,250,125,62.5,31.25,15.625, 
7.8 nM in BSA/saline. These concentrations would provide the necessary final 
concentrations when it would be diluted 1: 10 with PRP during the experiment. 
Further concentrations were prepared by dilutions during the experiment if needed. 
Thus the final concentrations of ADP ranged from 0.1 to 20 µM, PAF from 0.7 to 50 
nM and epinephrine fromO. 1 to 10 µM. 
7.3.5 Platelet Aggregation: 
Platelet aggregation was carried out according to Born's method. 801 using a 
Chronolog Aggregometer. Measurement was performed on aliquots of 450 µL of 
platelet-rich plasma with stirring at 1200 rpm at room temperature. 450 µL of platelet- 
poor plasma served as the reference. 50 µL of agonist was added to the platelet-rich 
plasma and the changes in light transmission recorded. The aggregation studies were 
conducted 60 minutes after venepuncture and were completed within 2 hours. 
In aggregometric studies, the parameter considered is light absorption, which is 
evaluated on a scale of 0-100%. Because platelets are randomly dispersed in platelet- 
rich plasma and virtually absent in platelet-poor plasma, light absorption is very high 
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with platelet-rich plasma and very low with platelet-poor plasma. At the beginning of 
each aggregometric experiment, light absorption of the platelet-rich plasma examined 
is conventionally set at 90% and light absorption of platelet-poor plasma at 10%. 
When platelets aggregate, light absorption is reduced and the reduction correlates with 
the extent of platelet aggregation. The extent of platelet aggregation can be 
determined by measuring the maximum amplitude of increase in light transmission, 
directly from the aggregometer tracings in light transmission units. A very reliable 
parameter to quantify platelet aggregation is the agonist concentration able to induce a 
value of maximal aggregation of 50% (EC50). For this purpose, at least four doses of 
each agonist are used. With the maximal aggregation values corresponding to 
different agonist concentrations, it is possible to obtain a dose-response curve. This 
curve is subsequently transferred to a semilogarithmic scale by plotting the logarithms 
of agonist concentrations on the x-axis and the corresponding maximal aggregation 
values on the y-axis. A sigmoidal dose-response curve is obtained and using the 
software Prism (Graphpad), the EC50 is determined using nonlinear regression. 
Reproducibility testing showed an intra-individual variance in response to agonist of 
10-15%. 
7.4 Results 
Thirty-six normal volunteers were included in the study. Those volunteers whose 
platelet aggregation measurements were not possible and those who could not be 
genotyped were not included. Table 7.4-1 summarises the demographics of this group. 
There were 13 (36%) with CC genotype, 15 (42%) with CT genotype and 8 (22%) 
with TT genotype. There were more females in the CC and CT groups but the 
difference was not significant. The BMI, systolic blood pressure were not 
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significantly different between the three groups. The TT group had a higher diastolic 
pressure compared to the other two groups. 
Table 7.4-1 Summary of the normal volunteers and stratified by their GNB3 genotype 
C T TT P 
N 
cc 
13 15 8 
Age 27.6 7.2 28.7 9.7 29.3 6.5 0.9 
Male: Female 5: 8 10: 5 4: 4 0.3 
BMI 24.2 2.9 23.6 2.1 25.8 6.9 0.5 
SBP 117.7 (11.5) 121.0 6.4 123.5 20.6 0.7 
DBP 70.1 7.0 62.9 4.4 74.3 13.5 0.06 
Smoker % 15.3 40 25 0.34 
Epinephrine ECso 13.25 (10.7) 19.37 (13.8) 16.06 5.7 0.43 
Epinephrine ECso- Males 22.1 12.1 20.9 15.4 14.2 6.9 0.79 
Epinephrine ECSO- Females 7.4( 3.9) 16.4 11.7 17.3 5.9 0.12 
PAF ECSO 226 58.8 231.1 (72.0) 267.4 (96.4) 0.65 
PAF EC50 - Males 243.8 (51.6) 319.3 ( 223.6) 340.4 (38.4) 0.76 
PAF ECso - Females 214.2 (64.8) 201.6 (44.6) 219.0 (92.3) 0.93 
ADP ECso 1.59 1.27 0.95 0.84 0.86 0.43 0.26 
ADP ECso - Males 1.33 (1.35) 1.08 0.99 1.07 0.46 0.92 
ADP EC50 - Females 1.76 1.32 0.71( 0.46) 1 
0.73 0.45 0.22 
Table 7.4-1 shows the dose response curve relating ADP concentration to platelet 
aggregation. For each individual, aggregation was carried out with the three agonists 
and dose response curve plotted and the EC50 derived using GraphPad Prism. The 
results were analysed using one-way ANOVA to check if GNB3 genotype influenced 
platelet aggregation. There is a lack of association between platelet aggregation and 
GNB3 genotype for all three agonists when the analysis was pooled or stratified by 
sex. 
Figure 7.4-2, Figure 7.4-3 and Figure 7.4-4 demonstrates the lack of association 
between GNB3 genotype and platelet aggregation. Though the numbers repeating the 
analysis for each sex separately also showed no association (Table 7.4-1). Using the 
general linear model to adjust for age, sex blood pressure and GNB3 genotype, only 
age and blood pressure were found to be significant predictors of epinephrine induced 
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Figure 7.4-1 An example of the dose response curve with log concentration of ADP plotted 
on the X-axis and percentage platelet aggregation on the Y axis. 
platelet aggregation (Table 7.4-2). There was no significant effect of any of these 
parameters on ADP or PAF induced platelet aggregation. GNB3 genotype did not 
affect any of the three agonist induced platelet aggregation. 
Age 10.19 0.011 
Sex 0.24 0.648 
Systolic BP 9.64 0.013 
Diastolic BP 6.63 0.030 
GNB3 Genotype 0.11 0.901 
Table 7.4-2 Epinephrine induced platelet aggregation used as the dependent variable and age, 
sex, blood pressure and GNB3 genotype used as predictors in a general linear model. 
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Figure 7.4-2 EC 50 of epinephrine induced platelet aggregation stratified by GNB3 genotype 
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Figure 7.4-3 EC 50 of PAF induced platelet aggregation stratified by GNB3 genotype. 
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Figure 7.4-4 EC 50 of ADP induced platelet aggregation stratified by GNB3 genotype. 
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7.5 Discussion 
This study found no relation between the GNB3 genotype and platelet aggregation in 
36 normal volunteers. In these individuals, age, systolic and diastolic blood pressure 
were found to be predictors of epinephrine induced platelet aggregation. But 
adjustment for these factors also did not show any association with the 
GNB3 
genotype. 
Naher et al. studied platelet aggregation in 34 healthy, non-smoking, male individuals 
between 18 and 40 years of age with no medication known to interfere with platelet 
function for at least 15 dayS. 723 They found slopes and maximum of the secondary 
aggregation were significantly enhanced in platelets from 825T allele carriers after 
epinephrine, and after combined epinephrine/ADP. This effect was more pronounced 
after inhibition of the cyclooxygenase-2 pathway by acetylsalicylic acid. This 
phenomenon appeared independent of platelet secretion, or inhibition of the adenylyl 
cyclase. However, in this study enhanced aggregation of platelets from individuals 
with TT genotype was only observed on combined stimulation of platelets by low 
concentrations of ADP plus epinephrine and more marked during inhibition of the 
cyclooxygenase pathway by aspirin. Moreover, the number of subjects included in 
that study was small so that TT and TC genotypes had to be combined. This study did 
not find any difference in the EC50 of agonist induced platelet aggregation and GNB3 
genotype. 
In contrast, Frey et al. 802 studied the effect of GNB3 polymorphism together with the 
platelet glycoprotein (GP) IIIa PI(A) polymorphism on platelet aggregation in 150 
healthy, non-smoking individuals aged 18-40. They found that individuals showing 
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the GNB3 CC-genotype display an enhanced platelet aggregation in response to low 
concentrations of agonists which act via G protein-coupled receptors. Moreover, non- 
responders to low concentrations of ADP were more likely to be T-allele carriers. 
This observation was particularly pronounced with agonists acting via Gi-coupled 
receptors. This is not surprising since the 03 subunit couples to Gi and altered cellular 
signalling via Gi coupled receptors has been shown to be associated with the GNB3 
genotypes. 579; 803 
Increased platelet aggregability is a major cardiovascular risk factor. Though some 
studies have shown individuals with GNB3 TT genotype have an increased risk for 
infarction and stroke, the relation between GNB3 and platelet aggregation is tenuous. 
Our experiment and the two other studies quoted above show no robust association. 
One can only speculate that other processes increase the risk for myocardial infarction 
in 825T allele carriers, e. g. increased vasoconstriction. 724 732'804 Also infarction is 
considered a complex process initiated by rupture of vulnerable plaques. It is sensible 
to assume that many different mechanisms contribute to this process like 
vasoconstriction, impaired endothelium function, and coagulation. 
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Chapter 8- MOLECULAR GENETIC STUDY OF GNB3 
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8.1 Introduction 
The ability to bind and hydrolyse guanine nucleotides as integral parts of their 
activation-deactivation cycle is perhaps the most prominent functional characteristic 
of signal-transducing heterotrimeric G proteins. Measurement of the effects of 
receptor activation on high-affinity GTPase activity provides the basis of a variety of 
methods used to probe G-protein function. 
The G protein signalling cycle is shown in Figure 1.5-3. Activation of receptor by the 
agonist initiates the release of guanosine 5'-diphosphate (GDP) from the a-subunit of 
the heterotrimer, followed by the binding of guanosine 5'-triphosphate (GTP). This 
leads to the dissociation of the aßy heterotrimer into the GTP-liganded a subunit and 
the free ßy dimer, both of which can interact with a variety of effectors to modulate 
intracellular second messenger concentrations. Deactivation occurs from hydrolysis of 
GTP by the intrinsic GTPase activity of the a subunit, and subsequent reassociation 
of the heterotrimer. (Section 1.5.2, page 169) 
As described in Section 1.5.4.1(ßy Targets, page 176), Gßy serves as the direct 
activator of certain G protein-responsive K+, Cat+, and perhaps also Na+ channels. 
Changes in the cytoplasmic free Ca 2+ concentration constitute one of the main 
pathways by which information is transferred from extracellular signals received by 
animal cells to intracellular sites. The intracellular Ca 2+ signal is conveyed by the 
magnitude, location and duration of the changes in Cat+. Increases in Ca 2+ in a given 
region of the cytoplasmic space are usually initiated by the binding of an extracellular 
signalling molecule (agonist) to its plasma-membrane receptors. The sarcoplasmic 
reticulum in excitable cells and the endoplasmic reticulum in non-excitable cells are 
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the major intracellular Ca 2+ stores. Ca 2+ ions flow from within these stores into the 
cytoplasm through two types of Ca 2+ channels: IP3Rs and ryanodine receptors 
(RyRs). IP3, released into the cytoplasm when cells are activated by external stimuli, 
activates the IP3R. Three isoforms of IP3Rs (IP3R1, IP3R2 and IP3R3) are known. 
Released Ca 2+ then exerts a positive feedback on its own release. Subsequent 
inhibition of the Ca 2+ release is then caused by the decreasing luminal Ca 2+ 
concentration and by the increase in the concentration of the cytoplasmic 
Ca2+/calmodulin-complex. 
The functional analysis of the GNB3 is performed by measuring GTPase activity and 
intracellular calcium signals in cells transfected with Gß3y5 along with a fusion 
construct of a2A-adrenoceptor with Ga; subunit. The a2-adrenoceptor subtypes 
represent the prototypic examples of G-protein-coupled receptors (GPCRs) which 
mediate inhibition of adenylate cyclase activity via interaction with members of the 
G; -subfamily of heterotrimeric G-proteins. 
805 With the exception of GZ, 806'807 the a 
subunits of the G; -like G-proteins all possess a conserved cysteine residue four amino 
acids away from the C-terminus which can act as the acceptor for ADP-ribosylation 
catalysed by pertussis toxin. 808 Thus Senoglesm and by Hunt et al 810 have described 
a scheme to replace the cysteine residue which acts as the target for pertussis toxin- 
catalysed ADP-ribosylation. In this way, treatment of a cell expressing this pertussis 
toxin-resistant form of a G; -like G-protein with pertussis toxin results in attenuation of 
the coupling of a GPCR to the endogenous wild-type G; -like G-proteins, thus 
allowing examination of the interaction of the GPCR with the mutationally modified 
G-protein in isolation. 
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The fusion constructs of a2-adrenoceptor and pertussis toxin resistant Ga; allowed 1: 1 
stoichiometry between the GPCR and G protein thus enabling specific functional 
assessment. GTPase activity is used to measure the capacity of a ligand to induce a 
functional response and allows comparison with various ß3 subunits. The single cell 
calcium signalling experiment is used to study the downstream effect of different ß3 
subunits. In these experiments as mentioned above, the a2A G protein and y subunits 
remained constant. The experiments were also performed using a2AG; (3172. 
8.2 Laboratory methods 
The high affinity GTPase assays were performed in HEK293 cells cotransfected with 
a2A adrenoceptor-Cys35'G; 1« fusion construct along with ß1y2 or ß3y5 or P3-s15. The 
plasmid DNA incorporating these cDNAs were initially amplified and for use in 
subsequent experiments. Section 3.3 Cell Transformation and Amplification of 
plasmid DNA (page 214) describes the procedure. After this cell lines were 
transfected with the cDNA as described in section 3.4 Transfections and membrane 
preparation of HEK293 and COS-7 (page 217). The formal protocol for the GTPase 
assay and calculations involved are described in section 3.6 High affinity GTPase 
assays (page 223). The calcium signalling study was performed in EF88 cells 
cotransfected with the a2A adrenoceptor-CyS351Gi1« fusion construct along with (3375 or 
0345" The protocol for calcium signalling experiment is given in section 3.7 Single 
cell (EF88) calcium (page 227). 
8.3 Results 
8.3.1 GTPase Assay a2AGI cotransfected with /3, and y2 
Figure 8.3-1 shows GTPase measured in HEK293 cells cotransfected with a2AG; and 
ß1y2. The experiment was carried out in three different transfected cell lines - Cells 
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transfected with a2AG; alone, a2AG; with ß1Y2,131Y2 alone, and PCDNA3 alone. High 
affinity GTPAse was measured in each case, after 24-hour incubation with pertussis 
toxin. In Hek293 cells transfected with a2AG; alone, the basal GTPase activity was 
8.19 ± 0.12 pmol/mg/min and after stimulation with 100µM epinephrine the GTPase 
activity was 36.46 ± 13.07 pmol/mg/min. In HEK293 cells after transfection with 
a2AG; and ß1Y2 subunits, the basal and stimulated GTPase activity were 11.31 ± 0.24 
pmol/mg/min and 47.47 ± 18.67 pmol/mg/min respectively. The basal and stimulated 
GTPase activity when measured in cells transfected 131y2 alone (9.35 ± 16.15 and 0.32 
± 7.60 pmol/mg/min respectively) and PCDNA3 alone (10.24 ± 0.64 and 16.64 ± 7.68 
pmol/mg/min respectively) without a2AG; were small indicating that the measured 
high affinity GTPase was indicative of the functional response mediated by the 
agonist epinephrine on the a2AG; construct. There was no difference in the expression 
level of the fusion construct in the different experiments. The expression of a2AG; in 
cells expressing this alone was 2.41 pmol/mg and in cells cotransfected with oc2AG; 
and ß1y2 was 2.27 pmol/mg. 
Figure 8.3-2 shows the result of high affinity GTPase measured over a range of 
concentration of GTP. Using Michaelis-Menten kinetics, the Vmax and Km is 
calculated for each experiment. The increase in Vmax due to epinephrine in cells 
expressing a2AG; alone was 43.63 pmol/mg/min and in cells expressing a2AG; with 
ß1y2 it was 47.77 pmol/mg/min. Given the expression levels above and since the 
receptor and G protein within the fusion are present in 1: 1 molar ratio, the agonist 
induced turnover number was calculated as 18.06 min-' and 21.02 min-' respectively. 
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Figure 8.3-1 Agonist stimulation of high affinity GTPase activity of a2AG; 
fusion protein. Membrane fractions from pertussis toxin treated HEK293 
cells cotransfected with a2AGi fusion protein, Gal and Gy2 subunits were 
used to measure GTPase activity. 
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Figure 8.3-2 GTPase assay a2AGi cotransfected with 01 and y2 
Agonist stimulation of high affinity GTPase activity of a2AG; fusion protein. 
Membrane fractions from pertussis toxin treated HEK293 cells cotransfected with 
a2AGi fusion protein, Gß1 and G72 subunits were used to measure GTPase activity. 
High affinity GTPase activity measured for varying concentrations of GTP in 
membranes of pertussis toxin treated HEK293 cells transfected to express a2AG; with 
and without ß1y2. In membranes expressing a2AG;: "- Basal GTPase activity and 0- 
GTPase activity in the presence of 1x10 M epinephrine. In membranes expressing 
a2AG; (3172:  - basal GTPase activity, Q- GTPase activity in the presence of 1x104M 
epinephrine. 
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8.3.2 GTPase Assay a2AG; cotransfected with ß3/ß3_s and r5 
To compare the functional response between the wild type 03 subunit and the splice 
variant ß3s subunit, the experiment was carried out in HEK cells cotransfected with 
a2AGI R3y5 and a2AGß3_sy5. The GTPase activity was measured in each case in 
response to 100µM Epinephrine and Vmax and Km measured by using graded 
concentrations of the substrate GTP. The results are shown in Figure 8.3-3 and Figure 
8.3-4. 
Figure 8.3-3 shows GTPase measured in HEK293 cells cotransfected with a2AG; and 
R3Y5 or P345. The experiment was carried out in cells transfected with a2AG; alone, 
a2AG; with ß375, a2AG; with ß345, ß3Y5 alone, ß3.5y5 alone and PCDNA3 alone and 
high affinity GTPAse was measured in each case, after 24 hour incubation with 
pertussis toxin. In Hek293 cells transfected with a2AG; alone and, the basal GTPase 
activity was 7.53 ± 2.15 pmol/mg/min and after stimulation with 100µM epinephrine 
the GTPase activity was 58.69 ± 1.46 pmol/mg/min. In HEK293 cells after 
transfection with a2AG; and 53y5 subunits, the basal and stimulated GTPase activity 
were 9.60 ± 0.56 pmol/mg/min and 76.75 ± 2.75 pmol/mg/min respectively. The basal 
and stimulated GTPase activity when measured in cells transfected with a2AG; and ß3. 
sY5 subunits were 6.62 ± 0.26 and 57.20 ± 1.59 pmol/mg/min respectively. 
Figure 8.3-4 shows the result of high affinity GTPase measured over a range of 
concentration of GTP. Using Michaelis-Menten kinetics, the Vmax and Km is 
calculated for each experiment. The increase in Vmax due to epinephrine in cells 
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expressing a2AG; alone was 98.94 pmol/mg/min, in cells expressing a2AG; with ß3r5 it 
was 110.22 pmol/mg/min and in cells expressing a2AG; with ß3_s75 it was 115.09 
pmol/mg/min. The expression of the fusion protein in cells transfected with a2AG; 
alone was 1.34 pmol/mg and thus the agonist induced turnover in these cells was 
73.75 min-'. In cells expressing a2AG; with ß3y5, the expression of the fusion protein 
was 2.20 pmol/mg and the agonist induced turnover 49.9 min-', and in cells 
expressing a2AG; with ß345, the expression of the fusion protein was 2.20 and the 
agonist induced turnover 52.2 min-1. 
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Figure 8.3-3 Agonist stimulation of high affinity GTPase activity of a2AG; fusion protein. 
Membrane fractions from pertussis toxin treated HEK293 cells cotransfected with a2AG; 
fusion protein, G03 or G03-, and yssubunits were used to measure GTPase activity. 
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Agonist stimulation of high affinity GTPase activity of a2AG, fusion protein. 
Membrane fractions from pertussis toxin treated HEK293 cells cotransfected with 
a, AG, fusion protein, G(3; or G(33-s and y5 subunits were used to measure GTPase 
activity. High affinity GTPase activity measured for varying concentrations of GTP in 
membranes of pertussis toxin treated transfected HEK293 cells. In membranes 
expressing a2AG,: "- Basal GTPase activity, 0- GTPase activity in the presence of 
1x10-4M epinephrine. In membranes expressing a, AG, ß375:  - Basal GTPase activity, Q- GTPase activity in the presence of I x10-4M epinephrine. In membranes expressing 
a2AG, P; ys: f Basal GTPase activity, O- GTPase activity in the presence of 1 x10- 'M epinephrine. 
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8.3.3 Calcium signalling in EF88 cells cotransfected with 
a2AGI, ß3l, 83. s and r5 
EF88 cells were transfected with a2AG; alone, a2AG; with ß3y5 and a2AG; with ß3_s75. 
The cells were grown on cover slips as described above [section 3.7 Single cell 
(EF88) calcium (page 227)] and single cell calcium signals recorded after stimulating 
with 100 µM epinephrine. The readings were taken from at least 3 cell per cover slip. 
The change in Fura-2 ratio in the three cell groups over time after stimulation with 
epinephrine is shown in Figure 8.3-6. Figure 8.3-6 to Figure 8.3-8 summarises the 
results of the calcium signalling experiments. Cells transfected with a2AG; do not 
show any significant change in Fura-2 ratio indicating undetectable calcium release. 
However the cells transfected with ß3y5 in addition to a2AG; show an early and 
significantly increased change in Fura-2 ratio indicating activation of the downstream 
pathway of G protein signalling releasing Ca from the endoplasmic reticulum. The 
rate of calcium release in cells expressing a2AG; alone was 0.0010±0.0001 sec-1 while 
that for cells expressing ß3y5 in addition was 0.004±0.0005 sec-1 (p<0.001) and cells 
expressing 13345 in addition was 0.003±0.0002 sec-1 (p<0.01) (Figure 8.3-8). Cells 
expressing a2AG; alone took 334.43 ± 19.74 seconds to reach peak calcium signal. 
This was significantly higher than cells expressing a2AG; along with ß3y5 (170.59 ± 
6.82 sec) or ß3_sY5 (162.81 ± 10.21 sec) (Figure 8.3-5). The lag between addition of 
epinephrine and appearance of a calcium signal was shorter in the cells expressing 
ß3Y5 (27.57 ± 1.51 sec) or ß3_s75 (30.24 ± 1.73sec) compared to cells expressing a2AG; 
alone (40.30 ± 2.41 sec) but the differenece was only significant with the cells 
expressing ß3Y5 (Figure 8.3-7). Though there was no difference between cells 
expressing ß+ and ß3_s in terms of onset delay of calcium 
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Figure 8.3-6 Graph showing the change in intracellular Fura-2 ratio after addition 
of Epinephrine to EF88 cells transfected with a2AG; with or without ßg/(33_9 and ys 
subunits. 
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Figure 8.3-5 Graph showing the time to attain peak calcium signal after addition of 
Epinephrine to EF88 cells transfected with ct2AG; with or without ß3/ß3-s and y5 
subunits. 
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Figure 8.3-7 Graph showing the delay in first detecting a calcium signal after 
addition of Epinephrine to FF88 cells transfected with UZA(i with or without X3314 
and ys subunits. 
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Figure 8.3-8 Graph showing the rate of calcium release after addition of 
Epinephrine to EF88 cells transfected with U2AG; with or without ß31ß3., and ys 
subunits. 
release and time to peak of calcium signal, cells expressing ß3_S showed a significantly 
lower rate of calcium release compared to cells expressing ß3. (Figure 3.7-1, Figure 
8.3-8). 
8.4 Discussion 
In this study I used a2AG; fusion constructs to determine any functional differences in 
the wild and truncated Gß3 subunits. I tested this by assaying GTPase activity and 
measuring single cell calcium signals after stimulation with epinephrine. There was 
no significant difference between ¢3 or 53s transfected cells in terms of GTPase 
activity after stimulation with epinephrine. In terms of calcium signalling 
experiments, though there was no difference between cells expressing ß3 and ß3_S in 
terms of onset delay of calcium release and time to peak of calcium signal, cells 
expressing ß3_s showed a significantly lower rate of calcium release compared to cells 
expressing (33. These results indicate no functional difference between the splice 
variant G protein ß3_s subunit and the wild type G protein ß3 subunit. 
Similar lack of functional effect have been reported by Ruiz-Velasco and Ikeda767 
who used a microinjection technique to demonstrate the potential functional 
significance of Gß3 and Gß3_S in rat sympathetic neurons in terms of modulating N- 
type Ca 2+ or G-protein-gated inwardly rectifying K+ channels. They also investigated 
whether G03_s can couple to a pertussis toxin-insensitive G2 mutant or to a2- 
adrenoceptors and whether G03_s can form a heterodimer with G72. Dimerisation of G 
protein ß-subunits with Gy is required for interaction with all known effectors, as the 
ß-subunits form a functional monomer 811 Their findings suggest that Gß3_S is 
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functionally inactive. First, in contrast to Gß3/Gy5 and Gß3/Gy2, neither G(33ý/Gy5 nor 
G033/Gy2 evoked any basal facilitation of Ca 2+ currents or enhancement of Ca 2+ 
current. Second, no functional effect of Gß3_S on K+ channels could be found. 
There are conflicting views regarding the association of the C825T allele and vascular 
disorders. Various studies, which have shown an association between C825T and 
disease states, have regarded G133, as a functional protein with an enhanced 
activity. 675`7z3'812 Nonetheless, the actual effect Gß3_., exerts on G protein signalling 
mechanisms remains unresolved and little direct evidence exists that demonstrates 
Gß3. possesses modulatory activity. 
Evidence available in the literature, which suggests Gß3_, is a functional and 
overactive G protein subunit, is rather indirect. Overall, there are three main 
observations that have led investigators to this conclusion. First, G protein signalling 
pathways in neutrophils and platelets were found to be enhanced in individuals 
carrying the T allele compared with noncarriers. That is, neutrophils of C825T allele 
carriers had a significantly greater N-formyl-methionyl-leucyl-phenylalanine (fMLP)- 
and interleukin-8-induced chemotaxis 675; 812 Chemotaxis in all three genotypes was 
PTX sensitive, suggesting coupling through either Ga; or Ga0. Moreover, a 
significantly greater epinephrine-induced platelet aggregation in those persons 
carrying the C825T allele was also reported. 723 Unfortunately, no direct evidence was 
provided to show G 33_S caused both the enhanced chemotaxis and platelet 
aggregation. These findings are in contrast to those of others that showed a significant 
effect on various cell functions and signal transduction components due to 
overexpressing Gß3-s. Overexpression of Gß3 in COS-7 (African green monkey 
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kidney) cells stimulated with lysophosphatidic acid was associated with a 
significantly increased chemotactic migration index (compared with the expression of 
Gß3) 675 Functional expression of Gß3-s in COS-7 cells (confirmed by Western blot 
analysis) evoked a significantly enhanced activation of G proteins as monitored by 
GTPS binding over that observed in mock- or Gß3 -transfected cells. When Sf9 insect 
cells were infected with Gß3 and Gß3, along with G12, Gys, and the m2-muscarinergic 
receptors, carbachol-stimulated binding of GTPS was enhanced 10-fold in those cells 
expressing Gß3. s compared with cells expressing Gß3. These differences were not 
explained by large differences in the expression levels of Gß3 or Gß3.5.813 These 
findings would suggest that G033 is capable of forming a functional heterodimer with 
Gy5. This is in contrast to the findings of Rosskopf et a168 ' who showed when Gß3_S 
was overexpressed in HEK-TS cells, there was a spontaneous activation of the 
mitogen-activated protein kinase (MAP kinase) pathway, which was three times more 
pronounced than that following overexpression of G¢1, G03, or G04. A 
straightforward interpretation of these results suggests that the truncated G03_s not 
only interacts with G subunits but is also capable of activating intracellular effector 
pathways with a greater efficacy than wild-type Gß3.767 However, two recent studies 
have reported that in the same expression system (i. e., Sf9 cells), the expressed Gß38 
could not be purified and thus not reconstituted with several y-subunits. 814; 815 These 
differences may be a result of different assay conditions employed. In this context, the 
experiments carried out in this study suggest no difference between the splice variant 
and the wild type 03 subunit, while Ruiz-Velasco and Ikeda767 report lack of function 
of the G034 subunit. 
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While only speculation can explain such divergent results, it must be emphasized that 
the original findings from Siffert et al 579 may be regarded as artificial as they were all 
obtained in systems in which G03-, was strongly overexpressed, e. g., in Sf9 insect 
cells or COS-7 and HEK TS cells, respectively. It appears reasonable to assume that 
such high expression levels greatly exceed those occurring under physiological 
conditions. An alternative explanation for the results of Ruiz-Velasco and Ikeda767 
would be that Gß33, due to its structural deletion, has lost its ability to interact with 
Cat' and K+ channels but retains its ability to stimulate the MAP kinase pathway. This 
latter hypothesis can seemingly be ruled out, as Ruiz-Velasco and Ikeda767 also 
reported lack of dimerisation of labelled Gß3.5 with Gy subunits and lack of formation 
of aG protein heterotrimer using fluorescence resonance energy transfer (FRET). 
Coprecipitation experiments of in vitro translated Gß subunits and epitope-tagged Gy 
subunits suggested dimerisation of G 03-s with Gy12 and Gys 813 However, the amounts 
of these latter products were significantly reduced compared with those obtained after 
in vitro translation of wild-type Gß3 together with these tagged G subunits. It can, 
therefore, not be ruled out that G03-s /Gy dimers form exclusively in artificial systems 
in which all components are strongly overexpressed. A definitive proof for the 
dimerisation and functional activity of Gß3-s with G subunits would require the 
purification and functional reconstitution of Gß3 -s. 
767 While the lack of dimerisation 
could explain the non-functionality of the G03 shown by Ruiz-Velasco and Ikeda, 767 
in my experiments there is definite evidence of functional activity suggesting that 
functional G protein heterotrimers were formed in the cell systems studied and 
resulted in nearly similar functional activity. Though I could not assay the expression 
level of the transfected G protein subunits, the use of pertussis toxin resistant a2AG; 
fusion constructs and measurements performed after treatment with pertussis toxin 
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would indicate that the signalling pathway studied is predominantly mediated through 
the transfected subunits. Even if the results are due to overexpression, they are 
different from the original findings from Siffert et al, 579 who also used similar similar 
systems with overexpression of the Gß3 subunits. 
One hypothesis to explain the lack of function associated with the Gß3_S, and its 
variable association with clinical phenotypes is the inability of the Gß3_, mRNA to 
form a functional protein in vivo and the resultant degradation of the G03-s mRNA. 
Thus, the 825T allele carriers would lack the functional wild-type G03i and the effect 
should be stronger in homozygous compared with heterozygous 825T allele carriers. 
Unfortunately, G03 tissue distribution has rarely been studied on the protein level and 
available antibodies lack sensitivity and specificity. However, the difficulties of 
demonstrating Gß3-, expression by means of Western blot analysis compared with the 
ease by which Gß33 mRNA is detected by means of RT-PCR adds supports to this 
hypothesis. 767 Aso in support of this hypothesis is the finding of significant expression 
of G03 but a lack of GJ3 in fat cells regardless of GNB3 genotype by Western Blot, 
resulting in individuals with the TT genotype with the lowest and individuals with the 
CC genotype with the highest amount of wild-type G033 in the fat cells and cells from 
CT individuals displaying intermediate levels. 816 This resulted in a blunted response 
toward the lipolytic effects of ß, - or (32-adrenoceptor agonists in fat cells from 825T 
allele carriers despite unchanged levels of adrenoceptors and G; /GS proteins. 
A consistent interpretation would strongly imply that the expression level of wild-type 
Gß3 correlates relatively strictly with, or may even determine the efficacy of, signal 
transduction via a variety of G protein-coupled receptors. Nevertheless, the amount of 
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expressed Gß3 wild-type protein may have an impact on the delicate balance between 
the different G protein ß- and -y subunits and their specific combination with 
heptahelical receptors. One way to assess the hypotheses mentioned above would be 
to express increasing amounts of Gß3 in cells and to measure the effect of this 
manipulation on specific cell responses or signal transduction events. It would not be 
too surprising if alternative splicing generating "mRNA junk" would result in a 
reduced amount of functional wild-type protein. Another question that need to be 
answered is whether Gi33.5 subunits are stable and whether they can dimerise with G 
subunits and form coordinated Gß complexes capable of combining with heptahelical 
receptors. Finally in addition, if G03_, can be detected as protein and their tissue 
distribution determined, it would shed light on the mechanisms and potentially 
explain the contrasting phenotypes associated with the C- and T-alleles. 
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G protein activation is the key event in intracellular signal transduction, so it is logical to 
assume that the C825T polymorphism may have an impact on a variety of disease 
processes, signal transduction in human cells and tissues, as well as responses to common 
drugs. Previous studies have shown the 825T allele in the white human population of 
European descent to variably increase the risk for obesity, 706; 708; 71° hypertension, 689; 690 
coronary heart disease, 718; 719 stroke, 713; 735 and depression 736; 737 In contrast, the association 
of the 825T allele with these disorders in non-Caucasian ethnicities remains 
controversial. 695; 697-699; 738 Furthermore, other reports have suggested that the 825T allele 
may serve as a pharmacogenetic marker for response to cardiovascular agents such as 
diuretics, 704 clonidine, 739 angiotensin 11,732 and endothelin-1.732 However these have not 
been replicated. It is not clear if this is a causal association, as functional effect of the 
polymorphism has not been proven unequivocally. Despite a large number of studies after 
the initial publication suggesting its association with hypertension, the molecular and 
biochemical mechanisms underlying these associations remained obscure. 
In this thesis, I have addressed the important question of whether the GNB3 C825T 
polymorphism is a candidate gene for hypertension and LV hypertrophy by studying 
association of blood pressure and LV mass phenotypes using both a family-based and 
population-based approach in independent groups. In addition I have studied the 
functional aspects of this polymorphism specifically looking for evidence supporting its 
pathogenic role in a physiologically meaningful way. 
The case-control study design is a highly efficient method for detecting association and 
the family based approach is less prone to errors stemming from admixture, given its use 
of unaffected family members as internal controls. The population I studied were not 
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ascertained for hypertension but were drawn from the west of Scotland region with high 
cardiovascular risk. The twin study confirms the genetic determination of blood pressure 
and LV mass in an independent population. For effects conferred by a single gene variant 
to be evident, they must either be very strong or found at a very high frequency to be 
statistically detectable. These analytic strategies have consistently and categorically 
demonstrated that the GNB3 gene does not play a significant independent role in 
hypertension and LV mass phenotypes. 
Further studies looking at epistatic interactions with this polymorphism would facilitate 
the genetic dissection of these phenotypes. In support of this I have demonstrated a 
significant gene-interaction interaction between GNB3, ACE and aldosterone synthase 
polymorphisms determination of ECG LV mass. This interaction is biologically plausible 
as G proteins are signal transduction molecules through which the actions of the renin- 
angiotensin-aldosterone system and the adrenergic system are mediated. Thus GNB3 may 
exert a major effect only in association with variation in these genes. However these 
findings need to be further tested in large association studies, especially with 
ascertainment for high blood pressure which can identify individuals in the extremes of 
LV mass distribution, as this can give power at the stage of defining genotype-phenotype 
association. 169 The significant heritability of ECG indices of LV mass that I have shown 
would recommend the use of electrocardiographic phenotypes rather than 
echocardiographic left ventricular mass, as it is inexpensive and practical in many 
thousands of individuals needed in large population genetic studies. 
I have shown that 825T allele has no significant functional effect on Gi mediated 
signalling as measured by platelet aggregation. Epinephrine-induced platelet aggregation 
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is considered to be exclusively mediated by Gi2 after activation of the a2A 
adrenoceptor, 797 ADP mediates platelet activation through two G-protein-coupled receptor 
subtypes Gq and Gi, 798 and PAF stimulation activates Gq coupled PLC and mobilisation 
of intracellular calcium. Given the activation of PTX-sensitive G proteins by epinephrine 
together with the observation that the a2A adrenoceptor activates G protein heterotrimers 
containing Gß3,800 epinephrine-mediated platelet aggregation should have bee enhanced in 
GNB3 825T allele carriers, in contrast to platelet activation evoked by ADP. The absence 
of this relationship excludes any major functional effect of the GNB3 polymorphism in 
biological systems. 
These findings are supported by molecular studies where I used pertussis toxin resistant 
a2AGi fusion constructs which provides a robust measure of G protein activity as I 
performed measurements after treatment with pertussis toxin restricting the signalling 
pathway studied to that predominantly mediated through the transfected subunits. I found 
no significant difference between (33 or ß3-s transfected cells in terms of GPTase activity 
after stimulation with epinephrine. But the 03 or ß3-s transfected cells showed a two-fold 
higher GTPase activity compared to cells transfected with only the a2A-Gi fusion 
construct. This suggests formation of the functional heterotrimer with the transfected 
ß3/ß3-s and y5 subunits, and pre-treatment with pertussis toxin would have neutralised 
any endogenous G protein activity. I used the single cell calcium signalling experiment to 
study the downstream effect of different ß3 subunits. Cells expressing either ß3 or ß3-s 
subunit showed significant differences in the measures of calcium signalling compared to 
cells not expressing them. Though there was no difference between cells expressing ß3 
and ß3-s in terms of onset delay of calcium release and time to peak of calcium signal, 
cells expressing ß3-s showed a significantly lower rate of calcium release compared to 
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cells expressing ß3. These results indicate that the ß3-s subunit is functional and that its 
functional effect is only slightly decreased compared to the wild type G protein ß3 
subunit. 
These findings are different from that reported by Ruiz-Velasco and Ikeda, 767 who studied 
calcium signalling in terms of modulating N-type Ca 2+ and G-protein-gated inwardly 
rectifying K+ channels, while my experiments assessed the activation of IP3 calcium 
channels in the sarcoplasmic reticulum in response to epinephrine which are activated by 
PLC-ß through both Ga and Gß3y5 subunits independently. Previous functional studies 
have shown three times more pronounced spontaneous activation of MAPK pathway in 
HEK-TS cells expressing Gß3-s compared to Gß3 and a10-fold increase in carbachol- 
stimulated binding of GTPS Sf9 insect cells expressing Gß3-s compared with cells 
expressing G33.68813 These results along with our findings would suggest that the 
truncated G03-s not only interacts with G subunits but is also capable of activating 
intracellular effector pathways like the wild-type Gß3.767 However this study does not 
support an enhanced activity of the Gß3-s, and in contrast to experiments which have 
shown an enhanced activity, I have controlled for the upstream factors in the signalling 
cascade by using the fusion construct and thus measuring functional activity specifically 
through the transfected subunits and thus these results are probably more accurate. 
The problems with genetic association studies need to be addressed if meaningful results 
are to be obtained. Critics have conceded that findings from many genetic association 
studies are inconsistent and cannot be replicated, and that these studies should be restricted 
to the study of polymorphisms that have been shown to have a direct effect on gene 
function. 817 In fact, in a recent review of genetic association studies, Hirschhorn et all86 
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found that over 600 positive associations between common gene variants and disease have 
been reported. Of the putative associations which have been studied three or more times, 
only 3.6% have been consistently replicated. Recently, more stringent criteria for the 
evaluation of these studies have been proposed . 
722 The guidelines say that association 
studies should have "large sample sizes, small p values, report associations that make 
biological sense and alleles that affect the gene product in a physiologically meaningful 
way. In addition, they should contain an initial study as well as an independent replication, 
the association should be observed both in family-based and population-based studies, and 
the odds ratio and/or the attributable risk should be high. 722 The analytic strategies 
undertaken in this study reflects the recommendations of these criteria and demonstrate the 
breadth of the analyses and the clear conclusions reached about the candidature of GNB3 
as a putative gene for hypertension. Ultimately, studies that meet these criteria will help to 
dissect clinically relevant genetic variants from single nucleotide polymorphisms without 
biological function in the system under investigation. 
Despite the perception that gene interactions are important, it is increasingly clear that 
existing strategies are inadequate to deduce the type of interactions. Most analyses of risk 
factors focus on identifying agents that have a consistent effect regardless of an 
individual's context, but context dependent genetic effects which may involve gene-gene 
interactions (epistasis) as well as gene environment interactions are important. 18 
Increasing evidence indicates that the genes contributing to the risk of hypertension do not 
have the same effects across time, in different environments, or in different genetic 
backgrounds. Current efforts in humans and other species to generate dense genetic maps 
using many polymorphic markers, such as SNPs, can be used to reconstruct common 
genomewide haplotypes. In future, it should then, at least theoretically, be possible to 
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obtain sufficient population sizes by sampling individuals from the general population and 
using highdensity SNP maps to reconstruct haplotypic relationships. It should be possible 
to perform genome scans for direct associations between haplotypes at one location or 
combinations of haplotypes at two locations with trait variation. The haplotypes could be 
used to reconstruct the genetic relationship between individuals, both at individual loci 
and for combinations of loci. QTL effects can then be predicted by using the variance- 
component approach to estimate the proportion of the genetic variance that results from 
the effects of individual loci and from the interactions between them. 818 The designs might 
therefore not be cost-effective for detecting novel epistatic patterns until the large-scale 
collection of haplotype data becomes feasible. An integration of biological knowledge 
with genetic associations is essential in interpreting as well as testing hypotheses about 
causal pathways, rather than just modelling the joint effects of genotype and environment. 
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10.1 Phenotypic variation 
For quantitative traits, the phenotype of a particular individual is called its phenotypic value. Two 
parameters are of interest for any quantitative trait, namely the mean and the variance. The mean (µ) is 
defined as the expected phenotypic value across all individuals in the population. The variance (a2) is 
defined as the expected value of the squared deviation of each phenotypic value from the population mean. 
The standard deviation equals the square root of the variance. 
Thus, for continuously measurable traits, it is simplest to characterize gene effects in the context of the 
gaussian distribution. If we consider a single locus L with two variant alleles A and a with population 
frequencies p and =1-p respectively, there are two important measures we can define - displacement and 
genetic variance. "' 
10.1.1 Displacement 
Displacement (t), is the number of standard deviations difference between the mean values of the two 
homozygotes AA and as (assuming the variance within genotype is the same for each genotype). There is an 
additional parameter, d, representing the mean value of heterozygotes Aa relative to the two homozygotes. 
Thus, a value of d=1 corresponds to equal means for genotypes AA and Aa (that is, A is dominant), whereas 
d=0 corresponds to equal means for genotypes Aa and as (that is, A is recessive). A value of d=0.5 
corresponds to the heterozygotes being exactly intermediate between the two homozygotes, a situation often 
described as additive. 
10.1.2 Genetic Variance 
The second measure of gene effect is the population variance attributable to segregation of the gene. A major 
assumption of quantitative genetics is that genetic and environmental effects on complex traits are additive. 
This assumption cannot be verified explicitly because the individual factors are not directly observable. But 
it allows the phenotypic value of any individual to be written as the sum of three terms: 
" The mean p of the entire population 
"A deviation from the population mean due to the genotype of the individual 
"A deviation from the population mean due to the environment of the individual 
The additivity assumption is written in symbolic form as 
P; = µ+G; + E; 
Where Pi is the phenotypic value of the ith individual of the population, µ is the mean of the population, Gi 
is the deviation of the ith individual from the population mean due to genetic factors, and E; is the deviation 
of the ith individual from the population mean due to environmental factors. 
This implies that the variance in phenotypic value (the phenotypic variance, o) can be partitioned into one 
component due to variation among genetic factors, which is called the genotypic variance, Qg , and another 
component due to variation among environmental factors, which is called the environmental variance, Ore . 
The basis of this partitioning is the definition of the variance in terms of the expected value of the squared 
deviations: 
Qp=E(P,. -, u)=E(G; 2)+E(E; 
)=a 
+ Qe 
In a genetically uniform population, or must equal zero, and the observed variance in that population 
provides an estimate of Ore . Whereas the observed variance of a randomly bred population provides an 
estimate of QR + o'e . An estimate of QR can be obtained by subtraction, since Qg =( Qg + cre 22 )- 0e 
This method of separating the genotypic and environmental variance has also been used in the studies of 
monozygotic twins in human populations, as they have shared identical genotypes but different 
environmental experiences. 
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10.2 Average effect 
For a quantitative trait, the mean phenotypes of AA, Aa, as are denoted a, d and -a, which are measured as 
deviation from the average of the homozygous genotypes. The symbols a and d represent the effect of the 
alleles. The quantity 2a measures the difference between the means of the homozygous genotypes, because 
a-(-a)=2a, and d/a serves as a measure of dominance 
d=a means that A is dominant to a 
d=0 implies additivity (Aa exactly intermediate between AA and aa) 
d=-a means that a is dominant to A 
If A and a have allele frequencies p and q, then in a random mating population the overall mean phenotypic 
value is given by 
p= pea + 2pqd +q2(-a) = (p-q)a +2pqd 
To obtain G; values, the mean phenotype of each genotype needs to be expressed as a deviation from the 
overall population mean. 
G, = a-p = 2q[a+(q-p)d]-2g2d = 2qa -2q2d 
G2 = d-p = (q p)(a+(q p)d]+2pgd = (q-p)a +2pqd 
G3 = -a-p = -2p[a+(4 p)d1-2p2d = -2pa-2p2d 
Each deviation can be expressed in terms of the quantity a+(q-p)d, which appears so often in the equations 
of quantitative genetics that it is assigned a special symbol a and given the special name average effect. 
a= a+(q-p)d 
The average effect can also be written as q[d-(-a)]+p(a-d), which more easily shows its biological meaning. 
It is the average change in mean phenotype that would result from choosing an allele at random (in whatever 
genotype it happens to be) and changing it to an A allele. 
The gaussian model described above has a direct extension to discrete outcomes (for example, 
affected/unaffected). In this case, the quantitative genetic variable is latent (unobserved) and often described 
as the genetic liability'. Superimposed on the genetic-liability distribution is a risk function, so that risk of 
disease also increases continuously with liability. If one assumes a gaussian form for this risk function, the 
model can be characterized as a 'threshold' model, wherein total liability is defined as the sum of genetic and 
non-genetic liabilities, and disease occurs when an individual's total liability exceeds a threshold T. As in the 
case of continuous outcomes, a single locus can influence the distribution of liability, where individual 
genotypes have different mean liabilities. The same measures used for quantitative outcomes can also be 
used here - namely displacement and proportion of variance explained, measured on the scale of liability. 
Alternatively, one can conceptualize measures of gene effect on the scale of risk rather than liability. For 
example, classical measures from epidemiology, such as the relative risk, can be used to quantify the risk of 
disease for one genotype (say AA) compared to another (say aa), a concept termed the genotype relative risk 
or genotypic risk ratio (GRR) Hw The GRR is analogous to displacement, in that it measures the effect of a 
particular allele or genotype, independent of its frequency. Another useful, more complex measure is the 
sibling relative risk (A.., ) attributable to locus L (ratio of risk to sibs of an affected case to the population 
prevalence). 82' If the GRR for genotype AA is g2 and that for genotype Aa is g,, and the frequency of allele A 
is p and q=1-p, A, can be calculated as 1+ (1/2VA + 1/4 VD)/K2, where K= p2$2 + 2pggl + q2, VA = 2pq(p( 
$2 - g, +q (g, - go ))2 and VD = p2g2(g 2+ g - 2g1)2. Note that these formulas are analogous to the continuous 
case except that the displacement t is now replaced by the GRR g2. 
10.3 Components of genotypic variation 
The genotypic variance can be expressed as V(; (L) = VA(L) + VD( L), where VA(L) is the 'additive' genetic 
variance and VD(L) is the 'dominance' genetic variance. Thus 
a,, = p2[2ga-2q2412 + 2pgl(q-p)a +2pgd]2 + q2[-2pa-2p2d]2 = 2pgo? + (2pgd)l 
The first term in the equation is termed the additive genetic variance given by 
o =2pga2 
The second term in the equation dominance variance given by 
cä = (2pgd )z 
Whereas the additive variance depends both on a (twice the difference between homozygous genotypes) and d (the dominance effect), the dominance variance depends only on d. Both variance components also depend 
on allele frequencies. 
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When multiple loci are considered, 2pgd can be replaced by the sum of such terms, one for each locus, and 
likewise (2pqd)2 can be replaced with a sum of similar terms. Each locus may have different values of 
p, q, a, d. There is also a term corresponding to nonadditive interactions between genotypes at different loci, 
which is called the interaction variance, symbolised 62. And in still more general models in which 
assortative mating is allowed, there is a term due to assortative mating symbolised by or.. 
m. The term 
assortative mating means that there is a positive correlation between the phenotypes of mating pairs, as 
occurs in human populations for height. With all these taken into account, the genotypic variance can be 
written as 
Qý = Uä +o22+ Ui + bam 
In principle one could also partition the environmental variance similarly. 
The proportion of total variance attributable to a locus (h2L), is then given by Vc(L)/(1 + VG(L)), assuming 
the variance within genotype to be 1.0. It is important to note that hL is a function of both displacement t 
and the allele frequency p. Thus, a rare gene with large displacement (that is, mendelian) may contribute the 
same proportion to variance as a common gene with modest displacement (that is, non-mendelian). In 
addition, because h2L is a function of p, its value can vary from one population to another when p varies, 
even when the displacement t is the same. 
10.4 Broad sense heritability 
For a complex trait, one measure of the aggregate effect of all genetic factors combined is the broad sense 
heritability (112), defined as the ratio of the genotypic variance to the phenotypic variance: 
i2 
H2=R = 
ý9 
Qp QÄ+a 
Hence if 112=0 , all of the phenotypic variance is attributable to differences in environment, and 
if H2=1, all 
of the phenotypic variance is attributable to differences in genotype. The variance components have a very 
limited utility and apply only to differences in phenotype within populations and not between populations. 
10.5 Artificial selection and narrow-sense 
heritability 
Genetic changes can sometimes occur slowly in traits affected by many genes in populations that are large 
enough, because, then selection can act on the genetic variation contributed by new mutations. Although 
genetic variation is essential for progress under selection, it is not sufficient. The reason is quite subtle. Only 
the additive genetic variance cr. -2 contributes to the response to selection. The genotypic variance Crg is not 
the key quantity. In plant breeding, in most genetically heterogeneous populations, artificial selection can 
change phenotype well beyond the range of variation found in the original population. A total selection 
response of 3-5 times the original phenotypic standard deviation is not unusual, and for selection to change a 
population of effective size N. halfway to its selection limit typically requires about O. 5Ne generations. 
The difference in mean phenotype between the selected parents (Ns) and the entire parental population (u) is 
called the selection differential and designated S: 
S=f5 -N The difference in mean phenotype between the progeny generation (p) and the previous generation (µ) is 
called the response to selection and designated R: 
R=A. p 
Any equation that defines the relationship between the selection differential S and the response to selection R is known as the prediction equation. For individual truncation selection, the prediction equation is 
R=h2S 
Where h2 is called the narrow-sense heritability of the trait. As with broad sense heritability, the narrow- 
sense heritability is a ratio of variances, but not the ratio of genotypic variance to phenotypic variance, but the ratio between the additive genetic variance to phenotypic variance. 
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hz_ýa 2 
P 
The usual way to estimate narrow-sense heritability is from correlation between relatives. 
10.6 Correlation between relatives 
Estimation of the additive genetic variance might at first seem to be very difficult, but in fact it is quite 
straightforward. The reason is that the theoretical covariance between certain types of relatives is a simple 
multiple of a2 . Suppose x and y represent the phenotypic values of a trait 
between any pair of relatives , 
then the covariance of x and y is defined as 
Cov(x, y) = E[x-E(x)][y-E(y)] 
Just as variance is the expected squared deviation from the mean, the covariance is the product of deviations 
from the mean. If x and y are independent, then Cov(x, y)=0. Based on a random sample of n pairs of values, 
the covariance is estimated as 
(xi 
- 
ny, 
- Y) 
Cov(x, Y)= `-' 
n-1 
The covariance is used in calculating the correlation coefficient r in phenotypic value between x and y: 
Cov(x, y) 
r= 
aWy 
where ax and ay are the phenotypic standard deviations of x and y. The correlation coefficient is sometimes 
preferred over the covariance as a measure of relationship between random variables, because r must always 
lie between -1 (perfect negative correlation, x=-y) and +1 (perfect positive correlation, x=y). Independence 
between x and y implies that r=0. 
10.6.1 Parent-Offspring correlation 
The parent-offspring correlation is often used to estimate the narrow-sense heritability because the 
covariance equals the additive genetic variance. The covariance can be calculated either from a single parent 
(usually chosen to be the father to avoid possible non-genetic maternal effects on the offspring) or from the 
average of the parents (called the midparent). The result is the same. The covariance is calculated as the 
product of the parent-offspring deviations, each weighted by the frequency of the parent-offspring pair. 
Letting Cov(PO) be the covariance between a single parent and offspring, 
Ca 
Cov(PO) = pqa2 = 2 
Alternatively, we can write the correlation coefficient between a single parent and offspring rp0 as 
_ 
Cov(PO) 
_ 
2QÄ h2 
rý, ý 2 
Q2 2 
PP 
where h2 is the narrow-sense heritability. 
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10.6.2 Heritability estimates from resemblance between 
relatives 
Theoretical covariances for common relationships are shown below - variance terms due to interaction 
between loci (epistasis) are ignored. 
Degree of relationship 
Offspring and one parent 
Covariance 
z or. /2 
Offspring and midparent 2 
a/2 
Half siblings Qa2/4 
Full siblings Qä /2)+ ad 
/4 
Monozygotic twins Qa +Q2 d 
Nephew and uncle Q2 ý4 
First cousins er 
Q 
/8 
Double first cousins (a2/4)+ ad /16 
*First cousins are the offspring of matings between siblings and unrelated individuals; double first cousins 
are the offspring of matings between siblings from two different families. 
The additive genetic variance can be estimated directly from covariance between parent and offspring, 
midparent (the average of parents) and offspring, half-siblings, uncle-nephew (or aunt-niece), or 
first 
cousins. What these degrees of relationships have in common is that the relatives can share at most one 
allele at any locus. The covariances between the other degrees of relationship in the above table include a 
contribution due to dominance because the relatives can share two alleles at any locus. The theoretical 
covariance between monozygotic twins is equal to the covariance of an individual with itself, or Cg . 
10.6.3 Offspring-on-parent regression 
A regression line can be drawn on a plot of parental phenotype on the x-axis and offspring phenotype along 
the y-axis. Parent-offspring regression is a convenient method for estimating the narrow-sense heritability 
because the slope of the line b0P, can be shown to satisfy 
h2 
_Coy(PO)_ 20 _ 
bop 
222 
PP 
Hence h2 can be estimated as 2b0 . 
(the regression coefficient of midparent on offspring, boM, equals h2). It 
makes no difference whether the offspring and parent are considered individually or are pooled and their 
mean used instead. 
10.6.4 Genotype-Environment interaction 
The measures described above for effects of single loci need to be considered in the context of their genetic 
and/or environmental background. The gaussian model provides the simplest context whereby all other 
genetic factors are assumed to have small and additive effects, and the environment is also assumed to be 
gaussian and additive. In this case, in addition to the components of genetic variance VA(L) and VD(L) 
defined for locus L, we have the components of residual genetic variance VA(R) and VD(R), which are the 
additive and dominance variance summed across all other loci, with VG(R) =V A(R) = VD(R) . The non- genetic component is assumed to have variance V1:. 
From the perspective of biometrical genetics, epistasis refers to non-additive interactions between gene 
effects (much as dominance refers to non-additive effects between alleles at a single locus). Thus, the 
genetic variance underlying a trait can include sources of variance involving interactive effects among any 
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number of loci, and these are termed epistatic variance components. Often, these are segregated into terms 
based on the number of loci involved in the interaction (for example, two, three or four loci). 19 
Genotype by environment interaction occurs when the genotypic and environmental effects are not additive, 
but differ according to which genotype is in which specific environment. A curve showing the phenotype of 
a genotype across the range of environments is called the norm of reaction for the genotype. Gene- 
environment interaction is indicated when the norms of reaction cross. The important implication of gene- 
environment interaction is that the deviations due to genotype are not independent of the deviations due to 
environment. 
10.6.5 Genotype-Environment association This is another cause of nonindependence of genotypic and environmental deviations. It occurs when the 
genotypes in a population are not distributed randomly in all the possible environments. With gene- 
environment association, it is difficult, if not impossible to separate the genetic and environmental causes of 
variation, because there is a systematic association of certain genotypes with certain environments. 
10.6.6 Genotype-by-sex interaction 
This occurs when the magnitude of a genotypic deviation depends on the sex of the individual. It is a 
potential problem in genetic analysis because the expression of many complex traits depends in part on 
developmental, hormonal, or other factors associated with sex. 
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